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ABSTRACT 
More cases of bronchogenic carcinoma are being reported in recent 
years and these patients are more prone to secondary aspergillosis. The 
early diagnosis for such secondary infection could be of great importance 
since early antifungal treatment is associated with an improved outcome. 
However, diagnosis in the early stages is very difficult, as clinical and 
radiological signs are nonspecific and the sensitivity of fungal culture is 
low (Bretagne et al. 1995). Circulating-antigen detection may contribute to 
the diagnosis but high false positivity has been reported (Stynen et al. 
1995). Therefore, the attention has now turned to molecular detection 
methods, like PCR. The role of PCR assays of Bronchoalveolar lavage 
(BAL) fluids for diagnosing aspergillosis does not clearly emerge in the 
literature (Spreadbury et al. 1993; Tang et al. 1993; Bretagne et al. 1995); 
moreover it is being investigated mainly for the diagnosis of definite- and 
probable-invasive pulmonary aspergillosis, but not extensively in possible-
and semi/non-invasive pulmonary aspergillosis. Again, it has been mostly 
studied in immunocompromised states like, neutropenic patients (Jones et 
al. 1998), organ transplantation (Kusne et al. 1992; Denning 1998) and 
hematological malignancies (Denning 1998; Pagano et al. 2001). The 
evaluation of role of BAL-PCR for the diagnosis of aspergillosis in 
patients of bronchogenic carcinoma is completely missing in the 
existing literature. Moreover, the gross data regarding Aspergillus 
infection in bronchogenic carcinoma is limited. During our search of 
literature via Pubmed Central, we could not get any published systematic 
report except one of our previously published (Malik et al. 2003) and few 
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occasional case reports published in languages other than English (Tsai et 
a!. 1984;Tanakae/a/. 1993). 
The patients of bronchogenic carcinoma are debilitated and 
immunocompromised, and hence the chances of secondary bacterial 
infections are also increased in such cases. The incidence of bacteria 
isolated in bronchoalveolar lavage fluids varied from series to series, 
ranging from 25% to 45% depending on the nature of lung diseases. 
However, studies analyzing the frequency of bacterial infections 
specifically in BAL fluids from patients of bronchogenic carcinoma are 
limited. It should also be emphasized here that, there has been a dramatic 
increase in the multidrug-resistance in recent years, and which is the major 
cause of concern globally (Shahid et al. 2007c). The presence of antibiotic 
resistance genes on bacterial plasmids has further helped in the 
transmission and spread of drug resistance among pathogenic bacteria 
(Robin et al. 1998; Beg & Ahmad 2000). A major feature in the emergence 
of muhidrug-resistant Gram-negative bacilli is the production of extended-
spectrum P-lactamases (ESBLs), which are responsible for resistance to (3-
lactam antibiotics. Plasmid mediated extended-spectrum ^-lactamases, 
including CTX-M-types and AmpC-types, in various Gram-negative 
bacterial species have been reported from various developed countries 
(Philippon et ol. 2002; Bonnet 2004, Pitout et al 2005; Eckert et al 2006; 
Woodford et al. 2007a; Woodford et al. 2007b; Tarrant et al. 2007), 
however, the data on this aspect is elementary from Indian hospitals. 
Therefore, we found worth looking occurrence of CTX-M and AmpC (3-
lactamases, their specific types, and genetic environment in the present 
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collection of E. coli and K. pneumoniae obtained from BAL of 
bronchogenic carcinoma patients. 
Keeping in view the above facts, the present study was conducted on 
patients of bronchogenic carcinoma attending the clinics or admitted in the 
in-patient wards of T. B. & Chest Diseases of Jawaharlal Nehru Medical 
College & Hospital, Aligarh Muslim University, Aligarh during the period 
from June 2003 to May 2006. The whole study was broadly divided in 
three parts v.i.z. Clinical, Mycological, and Bacteriological studies. 
During the above-mentioned study period, a total of 213 
bronchoscopy were performed and of which 159 were suspected cases of 
bronchogenic carcinoma. A total of 95, confirmed patients of bronchogenic 
carcinoma based on histopathological and cytological investigations, and 
not receiving any antifungal therapy prior to the study were included. A 
collection from 42 patients of bronchogenic carcinoma of the year 2001-
2002, on which mycological and bacteriological studies were ongoing, was 
also included. And thus, the study population comprised of a total of 137 
patients. Remaining 64 suspected patients of bronchogenic carcinoma were 
excluded from the study because of some other co-existing underlying 
immunosuppressive disorders or because the patients were taking 
antifungal therapy. Thirty-four, age and sex matched volunteers, not having 
history suggestive of any lung disease in the recent past were included as 
healthy controls. Informed written consent was taken prior to bronchoscopy 
in all study and control groups and the investigations were performed after 
the approval by Institutional Ethical Committee. 
Bronchoalveolar lavage fluids were collected to perform direct 
microscopic examination, fungal- and bacterial-culture, and PCR, and 
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blood samples for serological tests. Two consecutive BAL specimens were 
collected in sterile containers and each BAL specimen was divided in three 
parts for direct microscopy, culture and PCR. Direct microscopy and 
culture was performed immediately whereas BAL specimens for 
performing PCR were kept at -20° C till tested. Blood was collected in 
EDTA and plain vials for routine hematological investigations and fungal 
serology respectively. Additional BAL and blood samples were collected 
from 21 patients of possible- and non-IPA that could be followed-up and in 
whom initial culture or serology was negative and PCR was positive. Sera 
were separated and stored at -20° C till tested further. Specimens for 
histopathology and cytology were also collected and the investigations 
were performed by the expertise in the department of Pathology of J.N. 
Medical College, AMU, Aligarh. 
DEMOGRAPHIC AND CLINICAL STUDIES 
Majority (56.9%; 78/137) of the patients in the present study were in 
the age group of 45-<60 years, followed by in the age group of 60-<75 
years (35.8%). The median age of the study population was 58 years and 
male to female ratio was 11.5:1. One hundred twenty-four (90.5%) 
patients provided history of smoking; 40.1%) (55/137) patients were on 
chemotherapy and 29.9% (41/137) and 26.3% (36/137) patients were on 
prolonged antibiotics and corticosteroids therapy, respectively. The most 
common clinical presentation of the patients was with cough, which was 
noticed in 70%) patients followed by expectoration and chest pain noticed 
in 52.6%) and 50.4% patients, respectively. Hoarseness of voice was 
noticed in 15.3%o patients whereas history of brown plugs in sputum was 
elicited only in 8%) patients. 
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Histopathological and cytological examinations revealed squamous 
cell carcinoma as the most common cancer-type in 66.4% patients followed 
by adenocarcinoma, small cell carcinoma, and large cell carcinoma in 
24.8%, 4.4%, and 2.9% patients, respectively. During bronchoscopic 
examination of the patients, the most common bronchoscopic finding was 
intraluminal growth, which was observed in 79.6% cases, followed by 
bronchial secretions and bronchial congestion noticed in 48.2% and 35.8% 
cases, respectively. Vocal cord palsy and widened carina was noticed in 
22.6%) and 19% patients, respectively, whereas compression of bronchi was 
noticed in 31.4% patients. 
Based on clinical, radiological, microbiological, and 
histopathological examinations, 18 (13.1%) patients were considered to 
have definite-IPA; whereas, 17.5% (24/137) and 24.1% (33/137) patients 
were classified as cases of probable-IPA and possible-IPA, respectively. 
Sixty-two (45.3%) patients were classified as non-IPA cases as no signs of 
invasion were noficed, clinically, microbiologically, radiologically and 
histopathologically. 
MYCOLOGICAL STUDIES 
BAL culture of 42 (30.7%) pafients showed growth of Aspergillus species 
and 19 of these 42 patients revealed fungal elements in direct microscopic 
examination of BAL. Of these 42 culture-positive cases, 18 were 
categorized as cases of definite-IPA and 24 of probable-IPA. Of the 
Aspergillus spp. isolated, Aspergillus fumigatus was the predominant 
species isolated from 26 (61.9%) cases followed by Aspergillus flavus in 
38.1% (16/42) patients. No other species of Aspergillus was isolated in the 
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present study and none among the control group showed fungal growth in 
culture. 
On analysis of the isolation of Aspergillus spp. in various forms of IPA, it 
was noticed that A. fumigatus was isolated from 12 and 14 cases of 
definite- and probable-IPA, respectively, whereas, A. flavus was isolated 
from 6 and 10 cases of definite- and probable-IPA, respectively. No 
Aspergilli was isolated from cases of possible and non-IP A, and none 
among the healthy controls showed growth of Aspergilli in the culture. On 
determination of MIC for A. fumigatus isolates, the MIC range for 
itraconazole and amphotericin B was 0.0313-4 jig/ml and for voriconazole, 
it was 0.0313-1 |ig/ml. Whereas, for A. flavus, MIC ranges for 
itraconazole, amphotericin B, and voriconazole were 0.0313-0.5 |ig/ml, 
0.25-4 i^g/ml, 0.0313-1 p.g/ml, respecfively. 
On serological testing, the anii-Aspergillus antibodies could be 
detected in 48 (35%) patients, each, by DID and DBA. However, the 
anfibodies could be detected in 54 (39.4%) patients by ELISA. And, none 
among the healthy volunteers showed dinti-Aspergillus antibodies in any of 
the serological test. 
On analysis of BALs by polymerase chain reaction, the Aspergillus-
DNA could be detected in 51.8% (71/137) samples. The Aspergillus-UHk 
was detected in all the patients categorized as cases of definite-IPA and 
probable-IPA, however, it could be detected in 69.7% (23/33) and 9.7% 
(6/62) cases of possible- and non-IPA, respectively. The PCR assay 
perfonned on definite-IPA and probable-IPA cases showed amplicons of 
135 bp and 118 bp indicating the presence oi A. fumigatus and A. flavus, 
respectively. The Aspergillus species detected by the PCR, in these cases, 
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corresponded well with culture results. In cases of possible-IPA, 
Aspergillus-YMA could be detected in 23 patients, and of these, the PCR-
amplicons denoted the presence oi A. fumigatus and A. flavus in 19 and 4 
patients, respectively. In cases categorized as non-IP A, PCR was positive 
in 6 cases, and of which 5 showed amplicons denoting the presence oi A. 
fumigatus, and one with amplicon of A. flavus. None among the healthy 
control group showed presence of Aspergillus DNA by BAL-PCR. 
Based on the present study, a strong association between a positive 
PCR test and all forms of aspergillosis (P< 0.05) was noticed, with the 
strongest association correlation found with definite- and probable-IPA (P< 
0.001). Serological tests also showed strong association with positive test 
and aspergillosis in definite- and probable-IPA (P< 0.001); however the 
sensitivities dropped down drasfically in possible- and non-IPA. 
The sensitivity, specificity, PPV, and NPV of PCR and serological 
tests were 100% for definite- and probable-IPA when the data was 
compared against the the healthy volunteers. When the same data was 
compared with entire dataset, the sentitivity of PCR and serological tests 
still remained 100% while specificity ranged between 65-83%. This clearly 
denotes high diagnostic values of these tests in such cases. However, in 
cases of possible- IPA, the sensitivity, specificity, PPV, and NPV of PCR 
were 69.7%, 100%, 100% and 77.3%, respecfively, when compared with 
healthy controls and these values were 69.7%, 65.2%, 32.4%, and 90%), 
respectively, when compared against the entire dataset. These values for 
ELISA, in possible-IPA, were found as 24.2%, 100%, 100%> and 57.6%), 
respectively, when compared with healthy controls and were 24.2%), 
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66.7%, 14.8%, and 78.6%, respectively, when compared against the entire 
dataset. This strongly suggest that PCR has greater diagnostic role in 
possible-IPA as compared to those of serological tests. The diagnostic role 
of PCR was also higher than serological tests in cases with non-IPA. 
However, ELISA do play a diagnostic role in non-IPA, to an extent, as 
opposed to DID and DBA. To find out the robustness of the diagnostic 
values of these tests to discriminate the pulmonary invasion and airway 
colonization, we analyzed the data assuming definite- and probable-IPA as 
diseased group, and possible- and non-IPA as non-diseased group, and 
found them statistically significant (P< 0.0001). All patients with definite-
and probable-IPA had positive PCR tests, whereas all control patients had 
negative PCR tests (P< 0.0001). Similarly, all patients with definite- and 
probable-IPA had positive serological and culture results as compared with 
controls (P< 0.001). We could not get any case which was PCR negative 
but positive by any other test performed. There was a strong association 
between a positive PCR test and all forms of aspergillosis (P< 0.05), with 
the strongest associafion correladon found with definite- and probable-IPA. 
Serological tests also showed strong association with positive test and 
aspergillosis in definite- and probable-IPA (P< 0.001); however the 
sensitivities dropped down drastically in possible- and non-IPA. 
BACTERIOLOGICAL STUDIES 
A total of 143 bacterial isolates were obtained from bacterial culture of 137 
BAL specimens and many samples showed mixed growth of bacteria. 
Klebsiella pneumoniae was the most frequent isolated organism noticed in 
29.9% samples followed by Pseudomonas aeruginosa which was noticed 
in 26.3% BAL samples. Escherichia coli was isolated from 15.3% samples. 
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Only the isolates of E. coli and K. pneumoniae were selected for further 
studies. 
The isolates of E. coli showed maximum susceptibility to 
ceftriaxone-sulbactam, a combination recently launched in India, and to 
meropenem in 85.7%, each, followed by cefoxitin (53.2%) and amikacin 
(46.8%). The resistance to cefpodoxime, cefotaxime, and ceftazidime was 
noticed in 95.2% (20/21), 90.5% (19/21) and 85.7% (18/21) isolates, 
respectively. Concomitant high resistance to other antibiotics tested, 
including tetracycline {95.2%), co-trimoxazole (95.2%)), ciprofloxacin 
(90.5%)), aztreonam (85.7%)), trimethoprim (85.7%), gentamicin (66.7%o), 
was also noticed. All the K. pneumoniae isolates were susceptible to 
ceftriaxone-sulbactam and meropenem. Among aminoglycosides, the 
maximum resistance was noticed against gentamicin in 63.4%o isolates 
followed by amikacin (56.1%)) and tobramycin (36.6%)). Cefpodoxime, 
cefotaxime, and ceftazidime showed resistance in 97.6%o (40/41), 92.7%o 
(38/41) and 92.7%o (38/41) isolates, respectively. And similar to E. coli 
isolates, K. pneumoniae also showed concomitant high resistance to other 
antibiotics tested. 
Disk synergy test using co-amoxyclav disks detected ESBLs in 9.7%o 
(6/62) isolates, whereas phenotypic detection of ESBLs by a newly 
described disk synergy test (Shahid et al. 2007b), where piperacillin-
tazobactam is used in place of co-amoxyclav, was possible in total of 
90.3%) (56/62) isolates. Using combination disks, ESBLs could be detected 
in total of 82.3% (51/62) isolates. 
blacTx-u could be detected in a total of 77.4% (48/62) isolates using 
the multiplex PCR, and of which it could be detected in 81% (17/21) and 
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75.6% (31/41) isolates of E. coli and K. pneumoniae, respectively. Based 
on the multiplex PCR results, CTX-M phylogenetic Group 1 was identified 
in all the isolates studied, and RLH identified the presence of Z?/<3CTX-M-I5 
only. Sequencing of the representative isolates confirmed the presence of 
blacjx-M-M-
Noticing the recent appearance of IS2(5 elements in ISEcpl, in U.K. 
Enterobacteriaceae (Woodford et al. 2004), we also analyzed the genetic 
environment of the Indian Enterobacteriaceae. IS26 was detected in 20 of 
48 (41.7%) isolates carrying /^ACTX-M-IS (9 E.coli, 11 K. pneumoniae). It 
was interesting to note that amplicons of varying sizes (~650bp, ~750bp, 
~850bp, ~950bp, -llOObp, and >1400bp) were obtained; the most 
common being ~850bp amplicon. 
Unlike the situation in the UK where an epidemic E. coli clone A 
carrying blaax-M-is has been described (Woodford et al. 2004), no 
predominant clone was identified in our Indian isolates, indicating 
horizontal transfer of 6/(3CTX-M-I5 between unrelated strains. 
The apparent acquisition of IS26 elements in Indian strains is 
interesting. It perhaps suggests a 'turnover' of plasmids in the population 
over time, the IS26 insertion creating a selective advantage in those strains 
carrying the IS26 insertion. Although the numbers are small, the 
geographical consistency of the observation could make it broadly 
applicable and worthy of further investigation. None of the isolates was 
positive for IS26 elements in earlier studies, including the isolates collected 
during and before year 2000 (Karim et al. 2001; Walsh et al. 2007). We 
first noticed this insertion sequence in a collection of bacteria obtained 
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during 2003-2005 (Ensor et al. 2006b), and subsequently, in the present 
work. Therefore, it is possible that although /^acrx-M-is was widely 
established in India before 2000, the IS2d element had not yet inserted 
within ISEcpl (tnpA), and that this is a later event. In the present study, at 
least three IS26 insertion sites have been identified precisely and is being 
postulated that such an insertion into ISEcpl traps the ESBL gene thus 
preventing it from escaping the gene pool. The recent findings indicate that 
whilst the level of CTX-M-15-positive strains has not generally increased 
since the earlier sampled period, the genetic environment of blacjx.M-\5 has 
changed through the insertion of IS26 although the consequences of these 
events remain uncertain. 
bloampc of CIT-family were detected in 27.4% (17/62) isolates. Of 
these Z)/«ampc-carrying isolates, 23.8% (5/21) were E. coli and 29.3% 
(12/41) were K. pneumoniae. Sequencing of the representati\e isolates 
revealed the presence of CMY-6-like CMY-18-like AmpC ^-lactamase. Of 
the 62 isolates studied in the present study, 13 (21%) were simultaneously 
harboring bla^m^c and hlaCTX.u-M- The frequency of simultaneous 
occurrence in the respective species was noticed in 19% (4/21) and 22% 
(9/41) of £. coli and K. pneumoniae respectively. 
Plasmid analysis of the representative isolates showed the consistent 
presence of a single plasmid ranging between ca. -21 to ca. -23 kb. 
Successfully cured isolates became susceptible to cephamycins and 
cephalosporins and thus provide evidence of carriage of Zj/flampcand blacjx. 
M.,5 on same plasmid. However, we could not perform hybridization 
experiments, due to limited facilities in our Indian laboratory, to strengthen 
the above fact. RAPD-typing of the isolates demonstrated great diversity 
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and no predominant type was noticed, indicating either horizontal transfer 
and/or mobiUzation of these genes on plasmids. 
In nutshell, based on the present study we conclude that: 
• The frequency of secondary aspergillosis was noticed to be 46.7% 
(64/137; cases positive both by PCR and serology) in bronchogenic 
carcinoma which demonstarte the frequent association of this 
combination disesase. 
• It is thus suggested that every patient of bronchogenic carcinoma 
should be screened for the presence of secondary aspergillosis. 
• The sensitivity, specificity, PPV, and NPV of PCR and serological 
tests for definite- and probable-lPA denotes high diagnostic values 
of these tests in such cases. 
• PCR has greater diagnostic role in possible-IPA as compared to that 
of serological tests. 
• The diagnostic role of PCR was also higher than serological tests in 
cases with non-IPA. However, ELISA do play a diagnostic role in 
non-IP A, to an extent, as opposed to DID and DBA. 
• However, the laboratories which do not have facilities for PCR and 
ELISA should at least perform DID or DBA by the proposed 
protocol. 
• It is thus suggested that combining PCR with serological test 
detecting anti-aspergillus antibodies could be of help confirming the 
diagnosis of aspergillosis. This combinafion test strategy would also 
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help establishing the diagnosis in patients without signs of 
infiltration in radiological investigations. 
• It is also suggested that that performing PCR on consecutive BALs 
would help taking the decision to institute the antifungal therapy 
since we noticed that 10 (58.8%) out of 17 patients which were 
initially serologically negative, but PCR-positive, later on 
seroconverted into positive results. 
• This preliminary investigation suggests that both BAL-PCR and 
serological tests detecting ant\-Aspergillus antibodies might be 
beneficial for use in early diagnosis of aspergillosis, especially in 
patients which do not demonstrate signs of infiltration in radiology. 
• The present preliminary study demonstarte frequent association of 
this combination disesase (secondary aspergillosis in bronchogenic 
carcinoma). 
• This is among the premier reports defining the high frequency and 
evaluating various diagnostic tests for secondary aspergillosis in 
bronchogenic carcinoma patients. 
• We report here a 3GC resistance rate of 96.8% of all E. coli and K. 
pneumoniae obtained from BAL of bronchogenic carcinoma patients 
and in these, a CTX-M carriage rate of 77.4%. 
• Numerous reports from India have indicated a high prevalence of 
ESBLs in Gram-negative bacteria, which must be presumed to have 
taken a considerable time to reach a high prevalence. As our study 
suggests, CTX-M-15 is the most common (or maybe the only) CTX-
M type in India. 
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• This is amongst the premier systematic report from India 
characterizing the occurrence and prevalence of CTX-M enzymes. 
• Unlike the situation in the UK where an epidemic E. coli clone A 
carrying Z^ /^ CTX-M-IS has been described, no predominant clone was 
identified in our Indian isolates. 
• The acquisition of IS2(5 elements in Indian strains perhaps suggests a 
'turnover' of plasmids in the population over time. 
• It is speculated that blacjxMAs was widely established in India before 
2000, the IS26 element had not yet inserted within ISEcpI (tnpA), 
and that this is a later event. 
• In the present study, three IS26 insertion sites have been identified 
precisely and is being postulated that such an insertion into ISEcpJ 
traps the ESBLgene thus preventing it from escaping the gene pool. 
• To the best of our knowledge this is the second report of high 
mobility/diversity of IS26 insertion in ISEcpl, first being reported in 
year 2006 (Ensor et al. 2006b), which also included few of the 
isolates from the present Doctoral work. 
• bhan^pc of CIT-family were detected in 27.4% of Indian 
Enterobacteriaceae and the sequencing of the representati\e isolates 
showed presence of CMY-6- like and CMY-18-like AmpC P-
lactamases. 
• Concomitant occurrence of bla^m^c and 6/acTX-M-i5 were noticed in 
significant number of isolates and the genes were inferred to present 
on plasmids ranging between -21 to -23 kb. 
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• This is the first report looking for the carriage of blacjx-M and 
blacaiupc in Enterobacteriaceae from the patients of bronchogenic 
carcinoma. 
• This is also the first report looking for the co-carriage of blacjx-M 
and blacampc in Indian Enterobacteriaceae. 
• This would be the first report indicating the presence of CMY-6- and 
CMY-18- like ampC genes in Indian Enterobacteriaceae. 
• RAPD-typing demonstrated great diversity and indicate transfer of 
these resistance genes on plasmids, and also the dissemination of 
these resistance genes into the community. This probably also 
indicates horizontal transfer of /^acix-M-is between unrelated strains. 
• Our report supports the urgent need for regular screening and 
national surveillance characterizing the CTX-M types and to 
implement strict antibiotics policy to limit the irrational use of 
antibiotics, including cephalosporins, so as to minimize antibiotic 
selective pressure. 
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CHAPTER 1 
1. GENERAL INTRODUCTION 
Fungal infections of the lung, especially bronchopulmonary aspergillosis, 
are becoming increasingly common during the last few decades (Kusne et 
al 1992; Malik et al. 2003; Kurup et al 2004; Kurup 2005). More cases of 
bronchogenic carcinoma are also being reported, in recent years, due to 
advancement in diagnostic technologies and change in personal and 
environmental factors. These patients are more prone to secondary 
pulmonary aspergillosis due to cancerous involvement of the pulmonary 
tissue itself, and in particular, due to long term steroid, anticancer, and 
antibacterial therapy. The data regarding Aspergillus infection in various 
chronic lung diseases is available (Denning 1998; Shahid et al. 2001) and 
so in immunocompromised states like, neutropenic patients (Jones et al. 
1998), bone marrow transplantation (Denning 1998), liver transplantation 
(Kusne e/a/. 1992), AIDS (Bart-Delabesse ef a/. 1996) and hematological 
malignancies (Denning 1998; Pagano et al. 2001). However, the data is 
fragmentary on these fungal infections in bronchogenic carcinoma patients. 
During our search of literature via Pubmed Central, we could not get any 
published systematic report except one of our previously published (Malik 
et al. 2003) and few occasional case reports published in languages other 
than English (Tsai et al 1984; Tanaka et al. 1993). 
The early diagnosis of secondary aspergillosis, in patients of 
bronchogenic carcinoma, could be of great importance since early 
antifungal treatment is associated with an improved outcome (Aisner et al. 
1977). However, diagnosis in early stages is very difficult, as clinical and 
radiological signs are nonspecific and the sensitivity of fungal culture is 
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low (40 to 60%), even when combined with direct microscopic 
examination (Andrews & Werner 1981; Bretagne et al. 1995). Circulating-
antigen detection may contribute to the diagnosis significantly in invasive 
aspergillosis, but false positivity as high as 8% has been reported (Stynen 
et al. 1995). Therefore, the attention has now turned to molecular detection 
methods, like polymerase chain reaction (PCR). The role of PCR assays of 
Bronchoalveolar lavage (BAL) fluids for diagnosing aspergillosis does not 
clearly emerge in the literature (Spreadbury et al. 1993; Tang et al. 1993; 
Bretagne et al. 1995); moreover it is being investigated mainly for the 
diagnosis of definite- and probable-invasive pulmonary aspergillosis, but 
not extensively in possible- and semi/non-invasive pulmonary aspergillosis, 
and mostly studied in immunocompromised states like, neutropenic 
patients (Jones et al. 1998), organ transplantation (Kusne et al. 1992; 
Denning 1998) and hematological malignancies (Denning 1998; Pagano et 
al. 2001). The evaluation of this problem in patients of bronchogenic 
carcinoma grossly remained untouched. 
The patients of bronchogenic carcinoma are debilitated and 
immunocompromised, hence the chances of secondary fungal and bacterial 
infections are increased in such cases. While studying these patients we 
noticed high occurrence of multidrug-resistant- Enterobacteriaceae, during 
bacterial culture of BAL, which were resistant to almost all of the 
antibiotics tested, including, third and fourth generation cephalosporins, 
and cephamycins like cefoxitin. In recent years, non-TEM and non-SHV 
class A extended spectrum (3-lactamases (ESBLs) have been increasingly 
reported, especially the CTX-M types (Vahaboglu et al. 1995; Shannon et 
al. 1998a; Shannon et al. 1998b; Poirel et al. 1999; Tzouvelekis et al. 
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2000; Poirel et al. 2000; Walther-Rasmussen & Hoiby 2004; Bonnet 2004; 
Livermore & Hawkey 2005; Ensor et al. 2006). The first CTX-M class of 
extended spectrum ^-lactamase (ESBL) was described in Germany 
(Bauemfeind et al. 1996b), and since then more than 50 variants have been 
reported (http;//www.lahey.org/studies/inc_webt.asp). Whilst CTX-M-2 
was the first commonly encountered CTX-M ESBL type in South America 
(Radice et al. 2002; Quinteros et al. 2003), TEM- and SHV-types of ESBL 
were more commonly reported elsewhere in the world (M'Zali et al. 1997; 
Shannon et al. 1998a; Gaillot et al. 1998; Gniadkowski et al. 1998b; 
Dumarche et al. 2002). The limited distribution of CTX-M ESBLs is no 
longer observed. In the last 5 years CTX-M ESBLs have very rapidly 
disseminated and are now frequently reported from countries all over 
Europe (Bou et al. 2002; Markovska et al. 2004; Woodford et al. 2004; 
Monday et al. 2004a; Livermore & Hawkey 2005; Kim et al. 2005; Oliver 
et al 2005) and much of Asia (Pai et al. 2001; Nagano et al. 2003; 
Munday et al. 2004b). Dominant CTX-M genotypes vary geographically 
although some reports indicate diversity of CTX-M types within a single 
country (Chanawong et al. 2002; Dutour et al. 2002; Munday et al. 2004b; 
Kim et al. 2005; Shibata et al. 2006). 
In India a 10-centred survey was conducted to determine resistance 
to beta-lactams and ESBL phenotype was reported in over 60% 
Escherichia coli (Mathai et al. 2002). Other Indian surveys have reported 
the presence of ESBLs in clinical isolates based on phenotypic test results 
(Abigail et al. 1995; Khurana et al. 2002; Tankhiwale et al. 2004; Gupta & 
Datta 2006) although molecular characterization was not performed in any 
of these studies to identify ESBL genotype present. In a more recent study, 
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two collections of K. pneumoniae (prior to and after the introduction of 
cefepime in India) were retrospectively investigated for presence of ESBL 
(Grover et al. 2006). Isolates were screened for presence of blajEu and 
bla'^Yiw but not blacjx-u, which is unfortunate since the very first report of 
CTX-M-15 came from 6 unrelated Enterobacteriaceae in New Delhi, in 
May 2000 (Karim et al. 2001), and recent papers from other countries have 
reported on the sudden change in ESBL epidemiology due to the rapid rise 
of CTX-M-producing Enterobacteriaceae (Livermore & Hawkey 2005). 
Very recently, in collaboration with British researchers, we reported a 
systematic survey (Ensor et al. 2006b) determining CTX-M genotypes 
present in clinical isolates, including few isolates of Escherichia coli and 
Klebsiella pneumoniae obtained from BAL of bronchogenic carcinoma 
patients- a part of the collections of this Doctoral work, and determined the 
genetic environment of blacTx-u-M in those isolates. It is interesting to note 
that CTX-M-15 is the only existing type, reported to date, in India 
however, diversity of CTX-M types within a single country have been 
reported (Chanawong et al. 2002; Dutour et al. 2002; Munday et al. 2004b; 
Kim et al. 2005; Shibata et al. 2006). Therefore, we found worth looking 
occurrence of CTX-M genogroups, specific CTX-M types, and their 
genetic environment; and to compare any relatedness or diversity in CTX-
M carrying isolates obtained from bronchogenic carcinoma patients with 
those of isolates obtained from other clinical sources. 
Bacteria over expressing AmpC ^-lactamases are of major clinical 
concern because they confer resistance to a wide variety of p-lactams, (3-
lactam- (3-lactamase inhibitor combinations, and aztreonam, but are 
susceptible to fourth generation cephalosporins (4GC) and carbapenems 
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(Girlich et al. 2000; Thomson & Moland 2000; Perez-Perez & Hanson 
2002). However isolates simultaneously harboring extended-spectrum (3-
lactamases show resistance to 4GC as well; and loss of outer membrane 
porins together with plasmidic AmpC result in carbapenem resistance and 
thus may create serious therapeutic problems. Emergence of plasmid-
mediated AmpC P-lactamase is well recognized (Gazouli et al. 1996; 
Philippon et al 2002; Alvarez et al. 2004). Phenotypically they resemble 
chromosomal class C (3-lactamases in that they confer resistance to 
cephalosporins, including cefoxitin, and are not inhibited by clavulanate 
(Bush et al. 1995). AmpC ^-lactamase genes are native to the chromosome 
of many Gram-negative bacilli but are missing from Klebsiella spp. and are 
poorly expressed in E. coli. Mobilization from the genome of species 
typically carrying inducible/de-repressed bla^^pc such as Citrobacter spp. 
and Morganella morganii by plasmids into K. pneumoniae and E. coli in 
which they confer novel resistance pattern has been known since 1989. 
Recently, their occurrence has been noted in many countries including the 
USA (Alvarez et al. 2004; Coudron et al. 2003; Moland et al. 2002; 
Philippon et al. 2002). 
Plasmid-mediated AmpC-type enzymes are assumed to be as less 
common than extended-spectrum P-Iactamases as a mechanism for 
resistance to ceftazidime and other oxyimino- |3-lactams in K. pneumoniae 
and E.coli but such enzymes are important to recognize since they impart a 
broader spectrum of resistance on the producing bacterium (Moland et al. 
2002; Philippon e? a/. 2002). 
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Despite increased interest in the recognition and surveillance of 
ESBLs, the worldwide distribution and prevalence of AmpC-mediated 
resistance is fragmentary. This is partly due to the limited number of 
surveillance studies seeking clinical strains producing AmpC ^-lactamases 
and also due to the difficulty that laboratories have in accurately detecting 
these resistance mechanism(s) (Hanson 2003) particularly as there are no 
published CLSI (formerly NCCLS) criteria (Thomson 2001). There have 
been increasing reports on cefoxitin resistance and AmpC production 
(phenotypic detection) from India but the molecular reports are lacking. 
We could find only few published molecular reports (BIL-1-like and CMY-
4) in small Indian bacterial population performed by British and Swedish 
researchers (M'Zali et al. 1997; Cao et al. 2000). 
Keeping in view the above facts, especially the paucity of literature, 
globally, defining the association of secondary aspergillosis in 
bronchogenic carcinoma, and fragmentary Indian literature describing the 
existing CTX-M and AmpC-types, in general, and in bacterial isolates in 
particular obtained from BAL of bronchogenic carcinoma padents, the 
present study was proposed with the following broad objectives: 
AIMS AND OBJECTIVES 
• To find out the prevalence of aspergillosis in patients of 
bronchogenic carcinoma. 
• To study and categorize the clinical types of aspergillosis associated 
with bronchogenic carcinoma. 
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To evaluate the role of BAL-culture, BAL-PCR, and serological 
methods like ELISA, Dot Blot assay, and Double immunodiffusion 
for making early diagnosis of secondary aspergillosis. 
To determine the occurrence of blacTX-u and blaampc, arid the genetic 
environment of CTX-M P-lactamases in E. coli and K. pneumoniae 
isolates obtained from BAL of bronchogenic carcinoma patients. 
To compare any relatedness or diversity in CTX-M-carrying isolates 
obtained from bronchogenic carcinoma patients with those of 
isolates obtained from other clinical sources. 
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CHAPTER 2 
2. REVIEW OF LITERATURE 
2.1. Bronchogenic Carcinoma 
Carcinoma of the lung has become increasingly frequent during the last 
few decades (Anonymous a 1989). This may be attributed due to changed 
personal and environmental conditions and advancement in diagnostic 
technologies. The relationship of cigarette smoking with lung cancer is 
well documented and has been thoroughly demonstrated, since long back, 
by the meticulous histological observations of Auerbach et al. (1957) and 
confirmed by others (Peters et al. 1993). This increase in lung cancer is 
seen in male and female patients and applied to all the major microscopic 
types (Richardson & Johnson 1993), however a male: female ratio of 1.5:1 
has been reported and more than 90% of the patients of bronchogenic 
carcinoma are in the 4"^  and 5'^  decades of life at the time of diagnosis 
(Jubelirer & Wilson 1991). 
2.1.1, Classification of bronchogenic carcinoma 
Several microscopic classifications of carcinoma exist. The one most 
widely used is the scheme originally proposed by Kreyberg (1961) and 
includes following categories: 
1. Squamous cell carcinoma 
a. Well differentiated 
b. Moderately differentiated 
c. Poorly differentiated 
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2. Adenocarcinoma 
a. Not otherwise specified (NOS) 
b. Bronchoalveolar 
3. Adenosquamous carcinoma 
4. Small cell carcinoma 
a. Classic 
b. Mixed small cell/large cell 
c. Combined 
5. Undifferentiated large cell carcinoma 
6. Giant cell carcinoma 
2.1.1.1. Squamous cell carcinoma 
The majority of squamous cell carcinomas occur in males. Most cases are 
centered in segmental bronchi and therefore present as hilar or perihilar 
masses in chest X-ray film (Anonymous a 1989). They are larger than other 
types at the time of diagnosis (Bateson 1964) and signs of bronchial 
obstruction, such as obstructive pneumonitis or atelectasis, are found in 
approximately half of the patients (Anonymous a 1989). The tumors have a 
special tendency to undergo central necrosis with cavitation (Strang & 
Simpson 1953). Microscopically, the diagnosis of malignancy is based on 
cell atypia and invasiveness, and the diagnosis of squamous cell type on the 
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detection of keratin and/or intracellular bridges (Anonymous a 1989) (see 
Fig. I A). 
Squamous cell carcinomas are graded into well, moderately, and 
poorly differentiated on the basis of the amount of keratinization present. 
The bronchial mucosa adjacent to the tumor usually shows squamous 
metaplasia and sometimes carcinoma in situ, occasionally extending 
several centimeters from the main mass (Dosaka-Akita et al. 1994). 
2.1.1.2. Adenocarcinoma 
Adenocarcinomas comprise approximately half of all lung carcinomas in 
females and a lower percentage of those in males (Bennet et al. 1969). In 
absolute numbers, however, they are more common in males than in 
females. There is epidemiologic evidence suggesting that adenocarcinoma 
is becoming progressively more prevalent as compared with other 
microscopic types (Anonymous a 1989). Grossly, adenocarcinomas usually 
present as poorly circumscribed gray-yellow lesions. They may be single or 
multiple (McElvaney et al. 1989). If they secrete abundant mucin, they 
have a mucoid, glairy appearance. Microscopically, adenocarcinomas 
exhibit a wide range of differentiation, one extreme blending with 
bronchoalveolar carcinoma and the other with undifferentiated large cell 
carcinoma (Linnoila 1990) (Fig. I B). The two morphologic signs of 
glandular differentiation, often found together, are formation of tubules or 
papillae and secretion of mucin. Depending on the relative prominence of 
these features, adenocarcinomas have been sub-divided into acinar, 
papillary, and solid adenocarcinomas with mucin production. 
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2.1.1.3. Adenosquamous carcinoma 
The term adenosquamous carcinoma is used for lung tumors in which 
unquestionable evidence of squamous and glandular differentiation is 
found in the same neoplasm in a roughly equivalent amount (Fitzgibbons & 
Kern 1985). Most of the cases are located peripherally and often are 
associated with a scar suggesting a close relationship with adenocarcinoma 
than with squamous cell carcinoma. 
2.1.1.4. Small cell carcinoma 
Small cell carcinoma comprises 10% to 20% of all lung cancers. Most of 
the patients are males, their median age is 60 years, and 85%) or more are 
smokers (Diggs et al. 1992). Grossly, the tumor is white-tan, soft, friable, 
and extensively necrotic. When centered in a large bronchus, it may 
involve it in circumferential fashion and/or spread widely beneath the 
normal mucosa. The classic form of small cell carcinoma is characterized 
by small round or oval cells resembling lymphocytes (Warren et al. 1990). 
The nuclei are finely granular and very hyperchromatic, nucleoli are 
inconspicuous, mitoses are frequent, and the cytoplasm is so scanty as to be 
unrecognizable in routine preparations (Fig. I C). 
2.1.1.5. Undifferentiated large cell carcinoma 
Undifferentiated large cell carcinomas are pleomorphic epithelial tumors 
without definite evidence of either squamous or glandular differentiation 
(Ishida et al. 1990). The tumor cells are large (Fig. I D), and probably do 
not represent a specific entity but are rather poorly differentiated variants 
of squamous cell carcinoma, adenocarcinoma, and perhaps even small cell 
carcinoma (Yesner 1985). 
Description of Fig. I A-D 
Fig. I. Photomicrographs of the histopathological sections from patients of 
bronchogenic carcinoma showing squamous cell type (A), adenocarcinoma 
(B), small cell type (C) and large cell type (D). 
Fig. I A D 
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2.2. Mycological Aspects (Overview) 
Fungi and yeasts constitute eumycetes, and are eukaryotes with a 
differentiated nucleus and rigid chitinous cell walls. They were formerly 
regarded as plants without chlorophyll or differentiation of root, stem and 
leave, but now are not regarded as plants or animals, and grouped with 
protozoa, slime moulds and most algae as " Higher Protista ". The word 
fungus is derived from the Latin ''fungus", which came into use in the 
fifteenth century. The Latin was derived from the Greek ""spongers" or 
sponge. The term "mycosis" was derived from the Greek word ''mykes" for 
mushroom (Drouhet 1998) 
At present, more than 1,00,000 species of various fungi have been 
recognized, out of which over 300 are pathogenic and thus cause disease in 
humans or animals; and of which " Aspergillus " is well known for their 
role as opportunistic pathogens (Richardson, 1998). Aspergilli are 
extremely resilient and ubiquitous in the environment. Among the known 
species of Aspergilli, A. fumigatus is more frequently involved in human 
diseases (Kurup et al. 2004). Although the pathophysiology of the various 
pulmonary manifestations related to Aspergillus infection remains complex 
and poorly understood, the severity of these conditions seems to depend 
mainly on the quantity and virulence of the inhaled Aspergillus and on the 
status of the host defence (Tillie-Leblond & Tonnel 2005). Aspergillus may 
harm directly by tissue invasion, by producing mycotoxins, or by acting as 
allergens. Their role as opportunistic pathogen is increasing significantly 
with the greater use of immunosuppresive therapy (Denning 1998). 
2.2.1. Historical background of the Aspergillus 
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Micheli (1729) described the genus Aspergillus and derived its name from 
the Latin word ''aspergilluni". He distinguished conidiophores and heads, 
and he noticed that the heads were rough and covered with long chains of 
spores; hence he gave it the name Aspergillus, meaning, "rough head". He 
derived its name from the Latin word '"aspergillunC" (to sprinkle) which 
referred to the perforated globe used to sprinkle holy water during catholic 
religious ceremonies "aspergus te" (Drouhet 1998). Link delineated several 
distinct species in 1809 such as A. candidus, A. flavus and A. glaucus, 
which he had isolated from decaying vegetables (Drouhet 1998). The first 
report on infection with Aspergillus spp. were those of Mayer and Emmert 
in 1815, who described an infection in the lung of a European jay 
(Garrulus glandarius), but principally those of the German Fresenius, in 
1850, who observed air sac infection in a captive bird, the Great bustard 
{Otis tarda) at the Frankfurt zoo. Fresenius named the isolate Aspergillus 
fumigatus and first used the term aspergillosis (Drouhet 1998). The first 
reference to human invasion by Aspergillus is attributed to Hughes Bennett 
in 1842 (Naji 1959). Subsequently, Virchow (1856) described four cases of 
pulmonary Aspergillus infection in patients dying of other conditions and 
coined the term "mycoses" for fungous infections (Naji 1959). 
Chantemesse, Widal, and Dieulafoy, in 1890, described the disease 
in pigeon crammers and gave it the name ""maladie des gaveurs", as the 
pigeon crammers of Paris took mouthful of grains and water and spat it 
into the mouth of a pigeon (Chantemesse et ai 1890; Hinson et al. 1952). 
The growing importance of aspergillosis was recognized only after the 
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remarkable description, by Monod (surgeon), Pesle (physician), and 
Segretain (mycologist), of the development of bronchopulmonary 
aspergilloma (fungus ball) in the pulmonary cavities of tuberculous 
patients who had been treated with powerful anti-tuberculous medications 
{Monod etal. 1954). 
2.2.2. Description oi Aspergillus spp. and their habitat 
Micheli (1729) first described the genus Aspergillus that belongs to the 
family Aspergillacae, order Aspergillules, and class Ascomycetes. 
Although, the Aspergillus is included in Ascomycetes, perithecia and 
ascospores have never been found with certainty in this fungus, and for that 
reason some authors have classified it in the group Fungi Imperfect!i. 
Variations in names of class, order, and family are used by different 
workers (Naji 1959). Aspergilli are inhabitant of soil, especially when it 
contains an appreciable amount of decaying organic material (Richardson 
1998). These fungi are frequently isolated from cereal products, unmilled 
grains, hay and other stock feeds, the spores been mingled with grains, 
seed and flour. They play a big part in the decomposition process and grow 
successfully over a temperature range from below 20 °C up to 50 °C, and 
grow well at over 40 °C, when most other fungi are inactive, paving the 
way for bacterial action (Richardson 1998). They are also able to withstand 
a temperature of -12°C, and are notorious laboratory contaminant. 
The spores, which are very resistant, can be found in dust, dry 
leaves, chaff, tea dust and imperfectly dried grain, especially, rye. They are 
common soil inhabitant and are found in large number in dust and 
decomposing matters. Their spores are often found in the outside air 
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(Goodley et al. 1994; Anderson et al. 1996). 
2.2.3. Genus Aspergillus 
The genus belongs to moulds (simple morphological classification) or to 
the Ascomycetes (systemic classification) (Richardson 1998). The genus 
has septate hyphae and reproduces by asexual conidia produced in chains 
from elongated cells called sterigmata (phialedes), which are themselves 
bom on the expanded end or vesicles of a specialized aerial hyphae, the 
conidiophores (Fig. II A). These conidiophores arise from the specialized 
cells called foot cells. Each foot cell usually bear a single conidiophore. In 
mycelium phase, Aspergillus exists in the form of 7-10 )im-long, septate, 
uniform hyphae with dichotomous branching at an angle of 45° (Fig. IIB). 
The spores measure between 2 and 4 |im in diameter, and are 
thermotolerant. The morphology of these asexual sporing structures is used 
in species identification. 
The genus Aspergillus consist of hundreds of species, many of 
which can exploit a variety of substrates and both grow and reproduce 
within a wide range of environmental conditions. Raper & Thorn (1965) 
classified Aspergillus as a large genus containing 18 groups, 132 species 
and 18 varieties; the groups classified by Raper & Thom (1965) were: 
Aspergillus clavatus, A. glaucus, A. ornatus, A. cervinus, A. restrictus, A. 
fumigatus, A. ochraceus, A. niger, A. candidus, A. flavus, A. wentii, A. 
cr emeus, A. spars us, A. versicolor, A. nidulans, A. ustus, A. flavipes zndA. 
terreus. Since that time numerous new species and varieties have been 
described and, to date, over 185 species are recognized to which humans 
are constantly exposed (Richardson 1998). 
Description of Fig. II A & B 
Fig. II A. Photomicrograph demonstrates conidiophores with the 
characteristic head appearance and minute spores of Aspergillus. 
Fig. II B. Photomicrograph shows septate hyphae branching at an angle of 
approximately 45°. 
Fis. n A & B 
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2.2 A. Species of The Aspergilli 
Of the hundreds of recognized species of AspergiUi, only a small number 
of species have been verified to cause infection in humans, to name few of 
them as Aspergillus fumigatus, A. flavus, A. niger, A. terreus, A. glaucus, 
A. nidulans, A. ustus, A. flavipes, A. versicolor, A. candidus, A. wentii, A. 
tamarii, and only few of them are consistently and regularly encountered 
as a cause of disease; most important being A. fumigatus whereas other 
species have been implicated on occasions, like, A. flavus and A. niger 
(Richardson 1998). Collectively, over 95% of all infections of aspergillosis 
are caused by these 3 species, namely, A. fumigatus, A. flavus and A. niger 
(Richardson 1998). Of the documented species of Aspergilli, A. fumigatus 
causes the majority of cases of both invasive and non-invasive 
aspergillosis. Indeed, the allergic forms of the disease appear to be almost 
exclusively caused by this organism (Kwon-chung & Bennet 1992). 
Some of the important characteristics of the common pathogenic 
species of Aspergillus are shown in Table I, and brief descriptions of the 
colony characters and the microscopic morphology of few of the medically 
important, and frequently encountered, species of the Aspergilli are 
provided below. 
2.2.4.1. Aspergillus fumigatus 
Colony characters: On Sabouraud's dextrose agar (SDA) the colonies are 
, velvety or powdery at first and subsequently turns to smoky green (Fig. Ill 
A). Reverse of the culture is white to tan. On Czapek Dox agar (CDA), the 
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colonies are granular with smooth surface and without rugosities, and are 
green in color. The reverse of the culture shows characteristic green 
pigmentation (Shahid & Malik 2002). 
Microscopic features: Aspergillus fumigatus consists of a mycelium of 
septate hyphae, of about 2-3 jim in diameter. Few cells become enlarged to 
form foot cells, which have thicker walls and give rise to long, smooth-
walled conidiophores, of about 200-300 |im in length and 2-8 |im in 
diameter. These conidiophores are non-septate and end in club shaped 
expansions called vesicles, 20-30 jim in diameter, which bear over the 
distal half a single series of many crowded bottle shaped phialedes 
(sterigmata), 5-10 fim long and 2-4 |im at their maximum diameter. The 
sterigmata are single and in turn bear a single chain of spores (see Fig. IV 
A & Table I). 
2.2.4.2. Aspergillus flavus 
Colony characters: The colonies are velvety at first, then become yellow 
to green or brown on SDA (Fig. Ill B). The reverse is golden to red brown 
in color. On Czapek Dox agar (CDA), the colonies are velvety and 
yellowish-green in color. The reverse of the culture produces characteristic 
yellow pigmentation (Shahid & Malik 2002). 
Microscopic features: The hyphae are septate. The conidiophores are of 
variable length, rough pitted and spiny. The sterigmata are single and 
double, covers entire vesicle and points out in all direction (Fig. IV B & 
Table I), and that is why the term "Rough head" is defined for this species 
oi Aspergillus. 
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2.2.4.3. Aspergillus niger 
Colony characters: On SDA, the colonies are granular, initially white. 
and then turn dark brown to black (Fig. Ill C). There is no characteristic 
change on the reverse of the culture. On Czapek Dox agar (CDA), the 
colonies are granular and black in color. No characteristic change on the 
reverse is present (Shahid & Malik 2002). 
Microscopic features: The hyphae are septate. The conidiophores are of 
variable length. Sterigmata are double, covers entire vesicle and form 
radiate head (Fig. IV C & Table I). 
2.2.4.4. Aspergillus terreus 
Colony characters: On SDA, the colonies are velvety, and cinnamon 
brown (Fig. Ill D). Reverse of the culture is white to brown. 
Microscopic features: The hyphae are septate. The conidiophores are of 
variable length. Sterigmata are double, and compactly columnar in nature 
(Fig. IV D & Table I). 
18 
Description of Fig. Ill A-D 
Fig. Ill A. Photograph showing culture growth of A. fumigatus 
Fig. Ill B. Photograph showing culture growth of A. flavus 
Fig. Ill C. Photograph showing culture growth of A. niger 
Fig. Ill D. Photograph showing culture growth of A. terreus 
JIG. m A - D 
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TABLE I: Characteristics of Some Common Pathogenic Aspergillus 
Species 
SPECIES 
A. fumigatus 
A. flavus 
A. niger 
A. terreus 
A. glaucus 
A. nidulans 
PHIALIDES 
Uniseriate 
Uniseriate or 
biseriate 
Biseriate 
Biseriate 
Uniseriate 
Biseriate 
COLOUR OF 
CONIDA 
Grey, green or 
blue green 
Yellow to 
green 
Black 
Orange to 
brown 
Green to 
yellow 
Dark green 
CONIDIOPHORE 
Long, smooth 
Variable, pitted 
Variable length 
Short, smooth 
Variable, smooth 
Variable length 
PATTERN OF 
CONIDIA 
Covers upper 
IIV^ of the 
vesicle and in 
direction parallel 
to conidiophore 
Covers entire 
vesicle and points 
in all directions 
Covers entire 
vesicle and 
arranged radially 
Conidia in long 
columns from 
upper part of 
vesicle 
Conidia are 
globose to 
subglobose, fairly 
roughened to 
echinulate, and 
covers upper 
portion of vesicle 
Conidia are 
globose and 
rough, covers 
upper portion of 
vesicle 
Description of Fig. IV A-D 
Fig. IV A. Microphotograph showing fungal head of A. fumigatus 
Fig. IV B. Microphotograph showing fungal head of A. flavus 
Fig. IV C. Microphotograph showing fungal head of ^. niger 
Fig. IV D. Microphotograph showing fungal head of A. terreus 
ncrv AD 
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All the Aspergillus species are common saprophytes growing in the 
soil and on decaying plant materials. The spores are ubiquitous in 
environment. The human being are constantly exposed to these spores and 
particularly people working with the decaying vegetations, like moldy hay 
in agriculture, are maximally exposed (Richardson 1998). 
2.2.5. Disease-spectrum oi Aspergillus 
Aspergillus is a well-known opportunistic pathogen and can cause 
infections of variety of body organs/systems including lungs, paranasal 
sinuses, eyes, ears, skin, heart, central nervous system, and gastrointestinal 
system. Of these, pulmonary system is the most frequently involved system 
by Aspergillus spp. 
2.2.6. Classification of pulmonary aspergillosis 
Pulmonary aspergillosis can be subdivided into five categories: 
("o^  saprophytic aspergillosis (aspergilloma) 
(b) hypersensitivity reaction (allergic bronchopulmonary aspergillosis) 
(c) semi-invasive (chronic necrotizing) aspergillosis 
(d) airway-invasive aspergillosis (acute tracheobronchitis, bronchiolitis, 
bronchopneumonia, obstructing bronchopulmonary aspergillosis) and 
(e) angioinvasive aspergillosis. 
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2.2.6.1. AspergiJloma (Saprophytic Aspergillosis) 
Saprophytic aspergillosis (aspergilloma) is characterized by Aspergillus 
infection without tissue invasion. It typically leads to conglomeration of 
intertwined fungal hyphae admixed with mucus and cellular debris within a 
pre-existent pulmonary cavity or ectatic bronchus (Gefter 1992; Aquino et 
al 1994). 
The most common underlying causes are tuberculosis and 
sarcoidosis. Other conditions that occasionally may be associated with 
aspergilloma include bronchogenic cyst, pulmonary sequestration, and 
pneumatoceles secondary to Pneumocystis carinii pneumonia in patients 
with acquired immunodeficiency syndrome (AIDS) (Gefter 1992; Aquino 
et al. 1994; Logan & Miiller 1996). Although aspergillomas are usually 
single, they may also be present bilaterally. 
At radiography, mycetomas are characterized by the presence of a 
solid, round or oval mass with soft-tissue opacity within a lung cavity 
(Gefter 1992) (Fig. V A). Typically, the mass is separated from the wall of 
the cavity by airspace of variable size and shape, resulting in the "air 
crescent" sign (Aquino et al. 1994; Logan & Miiller 1996). 
Aspergillomas are often associated with thickening of the cavity wall 
and adjacent pleura (Franquet et al. 2000a; Sanson et al. 2000). In such 
cases, pleural thickening may be the earliest radiographic sign before any 
visible changes are seen within the cavity. Approximately 10% of 
mycetomas resolve spontaneously. Reversibility of the pleural thickening 
corresponding to the resolution of intracavitary fungal material has been 
demonstrated at follow-up radiography. This reversibility suggests that the 
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thickening of the cavity wall and pleura is due to a hypersensitivity reaction 
(Franquet et al. 2000a). 
2.2.6.2. Allergic Bronchopulmonary Aspergillosis (Hypersensitivity 
Reaction) 
Allergic bronchopulmonary aspergillosis is seen most commonly in 
patients with long-standing bronchial asthma (McAdams et al. 1995). At 
pathologic analysis, this form of aspergillosis is characterized by the 
presence of plugs of inspissated mucus containing Aspergillus organisms 
and eosinophils. This results in bronchial dilatation typically involving the 
segmental and subsegmental bronchi. 
Allergic bronchopulmonary aspergillosis is caused by a complex 
hypersensitivity reaction to Aspergillus organisms. The fungi proliferate in 
the airway lumen, resulting in the production of a constant supply of 
antigen. A type I hypersensitivity reaction with immunoglobin E and 
immunoglobin G release occurs. Immune complexes and inflammatory 
cells are then deposited in the bronchial mucosa, producing necrosis and 
eosinophilic infiltrates (type III reaction) with bronchial wall damage and 
bronchiectasis (McAdams et al. 1995). Excessive mucus production and 
abnormal ciliary function lead to mucoid impaction. Many patients cough 
up thick mucous plugs in which hyphal fragments can be demonstrated at 
culture or histologic analysis. Radiologic manifestations include 
homogeneous, tubular, fmger-in-glove areas of increased opacity in a 
bronchial distribution, usually predominantly or exclusively involving the 
upper lobes (Binder et al. 1982; Glimp & Bayer 1983; Thompson et al. 
1995). These shadows are related to plugging of airways by hyphal masses 
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with distal mucoid impaction (Fig. V B) and can migrate from one region 
to another. Occasionally, isolated lobar or segmental atelectasis may occur. 
2.2.6.3. Semi-invasive (Chronic Necrotizing) Aspergillosis 
Semi-invasive aspergillosis, also known as chronic necrotizing 
aspergillosis, is characterized at histologic analysis by the presence of 
tissue necrosis and granulomatous inflammation similar to that seen in 
reactivation tuberculosis. Factors associated with the development of this 
form of aspergillosis include chronic debilitating illness, diabetes mellitus, 
malnutrition, alcoholism, advanced age, prolonged corticosteroid therapy, 
and chronic obstructive pulmonaiy disease (Binder et al. 1982; Franquet et 
al. 2000b). 
Radiologic manifestations of semi-invasive aspergillosis include 
unilateral or bilateral segmental areas of consolidation with or without 
cavitation or adjacent pleural thickening, and multiple nodular areas of 
increased opacity (Gefter et al. 1981; Franquet et al. 2000b). 
Aspergillus necrotizing bronchitis may be seen at CT as an 
endobronchial mass, obstructive pneumonitis or collapse, or a hilar mass 
(Fig. V C). Only a few reports have described CT findings in Aspergillus 
necrotizing bronchitis involving the central airways; reported abnormalities 
include circumferential bronchial wall thickening and bronchial 
obstruction. In clinical practice, the diagnosis of Aspergillus necrotizing 
bronchitis is usually based on the presence of abnormal findings at chest 
radiography and bronchoscopic biopsy, which are consistent with tissue 
invasion (Gefter et al. 1981; Brown et al. 1994). 
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Description of Fig. V A-D 
Fig. V A. CT scan showing aspergilloma within a pulmonary cystic cavity. 
Fig. V B. CT scan demonstrating mucous plugs composed of mucin in a 
case of ABPA. 
Fig. V C. CT scan of a case of semi-invasive aspergillosis demonstrating 
bilateral rounded areas of consolidation with associated cavitation in both 
upper lobes. 
Fig. V D. CT scan of a case of angioinvasive aspergillosis which reveals a 
2-cm nodular lesion with a wide halo of ground-glass attenuation 
representing adjacent hemorrhage. 
Fig. \^  A -1) 
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2.2.6.4. Airway-invasive Aspergillosis 
Airway-invasive aspergillosis is characterized at iiistologic analysis by the 
presence of Aspergillus organisms deep to the airway basement membrane 
(Logan et al. 1994). It occurs most commonly in immunocompromised 
neutropenic patients and in patients with AIDS (Won et al. 1998; Brown et 
al. 1998). Clinical manifestations include acute tracheobronchitis, 
bronchiolitis, and bronchopneumonia. Patients with acute tracheobronchitis 
usually have normal radiologic findings. Occasionally, tracheal or 
bronchial wall thickening may be seen. Bronchiolitis is characterized at 
high-resolution CT by the presence of centrilobular nodules and branching 
linear or nodular areas of increased attenuation having a "tree-in-bud" 
appearance. The centrilobular nodules have a patchy distribution in the 
lung. /i577erg///wj'bronchopneumonia results in predominantly peribronchial 
areas of consolidation (Logan et al. 1994). Rarely, the consolidation may 
have a lobar distribution. 
2.2.6.5. Angioinvasive Aspergillosis 
Angioinvasive aspergillosis occurs almost exclusively in 
immunocompromised patients with severe neutropenia (Denning 1998). 
For many reasons, however, there has been a substantial increase in the 
number of patients at risk for developing invasive aspergillosis. These 
reasons include the development of new intensive chemotherapy regimens 
for solid tumors, difficult-to-treat lymphoma, myeloma, and resistant 
leukemia as well as an increase in the number of solid organ 
transplantations and increased use of immunosuppressive regimens for 
other autoimmune diseases. Despite having a normal neutrophil count, 
affected patients have functional neutropenia because the function of the 
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neutrophils is inhibited by the use of high-dose steroids. Angioinvasive 
aspergillosis is characterized at histologic analysis by the invasion and 
occlusion of small to medium-sized pulmonary arteries by fungal hyphae 
(Denning 1998). The CT scan of a patient diagnosed as a case of 
angioinvasive aspergillosis is shown in Fig. V D. 
2.2.7. Antigenic characters 
Fungal extracts are very complex mixtures of many different components. 
Consequently, high resolving biochemical as well as immunological 
methods are required for studying the antigenic/ allergenic properties and 
composition on a molecular level. The antigenic complexity of A. 
fumigatus has been reported in literature (Kurup et al 2000; Kurup 2003; 
Kurup 2005). Biochemical and immunochemical data obtained by 
Wallenbeck et al. (1984) indicated that considerable variations exists 
between the various isolates of Aspergillus fumigatus which were grown 
and harvested under identical conditions. They demonstrated 44 antigenic 
components in Crossed immuno-electrophoresis (CIE) oiA. fumigatus and 
18 different allergens in Crossed radio-immunoelectrophoresis (CRJE) 
which showed 2 major, 10 intermediate and 6 minor allergens. Kim & 
Chopra (1978) identified 52 precipitating antigenic components in a 
special fused rocket Immunoelectrophoresis system using A. fumigatus 
mycelial extracts grown in a synthetic asparagine glycerol medium. Heam 
et al. (1980) used A. fumigatus mycelium extract from two different strains 
for analysis of antigenic composition and identified 40 antigenic 
components against homologous rabbit antiserum and 12 antigens against 
human positive patients' sera. Kauffman and de Vries (1980), by using 
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CIE against pooled rabbit antiserum, identified 22 different precipitates, 
and furtiier, by using patients' sera, instead of rabbit antiserum, antibodies 
against the same number of antigens were identified. 
Despite complaints of batch variations, authors have achieved high 
rate of success in the detection of antibodies in the serum of patients with 
preparation from the cell wall (Kim & Chopra 1978; Kim et al. 1978; 
Shahid et al. 2001; Malik et al. 2003, Singh et al. 2003; Kurup 2005; 
Shahid et al. 2007a) or culture filtrates (Kim & Chopra 1978; Singh et al. 
2003; Kurup 2005) of Aspergillus fumigatus. Also there seem to be many 
antigenic components common to different Aspergillus species (Kurup & 
Apter 1998; Kurup & Crameri 2000; Shahid et al. 2001). These 
observations gave a strong indication that the humoral immune system is 
exposed to a multiplicity of individual antigenic components of the 
infecting fungus, so that most types of antigenic preparations made in vitro 
are likely to contain at least one component that will react with serum from 
patients. 
2.2.8. Antigens of Aspergillus 
The crude extracts from Aspergillus have been used for evaluating patients 
with possible pulmonary aspergillosis. These antigens have inherent 
drawbacks because of the lack of reproducibility and consistency and 
frequent cross reactivity with other antigens (Kurup & Apter 1998; Kurup 
& Crameri 2000; Kurup 2005). Culture filtrate, cell sap, and cell wall 
antigens have been studied in the past for developing reliable reagents for 
immunodiagnosis of allergic diseases (Singh et al. 2003). These extracts 
show considerable variation in their chemical composition, number of 
components, and in their reactivity with antibodies. These variations are 
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primarily due to growth conditions, the nutrient/media used to grow them, 
and the genetic differences among the strains used for antigen preparation. 
The presence of various toxins, proteolytic enzymes, and non-antigenic 
materials also contribute significantly to the quality of the antigens (Kurup 
2005). 
Extracts from A. fumigatus have been further characterized as to 
their chemical nature and attempts have been made to purify them by 
conventional methods. Chemically these antigens can be classified broadly 
into proteins, polysaccharides, and glycoproteins. On interaction with the 
immune system these antigens produce antibodies and factors mediating 
the disease. Based on the physico-chemical properties, these allergens have 
been classified as enzymes, such as proteases and enolases, transport 
proteins such as lipocalins, and regulatory proteins such as heat shock 
proteins. Other allergens possess diverse chemical nature and unknown 
biochemical functions and activities. 
2.2.8.1. Crude antigens 
All the earlier investigations depended on crude mycelial and spore extracts 
from stationary or aerated cultures of Aspergillus grown in synthetic or 
complex media. Antigenic components in these preparations vary 
considerably. Similarly, metabolic antigens secreted outside the cells into 
the broth have also bee isolated and used in various in vitro and in vivo 
assays for the diagnosis of Aspergillus allergies. 
2.2.8.2. Native antigens purified from crude Aspergillus extracts 
As the crude antigens contain a mixture of proteins, glycoproteins, 
carbohydrates, toxins, and inert components, attempts have been made to 
purify the active components. However, most of these conventional 
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methods involve harsh physical and chemical treatments, which have 
adverse effect on the antigenicity. There has been considerable research 
into purifying relevant antigens from Aspergillus. These include 
fractionation methods such as size exclusion chromatography, affinity 
chromatography using monoclonal antibodies, partition chromatography, 
electrophoresis, isoelectric focusing, and chromatofocusing (Heam et al. 
1980; Longbottom 1986; Singh et al 2003; Kurup 2003). None of these 
methods have yielded relevant allergens useful in the diagnosis of 
Aspergillus-m(\wzQd allergies. 
2.2.8.2.1. Polysaccharide antigens 
Polysaccharide fractions isolated from cell wall or cytoplasm of 
Aspergillus spp. were reported to demonstrate cross reactivity with other 
fungal antigens (Azuma er a/. 1967; Bennett e/a/. 1985; Singh e/a/. 2003). 
This limits their scope as diagnostic allergens for AspergiUus-'mductA 
diseases. Galactomannan antigen was isolated from mycelial extract using 
sequential chromatography on anion exchange and Con A affinity columns. 
Cell wall galactomannan of A. fumigatus shows structural similarities to 
galactomannan of A. flavus, and A. niger. The demonstration of 
galactomannan in the serum of patients with invasive aspergillosis has been 
suggested to be a useful criterion for diagnosis. 
2.2.8.2.2. Protein allergens from Aspergillus 
A number of proteins, particularly proteases, have been reported from A. 
fumigatus. Among these enzymes, proteinase, elastase, ribonuclease, 
chymotrypsin, catalase, and superoxide dismutase are the predominant ones 
(Heam 1992; Singh et al. 2003). Out of 22 protein anfigens recognized 
from Aspergillus, 13 showed various enzyme activities and reacted with 
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sera of ABPA patients (Iran-van Ky et al. 1969). Schonheyder et al . 
(1988) recognized a 250 kDa enzyme, possibly a tetramer of catalase 
showing binding to IgE, from the sera of patients with cystic fibrosis (CF) 
and allergic bronchopulmonary aspergillosis (ABPA). Another 90 kDa 
catalase antigen was reported from A. fumigatus that detected specific 
antibodies in more than 90% of the sera of aspergilloma patients (Lopez-
Medranoera/. 1995). 
Using gel filtration and SDS-PAGE, a major allergenic protein 
(group 55) has been purified from water-soluble extract of A. fumigatus. 
This protein has N-glycosidically linked oligosaccharides and showed 
specific IgE binding on immunoblot with the sera of ABPA patients 
(Sarma et al. 1998). A 45-kDa-glycoprotein allergen was purified and 
characterized, which on deglycosylation lost the IgE reactivity, but retained 
the IgG binding with patient sera (Banerjee et al. 1995). A glycoprotein of 
66 kDa was purified by ammonium sulfate precipitation, and 
immunoaffinity chromatography showed IgE reactivity when tested by 
crossed-radio-immunoelectrophoresis and ELISA using sera of patients 
with ABPA and those with CF and ABPA (Little & Warner 1996). In one 
of our recent studies, immunoglobulins against 18-kDa-protein antigen 
have been reported to be consistently present in patients of bronchogenic 
carcinoma (Malik e^  a/. 2003). 
2.2.8.2.3. Recombinant antigens 
The search for reliable and pure antigens has continued in spite of the 
difficulties faced with conventional fractionation. In recent years, 
molecular biology techniques and gene cloning procedures have attracted 
attention for obtaining purified antigens. Currently, a number of allergens 
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from A. fumigatus have been cloned and the relevant proteins expressed in 
suitable expression systems (Crameri pJuFo 1997). 
Recently, phage-display libraries have been constructed to aid in the 
understanding of the immune responses of the allergens expressed 
(Crameri et al. 1994). Among the various vectors used for expression of 
fungal allergens, the pET (pET expression protocol, Novagen, Madison, 
WI) has been the favored prokaryotic expression system (Tang et al. 2000). 
In this system, expression of the target protein is induced by a T7 RNA 
polymerase in the bacterial host, Escherichia coli. The allergen expressed 
can be purified using a histidine tag at the N- or C-terminal end of the 
protein. Most of these allergens of A. fumigatus expressed and purified 
showed a similar skin-test reactivity and in vitro IgE binding with native 
allergens. Since the IgE binding of these allergens is frequently directed to 
the protein parts of the molecules, post-translational modification of the 
antigen may not impart any significant role in the IgE binding. However, 
with antigens demonstrating post-translational modifications, such as 
glycosylation, it is possible to express the clones in eukaryotic systems 
(Kurup 2005). 
2.2.9. Xnti-Aspergillus antibodies in chronic lung modalities with 
special reference to bronchogenic carcinoma 
AspergilIus-a.ntibodiQS, of IgG, IgA and IgM class have been identified in 
various lung modalities. In cystic fibrosis patients, utilizing indirect 
immunofluoroscence (IIP) technique, IgG antibody titers of >640 was 
observed in 73% of patients with proven pulmonary aspergillosis. In other 
clinical groups studied, varying percentage of IgG titers were noticed. IgM 
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antibodies in titer between 10 -160 were found in 10-65% of patients in 
different groups studied, and thus provide evidence of non-significance of 
these antibodies as a diagnostic tool (Schonheyder et al. 1988a; 
Schonheyder et al. 1988b). 
Schonheyder & Anderson (1983) reported complement-binding 
antibodies to Aspergillus fumigatus in patients with pulmonary 
aspergillosis. They observed that clq binding Aspergillus antibodies were 
found in 67% patients with definite pulmonary aspergillosis, 57%) patients 
with suspected pulmonary aspergillosis, \4% patients with precipitating 
antibodies to A. fumigatus of undetermined clinical significance, and 7% of 
healthy blood donors. Patterson et al. (1983) demonstrated IgE and IgG 
antibodies against Aspergillus by Radioimmunoassay in patients with 
allergic bronchopulmonary aspergillosis. They reported that IgE and IgG 
antibody indices are most significant in diagnosis of aspergillosis in acute 
stage or in exacerbation of aspergillosis during the recurrent exacerbation 
stage. 
IgG antibodies against A. fumigatus had been determined by using 
enzyme-linked immunosorbent assay (ELISA) (Kauffman et al. 1983). In 
patients with an aspergilloma it is not unusual to find high levels of IgG 
antibodies against A. fumigatus by ELISA while most atopic pafients with 
allergic aspergillosis possesses much lower levels of specific IgG 
(Warnock & Eldred 1975). However, detecfion of total mti-Aspergillus 
antibodies has successfully been utilized for making the diagnosis on 
aspergillosis (Shahid et al. 2001; Malik et al. 2003). 
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Serodiagnosis of aspergillosis has been extensively used, most 
commonly by precipitation methods however, problem with inter-
laboratory reproducibility, low sensitivity in immunocompromised patients 
and low specificity has encouraged the development of alternative 
approach like ELISA for diagnosis (Richardson & Wamock 1993). Again, 
as the ELISA technique is time consuming and requires sophisticated and 
costly equipments, we developed a method of Dot blot assay (DBA) as an 
alternative and cheaper substitute of ELISA for diagnosing aspergillosis 
(Shahid et al. 2003b). Application of this DBA technique in subsequent 
studies demonstrated excellent sensitivity and specificity as compared to 
that of ELISA (Malik et al. 2003). Reaginic antibodies are present in 
patients with asthma and both reaginic and precipitating antibodies are 
found in cases of bronchopulmonary aspergillosis (Rippon 1982). In 
secondary aspergillosis in patients of bronchogenic carcinoma, as we 
noticed in our earlier studies (Shahid et al 2001; Malik et al. 2003), both 
reaginic and precipitating antibodies are present. 
Many workers have studied anXi-Aspergillus antibodies by using 
Western (immuno) blotting technique. Kurup et al. (1989) demonstrated 
consistent reactivity of low molecular weight A. fumigatus antigen against 
allergic bronchopulmonary aspergillosis (ABPA) sera but not against 
uncomplicated aspergilloma or normal sera. However sera from patients 
with aspergilloma frequently reacted with high molecular weight 
component oi A. fumigatus. Kobayashi et al. (1993) identified more than 
13 IgG binding components by Immunoblot analysis in sera from patients 
with aspergilloma and allergic bronchopulmonary aspergillosis. They 
observed IgG binding to high molecular weight component of over 30 kDa 
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in all patients' sera tested but IgG binding to low molecular weight of 
approximately 18 kDa was observed in 88% of patients sera which showed 
positive precipitin reaction by counter immunoelectrophoresis. Further, 
they reported strong IgE binding to 18 kDa component in sera from 
patients with ABPA during acute stage but not during convalescence stage 
and thus suggested that 18 kDa protien from A. fumigatus is the primary 
antigen in serological antibody response in patients with ABPA or 
aspergilloma. Antibodies against 90 kDa antigen o{ A. fumigatus were also 
reported as a helpfiil marker of aspergilloma (Lopez-Medrano et al. 1995). 
Surveying the existing literature of this aspect in bronchogenic carcinoma 
patients, we could not get any published report, except one of our previous 
report, which was published partly from this Doctoral study (Malik et al. 
2003). In that study, consistent presence of antibodies against 18-kDa 
protein antigens oi A. fumigatus was noticed in bronchogenic carcinoma 
patients and denoted diagnostic importance of presence oi diW^x-Aspergillus 
antibodies against 18-kDa antigens in bronchogenic carcinoma patients. 
During the search of our literature, we could get numerous reports 
studying the presence of anti-Aspergillus antibodies in various chronic 
lung diseases like asthma (Longbottom & Pepys 1964; Rippon 1982), 
allergic bronchopulmonary aspergillosis (Rippon 1982; Kurup etal. 2006), 
and aspergilloma (Lopez-Medrano et al. 1996), however we could not get 
any report on studies exclusively done in patients of bronchogenic 
carcinoma except one of our previous preliminary report (Malik et al. 
2003). 
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2.2.10. Diagnostic significance of BAL-culture for making diagnosis of 
aspergillosis 
The sensitivity of BAL-culture for making the diagnosis of aspergillosis 
has been reported to be low in various studies (Horvath & Dummer 1996). 
In a study performed by Verweij et al. (1994), the diagnostic yield of 
Aspergillus species from culture of BAL fluid sample was reported to be 
30%. In few other studies the diagnostic yield of Aspergillus is being 
reported to range between 50-57% of all cases (Albelda et al 1984; Kahn 
et al. 1986; Levy et al. 1992). Majority of the studies found the culture 
technique to be insensitive; yielding positive results in < 50% of cases of 
invasive pulmonary aspergillosis (Albelda et al 1984; Kahn et al. 1986; 
Saito et al 1988; Levy et al 1992; McWhinney et al 1993). The studies 
regarding the evaluation of BAL-culture in non-invasive/semi-invasive 
aspergillosis are fragmentary and none of the earlier studies has 
evaluated the role of BAL-culture exclusively in bronchogenic 
carcinoma patients (Shahid et al 2007a). 
2.2.11. Role of BAL-PCR in diagnosis of aspergillosis in bronchogenic 
carcinoma 
The limitations of antibody detection and the problems of sensitivity 
associated with antigen detection have prompted the evaluation of the PCR 
for the diagnosis of IPA. The main advantage of PCR appears to be that it 
detects low burdens of fungal genetic material and warns of the presence of 
possible invasive aspergillosis. A number of PCR techniques have been 
developed to detect either individual species or general primer-mediated 
methods to detect filamentous fungi in general (Melchers et al 1994; 
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Montone & Litzky 1995). Early reports described methods to amplify the 
gene for A. fumigatus 18-kDa ribonucleotoxin (Reddy et al. 1993). 
Subsequently, a PCR, based on universally conserved sequences within 
fungal large rDNA, including that of A. fumigatus, has been described 
(Haynes et al. 1995). Various clinical specimens, including Blood 
(Yamakami et al 1996; Yamakami et al. 1998; Kawamura et al. 1999; 
Buchheidt et al. 2001) and BAL (Tang et al 1993; Bretagne et al 1995; 
Hayette et al 2001; Buchheidt et al 2001; Sanguinetti et al 2003) have 
been analyzed by these PCR methods. Kawamura et al (1999) evaluated 
the role of PCR for detection of Aspergillus DNA in serum samples for 
diagnosis of pulmonary aspergillosis. Forty-four serum samples from 
patients with pulmonary aspergillosis (33 with pulmonary aspergilloma, 4 
with allergic bronchopulmonary aspergillosis, 4 with invasive pulmonary 
aspergillosis, and 3 with aspergillus pyothorax) were analyzed, and of 
which PCR detected Aspergillus DNA in serum samples of 39 patients. In 
another study performed by Verweij and colleagues (Verweij et al. 1995) 
on patients of hematological malignancies, the authors suggested that 
Aspergillus genus-specific PCR on BAL fluid might be beneficial for use 
in the early diagnosis of IPA. 
Sensitivity of PCR is an important issue. The lower limit of detection 
reported for A. fumigatus corresponds to 10-100 colony-forming units per 
sample (Tang et al. 1993; Spreadbury et al 1993; Reddy et al. 1993). 
Various investigators have reported high sensitivity of PCR assay in 
making the diagnosis of aspergillosis, especially the invasive pulmonary 
aspergillosis (Tang et al 1993; Spreadbury et al 1993; Reddy et al. 1993; 
Melchers et al. 1994). However, of equal concern is the question of false 
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positives. In a competitive PCR assa}/ applied to BAL samples, this 
problem was highlighted (Bretagne et al 1995). The studies regarding 
the evaluation of BAL-PCR in non-invasive/semi-invasive aspergillosis 
are limited and none of the earlier studies has evaluated the role of 
BAL-PCR exclusively in bronchogenic carcinoma patients (Shahid et 
al 2007a). 
2.3. Bacteriological Aspects with special reference to CTX-M- ESBLs 
(An overview) 
Infectious diseases are the world's leading cause of premature deaths, and 
an increase in the emergence of multidrug-resistant bacteria is worrying the 
world population (Shahid et al. 2007c). The incidence of bacteria isolated 
in bronchoalveolar lavage fluids varied from series to series, ranging from 
25% to 45% depending on the nature of lung diseases. In a study performed 
by Kumari et al. (1994) on BAL-fluids from patients of lung malignancies, 
98.3% yielded positive bacterial culture. Of which, Pseudomonas 
aeruginosa was the most common organism isolated in 34.8% cases 
followed by Klebsiella pneumoniae in 24.4% cases. Escherichia coli was 
isolated only in 2.2% cases. Many patients of this study population showed 
mixed bacterial phenomenon. The high incidence of bacterial growth seen 
in such cases could be attributed to the presence of lung malignancy and 
immunosuppression. The presence of antibiotic resistance genes on 
bacterial plasmids has further helped in the transmission and spread of drug 
resistance among pathogenic bacteria (Robin et al., 1998; Beg et al., 2000). 
The era of chemotherapy for infectious disease is now more than 5 decades 
old. Those years were marked by continuous development and introduction 
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of new and potent antimicrobial agents and by the relentless development 
and spread of significant antibiotic resistances among pathogenic bacteria. 
To combat the antibiotics resistance, a broad array of potent antibiotics is 
available to the contemporary clinicians. However, growing problems with 
antimicrobial drug resistance are beginning to erode our antibiotic 
armamentarium (Eichhoff, 1998). 
The (3-lactam antibiotics are among the most widely prescribed 
antibiotics and are important components of empirical therapy. Because of 
extensive use, resistance to these drugs has become a major problem 
especially after the introduction of newer broad-spectrum cephalosporins, 
P-lactamase inhibitor / p-lactam antibiotics, monobactams and 
carbapenems. The most common resistance mechanism to this important 
class of antibiotics is because of production of the beta-lactamases (TEM, 
SHV, CTX-M, & OXA) by resistant bacteria. B-Lactamases are bacterial 
enzymes that inactivate I3-lactam antibiotics by hydrolysis, which results in 
ineffective compounds (Bush 2001). At least 400 different types of 6-
lactamases, originating from clinical isolates, have been described and a 
web site has been created to monitor the latest developments among the 
newer types of B-lactamases (web site at 
http://www.lahey.org/studies/webt.htm) (Jacoby & Munoz-Price 2005). In 
recent years, CTX-M-type beta-lactamase has been increasingly reported 
from many countries, including the Asian subcontinent (Livermore & 
Hawkey, 2005). However, there is paucity of data on the current aspect 
from Indian hospitals. The only exceptions being a report on 6 
bacterial isolates, published by a French group (Karim et ai, 2001); a 
report on 130 bacterial isolates (Ensor et ai 2006b), which included 
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few isolates from this Doctoral work that were taken to U.K. while the 
candidate worked on a Fellowship (Commonwealth Academic 
Fellowship-2005-2006) in U.K.; and another recent report on blaxEM & 
'^«SHv (Grover et al. 2006). 
AmpC P-lactamases are produced by numerous pathogens 
(Bauemfeind et al. 1998). Acquisition of AmpC-type genes by plasmids in 
E. coli and K. pneumoniae has been known since long back to 1980s 
(Alvarez et al. 2004). Plasmidic ampC genes are derived from the 
chromosomal ampC genes of several (not all) members of the family 
Enterobacteriaceae, including Enterobacter cloacae, Citrobacter freundii, 
Morganella morganii, and Hafnia alvei (Bauemfeind et al. 1998). 
However, the studies regarding plasmid mediated AmpC p-lactamases 
are elementary in our country. Furthermore, no molecular study 
regarding the occurrence and detection of this class of p-lactamase is 
published from our country (Shahid et al. 2003). 
2.3.1. Extended-spectrum fi-lactamases (ESBLs) and classification 
ESBLs were first described in 1983, and have the ability to h\drol>se 
oxyimino-cephalosporins, and monobactams, but not cephamycins or 
carbapenems (Bradford 2001). Although ESBLs have been described in a 
range of Enterobacteriaceae and Pseudomonadaceae from different parts of 
the world, they are most often identified in Klebsiella pneumoniae and 
Escherichia coli. These enzymes belong to the Ambler class A and D fi-
lactamases (Ambler et al 1991). The activity of Class A enzymes is 
inhibited in vitro by 6-lactamase inhibitors such as clavulanic acid, 
sulbactam and tazobactam but those belonging to class D are not. The 
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majority of ESBLs identified in clinical isolates to date, have been SHV or 
TEM types, which have evolved from narrow-spectrum B-lactamases such 
as TEM-1, -2 and SHV-1 (Bradford 2001). The CTX-M enzymes have 
originated from Kluyvera spp., and recently gained prominence in 
Enterobacteriaceae with reports from Europe, Africa, Asia, South America 
and North America (Bonnet 2004). Other rare types of ESBLs include the 
GES/IBC, VEB and PER B-lactamases (Girlich et al. 2001; Tzelepi et al. 
2003; Weldhagen et al. 2003). The VEB enzymes are widely distributed in 
Enterobacteriaceae from South East Asia (Girlich et al 2001) and 
Acinetobacter spp. from France (Poirel et al. 2003), whereas the GES/IBC 
ESBLs are reported from hospital pathogens in countries such as South 
Africa and France (Weldhagen et al. 2003). PER-1 B-lactamase has been 
identified in nosocomial isolates of Pseudomonas aeruginosa and 
Acinetobacter sp^. from Turkey (Weldhagen et al. 2003). 
They are classified according to the scheme of Ambler et al. (1991) 
into four classes, designated classes A to D, on the basis of their amino acid 
sequences, with classes A and C being the most frequently occurring 
among bacteria. According to the ftinctional classification scheme of Bush 
et al. (1995), class A ESBLs are therefore clustered in group 2be, which 
can be subdivided on the basis of their activities against ceftazidime and 
cefotaxime as ceftazidimases (higher levels of hydrolytic activity against 
ceftazidime than against cefotaxime) and cefotaximases (higher levels of 
hydrolytic activity against cefotaxime than against ceftazidime), 
respectively (Jacoby 1994). However, class A ESBLs form a heterogeneous 
molecular cluster comprising fi-lactamases sharing 20 to >99% identity. 
The earliest class A ESBLs, which were reported from 1985 to 1987, 
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differed from widespread plasmid-mediated TEM-1/2 and SHV-1 
penicillinases by one to four point mutations, which extend their hydrolytic 
spectra (Kliebe et al. 1985; Sirot et al. 1987; Sougakoff e?«/. 1988). TEM 
and SVH ESBLs now comprise at least 130 members and have a 
worldwide distribution. Most of them are ceftazidimases, and only a few 
are cefotaximases. 
2.3.2. CTX-M class of extended spectrum p-lactamases 
Extended-spectrum P-lactamases cleave the amide bond in the B-lactam 
ring, rendering B-lactam antibiotics harmless to bacteria. Oxyimino-
cephalosporins such as cefotaxime and ceftazidime, which are inherently 
less susceptible to B-lactamases, were introduced in the early 1980s to treat 
infections caused by gram-negative bacilli that were resistant to established 
B-lactams and that produced class A, C, and D B-lactamases. Their 
repetitive and increased use induced the appearance of resistant strains, 
which overproduced class C enzymes (Ishii et al. 1995; Philippon et al. 
2002) and/or which produced extended-spectrum B-lactamases, mainly 
those of class A but also those of class D (Naas & Nordmann 1999; 
Bradford 2001). 
Class A ESBLs hydrolyze oxyimino-cephalosporins and aztreonam 
but not 7-a-substituted B-lactams. They are generally susceptible to B-
lactamase inhibitors (clavulanate, sulbactam, tazobactam). More recently, 
non-TEM and non-SHV plasmid-mediated class A ESBLs have been 
reported: ceftazidimases of the PER, VEB, TLA-1, and GES/IBC types and 
cefotaximases of the SFO-1, BES-1, and CTX-M types (Bonnet 2004). The 
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CTX-M 3-lactamases are the most widespread enzymes. They were 
initially reported in the second half of the 1980s, and their rate of 
dissemination among bacteria and in most parts of the world has increased 
dramatically since 1995. 
2.3.3. Classification of CTX-M fi-Iactamases 
The CTX-M B-lactamases, now exceeding over 50 different variants, can 
be divided into five clusters based on their amino acid identities (Bonnet 
2004): the CTX-M-1 group including CTX-M-1,-3, -10,-12,-15, -28, -30 
and FEC-1; the CTX-M-2 group including CTX-M-2, -4, -5, -6, -7, -20 and 
Toho-1; the CTX-M-8 group including CTX-M-8; the CTX-M-9 group 
including CTX-M-9, -13, -14 (also named CTX-M-18), -16, -17, -19, -21, -
24, -27 and Toho-2; and the CTX-M-25 group with CTX-M-25 and CTX-
M-26. 13-Lactamases of the CTX-M-2 group are structurally related to the 
naturally produced B-lactamase of Kluyyera ascorbata (Humeniuk et al. 
2002), CTX-M-8 is related to 6-lactamase oiKluyvera Georgiana (Poirel et 
al. 2002), and CTX-M-1 group enzymes are related to the B-lactamases of 
Kluy\'era cryocrescens (Decousser et al. 2001) although an enzyme 
identical to CTX-M-3 was isolated from a strain of K. ascorbata 
(Rodriguez et al. 2004). The CTX-M-9 group is related to enzymes from 
Kluyvera spp. isolated in Guyana, which were identical with CTX-M-14 
(Boyd et al. 2004). 
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23A. Phylogenies and origins of CTX-M enzymes 
The CTX-M family now comprises more than 50 variants. The most 
closely related B-lactamases (identities, 62 to 75%) are the chromosomal 
class A enzymes of Serratiafonticola, Klebsiella oxytoca, Proteus vulgaris, 
and Citrobacter koseri (Arakawa et al. 1989; Perilli et al 1991; 
Barthelemy et al. 1992; Peduzzi et al. 1994; Peduzzi et al. 1997). 
CTX-M enzymes can be subclassified by amino acid sequence 
similarities (Bonnet et al. 2000). Figure VI shows a dendrogram 
constructed by the neighbor-joining method on the basis of the peptide 
alignment (Thompson et al. 1994). The phylogenic study reveals five major 
groups of acquired CTX-M enzymes (the members of each group share 
>94% identity, whereas ^90% identity is observed between the members 
belonging to distinct groups), (i) The CTX-M-1 group includes six plasmid-
mediated enzymes (CTX-M-1, CTX-M-3, CTX-M-10, CTX-M-12, CTX-
M-15, and FEC-1) (Matsumoto et al. 1988; Barthelemy et al. 1992; 
Gniadkowski et al. 1998a; Karim et al. 2001; Kariuki et al. 2001; Oliver et 
al. 2001) and the unpublished enzymes CTX-M-22, CTX-M-23, and CTX-
M-28 (GenBank accession numbers AY080894, AF488377, and AJ549244, 
respectively), (ii) The CTX-M-2 group includes eight plasmid-mediated 
CTX-M enzymes (CTX-M-2, CTX-M-4, CTX-M-4L, CTX-M-5, CTX-M-
6, CTX-M-7, CTX-M-20, and Toho-1) (Ishii et al. 1995; Bauemfeind et al. 
1996b; Bradford et al. 1998; Gazouli et al. 1998a; Gazouli et al. 1998b; 
Tassios etal. 1999; Saladin et al. 2002). (iii) The CTX-M-8 group includes 
one plasmid-mediated member (Bonnet et al. 2000b). (iv) The CTX-M-9 
group includes nine plasmid-mediated enzymes (CTX-M-9, CTX-M-13, 
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CTX-M-14,CTX-M-16, CTX-M-17, CTX-M-19, CTX-M-21, CTX-M-27, 
and Toho-2) (Ma et al. 1998; Labia 1999; Sabate et al. 2000; Bonnet et al. 
2001; Pai et al. 2001; Poirel et al. 2001; Cao et al. 2002a; Saladin et al. 
2002; Chanawong et al. 2002; Bonnet et al. 2003) and two unpublished 
enzymes (CTX-M-24 [GenBank accession number AY 143430] and CTX-
M corresponding to accession no. JP0074). (v) The CTX-M-25 group 
includes the CTX-M-25 and CTX-M-26 enzymes (GenBank accession 
numbers AYl57676 and AF518567, respectively). 
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2.3.5. Chronology of CTX-M emergence 
Matsumoto et al (1988) discovered a non-TEM, non-SHV ESBL in Japan 
in 1986, and designated it as FEC-1, in a cefotaxime-resistant Escherichia 
coli strain isolated from the fecal flora of a laboratory dog which was used 
for pharmacokinetic studies of B-lactam antibiotics. In Germany at the 
beginning of 1989, Bauemfeind et al. (1990) reported on a clinical 
cefotaxime-resistant E. coli strain which produced a non-TEM, non-SHV 
ESBL, designated CTX-M-1, in reference to its hydrolytic activity against 
cefotaxime. At the same time, dissemination of cefotaxime-resistant 
Salmonella strains began in South America (Bauemfeind e? al. 1992; Power 
et al. 1999). The B-lactamases responsible for the resistance to cefotaxime 
observed in these different areas had alkaline pi values, conferred a higher 
level of resistance to cefotaxime than to ceftazidime, and exhibited a great 
hydrolytic activity against cefotaxime and susceptibility to inhibitors. 
In 1992, the same type of ESBL was reported in clinical E. co//strain 
MEN, isolated at the beginning of 1989 in France from a patient who was 
an Italian national (Bernard et al. 1992). In the same year, Barthelemy et al. 
(1992) sequenced this enzyme, designated MEN-1, which presented only 
39% identity with the TEM and SHV enzymes 
(http://www.lahev.org/Studies/). It was the first sequence of a plasmid-
mediated class A non-TEM, non-SHV ESBL. A few years later, Ishii et al. 
(1995) reported on a MEN-1-related enzyme (83% homologous), 
designated Toho-1, which was produced by a cefotaxime-resistant E. coli 
strain isolated in 1993 in Japan. The sequencing of two non-TEM, non-
SHV ESBL-encoding genes in 1996 revealed that CTX-M-1 is identical to 
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MEN-1 and is a variant of Toho-1, designated CTX-M-2 in a cefotaxime-
resistant Salmonella strain isolated in Argentina in 1990 (Bauemfeind et al. 
1996). In Poland, Gniadkowski et al. (1998a) identified a variant of CTX-
M-1, designated CTX-M-3, in different members of the family 
Enterobacteriaceae isolated in 1996. A few years later, sequencing of the 
FEC-1-encoding gene (GenBank accession number AB098539) showed 
that the FEC-1 enzyme differs from the CTX-M-3 enzyme by only two 
substitutions in the signal peptide. Since then, the CTX-M enzymes have 
formed a rapidly growing family of ESBLs distributed both over wide 
geographic areas and among a wide range of clinical bacteria, in particular, 
members of the family of Enterobacteriaceae. They are also in 
environmental species of genus Kluyvera, from which they have been 
characterized by investigation of the mechanisms of natural resistance to 6-
lactams (Decousser et al. 2001; Humeniuk et al. 2002; Poirel et al. 2002). 
2.3.6. Chronology of discovery and the distribution of the CTX-M 
enzymes 
2.3.6.1. Far East: Japan, China, Korea, Taiwan, Vietnam, and India 
In the Far East, the first clinical strain producing CTX-M enzymes was 
observed in Japan in 1993 with the characterization of the Toho-1 enzyme 
from an E. coli strain (Ishii et al. 1995). Since then, between 1995 and 
2000, five other CTX-M 13-lactamases have been isolated from E. coli 
strains in that country: CTX-M-2 (Yamasaki et al. 2003), CTX-M-3 
(Yamasaki et al. 2003), CTX-M-15 (designated UOE-1 in GenBank 
[accession number AYO13478]), Toho-2 (Ma et al. 1998), and CTX-M-14 
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(designated UOE-2 by Muratani et al (2000) and Toho-3 by Ishii et al. 
(2000). Surveys of ESBL-producing Enterobacteriaceae conducted in 
Japan showed that the CTX-M-2 and CTX-M-3 enzymes predominate 
(Yagi et al. 2000; Yamasaki et al. 2003). At least three outbreaks involving 
CTX-M enzymes have occurred in Japan, implicating clonal E. coli spread. 
In one case, the strain was spread by intra- and interhospital dissemination 
and persisted for 22 months (Yagi et al. 1997; Muratani et al. 2000; Ma et 
al. 2002a). 
In China, CTX-M-3, CTX-M-9, CTX-M-13, and CTX-M-14 
enzymes have been reported from E. coli, Klebsiella pneumoniae, and E. 
cloacae strains. At the Huashan Hospital in Shanghai, China, CTX-M 
enzymes were the second most frequent ESBLs after SHV enzymes in K. 
pneumoniae (8 of 80) and E. coli (13 of 58) strains in 1999 (Xiong et al. 
2002) and were the most frequent ESBLs in the Enterobacteriaceae in the 
southern part of China in 1997 and 1998 (Chanawong et al. 2002) and in 
Peking at the Union Medical College Hospital in 1999 (Wang et al. 2003). 
In Taiwan, at the National Cheng Kung University Hospital, a study 
of ESBL-producing K. pneumoniae strains conducted in 1999 revealed the 
predominance (57.9%) of unrelated CTX-M-3-producing strains (Yan et al. 
2000; Ma et al. 2002b). Another survey perfomied in 24 hospitals between 
1998 and 2000 showed inter- and intrahospital clonal dissemination of 
CTX-M-3-producing (28 of 50) and CTX-M-14-producing (22 of 50) K. 
pneumoniae strains (Yu et al. 2002). 
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In different parts of Korea, the CTX-M-14 enzyme was also 
observed in clinical K. pneumoniae and E. coli strains between 1995 and 
1996 and in an Shigella sonnei strain isolated during an outbreak of 
gastroenteritis in 2000 (Pai et al 2001; Ma et al. 2002b). 
In Ho Chi Minh City, Vietnam, CTX-M-14 and a variant designated 
CTX-M-17 have commonly been observed in E. coli and K. pneumoniae 
strains since at least 1996 (Cao et al. 2002a; Cao et al. 2002b). 
In India, a variant of the CTX-M-3 enzyme, designated CTX-M-15, 
was reported from six unrelated members of the family Enterohacteriaceae 
(four E. coli strains, one K. pneumoniae strain, and one E. aerogenes strain) 
isolated between April and May 2000 (Karim et al. 2001). Subsequently, 
Indian and British researchers, in collaboration, reported occurrence of 
only CTX-M-15 type ESBL in a systematic survey performed on a 
collection of 130 cephalosporin-resistant isolates of E. coli and K. 
pneumoniae (Ensor et al. 2006b). To date, CTX-M-15 type has been 
reported as the only existing type in India (Karim et al. 2001, Ensor et al. 
2006b). 
2.3.6.2. Eastern Europe: Poland, Latvia, Russia, Greece, Hungary, 
Bulgaria, Romania, and Turkey 
Eastern Europe is another important area affected by the emergence and 
spread of CTX-M enzymes. In Poland, the CTX-M-3 enzyme was 
characterized from three C. freundii strains collected in 1996 (Gniadkowski 
et al. 1998a). In the Praski Hospital in Warsaw, Poland, during a 4-month 
period between the end of 1996 and the beginning of 1997, the majority (27 
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of 35) of ESBL-producing strains of the family Enterobacteriaceae 
expressed a CTX-M-3-like enzyme (Palucha et al. 1999). A 4-month 
survey performed in seven Polish hospitals in 1998 revealed the 
predominance of an SHV ESBL (60.4%) and similar frequencies of TEM 
and CTX-M ESBLs (20.8% and 18.8%, respectively). A wider survey 
undertaken between 1998 and 2000 in 15 hospitals in 10 different cities of 
Poland revealed the countrywide dissemination of the CTX-M-3 enzyme 
(Baraniak et al. 2002b). This great inter- and intrahospital outbreak was due 
to the clonal spread of few strains and more particularly to the 
dissemination of a CTX-M-3-encoding plasmid in E. coli, K. pneumoniae, 
K. oxytoca, C. freundii, S. marcescens, E. cloacae, and M morganii. S. 
enterica serovar Typhimurium strains harboring a distinct CTX-M-3-
encoding plasmid have also been reported recently (Baraniak et al. 2002a). 
CTX-M-15, a variant of CTX-M-3 previously described in India, has also 
been observed in Poland (Baraniak et al. 2002c) as well as Bulgaria, 
Romania, and Turkey (Schneider et al. 2002). 
In Latvia in 1990, CTX-M-producing S. enterica serovar 
Typhimurium isolates were implicated in a large outbreak of gastroenteritis 
that involved 4,000 children. The characterization of the CTX-M enzyme 
from one of these isolates revealed a variant of CTX-M-2, designated CTX-
M-5 (Bradford et al. 1998). A small outbreak involving CTX-M-4-
producing S. enterica serovar Typhimurium strains also occurred in Russia 
in 1996 (Gazouli et al. 1998b; Gazouli et al. 1998d). The strain involved 
has been observed in Greece and Hungary (Gazouli et al. 1998c; 
Tzouvelekis et al. 1998; Tassios et al. 1999). These data show the clonal 
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spread of CTX-M-producing S. enterica serovar Typhimurium strains in at 
least three European countries. The enzymes implicated (CTX-M-4, CTX-
M-6, and CTX-M-7) were variants of CTX-M-2, like CTX-M-5 observed 
in the Latvian strain. A possible epidemiological link with the Latvian 
outbreak has not been investigated. CTX-M-3-producing E. coli strains 
unrelated to those reported in Poland were also isolated in Greece 
(Mavroidi et al. 2002). 
2.3.6.3. Western Europe: France, Germany, Spain, and the United 
Kingdom 
The CTX-M enzyme was first characterized in Western Europe in two E. 
coli strains isolated in 1989 in Germany (Bauemfeind et al. 1990) and in 
France from an Italian patient (Bernard et al. 1992). Since 1989, 11 
different CTX-M enzymes have been reported in France from sporadic E. 
coli (CTX-M-1, CTX-M-2, CTX-M-9, CTX-M-14, CTX-M-21, CTX-M-
27), P. mirabilis (CTX-M-1, CTX-M-2, CTX-M-20), and E. cloacae 
(CTX-M-1, CTX-M-3) isolates (Doucet-Populaire et al. 2000; Sabate et al. 
2000; Poirel et al. 2001; Dutour et al. 2002; Saladin et al. 2002; Bonnet et 
al. 2003). However, CTX-M-producing strains were not detected in France 
until 1998, during a survey of ESBLs, suggesting that the prevalence of 
CTX-M enzymes was low but probably growing (De Champs et al. 2000). 
At the Hospital Ramon y Cajal in Madrid, Spain, the investigation of 
ESBL-producing Enterobacter strains from 1989 to 2000 showed the 
persistence of a CTX-M-3 variant, designated CTX-M-10, over a 12-year 
period in unrelated isolates (Oliver et al. 2001; Canton et al. 2002; Coque 
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et al. 2002). At the Hospital de la Santa Creu i Sant Pau in Barcelona, 
Spain, the majority (6 of 10) of ESBL-producing Enterobacteriaceae 
isolated between 1994 and 1996 produced CTX-M-9 enzymes (Sabate et al. 
2000; Sabate et al. 2002a). In the same area, a CTX-M-9-like enzyme was 
also observed in three 5. enterica serovar Virchow strains isolated between 
1997 and 1998 (Simarro et al. 2000). In the northwest area of Spain, 50% 
(17 of 50) of ESBL-producing strains of the family Enterobacteriaceae 
isolated in 2001 produced the CTX-M-14 eiizyme, the dissemination of 
which probably occurs by plasmid spread (Bou et al. 2002). The CTX-M 
enzyme was observed in the United Kingdom from sporadic K. oxytoca 
strains isolated in 2000 and during an outbreak of CTX-M-producing K. 
pneumoniae strains between July 2001 and February 2002 (Brenwald et al. 
2003; Alobwede et al. 2003). The UK dominant genotypes appear to be 
mainly CTX-M-14 and CTX-M-15, although CTX-M-26 and CTX-M-9 
have also been reported, and indeed CTX-M-15 is the most widespread and 
has become the dominant ESBL in the UK (Tarrant et al. 2007; Woodford 
et al. 2007a). 
Although the first CTX-M enzymes were characterized from strains 
isolated in 1989, their significant expansion started only in 1995. CTX-M 
enzymes are now endemic over a wide geographic area, including Latin 
America, the Far East, Europe and the near East (Bauemfeind et al. 1996b), 
North America (Moland et al. 2003), and Africa (clonal CTX-M-12-
producing K. pneumoniae strains were isolated in Kenya (Kariuki et al. 
2001). 
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CTX-M-14, CTX-M-3, and CTX-M-2 are the most widespread 
enzymes (Bonnet 2004). They have been delected in strains isolated from 
humans and healthy animals, which could be reservoirs of CTX-M-
producing strains (Brinas et al. 2003). They are implicated in small, 
countrywide, or international outbreaks. The emergence and dissemination 
of these enzymfes involve plasmid or strain epidemics, but they also involve 
mobile elements, like \Mcpl. Most strains producing CTX-M enzymes 
seem to be implicated in nosocomial infections. However, in contrast to 
SHV and TEM ESBLs, CTX-M enzymes also emerge in community strains 
like V. cholerae, nontyphoid Salmonella, and Shigella sp. isolates. This 
point may have important implications for control of the spread of the 
CTX-M enzyme. The widespread use of ceftriaxone or cefotaxime has been 
proposed as a reason for the emergence of CTX-M enzymes (Pai et al. 
2001; Wang e/a/. 2003). 
The simultaneous observation of CTX-M enzymes in nosocomial 
and community strains from multiple geographic locations is consistent 
with their emergence from a widespread reservoir, owing to independent 
genetic events, like the mobilization of blacjx-M genes from the 
chromosomes of environmental Kluyvera bacteria. This process could also 
explain the delayed expansion of CTX-M enzymes, as opposed to the 
explosive emergence since 1985 of TEM and SHV ESBLs, which derived 
from widespread plasmid-mediated enzymes. 
2.3.6.4. South America: Argentina and Brazil 
In South America, an explosive dissemination of nontyphoid Salmonella 
strains resistant to cefotaxime was observed beginning in 1989. Starting in 
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a hospital in La Plata, Argentina, the strains spread to neonatology units of 
pediatric hospitals in Buenos Aires, Argentina, and from there to 
neighboring countries (Bauemfeind et al. 1990; Power et al. 1999; Radice 
et al. 2002; Petroni et al. 2002). The blacjx-M-i gene was characterized 
from a conjugative plasmid of S. enterica serovar Typhimurium strain 
CAS-5 isolated during this outbreak in 1990 (Bauemfeind et al. 1996b). 
The dissemination of the gene has been suspected or demonstrated in 
different members of the family Enterobacteriaceae, such as E. coli. 
Shigella sonnei, Proteus mirabilis, Morganella morganii, Citrobacter 
freundii, S. marcescens, and Enterobacter aerogenes; in Vibrio cholerae; 
and in Aeromonas hydrophila. The CTX-M-2 enzyme seems to be the most 
frequent ESBL (75%) in Enterobacteriaceae in Argentina (Quinteros et al. 
1999). In Rio de Janeiro, Brazil, of 18 representative ESBL-producing 
strains of the family Enterobacteriaceae collected in 1998 and 1999, CTX-
M enzymes (« = 6) were the second most frequent ESBLs after SHV B-
lactamases {n= 10) and were diverse: CTX-M-2 in P. mirabilis; CTX-M-9 
and CTX-M-16 in E. coli; andCTX-M-8 in Citrobacter amalonaticus, E. 
cloacae, and Enterobacter aerogenes (Bonnet et al. 2000a; Bonnet et al. 
2000b; Bonnet e/a/. 2001). 
2.3.7. Laboratory detection of organisms producing ESBLs 
The Clinical and Laboratory Standards Institute (CLSI; formerly known as 
the National Committee for Clinical Laboratory Standards) has published 
guidelines for ESBL detection in Enterobacteriaceae specifically for E. coli, 
Klebsiella spp. and Proteus spp. (Clinical and Laboratory Standards 
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Institute 2005). In the UK, the Health Protection Agency (HPA) has also 
prepared guidelines (British Society for Antimicrobial Chemotherapy 
2007). These guidelines include an initial screening with either 8 mg/L 
(CLSI) or 1 mg/L (HPA) of cefpodoxime, 1 mg/L each of cefotaxime, 
ceftazidime, ceftriaxone, or aztreonam, followed by confirmatory tests 
using both cefotaxime and ceftazidime in combination with clavulanate, or 
the Etest ESBL strips. Automated systems that use similar detection 
principles have proved to be popular in clinical laboratories, especially 
those in North America. Clinical laboratories from several countries, 
especially in Europe, have taken a more pro-active approach to the 
detection of ESBL-producing organisms. First-line screening tests in these 
countries are based on double disc synergy testing, combination discs and 
microdilution tests (with isolates grown in broth containing 1 mg/L of 
extended-spectrum cephalosporins). Second-line, confirmatory tests require 
determination of MIC by broth dilution of extended-spectrum 
cephalosporins with and without clavulanic acid or Etest ESBL 
confirmation tests. 
2.3.7.1. Phenotypic detection of CTX-M ESBLs 
Ceftazidime resistance is used in practice as an indicator of the presence of 
ESBLs, and ceftazidime is usually the best substrate for TEM and SHV 
ESBLs. When used alone this practice could fail to recognize CTX-M-
producing strains susceptible to ceftazidime as ESBL producers and 
therefore greatly hamper the control of the spread of the CTX-M enzyme. 
Many strains producing ESBLs demonstrate an inoculum effect, in that the 
MICs of expanded-spectrum cephalosporins rise as the inoculum increases 
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(Bradford 2001). CTX-M-producing isolates, which are not resistant to 
ceftazidime in vitro, according to European and NCCLS guidelines, could 
therefore be resistant to ceftazidime in vivo. The use of ceftazidime to treat 
infections caused by CTX-M-producing strains can therefore lead to 
therapeutic failure and promote the emergence of CTX-M enzymes with 
significant hydrolytic activities against ceftazidime. Interpretive 
antibiograms of CTX-M-producing strains should therefore result in 
resistance to all expanded-spectrum cephalosporins and aztreonam, 
whatever the MICs of these molecules are. 
In addition to susceptibility to ceftazidime, susceptibility to 
cefotaxime should also be tested to reduce the risk of overlooking CTX-M 
production (Brenwald et al. 2003; Alobwede et al. 2003). Testing for 
susceptibility to cefpodoxime, which is hydrolyzed by both TEM and SHV 
ESBLs and CTX-M ESBLs, is an alternative but might yield a significant 
number of false-positive results. In both cases, therefore, class A ESBL 
production should be confirmed by appropriate synergy tests (Bradford 
2001). 
2.3.7.1,1. Phenotypic dtection of ESBLs and AmpC enzymes by double 
disk and three-dimensional tests 
Double disk-synergy test (DDST) and three-dimensional extract tests 
(TDET) have been used for the detection of ESBLs in members of the 
family Enterobacteriaceae (Thomson & Sanders 1992). The current CLSI 
documents (formerly NCCLS) do not indicate the screening and 
confirmatory tests that should be used for the detection of AmpC P-
lactamases. However, various workers (Coudron et al. 2000, Manchanda & 
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Singh 2003) have designed the TDET for the detection of AmpC enzymes 
in Gram-negative bacterial isolates. As the TDET is a labor-intensive 
procedure, there is always a search for newer methods and the aim to make 
existing methods user-friendlier to incorporate them in routine diagnostic 
laboratories (Manchanda & Singh 2003). In the search of more convenient 
and user-friendlier method, during this Doctoral work, we designed a user-
friendly and effective protocol to be applied as phenotypic characterization 
for the detection of ESBLs and AmpC enzymes (Shahid et al. 2004). 
Methods of detecting ESBL producing bacteria have been evolving for 
more than a decade, beginning with the description of the disk 
approximation test by Brun-Buisson et al. (1987) and subsequently 
described by Jariier and colleagues (1988). The three-dimensional test, 
originally described by Thomson etal. (1984) is a more sensitive procedure 
for the detection of ESBLs. However, this technique had its own 
limitations. Subsequently, the test was modified with the use of a slit 
technique with bacterial suspensions and enzyme extracts, but filling these 
slits was a fastidious procedure (Vercauteren et al. 1997, Coudron et al. 
2000). Despite of different modifications tried by various researchers, to 
date, no satisfactory technique has been established. Keeping all these 
points in mind, we tried some modifications in search of simple and user-
friendlier procedure than existing conventional phenotypic tests (Shahid et 
al. 2004). Very recently, we introduced a new double disk synergy test 
utilizing synergy between ceftriaxone/sulbactam (sulbactam as a source of 
ESBL-inhibitor) and cephalosporin disks and evaluated its detection 
potential in CTX-M-15 carrying Enterobacteriaceae (Shahid etal. 2007b). 
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2.3.7.2. Molecular Detection of CTX-M enzymes 
Different workers have designed various PCR protocols for detection of 
blacrx-M and of which multiplex PCR protocol for detection of blacrx-u 
detecting the CTX-M-genogroups is being widely used with modifications 
adopted in individual laboratories (Ensor et al. 2006b). Precise CTX-M 
genotypes could be identified either by using monoplex PCR for specific 
types, by reverse line hybridization (Ensor et al. 2006a), or by sequencing. 
2.3.8. Genetic support and environment of natural blacTx-M genes 
The blacTx-M genes have been described or presumed to be natural and 
chromosome mediated in the species K. cryocrescens {blai^wc-\), K. 
ascorbata ( /^AKLUA), and K. georgiana (bla^wG-])- The DNA sequences 
surrounding these B-lactamase genes exhibited similarities (Decousser et al. 
2001; Humeniuk et al. 2002; Poirel et al. 2002). Open reading frames 
(ORFs), designated Orfl and encoding a putative aspartate 
aminotransferase, have been identified upstream of the /^^ KLUA and /^^ KLUC-
1 genes and share 96% identity. In the intergenic region located 
immediately upstream of the three natural blacjx-u genes, 87 to 90% 
nucleotide identity has been found. No ampR gene has been detected, 
whereas this Lys-type gene regulates some enzymes related to CTX-M 
enzymes (the natural B-lactamasesof e^rra/'zV? marcescens, P. vulgaris, and 
C. koseri). ORFs, designated Orfi and encoding a putative protein that 
shares 69% identity, have been detected downstream of the /^OKLUA and 
bla^wc-i genes. 
57 
Review of Literature 
2.3.9. Genetic support of acquired 6/acTx-M genes 
In clinical strains, CTX-M-encoding genes have commonly been 
located on plasmids that vary in size from 7 kb (Cao et al. 2002a) to 160 kb 
(Kariuki et al. 2001; Pai et al. 2001). The blajEu-\ gene often coexists on 
the same plasmid; and associations with 6/aTEM-2, 6^ <3oxA-rtype, and bla^ww-
type genes are probable (Sabate et al. 2000; Karim et al. 2001). These 
plasmids can also carry genes for resistance to multiple other antibiotics, 
including aminoglycosides, chloramphenicol, sulfonamide, trimethoprim, 
and tetracycline. 
CTX-M-encoding plasmids are often transmissible by conjugation/« 
vitro. Their frequency of transfer varies from 10" to 10' per donor cell. 
This property explains the easy dissemination of Z?/acTx-M-harboring 
plasmids. For example, the same Pstl restriction type of a blacTx-M-3-
harboring plasmid has been observed in seven different species of the 
family Enterobacteriaceae in Poland (Paiucha et al. 1999; Baraniak et al. 
2002b). In contrast, 7-kb Z)/flcTx-M-i7-harboring plasmid pI843, which has 
been completely sequenced, does not possess the genes required for 
conjugation (Cao et al. 2002a). However, the non-self-transmissible 
plasmids can usually transfer by transformation or can be mobilized 
(Tassios e/^/. 1999). 
Identical blacTx-u genes that are geographically and temporally 
clustered have been observed on different genetic supports. A blacix-u-^ 
gene has been characterized on plasmids exhibiting two distinct Pstl 
restriction types in Warsaw, Poland (Paiucha et al. 1999). The same type of 
observation has been reported for the same gene in Peking, China (Wang et 
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al 2003); for the blacjx-M-?, gene in Rio Janeiro, Brazil (Bonnet et al. 
2000b); and for the bhcTx-M-u gene in the Juan Canalejo Hospital in A 
Coruna, Spain (Bou et al. 2002). The gene has been observed in China on a 
BamUl- and £coRI-restricted fragment located on plasmids ranging in size 
from 60 to 150 kb, as well as on the chromosomes of E. coli and 
Enterobacter cloacae strains (Chanawong et al. 2002). Secondary 
chromosomal insertions ofblacix-u genes have also been observed in Japan 
in clinical E. coli strain HK56, which harbored three copies of the gene 
(Yagi et al 1997). These data suggest the mobility ofblacjx-M genes, which 
allows their transfer between plasmids and from plasmids to chromosomes. 
2.3.10. Genetic environment of acquired blacjx-M genes 
Genetic arguments show the mobilization of natural blacjx-u genes from 
the K. ascorbata and K. georgiana chromosomes to plasmids. The 
sequences upstream and downstream of the plasmid-mediated bhcTx-M-s 
gene (138 and 34 bp, respectively) share 95 and 94% identities with those 
surrounding blaKwc-] on the chromosome of K. georgiana (Poirel et al. 
2002; Humeniuk et al. 2002). Likewise, the sequences surrounding the 
genes of plasmid-mediated B-lactamases belonging to CTX-M-2 group 
share 80 to 100% identities with those surrounding the /^OKLUA genes on the 
chromosome of K. ascorbata (Humeniuk et al. 2002). In plasmids pS21 
and pMAR-12, a 1,043-bp sequence downstream ofblacTx-u-i shares 99%) 
identity with the chromosomal DNA of A^. ascorbata and harbors the OrO 
sequence of the species K. ascorbata {D'l Conza et al. 2002; Arduino et al. 
2002). 
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In CTX-M-9-encoding plasmid pMSP071, an 823-bp sequence 
downstream of the blacrx-u gene harbors an OrO-like region that shares 
78% identity with Orfi of K. ascorbata, suggesting that blacTx-u-g and the 
surrounding sequences could come from a related Kluyvera strain (Bonnet 
2004). Accordingly, it has been suggested that conserved sequences of 42 
and 79 bp upstream of the blacix-u-\ and Z>/(3CTX-M-9 genes, respectively, are 
part of the chromosome of a Gram-negative rod that could be the 
progenitor of corresponding clusters (Saladin et al. 2002). 
Different elements may be involved in the mobilization of blacjx-M 
genes. ISEcpl or ISEcpI-like insertion sequences have repeatedly been 
observed 42 to 266 bp upstream of ORFs encoding the CTX-M-1, CTX-M-
2, CTX-M-3, CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-15, CTX-M-17, 
CTX-M-19, CTX-M-20, and CTX-M-21 enzymes (Karim et al. 2001; Bou 
et al. 2002; Chanawong et al. 2002; Dutour et al. 2002; Saladin et al. 2002; 
Alobwede et al. 2003; Ensor et al. 2006b), which is also the case for 
certain plasmid-mediated ampC genes (Wu et al. 1999; Phillipon et al. 
2002). This insertion sequence is composed of two imperfect inverted 
repeats and an ORF encoding a 420-amino-acid putative transposase. Its 
amino acid sequence displays only 24% identity with the 1S492 transposase 
from Bacteroides fragilis, the most closely related transposase. Stapleton 
(1999) suggests that the ISEcpl element is able to achieve the transfer of 
the downstream DNA sequence by a one-ended transposition process. 
Plasmid conduction experiments have confirmed the potential involvement 
of ISEcp] in the mobility of blacjx-M (Cao et al. 2002a). In addition, the 
mapping of the blacjx-u-M promoter region by primer extension has 
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revealed -35 (TTGAAA) and -10 (TACAAT) promoter sequences at the 3' 
end of an IS£c/?7-like sequence (nucleotides 2690 to 2719 of GenBank 
sequence number AY033516) which probably provides the promoter for 
expression of blacxxM genes associated with the ISEcpl element (Karim et 
al 2001; Caoe/a/. 2002a). 
CTX-M-9- and CTX-M-2-encoding genes have also been observed 
in unusual class 1 integrons, designated InS21 (plasmid pS21) (Di Conza et 
al. 2002), In35 (plasmid pMAR-12) (Arduino et al. 2002), and In60 
(plasmid pMSP071) (Sabate et al. 2002b). These integrons contain the 5' 
conserved segment (5' CS) and a partial or a complete duplication of the 3' 
CS. Gene cassettes, which are characterized by 59-BE element-type 
sequences, are located between the 5' CS and the first copy of 3' CS. 
Between the two 3' CSs lies a 2,100-bp conserved region that includes 
Orf513 (previously designated Orf341) and a variable region which harbors 
no gene cassette. For integrons InS21 and In35, the 2,100-bp conserved 
region contains a 2,185-bp sequence harboring the blacjx-M-i gene and 
Orf3, which probably originated from K. ascorbata. For integron In60 
(plasmid pMSPOVl), this variable region contains the blacTx.M-9 gene, an 
Orf-3-like element, and a putative insertion sequence designated IS3000. 
Other resistance genes have been observed in this variable region, such as 
the catA2 gene in the In6 integron, the dfrAlO gene in the In? integron, and 
the dha-1 gene associated with its ampR regulator gene in the integron of 
plasmid pSAL-1. Hence, it has been suggested that Orf513, the so-called 
CR (common region) element (Partridge & Hall 2003), might encode a 
putative site-specific DNA recombinase which may have been able to 
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capture genes from the chromosome, like ^/acix-M-harboring loci of 
Kluyvera strains. A conserved 28-bp segment located downstream of 
OrfS 13 has been proposed to be a recognition site for the OrfS 13 putative 
recombinase. A 17-bp fragment of this segment has been observed 
downstream of certain ISEcpl sequences (Saladin et al. 2002), suggesting 
complex mobilization processes involving the OrfS 13 putative recombinase 
and the ISEcpl insertion sequence. In addition, Partridge and Hall (2003) 
showed that the CR element (OrfS 13), the associated variable region, and 
the second 3' CS element could be transferred by homologous 
recombination between 3' CS elements. Other elements may be involved in 
the mobilization of blacjx-M genes, such as ISIO and IS2(5, partial 
sequences of which have been observed upstream of 6/^CTX-M-8 (Bonnet et 
al. 2000b) and ^/«CTX-M-I (Saladin et al. 2002), respectively, and an IS903-
like element observed downstream of the 6/acTx-M-i4 and 6/acTx-M-i7 genes 
(Pai etal. 2001; Cao et al. 2002a). 
2.4. Bacteriological Aspects with reference to AmpC beta-lactamases 
(An overview) 
The predominant mechanism for resistance to B-lactam antibiotics in gram-
negative bacteria is the synthesis of B-lactamase. To meet this challenge, 6-
lactams with greater 13-lactamase stability, including cephalosporins, 
carbapenems, and monobactams, were introduced in the 1980s. Resistance 
appeared initially in organisms such as Enterobacter cloacae, Citrobacter 
Jreundii, Serratia marcescens, and Pseudomonas aeruginosa that could, by 
mutation, overproduce their chromosomal AmpC (also termed class C or 
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group 1) B-lactamase, thus providing resistance to both oxyimino- and 1-a-
methoxy-cephalosporins and monobactams (Sanders 1992). 
Later, resistance appeared in bacterial species that lack an inducible 
AmpC enzyme, such as Klebsiella pneumoniae, Escherichia coli, 
Salmonella spp., and Proteus mirabilis, and this resistance was found to be 
mediated by plasmids encoding extended-spectrum 6-lactamases (ESBLs), 
which are enzymes that arose by mutations in TEM or SHV B-lactamases 
of more limited hydrolytic capacity (Philippon et al. 1989; Jacoby & 
Medeiros 1991; Jacoby 1994). Such resistance included oxyimino-
cephalosporins and monobactams but not 7-<a-methoxy-cephalosporins and 
was blocked by clavulanate, sulbactam, or tazobactam, which are inhibitors 
that are generally ineffective against class C enzymes (Sanders 1992; 
Livermore 1995). 
With continuing use of 7-a-methoxy-cephalosporins (cefoxitin and 
cefotetan) and the clinical introduction of 6-lactamase inhibitor 
combinations (clavulanate with amoxicillin or ticarcillin, sulbactam with 
ampicillin, and tazobactam with piperacillin), plasmids encoding class C 6-
lactamases appeared (Medeiros 1997). Like their counterpart on the 
chromosome, such enzymes provided a broader spectrum of resistance than 
ESBLs and were not blocked by commercially available inhibitors. 
Furthermore, in a strain with decreased outer membrane permeability such 
enzymes can provide resistance to carbapenems as well, as has been 
observed with clinical isolates of K. pneumoniae during an outbreak in 
New York (Bradford et al. 1997) and in individual isolates of/s. coli in the 
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United Kingdom (Stapleton et al. 1999) and of K pneumoniae in Sweden 
(Cao et al 2000). 
2.4.1. History 
AmpC B-lactamases, demonstrated or presumed to be chromosomally 
mediated, have been described in Acinetobacter spp., Aeromonas spp., 
Chromobacterium violaceum, Citrobacter freundii, Enterobacter spp., 
Escherichia coli, Hafnia alvei, Lysobacter lactamgenus, Morganella 
morganii, Ochrobactrum anthropi, Proteus rettgeri, Providencia stuartii, 
Pseudomonas aeruginosa, Psychrobacter immobilis, Rhodobacter 
sphaeroides, Serratia marcescens, and Yersinia enterocolitica. In many 
genera, AmpC is inducible via a system involving ampD, ampG, ampR, and 
intermediates in peptidoglycan recycling (Jacobs et al. 1997; Wiedemann 
et al. 1998). The ampC gene ofE. coli is normally expressed at a low level, 
regulated by a growth rate-dependent attenuation mechanism (Jaurin et al. 
1981) but not by induction, since ampR is missing (Honore et al. 1986). In 
Shigella flexneri and Shigella dysenteriae, ampC is included in a large 
deletion (Maurelli et al. 1998). An ampC locus appears on the genetic map 
of Salmonella (Sanderson et al. 1995), but the evidence for its existence 
was indirect and its presence has not been confirmed in the sequenced 
genomes of Salmonella enterica serotypes Typhimurium or Paratyphi 
(Morosini et al. 2000), so that Salmonella is considered to be AmpC 
(Medeiros 1997). A chromosomal a/wpC gene is also lacking in Klebsiella 
spp. (Morosini et al. 2000) and P. mirabilis. 
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In 1976, Bobrowski et al. described a plasmid-mediated fi-lactamase 
indistinguishable from the AmpC enzyme of E. coli in a strain of P. 
mirabilis (Bobrowski et al. 1976). Unfortunately, the original plasmid was 
lost, there was some doubt about the transfer experiments, and molecular 
studies were not done. In 1982, Levesque et al. reported a plasmid-
mediated cephalosporinase in Achromobacter spp. (Levesque et al. 1982). 
Regrettably, the original strain was lost, the B-lactamase gene was not 
sequenced, and in retrospect the biochemical properties of the enzyme 
resembled those of a group 2b broad-spectrum enzyme rather than of a 
group 1 cephalosporinase. In 1983, Knothe et al. (1983) reported the 
transfer of cefoxitin resistance from S. marcescem to Proteus or 
Salmonella spp., but resistance segregated on transfer to E. coli and no 
biochemical or molecular studies were done (Knothe et al 1983). 
In 1989, Bauemfeind et al. (1989) described a K. pneumoniae isolate 
from South Korea that could transfer resistance to cefoxitin and cefotetan 
as well as to penicillins, oxyimino-cephalosporins, and monobactams to E. 
coli. The enzyme, termed CMY-1 for its cephamycinase activity, had an 
isoelectric point (pl) of 8.0 and was more sensitive to inhibition by 
sulbactam than by clavulanate or tazobactam, suggesting that it might be a 
class C enzyme. However, the first proof that a class C 6-lactamase had 
been captured on a plasmid was provided by Papanicolaou et al. (1990), 
who described transmissible resistance to a-methoxy- and oxyimino-B-
lactams mediated by an enzyme (MIR-1) with the biochemical properties of 
a class 1 6-lactamase and showed that part of the MIR-1 gene was 90% 
identical to the ampC gene ofE. cloacae (Papanicolaou et al. 1990). 
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Subsequently, plasmid-mediated class C B-lactamases have been 
discovered worldwide (Table II). They have been named with 
inconsistency typical of 6-lactamase nomenclature according to the 
resistance produced to cephamycins (CMY), cefoxitin (FOX), and 
moxalactam (MOX) or latamoxef (LAT), to the type of B-lactamase, such 
as AmpC type (ACT) or Ambler class C (ACC), and to the site of 
discovery, such as the Miriam Hospital in Providence, RT. (MIR-1) or 
Dhahran hospital in Saudi Arabia (DHA). BIL-1 was even named after the 
patient (Bilal) who provided the original sample (D. J. Payne, personal 
communication). 
2.4.2. Chronology of discovery of AmpC plasmid-encoded B-lactamases 
Barlow and Hall (Phillipon et al. 2002) recently reanalyzed several 
plasmid-mediated AmpC genes and concluded that the amino acid 
sequences of CMY-2, BIL-1, and LAT-2 were identical, as were LAT-1 
and LAT-4 and also LAT-3 and CMY-6. The chronology of discovery of 
AmpC 3-lactamases is provided in Table II. 
66 
Review of Literature 
TABLE II. Chronology of discovery of plasmid-encoded AmpC fi-
lactamases" 
Name 
MIR-1 
CMY-i 
BIL-1 
FOX-1 
CMY-2 
MOX-1 
DHA-l 
DHA-2 
FOX-2 
LAT-1 
FOX-3 
LAT-2 
Country 
United States 
South Korea 
United Kingdom 
(Pakistan) 
Argentina 
Greece 
France (Algeria) 
Japan 
Saudi Arabia 
France 
France 
Germany 
(Guatemala) 
Greece 
Italy 
Greece 
Year" 
1988 
1988 
1989 
1989 
1990 
1994 
1991 
1992 
1998 
1992 
1993 
1993 
1994 
1994 
Species 
K. pneumoniae 
K. pneumoniae 
E. coli 
K. pneumoniae 
K. pneumoniae 
Salmonella 
senftenberg 
K. pneumoniae 
S. enteritidis 
K. pneumoniae 
K. pneumoniae 
K. pneumoniae 
K. pneumoniae 
K. oxytoca, 
pneumoniae 
K. pneumoniae, 
coli, E. aerogenes 
Pl 
8.4 
8.0 
8.8 
6.8-7.2 
9.0 
9.0 
8.9 
7.8 
7.8 
7.8 
6.7 
9.4 
K. 7.25 
K 9.1 
ACT-1 United States 1994 K. pneumoniae, E. 9.0 
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MOX-2 France (Greece) 1995 
CMY-4 Tunisia 1996 
coli 
K. pneumoniae 
P. mirabilis 
United Kingdom 1999(P) E. coli 
Sweden (India) 1998 
ACC-1 Germany 1997 
France (Tunisia) 1998 
K. pneumoniae 
K. pneumoniae 
K. pneumoniae 
9.2 
9.2 
>8.5 
9.0 
7.7 
7.8 
Tunisia 1997-2000 K. pneumoniae, P. 7.8 
mirabilis. Salmonella 
France (Tunisia) 2000 
spp. 
P. mirabilis, E. coli 1.1 
CMY-
3. 
LAT-3 
LAT-4 
CMY-8 
CMY-5 
FOX-4 
France 
Greece 
Greece 
Taiwan 
Sweden 
Spain 
1998(P) 
1998(P) 
1998(P) 
1998 
1999(P) 
2000(P) 
P. mirabilis 
E. coli 
E. coli 
K. pneumoniae 
K. oxytoca 
E. coli 
9.0 
8.9 
9.4 
8.25 
8.4 
6.4 
" Other plasmid-mediated AmpC-type B-lactamases have been described in GenBank but are not 
yet published, including CMY-6, CMY-7, CMY-9, CMY-10, CMY-11, and FOX-5. 
' Country of isolation (if different, probable country of origin is indicated in parentheses). 
Year of isolation or date of publication (P). 
' Chromosomal location. 
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2.4.3. Relationship of chromosomal and plasmid-encoded AmpC 
enzymes 
A dendrogram of chromosomal and plasmid-encoded AmpC enzymes (Fig. 
VII) demonstrates the diversity of chromosomal AmpC genes and the close 
relationship of some plasmid-mediated enzymes to chromosomal enzymes 
of particular organisms. The plasmid-mediated enzymes can be divided into 
five or six clusters: the C. freundiigroup with LAT types and certain CMY 
types, the Enterobacter group with MIR-1 and ACT-1, the M. morganii 
group with DHA-1 and DHA-2, the H. alvei group represented by ACC-1, 
and the Aeromonas group with MOX-, FOX-, and other CMY-type 
enzymes. The relationship between plasmid-encoded enzymes and certain 
chromosomal 6-lactamases is very close: there is 100% amino acid 
homology within the M morganii and H. alvei groups and more than 94% 
homology within the C. freundii group. ACT-1 and MIR-1 share 91.4% 
amino acid identity with each other but only 85 to 87%o identity with most 
E. cloacae AmpC enzymes. However, the enzyme from E. cloacae strain 
GN7471 (Kuga et al. 2000) has 91.1% identity to ACT-1 and MIR-1, and 
an environmental strain of Enterobacter was 98% identical (M. Rottman 
and G. Arlet, personal communication), so that origin from some 
Enterobacter species is likely. FOX enzymes have 95% or more sequence 
identity within the group, and CMY-1, CMY-8, and CMY-9 are more than 
97% identical, but either group has only about 1A% identity with the 
available Aeromonas sobria AmpC sequences, which in turn differ from 
each other by fully 25%. The AmpC sequence of P. aeruginosa is even 
more distant, so the origin of these enzymes remains uncertain. 
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FIG. VII. Dendrogram for chromosomal and plasmid-encoded 
AmpC B-lactamases, calculated by Clustal X and the neighbor-
joining method. Branch lengths are proportional to the number of 
amino acid exchanges. GenBank accession numbers for blaAmpc can 
be found at 
http://www.rochester.edU/College/BIO/labs/HallLab/AmpC_Phylo.h 
tml. The dedrogram is adopted from Philippon et al. 2002 
(Antimicrob. Agents Chemother. 46: 1-11). 
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2.4.4. Genetic Features 
Genes for the AmpC enzymes have been located on plasmids of sizes 
varying from 7 to 180 kb (Horii et al 1994; Stapleton et al. 1999). A few 
of the plasmids have not been self-transmissible but are transferable by 
transformation (Papanicolaou et al. 1990; Stapleton et al. 1999; Wu et al. 
1999) or mobilization (Tzouvelekis et al. 1993; Gazouli et al. 1996; 
Gazouli et al. 1998c; Verdet et al. 2000). Plasmids encoding AmpC 
enzymes often carry multiple other resistances, including resistance to 
aminoglycosides, chloramphenicol, sulfonamide, tetracycline, 
trimethoprim, or mercuric ion (Papanicolaou et al. 1990; Bauemfeind et al. 
1996a; Bauemfeind et al. 1997; Bradford et al 1997; Stapleton et al 
1999). A plasmid encoding a FOX-type enzyme even carried a gene for 
fluoroquinolone resistance (Martinez-Martinez et al. 1998). Clinical 
isolates often produce other fi-lactamases in addition to an AmpC enzyme. 
The bla genes may be on different plasmids, but often they coexist on the 
same plasmid. For example, the gene for ACT-1 was found in clinical 
isolates along with a pi 5.6 B-lactamase consistent with TEM-10 or TEM-
26 and a pi 7.6 enzyme consistent with SHV-1, and on cloning the ACT-1 
gene was found in a 15-kb cluster with genes for a B-lactamase of pi 5.4, 
presumably TEM-1, and pi 7.0, possibly another SHV-type enzyme 
(Bradford et al. 1997). Furthermore, an ACT-1 probe hybridized to 
chromosomal DNA of these clinical strains, implying mobility of the gene 
by carriage on a transposon. Indirect evidence suggests that CMY-3 and 
CMY-4 could be transposon-mediated as well: CMY-3 because its gene is 
located on the chromosome of a species {P. mirabilis) lacking a native 
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AmpC gene (Bret et al. 1998), and CMY-4 because in E. coll clinical 
isolates from London a CMY-4 probe hybridized to both 7-kb and 45-kb 
plasmids, a dual location that could be explained by transposability 
(Stapleton et al. 1999). The MIR-1 gene is located near a sequence closely 
related to an insertion sequence transposase, but direct attempts to 
demonstrate transposability of MIR-1 or BIL-1 (CMY-2) have not been 
successful (Fosberry et al. 1994; Jacoby & Iran 1999). 
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CHAPTER 3 
3. CLINICAL AND MYCOLOGICAL STUDIES 
3.L BRIEF INTRODUCTION 
More cases of bronchogenic carcinoma are being reported in recent years 
and these patients are more prone to secondary aspergillosis. However, the 
frequency of secondary aspergillosis in bronchogenic carcinoma is still 
not clearly defined in the literature. The early diagnosis for such 
secondary infection could be of great importance since early antifungal 
treatment is associated with an improved outcome (Aisner et al 1977). 
However, diagnosis in early stages is very difficult, as clinical and 
radiological signs are nonspecific and the sensitivity of fungal culture is 
low (Andrews & Werner 1981; Bretagne et al. 1995). Circulating-antigen 
detection may contribute to the diagnosis significantly in invasive 
aspergillosis, but false positivity as high as 8% has been reported (Stynen 
et al. 1995). Therefore, the attention has now turned to molecular detection 
methods, like PCR. The role of PCR assays of Bronchoalveolar lavage 
(BAL) fluids for diagnosing aspergillosis does not clearly emerge in the 
literature (Spreadbury et al. 1993; Tang et al. 1993; Bretagne et al. 1995); 
moreover it is being investigated mainly for the diagnosis of definite- and 
probable-invasive pulmonary aspergillosis, but not extensively in possible-
and semi/non-invasive pulmonary aspergillosis, and mostly studied in 
immunocompromised states like, neutropenic patients (Jones et al. 1998), 
organ transplantation (Kusne et al. 1992; Denning 1998) and hematological 
malignancies (Denning 1998; Pagano et al 2001). The evaluation of role 
of BAL-PCR for the diagnosis of aspergillosis in patients of 
bronchogenic carcinoma is completely missing in the existing 
literature. 
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Moreover, the gross data regarding Aspergillus infection in various 
other chronic lung diseases (Denning 1998; Shahid et al. 2001), and in 
immunocompromised states like, neutropenic patients, bone marrow 
transplantation, liver transplantation, AIDS, and hematological 
malignancies (Kusne et al. 1992; Bart-Delabesse et al. 1996; Denning 
1998; Jones et al. 1998; Pagano et al. 2001) is available in the literature. 
However, the data is fragmentary on these fungal infections in 
bronchogenic carcinoma patients. During our search of literature via 
Pubmed Central, we could not get any published systematic report except 
one of our previously published (Malik et al 2003) and few occasional 
case reports published in languages other than English (Tsai et al. 1984; 
Tanakae^fl/. 1993). 
Keeping in view the above facts, the present study was therefore 
proposed with the following specific objectives 
Aims and Objectives 
• To find out the prevalence of pulmonary aspergillosis in 
patients of bronchogenic carcinoma. 
• To evaluate the role of BAL-PCR in making the early 
diagnosis, and to compare it with conventional methods like 
BAL-culture and direct microscopy. 
• To analyze the presence of anti-aspergillus antibodies by 
serological methods like double immunodiffusion (DID), 
enzyme-linked immunosorbent assay (ELISA), and Dot Blot 
assay (DBA), 
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• And to analyze the diagnostic role of the above-mentioned 
tests in various forms of aspergillosis associated with 
bronchogenic carcinoma. 
3.2. SUBJECTS AND METHODS 
3.2.1. Study population 
The present study was conducted in the department of Microbiology 
on patients of bronchogenic carcinoma attending the outpatient department 
or admitted in the wards of Tuberculosis and Chest Diseases of Jawaharlal 
Nehru Medical College & Hospital, Aligarh Muslim University, Aligarh, 
India, during June 2003 to May 2006. During this period, a total of 213 
bronchoscopy were performed and of which 159 were suspected cases of 
bronchogenic carcinoma. A total of 95, confirmed patients of bronchogenic 
carcinoma based on histopathological and cytological investigations, and 
not receiving any antifungal therapy prior to the study were included. A 
collection from 42 patients of bronchogenic carcinoma of the year 2001 -
2002, on which mycological and bacteriological studies were ongoing, was 
also included. Therefore, the study population for this study comprised of a 
total of 137 patients. A detailed clinical history was recorded in each 
patient especially regarding duration of illness, history of smoking, 
institution of broad-spectrum antibiotics, corticosteroids and chemotherapy. 
Remaining 64 suspected patients of bronchogenic carcinoma were 
excluded from the study because of some other co-existing underlying 
immunosuppressive disorders like diabetes, Cushing's syndrome, 
Hodgkin's disease, leukemia, lymphoma, and SLE or because the patients 
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were taking antifungal therapy. Thirty-four, age and sex matched 
volunteers, not having history suggestive of any lung disease in the recent 
past were included as healthy controls, informed written consent was taken 
prior to bronchoscopy in all study and control groups and the investigations 
were performed after the approval by Institutional Ethical Committee. 
3.2.2. Clinical classiflcation of Aspergillosis 
All cases were categorized into one of four categories as per the criteria 
used by Raad et al. (2002): 1) definite-invasive pulmonary aspergillosis 
(IPA), 2) probable-IPA, 3) possible-IPA, 4) non-IPA. Definite-IPA was 
defined based on histopathological evidence of lung tissue invasion, 
associated with clinical and radiological findings suggestive of IPA. 
Probable-IPA was defined as positive culture for Aspergillus species from 
BAL with clinical and radiological findings (X-Ray and Computed 
Tomography) suggesdve of IPA. Possible-IPA was defined, as clinical and 
radiological findings suggestive of IPA in the absence of histopathological 
and microbiological evidence, and non-IPA were those without any 
evidence of IPA in microbiological, clinical and histopathological 
investigations. The clinical and radiological criteria used in the present 
study were part of a diagnostic protocol followed at our institution and 
largely based on criteria set by EORTC (European Organization for 
Research in the Treatment of Cancer). The criteria in brief are described 
below as: 
Clinical criteria: 
Persistent high grade fever of > 38° C despite use of broad-spectrum 
antibiotics, non productive cough, pleuritic pain and/or slight hemoptysis 
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with expectoration of necrotic material with fungal hyphae, progression to 
pneumonia in 1-2 days especially in immunocompromised patients, current 
negative blood culture and no presumptive diagnosis of infection by other 
microorganisms including viruses. 
Radiological criteria: 
On Plain X-ray. One or more well-defmed nodules or patchy density, and 
progression to consolidation or cavitations with surrounding infiltrate 
followed by thirming of the cavity wall. 
On CT scan: Signs confirming those present in plain X-ray, CT "halo 
sign" of a zone of low attenuation surrounding a non-specific pulmonary 
mass or infiltrate, and hemorrhagic contents of pulmonauy legioftSfli/ r. ^ 
3.2.3. Collection of specimens 
Bronchoalveolar lavages were collected to perfoi^ direct microscopic' 
examination, culture, and PCR, and blood samples for sei;,glggi,c»l- tests. 
Bronchoscopy was performed by the expertise, according to method of 
Wimberley et at. (1979). Written and Informed consent was taken prior to 
bronchoscopy. Two consecutive BAL specimens were collected in sterile 
containers with all aseptic precautions. Each BAL specimen was divided in 
three parts for direct microscopy, culture and PCR. Direct microscopy and 
culture was performed immediately whereas BAL specimens for 
performing PCR were kept at -20° C till tested. Blood was collected in 
EDTA and plain vials for routine hematological investigations and fungal 
serology respectively. Additional BAL and blood samples were collected 
from 21 patients that could be followed-up and in whom initial culture or 
serology was negative and PCR was positive. Sera were separated and 
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stored at -2{f C till tested further. Specimens for histopathology and 
cytology were also collected and the investigations were performed by 
expertise in the department of Pathology of J.N. Medical College, AMU, 
Aligarh. Biopsy specimens for histopathology were collected by bronchial 
biopsy with the help of fibreoptic bronchoscope (Olympus, BF Type TE2) 
and biopsy forceps (FB 20C-1) in majority of patients that presented with 
intraluminal growth. In patients that did not present with intraluminal 
growth, either transbronchial needle biopsy or percutaneous lung biopsy 
was performed. 
3.2.4. Processing of the BAL and culture 
BAL was homogenized with the help of sterile magnetic stirrer and 
subjected to direct microscopy by using 10% KOH mount and Lacto 
Phenol Cotton Blue (LPCB) Mount (Shahid et al 2001; Malik et al. 2003). 
Subsequently, BAL was streaked on two sets of Sabouraud's Dextrose agar 
(SDA) and Czapek Dox agar (CDA) (Shahid & Malik 2002) containing 
chloramphenicol (0.05 mg/ml). One set of both the media was incubated at 
25° C and the other at 37*^0. 
3.2.5. Characterization oi Aspergillus spp. 
The fungal isolates were characterized according to i) the characteristic 
colony morphology on SDA and CDA ii) by seeing the pigment on the 
back of SDA and CDA produced by fungal growth iii) by making tease-
mount preparation and identifying the morphology of conidiophore and 
fungal heads (i.e. single and double sterigmata and the pattern of conidia on 
the vesicle; details for differentiating Aspergillus spp. are shown in Table I) 
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iv) and in doubtful case, by using Micro-slide culture technique and 
identifying the exact morphology of the hyphae, conidiophore and fungal 
heads. 
3.2.5.1. Colony Characters 
On SDA, the colonies of A. fumigatus were velvety, with rugosities, and 
smoky-green in color. The colonies of A. flavus were velvety at first, then 
became yellow to green or brown. The colonies of ^ . niger were granular, 
initially white, and then turned dark brown to black in color. On CDA, the 
colonies of A. fumigatus were granular, smooth, and without rugosities, 
green in color. The colonies of ^ . flavus were velvety and yellowish-green 
in color. While the colonies of ^ . niger were granular, initially white, and 
then turned dark brown to black in color. 
3.2.5.2. Pigmentation of the reverse of culture tube 
On SDA-culture, the reverse of the culture tube was white to tan for A. 
fumigatus, while the reverse was golden to red brown in color for A. flavus, 
and without any characteristic change for A. niger. The reverse of the 
culture on CDA demonstrated characteristic green pigmentation for A. 
fumigatus and yellow pigmentation for A. flavus. The reverse of ^. niger 
culture did not show any characteristic pigmentation on SDA or CDA. 
3.2.5.3. Tease Mount Preparation 
One drop of LPCB was placed on a clean sterile 
slide and a small portion of the colony was removed from the culture 
medium with the help of a L-wire and placed in LPCB stain. The mycelial 
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mass of the colony was teased apart gently with the help of dissecting 
needles. It was then covered with a cover slip, pressed slightly and 
examined under the microscope. 
3.2.5.4. Micro-slide culture 
The slide culture was performed according to the method of Procop & 
Roberts (1998). Briefly, a sterile microscopic slide was put on a V-shaped 
bent glass rod positioned on a piece of filter paper in a sterile petridish 
(Fig. VIII). A 2-mm^ small block of Sabouraud's Dextrose Agar was cut 
using a sterile scalpel blade, scooped out using the tip of a scalpel blade, 
and placed on the slide. With an L-wire, the four quadrants of the agar 
block were inoculated with the fungal colony to be tested, and a sterile 
cover slip was put on agar block. The filter paper was moistened with 
sterile water; the culture dish was covered with its lid and was incubated at 
25°C. On appearance of satisfactory fungal growth, the cover slip was 
removed and placed on a microscopic slide containing few drops 
of LPCB. The agar block was removed, a drop of LPCB was placed on the 
area of growth adhered to slide, and a cover slip was placed on it. The two 
preparations were observed microscopically to see the characteristic 
morphology of the fungus. 
3.2.6. Antifungal susceptibility testing and MIC determination 
Antifungal susceptibility against voriconazole, itraconazole and 
amphotericin B was performed by broth microdilution method according to 
the guidelines of National Committee for Clinical Laboratory Standards 
(now CLSI). The NCCLS document M38A (NCCLS 2002) was followed 
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Fig. VIII. Photograph showing the slide culture apparatus used for the 
slide culture technique; consisting of petridish, bent glass tube, glass slide 
on which agar block is kept, cover slip and a piece of filter paper. Arrows 
show the edges of the agar block with fungal growth. 
Fig. Mil 
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to detail. The medium used for sensitivity testing was RPMI-1640 buffered 
with 0.165. Mol/L MOPS (Hi-Media Laboratories). 
3.2.6.1. Medium used and its preparation 
The medium used for sensitivity testing was RPMI-1640 buffered with 
0.165. Mol/L MOPS (Hi-Media Laboratories). The powdered RPMI-1640 
medium (10.4 g) was dissolved in 900 mL of sterile distilled water. MOPS 
was added to a final concentration of 0.165 mol/L and stirred until 
dissolved. While stirring, the pH was adjusted to 7.0 at 25V using 1 mol/L 
sodium hydroxide. Additional water was added to bring the medium to a 
final volume of 1 L. It was filter sterilized and stored at A^C until use. 
3.2.6.2. Antifungal agents used and their preparation 
The antifungal agents used were amphotericin B (Hi-media Laboratories), 
itraconazole (Janssen), and voriconazole (Pfizer). 
The drugs were stored as recommended by the manufacturer. To determine 
the amount of antifungal powder needed for a standard solution, the 
following formulae were applied, 
Weight (mg)= volume (ml)x concentration (g/ml) 
Assay potency (jig/ mg) 
Volume (mL) = weight (mg) x assay potency (|ig/mg) 
Concentration {\igl ml) 
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3.2.6.2.1. Preparing stock solutions 
The highest desired test concentration was 1600 \iglm\. Hence 4.8 mg of 
the antifungal agent was weighed and dissolved in 3 ml of solvent i.e. 
DMSO (assuming 100% potency of the drug). 
3.2.6.2.2. Preparing diluted antifungal agents 
Sterile glass test tubes were used to prepare the drug dilutions and sterile, 
disposable multi-well microdilution plates (96 U-shaped, flat-bottomed) to 
perform the tests. The solvent used for all the drugs tested was DMSO. A 
series of dilutions at 100 times the final concentration (lOOX) was prepared 
from the antifungal stock solution in the same solvent (i.e. DMSO). For 
performing broth microdilution test the intermediate solution was diluted 
1:50 to final strength in the test medium (i.e. RPMI 1640). This gave 2X 
the strength of drug concentrafion (working solution). The dilution series 
were in the range of 16 |i.g/ml to 0.0313 p-g/ml for all the drugs (see Table 1 
for the detailed procedure for preparing the diluted antifungal agents). 
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Table 1: Showing the dilution series of antifungal agents used for the 
broth dilution procedure 
Steps 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Concen-
tration 
1600 
1600 
1600 
1600 
200 
200 
200 
25 
25 
25 
Source 
Stock 
Stock 
Stock 
Stock 
Step 4 
Step 4 
Step 4 
Step? 
Step? 
Step? 
Volume 
(ml) 
-
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
Solvent, 
DMSO 
(mL) 
-
0.5 
1.5 
3.5 
0.5 
1.5 
3.5 
0.5 
1.5 
3.5 
Intermediate 
concentration 
1600 
800 
400 
200 
100 
50 
25 
12.5 
6.25 
3.13 
Final 
concentratio 
n at 1:10 in 
RPMI 1640 
16 
8.0 
4.0 
2.0 
1.0 
0.5 
0.25 
0.125 
0.0625 
-
Final concen-
tration at 1:50 in 
RPMI 1640 
32 
16 
8.0 
4.0 
2.0 
1.0 
0.5 
0.25 
0.125 
0.0625 
3.2.6.3. Inoculum preparation 
Conidia formation was induced by growing the isolates on com meal agar 
at 35V. Fungal colonies were covered with 1ml of sterile saline and the 
conidia were harvested by probing the colonies with the tip of a sterile 
Pasteur pipette. The resulting mixture of conidia and hyphae was 
transferred to a sterile tube. Heavy particles of the suspension (When they 
were present) were allowed to settle for 3 to 5 min, and the upper 
homogenous suspension after vortexing for 15 seconds was adjusted 
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spectrophotometrically to optical densities that ranged from 0.09 to 0.11 (at 
625 nm) i.e. 80 to 82% transmittance. 
The inoculum suspension was diluted 1:50 in RPMI, which 
corresponded to two times the density (2X) needed for the test 
(approximately 4 x lO"* to 5 x 10"* CFU/ml). The test inoculum was made in 
sufficient volume to directly inoculate each well with 0.1 ml of the 
corresponding diluted inoculum suspension. A growth control well 
containing RPMI-1640 broth without an antifungal agent was put each time 
a test is performed. 
Inoculum quantification for each isolate was performed by plating 0.01 
ml of a 1:100 dilution of the adjusted inoculum suspension on Sabouraud's 
dextrose agar plates to determine the viable number of CPU per milliliter. 
The plates were incubated at 28-30°C and observed daily for fungal 
colonies. 
3.2.6.4. Broth microdilution test 
Each microdilufion well was inoculated with 100 \i\ of the diluted 2X drug 
concentration and 100 |J.I of the diluted 2X conidial inoculum suspensions. 
The final volume in each well was 200|il. The last well of each row served 
as the growth control. One well of the microdilution plate containing 100p,l 
of uninoculated, drug-free medium served as a sterility control. The micro 
plates were incubated at 35°C without agitation and examined after 36-48 
hr. for determining MIC results. 
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3.2.6.5. Reading of results 
The growth in each well was compared with that of the growth control with 
a reading mirror. The wells were then given a numerical score as follows: 
A score of 0 (zero) i.e. optically clear well for amphotericin B; 
A score of 2 (50% reduction in turbidity) for azoles. 
3.2.6.6. Quality control 
Two QC organisms v.i.z. A.flavus, ATCC 204304 and A. fumigatus ATCC 
204305 were included each time a set of isolates was tested with each drug. 
Sterility control was performed by including 1ml of un-inoculated, drug-
free medium. 
3.2.7. Serological methods 
3.2.7.1. Antigenic preparations of Aspergillus spp. 
Antigens of A. fumigatus, A. flavus, and A. niger were prepared in our 
laboratory as described in our previous reports (Shahid et al. 2001; Malik 
et al. 2003). Briefly, The fungi were grown for 3 weeks in glucose 
asparagine broth. When satisfactory growth appeared, the culture was 
killed with merthiolate. The mycelial mat was then separated and 
transferred into 95% alcohol and kept for 48 hours. It was squeezed gently 
between two layers of filter paper and dried in a dessicator with anhydrous 
calcium chloride. The dried fungal pellicles were finely pulverized and 
passed through sieve of 150-mesh/ cm^ to get fine powder. This powder 
was deffated by shaking in the solvent acetone (3 to 4 volume of material). 
The active allergenic substances from the deffated powders were extracted 
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with highly alkahne buffer (NaCl- 7 gm, Potassium phosphate- 0.36 gm, 
double distilled water- 1 lit.) having a pH of 8.0. The soluble active 
ingredients were filtered and dialyzed against normal saline for 48 hr, fluid 
being changed 8 hourly. Allergenic extract was sterilized by filtration and 
standardized by weight by volume method (1:50). 
3.2.7.2. Double immunodiffusion technique (DID) 
DID was carried out according to the method of Ouchterlony (1953) with 
minor modifications as adopted in our previous studies (Shahid et al. 2001; 
Malik et al. 2003). The method, in brief, is described below. 
3.2.7.2.1. Materials/Chemicals/Equipments used 
Patients sera, Aspergillus antigen, agarose (Sigma), Sodium chloride, 
Sodium azide. Acetic acid. Methanol, Amidoschwarz, microscopic 
glass slides, micropipettes, incubator, refrigerator, and water bath. 
3.2.7.2.2. Preparation of solutions 
(A) Normal saline : 0.1 5 M NaCl 
8.76 g of sodium chloride and 2.0 g of sodium azide was dissolved in 
300 ml of distilled water and the volume was made to 1 litre. 
(B) Staining solution: 1% amidoschwarz 
1 g of amidoschwarz was dissolved in 100 ml of methanol to get 1% 
amidoschwarz solution in methanol. 
86 
Clinical and Mycological studies 
(C) Destaining solution : 10% glacial acetic acid 
To 100 ml of glacial acetic acid, 100 ml of methanol and 800 ml of 
distilled water was dissolved to get the destaining solution. 
3.2.7.2.3. Procedure to perforin DID 
1. 0.3 g of agarose was dissolved in 100 ml of distilled water by 
heating in a boiling water bath. 
2. The agarose solution was pipetted on to clean dry slides enough 
to just cover one surface of the slides and thus pre-coated slides 
were obtained. 
3. 1 g of agarose was dissolved in 100 ml of normal saline 
containing Sodium azide (0.2%) by heating in a boiling water 
bath. 
4. Approximately 8 ml of this melted agar was poured over 
pre-coated slide and it was allowed to solidify. 
5. Wells were punched in the agar gel; one central and 
four peripheral, equidistant from each other. 
6. The central well was filled with specific Aspergillus 
antigen and the peripheral wells with the sera of patients. 
7. The slides were incubated for 2 hours at 37°C in a 
humid chamber and then at 8°C, in a refrigerator, for 24 to 
48 h. 
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8. The geJs were examined for precipitin bands and 
photographed, and then washed thoroughly with normal 
saline to remove extraneous proteins. 
9. To make permanent mount, the slides were covered with 
filter paper and left for drying at 37°C. 
10. The paper was dampened and removed, and slides 
were stained with staining solution for 30 seconds. 
11. Destaining was done by using the destaining solution until 
a clear background was obtained. 
3.2.7.2.4. Interpretation 
Appearance of one or more precipitation bands were regarded 
as positive for precipitating antibodies in that sera of patient 
against particular fungal antigen. If no precipitation band 
appeared within 72 hour, it was regarded as negat ive for 
precipitating antibodies. 
3.2.7.3. Enzyme-linked immunosorbent assay 
Indirect ELISA was performed for the detection of total immunoglobulins 
against Aspergillus crude antigens according to the method described by 
Kauffman et al. (1983) with minor modifications as adopted in our 
previous studies (Shahid et al. 2001; Malik et al. 2003). 
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3.2.7.3.1. Materials and equipments used 
96-welI Microtitre plates (Maxisorp E Plates; Nagle NUNC), 
Micropipettes, Automatic ELISA washer, ELISA reader (Labsystems 
Multiscan Plus, U.S.A.), Incubater, Aspergillus Antigens, Patients' 
Sera. 
3.2.7.3.2. Buffers and reagents used 
(A) Tris buffer saline (TBS): 10 mM Tris , 150 mM NaCl, pH 7.4. 
(B) Tris buffer saline Tween-20 (TBS-T): 20mM Tris, 144 
mM NaCI, 2M mM KCl and 50 ml Tween-20, pH 7.4. 
(C) Biocarbonate buffer: 15 mM Sodium carbonate, 
35 mM Sodium bicarbonate, pH 9.6. 
(D) Conjugate: Anti-Human Alkaline phosphatase. 
(E) Substrate: P - Nitrophenylphosphate. 
3.2.7.3.3. Procedure for ELISA 
1) Microtitre plates were sensitized with antigen (50 \igl ml) in 
bicarbonate buffer (pH 9.6) in a volume of 200 [0,1/ well, in an 
incubator, for two h at 37° C and followed by overnight 
incubation at 4°C. 
2) The plates were washed thrice with TBS-T and 
unoccupied sites were blocked with 200 \i\ of fat 
free dry milk (5%) in TBS. 
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3) 200 |Lil of patients sera, diluted 1:100, along with 200 \i\ of 
positive as well as negative control sera were added in the 
wells and they were allowed to act for 2 hours at 37°C followed 
by overnight incubation at 4°C. 
4) Microtitre plates were washed thrice with TBS-T & TBS, 
respectively. 
5) 200 |il of anti-immunoglobulin alkaline phosphatase 
conjugate (diluted in TBS) was added and incubated 
for 2 h at room temperature. 
6) Plates were again washed and 200 \i\ of substrate 
(P-Nitrophenyl phosphate) was added and the 
reaction was allowed to develop for 30 min. 
7) Reaction was stopped by adding IN NaOH Solution 
and absorbance was recorded at 405 nm with the help of 
ELISA reader. 
3.2.7.3.4. Interpretation 
The titers of the individual sera (As) were expressed as 
percentage of the titer of the positive serum by the formula: 
As-Ay 
% As -- X 100 
Ax-Ay 
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where. 
As is the titer of test serum. 
Ay is titer of negative serum, and 
Ax is titer of positive sera found with 1 |il of serum. The titer of 
individual sera exceeding + 2 S.D. were regarded as positive. 
3.2.7.4. Dot Blot assay 
The method for Dot Blot was that developed in our laboratory 
(Shahid et al. 2001; Shahid et al. 2003b). Briefly, strips of 
Immobilon-polyvinylidene difluoride (PVDF) membrane 
were coated with 2 \i\ of Aspergillus antigen in a 
concentration of 2mg/ml as drops, and strips were kept at 60°C 
for 30 min. Strips were washed with TBS and unoccupied sites 
were blocked by 1% bovine serum albumin (BSA) for 2 
hours. Strips were again washed with TBS, and a drop of 1:100 
diluted individual sera were added over the antigen drops and 
strips were incubated at 37°C for 30 min. Secondary HRP 
conjugate diluted in TBS was added after washing and 
allowed to stay at room temperature for 1 h. Strips were washed, 
HRP color substrate system (50 mM Tris-HCl , pH 8.0 ; 0.48 
mM 4-chloro-l- naphthol , 200 mM NaCl, and 17 % methanol 
was added . The reaction was started with the addition of Hydrogen 
peroxide (0.01 % v/v). The color was allowed to develop for 5 min. 
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the substrate was removed, and the membrane was dried and 
photographed same day. 
3.2.7.5. Western blot analysis 
An attempt was made, in limited cases, to explore the anti-
Aspergillus antibodies reacting against individual Aspergillus 
antigenic proteins. Fourteen serum samples, positive by DID, 
ELISA and DBA, were selected for western blot analysis. 
Before performing western blotting, Sodium Dodecyl Sulphate 
Polyacrylamide gel electrophoresis (SDS-PAGE) was performed for 
Aspergillus antigen. 
3.2.7.5.1. Sodium Dodecyl Sulphate Polyacrylamide gel 
electrophoresis (SDS-PAGE) 
SDS-PAGE was performed according to the method described by 
Laemmli (1970) with minor modifications as adopted in our 
previous studies. 
3.2.7.5.1.1. Materials and equipments used for SDS-PAGE 
(A) Chemicals: Acrylamide, N',N'-methylene bis acrylamide, 
sodium dodecyl sulphate (SDS), Tris-hydroxymethyl 
aminomethane (Tris), ammonium per sulphate (APS), 
N',N',N',N'-Tetramethyl ethylene diamine (TEMED), dichloro 
dimethyl silane, acetic acid, bromophenol blue, Coomassie 
brilliant blue R-250, glycerol and methanol. 
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(B) Equipments: Vertical Slab-gel electrophoresis unit with 
power supply. 
3.2.7.5.1.2. Preparation of solutions 
(A) Solution A: 29.2g of acrylamide and 0.8 g of bisacrylamide were 
dissolved in 100 ml of distilled water. It was treated with activated 
charcoal and the product was filtered. 
(B) Solution B (Resolving gel buffer)- 1.5 M Trls-HCL (pH 8.8), 0.4% 
SDS: 18.2 g of Tris and 0.4 g of SDS was dissolved in 50 ml of 
distilled water. The pH was adjusted to 8.8 by adding concentrated 
HCL (about 12.9 ml). Volume was made up to 100 ml with distilled 
water. 
(C) Solution C (Stacking gel buffer)- 0.5 M Tris -HCL (pH 6.8), 0.4% 
SDS: 6.057 g of Tris and 0.4 g of SDS was dissolved in 50 ml of 
distilled water and the pH of the solution was adjusted to 6.8 by 
adding HCL (-4.3 ml of concentrated HCL). Volume was made to 
100 ml by distilled water. 
(D) Solution D (10% ammonium per sulphate): 100 mg of 
ammonium per sulphate was dissolved in 1ml of distilled water. 
(E) Electrophoretic buffer (0.05 M Tris (pH 8.3), 0.384 M 
glycine, 0.1% SDS: 6 g of Tris (0.05 M), 28.8 g of glycine (0.384 M) 
and 1 g of SDS was dissolved in distilled water and the volume 
was made to 1 liter. 
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(F) Sample buffer (0.0625 M Tris-HCL (pH 6.7), 1% SDS): 
7.57 g of Tris and 10 g of SDS was dissolved in about 500 ml of 
distilled water and its pH was adjusted to 6.7 by concentrated 
HCL. The volume was made to 1 liter. 
(G) Staining solution: 10 g of Coomassie brilliant blue R-250 
was dissolved in 125 ml of methanol and the volume was made 
up to 500 ml by distilled water. 
(H) Destaining solution: 100 ml of acetic acid was dissolved in 
900 ml of distilled water to make 10% acetic acid solution. 
3.2.7.5.1.3. Casting of the gels 
1. The plates were thoroughly washed with detergent 
and then with chromic acid. They were then rinsed with distilled 
water and air-dried. 
2. The slab gel mould was assembled and checked for leakage. 
3. The solutions for the resolving gel were mixed according to 
the cross linking required as shown in Table 2. 
4. The solution D and TEMED were added just before pouring 
the solution into the slab mould. 
5. The solution was poured between the plates so as to 
fill three fourth of the height of slab. The surface of the 
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gel was overlaid with distilled water to avoid contact with air 
and the gel was left to polymerize for about 45 minutes. 
6. The water was drained out and the surface of the plates was dried 
carefully with filter paper. 
7. The solutions for the stacking gel (Table 3) were mixed, and solution 
D and TEMED were added in the last. 
8. The solution of stacking gel was poured over the resolving gel and 
the comb was inserted to form the sample wells. The gel was left to 
polymerize for about 45 minutes. 
Table 2. Showing the quantity of reagents required to prepare 8% 
resolving gel 
8% Gel 
H2O 
30% Acrylamide 
1.5Mtris(pH8.8) 
10% SDS 
10% APS 
TEMED 
5ml solution 
2.3 ml 
1.3ml 
1.3ml 
.05ml 
.05ml 
.003ml 
10ml solution 
4.6 ml 
2.7ml 
2.5ml 
0.1ml 
0.1ml 
.006ml 
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Table 3. Showing the quantity of reagents required to prepare 2.5 % 
stacking gel 
2.5 % 
H2O 
30% Acrylamide 
1.5Mtris(pH6.8) 
10%SDS 
10% APS 
TEMED 
5ml solution 
1.4 ml 
.33ml 
.25ml 
.02ml 
.02ml 
.02ml 
10ml solution 
2.1ml 
0.5ml 
.38ml 
.03ml 
.03ml 
.003ml 
3.2.7.5.1.4. Sample preparation 
50 f^ l of 2-mercapto ethanol (final concentration of 5%), few drops of 
glycerol and 1 drop of 0.01%) bromophenol blue was added to 1 ml solution 
oiAspergillus antigen containing the proteins. This sample was heated in a 
boiling water bath for 30 minutes and then cooled at room temperature. 
3.2.7.5.1.5. Application of sample and electrophoresis 
1. The comb was carefully removed from the stacking gel and the wells 
were cleaned of any un-polymerized acrylamide with electrophoretic 
buffer. 
2. Both the chambers of the electrophoretic assembly were filled with 
electrophoretic buffer, including, layering of the wells. 
3. 40|il of the protein samples were carefiilly loaded in different wells 
with the help of a micropipette. 
4. The electrophoretic assembly was connected to the power supply 
with anode at the bottom and the current was applied at the rate of 2 
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mA per well in the stacking gel and at 4 mA per well in the resolving 
gel. 
5. The assembly was disconnected when the dye front reached 3/4"^  of 
the gel length. 
6. The gel was removed and washed with double distilled water. 
3.2.7.5.2. Procedure of Western Blotting 
Western blotting was performed by the method as adopted previously 
(Malik et al 2003). SDS - PAGE of the proteins were performed as 
described earlier (Malik et al. 2003). Proteins from washed SDS gel were 
electro blotted 3 hr., at A°C at 3200 volts, onto nitrocellulose membrane 
using BioRad transblot cell. The transfer buffer contained 25mM Tris, 192 
mM glycine pH 8.3, 20% v/v methanol and 0.02% SDS. After transfer was 
over, the nitrocellulose membrane was taken out and kept in 5% non-fat 
dry milk dissolved in TBS (lOmM Tris-HCL, pH 7.4, 150mM NaCl) for 2 
hr. at room temperature. The membrane was washed with TBS-T (lOmM 
Tris-HCL, pH 7.4, 150 mM NaCl and 0.02% tween 20) and TBS. The 
primary antibody (patient's sera), diluted in TBS was added and incubated 
at room temperature for 2 hours with constant shaking. After removing the 
primary antibody, membrane was washed thrice with TBS-T and once with 
TBS (8 minutes each). Secondary antibody HRP conjugate diluted in TBS 
was added after washing and allowed to stay for 1 hr. at room temperature. 
The membrane was washed again thrice with TBS-T and once with TBS (8 
min each). HRP color substrate systems (50 mM Tris-HCl, pH 8.0; 0.48 
mM 4-chloro-l-naphthol; 200mM NaCl; and 17% methanol) was added 
and the reaction was started with the addition of H2O2 to the concentration 
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of 0.01% v/v. The color was allowed to develop until the bands became 
visible. The substance was removed and the membrane was dried and 
photographed the same day. 
3.2.8. Detection of Aspergillus-BNA in BAL-PCR 
3.2.8.1. Template preparation for PCR 
DNA extraction was done according to the method described by Lee & 
Taylor (1990) with minor mdifications. Briefly, to 100 |il of the 
homogenized BAL, 400 [il of lysis buffer containing 50 mM Tris-HCl (pH 
7.2), 50 mM EDTA, 3% SDS, and 1% P-mercaptoethanol was added. The 
mixture was vortexed for 15 sec, incubated at 65 °C for 1 h and then boiled 
for 10 min. An equal volume of phenol-chloroform-isoamyl alcohol 
(25:24:1) was added to the mixture and vortexed for 10 sec. The mixture 
was centrifuged at 14,000 rpm for 15 min and to the aqueous phase, 10 \i\ 
of 3M Sodium Acetate (pH 5.2) and 0.54 volume of isopropanol were 
added. The tubes were inverted to mix gently, and the DNA was 
precipitated at -20 °C for 1 h. The tubes were again microcentrifuged at 
14,000 rpm for 10 min and the supernatant was decanted. The DNA-pellets 
were washed with 70% ethanol, dried, and resuspended in 25 jil of sterile 
Millipore water. Ten |il of DNA template was used in PCR reaction. 
3.2.8.2. PCR assay 
The primers used in the study (5'- GAA AGO TCA GOT GTT CGA GTC 
AC 3' and 5'- CTT TGG TTG CGG GTT TAG GGA TT 3') amplified 135 
base pairs (bp) of A. fumigatus, 118 bp of A. flavus, and 180 bp of^. niger 
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(Bretagne et al 1995). All PCR reactions were carried out with 50 \A 
reaction volume in 0.2 ml thin wall polypropylene tubes (Axygen Inc, 
USA). The reagents added to the PCR tube were 5 jil of lOx buffer (15 mM 
MgCl2, 500 mM KCl, 100 mM Tris-HCl and 0.01% gelatin), 8 |il dNTP 
(1.25 mM), 10 pM of each primer, 1 U Taq polymerase (Bangalore Genei, 
India), 10 jxl of DNA template and sterile Millipore water to make up the 
volume to 50 ]A. The PCR cycle consisted of an initial denaturation step at 
95 °C for 5 min, followed by 35 cycles of 94 °C for 30 sec, 60 °C for 30 
sec, 72 °C for 1 min, and a final elongation at 72 °C for 10 min. Two-
microliter of PCR products was analyzed by gel electrophoresis with 2% 
agarose containing ethidium bromide (5 |ig/ml). A 100 bp ladder was used 
as molecular weight marker. To prevent carryover contmination, GeneAmp 
PCR carry-over prevention kit (Perkin-Elmer) was used and in each PCR 
reaction, deoxyuridine triphosphate (dUTP) was substituted for 
deoxythymidine triphosphate (dTTP), and each PCR reaction mix was 
treated with uracil-N-glycosidase prior to amplification. In each 
experiment, a reagent mix without DNA was used as negative control. 
3.2.9. Follow-up study 
A total of 49 patients comprising of definite-IPA (n=12), probable-IPA 
(n^l6), possible IPA (n=14) and non-IPA (n=7) could be followed during 
the study period to evaluate the clinical and diagnostic outcome. Additional 
BAL and blood samples were collected only in cases of possible- and non-
IPA that could be followed (n=21). 
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3.2.10. Statistical analysis 
Sensitivities, specificities, positive and negative predictive values of PCR, 
ELISA, DID, DBA, and culture for definite-, probable-, possible-, and non-
IPA, respectively, were determined in comparison to control volunteers as 
well as against the entire dataset. For other variables, statistical analyses 
were performed by chi-square or Student's "t" test and P values <0.05 were 
considered statistically significant. SPSS software (SPSS, Inc., Chicago, 
IL) was used for statistical analyses. 
3.3. RESULTS 
3.3.1. Patients' demographic information and clinical presentations 
Of the 137 patients included in the study, majority (56.9%) were in the age 
group of 45-<60 years, followed by 60-<75 years (35.8%). The median age 
of the study population was 58 years and male to female ratio was 11.5:1. 
One hundred twenty-four (90.5%)) patients provided history of smoking. In 
addition, 40.1%) (55/137) patients were on chemotherapy and 29.9%) 
(41/137) and 26.3%o (36/137) patients were on prolonged antibiotics and 
corticosteroids therapy, respectively (see Table 4 for detailed demgraphic 
information). 
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Table 4. Demographic information of the patients (n=137) 
Patients 
Age Group 
15-<30 
30-<45 
45-<60 
60-<75 
>75 
Age, Median years 
Chemotherapy during 
prior 6 months 
Steroids during prior 
6 months 
Antibiotic therapy 
History of smoking 
Total (%) 
137(100) 
-
9 (6.6) 
78 (56.9) 
49(35.8) 
-
58yrs 
55(40.1) 
36 (26.3) 
41 (29.9) 
124(90.5) 
Male (%) 
126(92.0) 
-
8 (88.9) 
76 (97.4) 
41 (83.7) 
-
-
-
-
Female (%) 
11(8.0) 
-
1(11.1) 
2 (2.6) 
8(16.3) 
-
-
-
-
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The detailed presenting features of the patients are shown in table 5. 
The most common presentation was with cough, which was noticed in 70% 
patients followed by expectoration and chest pain noticed in 52.6% and 
50.4%) patients, respectively (Table 5). Hoarseness of voice was noticed in 
15.3%) patients whereas history of brown plugs in sputum was elicited only 
in 8%o patients (Table 5). 
Table 5. Presenting features of the patients of bronchogenic 
carcinoma included in the present study. 
Presenting features 
Cough 
Expectoration 
Chest pain 
Dyspnoea 
Appetite loss 
Weight loss 
Hemoptysis 
Voice Hoarseness 
No. of patients 
96 
72 
69 
64 
59 
52 
27 
21 
Percentage 
70.1% 
52.6% 
50.4% 
46.7% 
43.1% 
38.0% 
19.7% 
15.3% 
Fever 19 13.9% 
Brown plugs in sputum 11 8.0% 
* Most of the patients presented with multiple presenting features 
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3.3.2. Bronchogenic carcinoma types and bronclioscopic features 
Based on histopathological examinations, the most common type of 
bronchogenic carcinoma diagnosed was squamous cell carcinoma in 66.4% 
(91/137) patients, followed by adenocarcinoma, small cell carcinoma, and 
large cell carcinoma in 24.8%, 4.4%, and 2.9% patients, respectively. In 
two patients the exact type of bronchogenic carcinoma could not be 
identified (Fig. 1). The cytopathological features in various types of 
carcinoma noticed in the present study population are shown in Fig. 2 A-D. 
The detailed bronchoscopic features of the patients, as revealed 
during bronchoscopy, are shown in Table 6, The most common finding 
noticed in the bronchoscopy was intraluminal growth (Fig. 3 A), which was 
observed in 79.6% cases followed by bronchial secretions and bronchial 
congestion in 48.2% and 35.8% cases, respectively. Vocal cord palsy (Fig. 
3 B) and widened carina (Fig. 3 C) was noticed in 22.6% and 19% patients, 
respectively, whereas compression of bronchi (Fig. 3 D) was noticed in 
31.4%) patients. Most of the patients presented with mixed bronchoscopic 
findings. 
Fig. 1. Bronchogenic carcinoma cell-types as identified 
by histopathological examination 
4% 3%1% 
25% 
67% 
El Squamous cell •Adenocarcinoma D Small cell D Large cell • unidentified 
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Description of Fig. 2 A-D 
Fig. 2. Photomicrographs of the cytopathological examinations from 
patients of bronchogenic carcinoma showing squamous cell type (A), 
adenocarcinoma (B), small cell type (C) and large cell type (D). 
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Description of Fig. 3 A - D 
Fig. 3. Photographs showing bronchoscopic findings noticed during 
bronchoscopic procedures in patients of bronchogenic carcinoma. (A) 
Intraluminal growth of carcinomatous tissue, (B) Right vocal cord palsy, 
(C) Widened carina, and (D) Bronchial compression. 
Fig. 3 A - D 
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3.3.3. Clinical classification of Aspergillosis 
According to the criteria used by Raad et al. (2002), based on clinical, 
radiological, microbiological, and histopathological examinations, 18 
(13.1%) patients were considered to have definite-IPA; whereas, 17.5% 
(24/137) and 24.1% (33/137) patients were classified as cases of probable-
IPA and possible-IPA, respectively. Sixty-two (45.3%) patients were 
classified as non-IPA cases as no signs of invasion were noticed, clinically, 
microbiologically, radiologically and histopathologically (see Fig. 4 and 
Table 7). Fig. 5 A & B shows the radiological evidence of invasive-IPA, in 
one of the patients, as demonstrated by signs of infiltrations in CT scan and 
X-Ray chest. Fig. 5 C & D demonstrate the CT scan and X-Ray chest from a 
patient of bronchogenic carcinoma which was categorized with non-invasive 
type of aspergillosis and in which Aspergillus DNA was amplified in BAL-
PCR. Fig. 6 A & B shows the histopathological evidence of invasive-IPA 
demonstrating the presence of fungal hyphae in tissue section. 
Fig. 4. f 
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Description of Fig. 5 A - D 
Fig. 5 A. CT Scan showing cancerous mass in right bronchus and signs of 
infiltrations. 
Fig. 5 B. X-Ray of the same patient showing cancerous mass and signs of 
infiltrations. 
Fig. 5 C. CT Scan of a patient showing bronchial mass and no signs of 
infiltrations 
Fig. 5 D. X-Ray of the same patient showing cancerous mass without signs 
of infiltrations. 
Fig, 5 A - D 
Description of Fig. 6 A & B 
Fig. 6 A. Photomicrograph of histopathological section showing squamous 
cell carcinoma and ftingal hyphae. 
Fig. 6 B. Photomicrograph showing fungal hyphae in PAS staining. 
^ • * J 
Fig. 6A&B 
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Table 7. Detection of Aspergillus by various conventional, serological, and molecular 
methods 
Aspergillosis-
types 
Direct Culture Serology PCR 
ELISA DID DBA 
Definite IPA 
(n=18) 
Probable IPA 
(n=24) 
Possible IPA 
(n=33) 
Non-IPA 
(n=62) 
Healthy controls 
(n=34) 
18* 
24* 24 24 
4 (weak) 0 
18 18' 
24 24" 
23'= 
Total 19 42 54 48 48 71 
* Culture showed growth of A. fumigatus (n=12) and A.flavus (n=6) 
* Culture showed growth of A. fumigatus (n=14) and A.flavus (n=10) 
*these 4 cases with initial weak positive results in ELISA were PCR positive and later on, 
during follow-up, became ELISA, DID and DBA positive. 
'PCR-amplicons corresponded with Aspergillus species isolated in culture from 
respective cases 
''PCR-amplicons corresponded with Aspergillus species isolated in culture from 
respective cases 
"Nineteen cases showed DNA of A. fumigatus and 4 showed DNA of A.flavus 
' 'BAL of 5 patients showed amplicons of A. fiitnigatus and from one patient showed 
amplicon of A.flavus 
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3.3.4, Aspergillus detection by conventional methods 
BAL culture of 42 (30.7%) patients, which included 18 patients of definite-
IPA and 24 of probable-IPA, showed growth of Aspergillus species at least 
in 2 consecutive specimens. Nineteen of these 42 patients revealed fungal 
elements in direct microscopic examination of BAL by KOH and LPCB 
Mount (Table 7). Of ihd Aspergillus spp. isolated, Aspergillusfumigatus was 
the predominant species isolated from 26 (61.9%) cases followed by 
Aspergillus flavus in 38.1%) (16/42) patients. No other species o{Aspergillus 
was isolated in the present study and none among the control group showed 
fungal growth in culture. The cultural characters of the Aspergillus 
fumigatus on SDA and CDA are shown in Fig. 7 A & B, respectively, and 
those of ^ . flavus are shown in Fig. 8 A & B, respectively. The characteristic 
pigmentation of the reverse of the culture on CDA is shown in Fig. 9 A {A. 
fumigatus) and Fig. 9 B {A. flavus). Photomicrographs demonstrating the 
fungal heads oi A. fumigatus and A. flavus are shown as Fig. 10 A & B. 
Analyzing the isolation of Aspergillus spp. in various forms of IPA, A. 
fumigatus was isolated from 12 and 14 cases of definite- and probable-IPA, 
respectively, whereas, A. flavus was isolated from 6 and 10 cases of definite-
and probable-IPA, respectively. No Aspergilli was isolated from cases of 
possible and non-IP A, and none among the healthy controls showed growth 
of Aspergilli in the culture. The details of the Aspergillus species isolated in 
various categories of invasive pulmonary aspergillosis are shown in Fig. 11. 
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Description of Fig. 7 A «& B 
Fig. 7 A. Photograph showing the culture of A. fumigatus on SDA. 
Fig. 7 B. Photograph showing the culture of A. fumigatus on CDA. 
Fig. • A c<;: B 
Description of Fig. 8 A & B 
Fig. 8 A. Photograph showing the culture of A. flavus on SDA 
Fig. 8 B. Photograph showing the culture of A. flavus on CDA 
Fig* 8 A & B 
Description of Fig. 9 A & B 
Fig. 9 A. Photograph of the cuhure of A. fumigatus on CDA showing 
characteristic green pigmentation on the reverse of the culture tube. 
Fig. 9 B. Photograph of the culture of A. flavus on CDA showing 
characteristic yellow pigmentation on the reverse of the culture tube. 
Fig, 9 A & B 
Description of Fig. 10 A & B 
Fig. 10 A. Photomicrograph sowing the fungal heads of Aspergillus 
fumigatus. 
Fig. 10 B. Photomicrograph sowing the fungal heads of Aspergillus flavus. 
Fig. 10 A & B 
Clinical and Mycological Studies 
Fig. 11. Aspergillus species isolated in various 
categories of invasive pulmonary aspergillosis 
and healthy controls 
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3.3.5. MIC determination 
For A. fumigatus isolates, the MIC range for itraconazole and amphotericin 
B was 0.0313-4 |ig/ml and for voriconazole, it was 0.0313-1 ng/ml. 
Whereas, for A. flavus, MIC ranges for itraconazole, amphotericin B, and 
voriconazole were 0.0313-0.5 iig/ml, 0.25-4 [xg/ml, 0.0313-1 |ig/ml, 
respectively (Table 8). 
Table 8. MIC ranges for amphotericin B, itraconazole, and voriconazole 
against the Aspergillus spp. isolated 
Antifungal agents MIC range (ng/ml) 
A.fum igatus A. flavus 
Amphotericin B 
Itraconazole 
Voriconazole 
0.0313-4.0 
0.0313-4.0 
0.0313-1.0 
0.25-4.0 
0.0313-0.5 
0.0313-1.0 
3.3.6. Detection of anti-aspergillus antibodies 
On initial screening of all the 137 patients, anti-aspergillus antibodies could 
be detected in 48 (35%) patients, each, by DID and DBA (Figs. 12 & 13). 
However, antibodies could be detected in 54 (39.4%) patients by ELISA and 
of which 4 patients showed borderline ELISA-results (Table 7). These 
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Description of Fig. 12 
Fig. 12. Photograph showing the precipitin lines (thin arrows) formed in 
positive samples in double immunodiffusion test. No precipitin lines were 
formed in samples negative for ^nh-Aspergillus antibodies (bold arrow). 
Fig. 12 
Description of Fig. 13 
Fig. 13. Photograph showing the pieces of Immobilon-polyvinylidene 
difluoride (PVDF) membrane with some of the positive (Thin 
arrows) and negative reactions (Bold arrows). 
^ M P 
Fig. 13 
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weakly positive cases later on, during follow-up, became strongly positive 
for ELISA, as well as for DID and DBA. None among the healthy volunteers 
showed anti-aspergillus antibodies in any of the serological tests performed. 
The detailed serological results obtained in various categories of 
aspergillosis are shown in Table 7. Western Blotting in 14 representative 
cases revealed consistent presence of anti-Aspergillus antibodies against 18-
kDa-protein antigen. Similar findings have also been reported earlier (Malik 
etal. 2003). 
3.3.7. Aspergillus detection by PCR 
Aspergillus-DNA could be detected in BALs of 51.8% (71/137) 
bronchogenic carcinoma patients. The Aspergillus-DNA was detected in all 
the patients categorized as cases of definite-IPA and probable-IP A, however, 
it could be detected in 69.7% (23/33) and 9.7% (6/62) cases of possible- and 
non-IPA, respectively (Table 7). The PCR assay performed on definite-IPA 
and probable-IPA cases showed amplicons of 135 bp and 118 bp indicating 
the presence of A. fumigatus and A. flavus, respectively (Fig. 14). The 
Aspergillus species detected by the PCR, in these cases, corresponded well 
with culture results (Table 7). In cases of possible-IP A, Aspergillus-UNA 
could be detected in 23 patients, and of these, the PCR-amplicons denoted 
the presence of ^ . fumigatus and A. flavus in 19 and 4 patients, respectively. 
In cases categorized as non-IPA, PCR was positive in 6 cases, and of which 
5 showed amplicons denoting the presence of A. fumigatus, and one with 
amplicon of A. flavus. None among the healthy control group showed 
presence of Aspergillus DNA by PCR (Table 7 & Fig. 15). 
Description of Fig. 14 
Fig. 14. Electrophoretogram of BAL-PCR on 2% agarose gel showing 
amplicons of 135 bp of A. fumigatus (Lanes 3 & 4), and 118 bp of A. flavus 
(Lane 5). Lanes 6-8 show amplicons from controls strains of A. flavus, A. 
fiimigatus, and A. niger, respectively, as positive controls. Lane 1 shows 
negative sample and Lane 2 negative control. Lanes M show molecular 
weight markers. 
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3.3.8. Diagnostic values of various tests 
The detailed results of sensitivity, specificity, and the positive and negative 
predictive values of PCR, ELISA, DID, DBA, culture and direct 
microscopy, in different forms of aspergillosis, against healthy volunteers as 
well as against entire dataset are shown in Table 9 a & b. To find out the 
robustness of the diagnostic values of these tests to discriminate the 
pulmonary invasion and airway colonization, we analyzed the data assuming 
definite- and probable-IPA as diseased group, and possible- and non-IPA as 
non-diseased group, and found them statistically significant (P< 0.0001) (see 
Table 9c for detailed results). All patients with definite- and probable-IPA 
had positive PCR tests, whereas all control patients had negative PCR tests 
(P< 0.0001). Similarly, all patients with definite- and probable-IPA had 
positive serological and culture results as compared with controls (P< 
0.001). Twenty-three of the 33 patients with possible-IPA and 6 of the 62 
patients with non-IPA had positive PCR tests. There was a strong 
association between a positive PCR test and all forms of aspergillosis (P< 
0.05), with the strongest association correlation found with definite- and 
probable-IPA. Serological tests also showed strong association with positive 
test and aspergillosis in definite- and probable-IPA (P< 0.001); however the 
sensitivities dropped down drastically in possible- and non-IPA. 
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Table 9c. Evaluation of the discriminatory power of PCR and 
serological tests (ELISA, DID, and DBA) between pulmonary invasion 
(true disease) and airway colonization (no disease) assuming definite-
and probable-IPA representing true disease and possible- and non-IPA 
representing no disease 
Test used Invasive-Aspergillosis Aspergillus-co\omzdLi\on Chi-square P value 
PCR + 
PCR-
ELISA + 
ELISA -
DID + 
DID-
DBA + 
DBA-
42 
0 
42 
0 
42 
0 
42 
0 
29 
66 
12 
83 
6 
89 
6 
89 
56.3 
93.1 
112.3 
112.3 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
* Pearson correlation was found significant at the 0.01 level (2-tailed) for all the 
diagnostic tests used. 
3.3.9. Follow-up results 
The clinical outcome of the followed patients, after institution of appropriate 
antifungal therapy based on MIC results in definite- and probable-IPA cases, 
and institution of itraconazole in possible- and non-IPA cases, is shown in 
Table 10. Nine of the 12 cases of definite-IPA, which could be followed, 
died during the study and only 3 could survive. Of the 16 foUowed-up cases 
of probable-IPA, 5 died and 11 patients survived. All patients of non-IPA 
group (n= 7) survived, however, 2 of the 14 followed-up patients of 
possible-IPA died and 12 survived during follow up study. Analyzing the 
diagnostic outcome of 21 patients in whom additional samples were 
117 
Clinical and Mycological Studies 
collected during follow-up, 4 patients which were initially weakly ELISA 
positive later on became positive for DID and DBA and these cases 
consistently remained positive for PCR during the whole study period. Out 
of the 17 cases that were initially serologically negative but PCR-positive, 
10 cases (8 from possible-IPA and 2 from non-IPA) later on became positive 
for serological tests. In the culture performed during follow-up, BAL of 2 
patients showed the growth of y^ . fumigatus and one of ^ 4. flavus. 
Table 10. Clinical outcome of the patients that could be followed during 
study (n=49) 
Aspergillosis type Deceased Survived 
Defmite-IPA 9 3 
(n=12) 
Probable-IPA 5 11 
(n=16) 
Possible-IPA 2 12 
(n=14) 
Non-IPA 0 7 
(n=7) 
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3.4. Discussion 
Substantial progress has been made during the past decade in the 
development of new approaches and methods for the diagnosis of mycoses, 
including, aspergillosis. Majority of the existing studies, in literature, are 
performed specifically on invasive pulmonary aspergillosis and especially in 
severely debilitated individuals. However, the prospective studies analysing 
properly the diagnostic problem of non/semi-invasive apsergillosis are 
limited. Moreover, such problem has never been studied earlier in 
bronchogenic carcinoma. Definitive diagnosis of IPA requires 
histopathological evidence of deep-tissue invasion or a positive culture from 
normally sterile sites (Denning 1998). However, invasive diagnostic 
procedures can be risky for debilitated patients (Latge 1999) and culture for 
the fungus are characterized by low sensitivity ( Levy et al. 1992; Denning 
1998). Therefore reliable non-invasive methods are essential for diagnosis 
and management of IPA in high risk patients (Sanguinetti et al. 2003). Other 
promising alternatives to culture of deep sterile sites or biopsy could be 
culture of BAL, ELISA for detection of antigen/antibody in serum, and 
PCR-based detection of Aspergillus DNA in BAL or blood. Unfortunately, 
BAL often presents with false negative results in culture and it is admitted 
that Aspergillus spp. are isolated from BAL fluid in only 50-57% of all cases 
(Albelda et al. 1984, Kahn et al. 1986, Levy et al. 1992). Circulating 
Galactomannans may be noticed in the blood of definite- or probable-IPA 
patients, but could be absent in patients where the invasion of Aspergillus to 
blood vessels has not yet occurred (non/semi-invasive type); however, 
response to antigens in the form of immunoglobulins could be present in 
such cases. 
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To categorise cases as of definite-IPA and possible-IPA, presence of 
Aspergillus is to be demonstrated in tissue histopathology or in culture. 
However, clinical outcome of the patients is still poor even if confirmed 
diagnosis is being made and proper antifungal therapy has been instituted. 
We personally feel that since a large proportion of patients are categorised as 
possible-IPA and non-IPA based on clinical, radiological and 
histopathological investigations, an alternative diagnostic approach in high 
risk patients could help minimize the poorer outcome in such patients. 
Therefore, in the present study we evaluated the role of serological tests 
(ELISA, DID, DBA) and BAL-PCR to establish the early diagnosis of 
aspergillosis in invasive and non-invasive form of aspergillosis in 
bronchogenic carcinoma patients and compared it with the conventional 
methods of detection. We have selected the study population of 
bronchogenic carcinoma because such patients are at risk of developing 
aspergillosis which could complicate the existing problem, and still the 
burden of secondary aspergillosis in bronchogenic carcinoma do not appear 
clearly in the literature. In the present prospective study, Aspergillus DNA 
could be detected in 51.8% (71/137) cases. We find BAL-culture positivity 
of 59.2% (42/71) in PCR-positivite cases. However, the BAL-culture 
positivity increased to 63.4% (45/71) during follow-up. This is not a 
significant rise when compared with the denominator of additional BAL 
samples studied. The overall frequency of the BAL-culture positivity, in 
cases having secondary aspergillosis, was in accordance with the previously 
published reports (Bretagne et al. 1995, Stynen et al. 1995). However, the 
sensitivity and PPV of culture, when compared to healthy control group, in 
definite- and probable IPA was 100% and it dropped drastically to 0% in 
cases of possible- and non-IPA. On analyzing the data against entire dataset. 
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the sensitivity of culture in definite- and probable- IPA was still 100% 
whereas the PPV dropped down to 42% and 57%, respectively. Still, the data 
analysis by both approaches denote that culture do not play significant role 
in cases of possible- and non-IPA and its diagnostic role is limited only to 
definite- and probale-IPA. Aspergillus fumigatus was the predominat species 
isolated in the present study however the high frequency of occurrence of A. 
flavus in the present study is noteworthy. Comparing the seropositivity with 
PCR-positivity, initially it was 76.1% (54/71) which increased to 90.1% 
(64/71) during follow-up. The sensitivity, specificity, PPV, and NPV of PCR 
and serological tests were 100%o for definite- and probable-IPA (when 
compared against healthy volunteers) and these values were 100%), 65.4%), 
25.4%, and 100%, respectively for definite-IPA and 100%, 68%, 33.8%, and 
100%), respectively for probable-IPA (when compared against entire dataset) 
and denotes high diagnostic values of these tests in such cases. However, in 
cases of possible- IPA, the sensitivity, specificity, PPV, and NPV of PCR 
were 69.7%), 100%), 100%o and 77.3%), respectively, when compared with 
healthy controls, and these values were 69.7%o, 65.2%, 32.4%, and 90%, 
respectively, when compared with entire dataset. Comparing these values for 
ELISA, in possible-IPA, we found them as 24.2%, 100%, 100% and 57.6%, 
respectively, when compared against healthy controls and the values were 
24.2%o, 66.7%o, 14.8%o, and 78.6%), respectively, when compared against the 
entire dataset. This strongly suggest that PCR has greater diagnostic role in 
possible-IPA as compared to that of serological tests. The diagnostic role of 
PCR was also higher than serological tests in cases with non-IPA. However, 
ELISA do play a diagnostic role in non-IPA, to an extent, as opposed to DID 
and DBA. We could not get any case which was PCR negative but positive 
by any other test performed. Since false positivity is being reported with 
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PCR (Bretagne et al. 1995), we personally feel that combining PCR with 
serological test detecting anti-aspergillus antibodies could be of help 
confirming the diagnosis of aspergillosis. This combination test strategy 
would also help establishing the diagnosis in patients without signs of 
infiltration in radiological investigations. We also feel that performing PCR 
on consecutive BALs would help taking the decision to institute the 
antifungal therapy since we noticed that 10 (58.8%) out of 17 patients 
which were initially serologically negative, but PCR-positive, later on 
seroconverted into positive results. 
This preliminary investigation suggests that both BAL-PCR and 
serological tests detecting anti-Aspergillus antibodies might be beneficial for 
use in early diagnosis of aspergillosis, especially in patients which do not 
demonstrate signs of infiltration in radiology. Noticing the time required for 
analysis of results, DID could be analysed within 24-48 h, PCR < 24 h, 
ELISA < 5 h, and DBA in < 2 h. However, the detection time was 
significantly reduced to < 45 min when, in limited cases, we utilized the 
technique of counter current immunoelectrophoresis instead of DID. To 
establish firmer diagnosis, any of the above-mentioned serological tests, 
preferably ELISA, should be combined with PCR and the results can be 
forwarded to the clinician on the day following the BAL. The laboratories 
which do not have the facilties for ELISA may utilize the technique of 
immunodiffusion or DBA. However, further carefully designed prospective 
studies need to be performed in order to evaluate the accurate diagnostic 
values of these assays. Based on the present study, we propose a 
diagnostic/therapeutic protocol to establish firmer diagnosis of secondary 
aspergillosis in bronchogenic carcinoma patients as shown in Fig. 16. 
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Fig. 16. Schematic representation of the diagnostic /therapeutic protocol. 
Foot-notes to Fig. 16. 
BAL-culture with any of the serological test mentioned above, or BAL-
PCR, is suggested to confirm aspergillosis in defmite-IPA. In probable-
IPA, BAL-culture, any of the serological test, and BAL-PCR is 
suggested (although sensitivity and PPV of serology and BAL-PCR was 
100% in present study, few other studies showed slightly lower 
sensitivities to these tests). In possible- and non-IPA cases, BAL-culture 
along with ELISA, and BAL-PCR is suggested to confirm the diagnosis. 
^ Positive ELISA with PCR-positivity confirms the diagnosis of 
secondary aspergillosis. 
^ Follow-up the patients, judge the severity of illness, and correlate 
clinically to initiate the antifungal therapy. 
Positive seiobgy Negative serobgy 
Fig 16 Diagnostic/therapeutic protocol to establish firmer diagnosis 
of secondary aspergillosis m bronchogenic carcinoma patients 
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To conclude, based on the present prospective study, we noticed the 
frequency of secondary aspergillosis, at least, to be 46.7% (64/137; cases 
positive both by PCR and serology) in bronchogenic carcinoma which 
demonstarte the frequent association of this combination disesase. This 
premier finding is quite alarming and we suggest that every patient of 
bronchogenic carcinoma should be screened for the presence of secondary 
aspergillosis. Combination of PCR and serological tests, especially ELISA, 
detecting anti-Aspergillus antibodies should be performed to make early 
diagnosis and institution of antifungal therapy; however the laboratories 
which do not have facilities for PCR and ELISA should at least perform DID 
or DBA by the proposed protocol. This is among the premier reports 
defining the high frequency and evaluating various diagnostic tests for 
secondary aspergillosis in bronchogenic carcinoma patients. 
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CHAPTER 4 
4. BACTERIOLOGICAL STUDIES 
4.1. Brief Introduction 
The frequency of secondary bacterial lung infection is high in lung 
malignancies due to the immunosuppressive state. The studies looking for 
the bacterial profile in BAL-fluids from patients of bronchogenic carcinoma, 
and especially the Extended-spectrum (3-lactamases (ESBLs) producing 
isolates, are fragmentary. ESBLs are enzymes manifesting considerable 
hydrolytic activity on a wide variety of P-lactam antibiotics including 
oxyimino- cephalosporins and aztreonam, and are inhibited by clavulanic 
acid. AmpC ^-lactamases are clinically important because they may confer 
resistance to a wide variety of P-lactam drugs, including a-methoxy-P-
lactams, such as cefoxitin, narrow-, expanded-, and broad-spectrum 
cephalosporins, P-lactam-beta-lactamase-inhibitor combinations, and 
aztreonam. 
In recent years, non-TEM and non-SHV class A extended spectrum p-
lactamases (ESBLs) have been increasingly reported, especially the CTX-M 
types (Vahaboglu et al. 1995; Shannon et al. 1998a; Shannon et al. 1998b; 
Poirel et al. 1999; Tzouvelekis et al. 2000; Poirel et al. 2000; Walther-
Rasmussen & Hoiby 2004; Bonnet 2004; Livermore & Hawkey 2005; Ensor 
et al. 2006b). The first CTX-M ESBL was described in Germany 
(Bauemfeind et al. 1996b), and since then more than 50 variants have been 
reported (http://www.lahey,org/studies/inc_webt.asp). In the last few 
decades CTX-M ESBLs have very rapidly disseminated and are now 
frequently reported from countries all over Europe (Bou et al. 2002; 
Markovska et al. 2004; Woodford et al. 2004; Munday et al. 2004a; 
Livermore & Hawkey 2005; Kim et al. 2005; Oliver et al 2005) and much 
of Asia (Pai et al. 2001; Nagano et al. 2003; Munday et al. 2004b). 
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Epidemiological reports demonstrate that some enzymes are more frequently 
reported than others, that predominant enzyme tj.'pe varies with country and 
that diverse CTX-M types often exist within a single country (Livermore & 
Woodford 2006). 
In India, the very first report of the presence of CTX-M-producing 
Enterobacteriaceae came from New Delhi (Karim et al. 2001). Six isolates 
from 2000 were investigated, all of which were found to be unrelated and all 
produced CTX-M-15. Since then several Indian surveys have reported the 
presence of ESBLs in clinical isolates based on phenotypic tests. Recent 
reported rates vary widely (12.6-71%) (Datta et al. 2004; Grover et al. 
2006), with most studies reporting a prevalence rate of around 50% and 
upwards. Considering a population of-1.1 billion in India, this represents a 
very large reservoir of resistance genes. We were unable to find any report in 
our search of the literature using the Entrez PubMed database provided by 
the National Centre for Biotechnology Information 
(www.ncbi.nlm.nih.gov/entrez) that specifically looked for blacjx-M and then 
determined the precise genotype present, except one of our recently 
published report (Ensor et al. 2006b) and which included few of the isolates 
from this Doctoral work. 
It is interesting to note that CTX-M-15 is the only existing type, 
reported to date, in India however, diversity of CTX-M types within a single 
country have been reported (Chanawong et al. 2002; Dutour et al. 2002; 
Munday et al. 2004b; Kim et al. 2005; Shibata et al. 2006). Therefore, we 
found worth looking occurrence of CTX-M genogroups, specific CTX-M 
types, and their genetic environment in CTX-M carrying- E. coli and K. 
pneumoniae isolates obtained from bronchogenic carcinoma patients; and to 
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compare any relatedness or diversity with those of isolates obtained from 
other clinical sources. 
Bacteria over expressing AmpC p-lactamases are of major clinical 
concern because they confer resistance to a wide variety of ^-lactams, P-
lactam- P-lactamase inhibitor combinations, and monobactams, but are 
susceptible to fourth generation cephalosporins (4GC) and carbapenems 
(Girlich et al. 2000; Thomson & Moland 2000; Perez-Perez & Hanson 
2002). However, isolates simultaneously harbouring extended-spectrum P-
lactamases (ESBLs) show resistance to 4GC as well; and loss of outer 
membrane porins together with plasmidic AmpC result in carbapenem 
resistance and thus may create serious therapeutic problems. Plasmid 
encoded AmpC p-lactamases are produced by numerous pathogens 
(Bauemfeind ef al. 1998) and the emergence of plasmid-mediated AmpC P-
lactamase producing strains is well recognized (Gazouli et al. 1996; 
Philippon et al 2002; Alvarez et al. 2004). Phenotypically bacteria resemble 
chromosomal class C P-lactamase-producers in that they confer resistance to 
cephalosporins and cephamycins such as, cefoxitin, and are not inhibited by 
P-lactam-p-lactamase inhibitors (Bush et al. 1995). Despite increased 
interest in the recognition and surveillance of ESBLs, the worldwide 
distribution and prevalence of AmpC-mediated resistance is fragmentary. 
This is due in part to the limited number of surveillance studies seeking 
clinical strains producing AmpC P-lactamases and the difficulty that 
laboratories have in accurately detecting these resistance mechanism(s) 
(Hanson 2003) particularly as there are no published CLSI (formerly 
NCCLS) criteria (Thomson 2001). Acquisition of ampC-type genes by 
plasmids in K. pneumoniae and E. coli has been known since 1989, but only 
recently they are being reported with increasing frequency (Moland et al. 
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2002; Alvarez et al. 2004). Despite of increasing recognition of this 
resistance mechanism worldwide, there is paucity of data from India (Shahid 
et al. 2003; Shahid et al. 2007c), and most studies only present phenotypic 
data (Manchanda & Singh 2003; Subha et al. 2003). In our search of the 
scientific literature from the Indian subcontinent, we found only two 
publications that have characterized /^flampc at the molecular level, and these 
report the presence of Z?/flBiL-i-like and blacMY-4 (M'Zali et al. 1997; Cao et 
al. 2000). 
Keeping in mind the fact of paucity of Indian molecular studies in 
existing literature, and specifically, the global unavailability of data on the 
current aspect in bacterial isolates obtained from BAL of bronchogenic 
carcinoma patients, the present study was designed with the following 
specific objectives: 
Aims and Objectives 
• To find out the frequency of ESBL phenotype in E. coll and K. 
pneumoniae isolates obtained from BAL of bronchogenic 
carcinoma patients, 
• To study the occurrence of CTX-M genogroups and specific 
CTX-M types present in the isolates, and 
• To determine their genetic environment. 
• To study the frequency of the AmpC phenotype in isolates of £. 
coli and K. pneumoniae, 
• To identify the occurrence, prevalence and precise type of 
bla^^c genes, 
• To find out the frequency of co-carriage of bhampc with blacTx-
M-
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• To analyze the plasmids in isolates simultaneously carrying 
bla^pc and blacrx-u, and 
• To find out any relatedness or diversity in blacjx-M and bhampc -
carrying isolates by RAPD-typing, and also to compare with 
some of the representative isolates obtained from other clinical 
sources. 
4.2. Materials and methods 
4.2.1. Direct Microscopy 
Direct microscopic examination of the BAL was performed by Gram's-
staining and examined for the presence of Gram-positive or negative 
cocci/bacilli. The portion of the BAL collected for direct microscopic 
examination by KOH and LPCB mounts was used to perform Gram's-
staining. 
4.2.2. Bacterial Culture and identiflcation 
BALs were subjected to bacterial culture on Blood agar, Mac Conkey's agar, 
and chocolate agar. The Blood agar and Mac Conkey's agar plates were 
incubated aerobically, and chocolate agar plates in CO2 enriched 
environment, in candled jar, at 37° C overnight, and the organisms were 
identified as per standard techniques (Anonymous b 1996). 
4.2.3. Clinical isolates for study 
Of the various bacterial isolates obtained from the culture of BAL 
specimens, only the isolates of £•. coli and K. pneumoniae were selected for 
further phenotypic and molecular studies. The bacterial population consisted 
oiE. coli (n=21) and K. pneumoniae (n=41) 
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4.2.4. Control strains used during antibiotics susceptibility, phenotypic 
ESBL and A/ACTX-M and A/flampc detection 
E. coli ATCC 25922, E. coll ATCC 35218, K. pneumoniae ATCC 700603, 
and ESBL producing isolates, as used in our previous studies (Shahid et al. 
2004, Shahid et al. 2007b), were used as control strains for susceptibility 
testing and phenotypic ESBL detection. For molecular studies (multiplex 
PCR CTX-M) the control strains used were of group 1: CTX-M-1, -3, and -
15; group 2: CTX-M-2; group 8: CTX-M-8, and -26 and group 9: CTX-M-9, 
and -13. The control strains were those used in our previous studies (Ensor et 
al. 2006a; Ensor et al. 2006b). 
The control strains carrying ampC genes of groups- CIT {E. coli J53 
pMG250), DHA {E. coli J53 pMG247), ACC {E. coli J53 pSLK54), EBC 
{E. coli J53 pMG251 and E. coli J53 pMG233), and FOX {E. coli J53 
pMG252) were used during multiplex PCR for bhampc detection. 
4.2.5. Antibiotics susceptibility testing 
Disk susceptibility tests were performed against the first and second line 
antibiotics prescribed in our institution and interpreted according to CLSI 
(formerly NCCLS) criteria (NCCLS 2003) by using Mueller-Hinton agar 
(HiMedia Lab. Ltd., India). The antibiotics used and their concentrations 
(|j.g) were: ampicillin (10), co-trimoxazole (trimethoprim/sulfamethoxazole, 
1.2/23.8), tetracycline (30), amikacin (30), gentamicin (10), tobramycin (10), 
cefotaxime (30), ceftazidime (30), cefpodoxime (10), cefpirome (30), 
cefepime (30), cefoxitin (30), aztreonam (30), ciprofloxacin (1), 
trimethoprim (2.5), meropenem (10), piperacillin (100), 
piperaciDin/tazobactam (100/10), ticarcillin (75), and ticarcillin/clavulanate 
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(75/10). The antibiotics disks used were from HiMedia Lab. Ltd., India, 
except piperacillin, piperacillin/tazobactam, and meropenem, which were 
obtained from Oxoid, Basingstoke, UK. In vitro efficacy of 
ceftriaxone/sulbactam (30/15), a recently launched combination in India, 
was also evaluated in isolates of E. coli and K. pneumoniae. The 
ceftriaxone/sulbactam antibiotics disks were kindly provided by Ranbaxy 
Lab. Ltd., Gurgaon, India. Since there are no published breakpoints for 
ceftriaxone/sulbactam combination, the susceptibility criteria used for this 
combination was >8 mm increase in zone diameter of ceftriaxone-sulbactam 
in comparison to that of ceftriaxone alone, as adopted in our recent study 
which included few isolates from the present Doctoral study (Shahid et al. 
2007b). 
4.2.6. ESBL studies with special reference to CTX-M-types 
4.2.6.1. Phenotypic ESBL detection by disk synergy tests 
Phenotypic ESBL detection was performed on all the isolates of £. coli and 
K. pneumoniae by disk synergy tests (using co-amoxiclav (Jarlier et al. 
1988) and piperacillin-tazobactam discs (Shahid et al. 2007b) as a source of 
inhibitors. Phenotypic detection was also performed by combination disk 
method using cephalosporin disks alone, and in presence of clavulanate. 
4.2.6.1.L Conventional disk synergy test using co-amoxyclav discs 
(Jarlier et al. 1988) 
For the disk synergy test by using co-amoxyclav, the test inoculums (0.5 
McFarland turbidity) were streaked on Mueller-Hinton agar. Disks of co-
amoxiclav (20/10 |ig) were placed 20 and 30 mm, center to center, from 
disks containing cefotaxime (30 |ig), ceftazidime (30 i^g) and cefpirome (30 
^g) (cefpirome was used as an indicator for simultaneous production of 
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ESBL and AmpC enzymes) and plates were incubated at 37 °C overnight. 
Another set using ceftriaxone, ceftazidime, cefpirome, and co-amoxyclav 
was put to analyze the sensitivity of the respective cephalosporins in ESBL 
detection. Enhancements of zones of inhibition of cephalosporins towards 
amoxicillin-clavulanate were considered as positive ESBL results. All tests 
were performed in duplicate. 
4.2.6.1,2. Disk synergy test using piperacillin/tazobactam disks (Shahid 
et al 2007b) 
The test inoculums (0.5 McFarland turbidity) were streaked on Mueller-
Hinton agar. Disks of piperacillin-tazobactam (100/10) were placed 20 and 
30 mm, center to center, from discs containing cefotaxime (30 jag), 
ceftazidime (30 |ig) and cefpirome (30 p.g) and plates were incubated at 37 
°C overnight. Similar to the methodology used above, another set using 
ceftriaxone, ceftazidime, cefpirome, and piperacillin/tazobactam was put to 
analyze the sensitivity of the respective cephalosporins in ESBL detection. 
Enhancements of zones of inhibition of cephalosporins towards piperacillin-
tazobactam were considered as positive ESBL results. All tests were 
performed in duplicate. 
4.2.6. L3. ESBL detection by combination disk method 
The combination disc test (CDT) method using cefpodoxime alone and in 
the presence of clavulanate, cefotaxime versus cefotaxime plus clavulanate, 
and ceftazidime versus ceftazidime plus clavulanate was used for the 
detection of ESBL in E.coli and K. pneumoniae. ESBL production was 
inferred to be present when the inhibition zone was enhanced by at least 
5mm in the presence of clavulanate compared to that of the third generation 
cephalosporin alone. To detect ESBL production in isolates simultaneously 
producing an AmpC-type P-lactamase (those demonstrating resistance to 
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cefoxitin), combination discs containing the fourth generation cephalosporin 
cefepime, alone and with clavulanate (Oxoid, Basingstoke, UK) were used 
as recommended by the British Society for Antimicrobial Chemotherapy and 
Health Protection Agency 
(http://www.bsac.org.uk/_db/_documents/qsop51 il. 1 .pdf). Simultaneous 
AmpC production was inferred to be present when the inhibition zone was 
enhanced by at least 4mm in the case of cefepime, as detailed in the 
manufacturers instructions (Oxoid, Basingstoke, UK). 
4.2.6.2. Multiplex PCR for detection oiblacjx-u 
4.2.6.2.1. Preparation of DNA template 
Template DNA was prepared from freshly cultured bacterial strains by 
touching two or three discrete colonies and suspending the collected material 
in 50 |iL of molecular grade water, and then heating at 95°C for 5 min and 
immediately chilling at 4°C. 
4.2.6.2.2. PCR Reaction 
Each reaction consisted of 21.75 |iL of Mastermix (ABgene, Epsom, UK), 
0.25 (iL of each primer (100 pmol) (the primers used in the study are shown 
in Table 11) and 2.0 |iL of template DNA. PCR conditions were as follows: 
1 cycle at 95°C for 5 min followed by 25 cycles of 95°C for 30 s, 63°C for 
30 s and 72°C for 1 min, with a final elongation at 72°C for 10 min. 
Amplicons were finally visualized using a transilluminator in a Gel 
documentation system (Genei, India) , after running on 2% agarose gel at 
150 V for 2 h and staining inethidium bromide, and the precise size of the 
band was determined using the software provided with the Gel 
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documentation system. The presence of a band of the predicted size 
indicated carriage of 6/acTx-M by the test isolate, and CTX-M phylogenetic 
groups were identified by the amplicon size (see Table 11 for detailed 
description). 
Table 11. Primers used for multiplex PCR for detection of CTX-M 
groups, and for sequencing reactions, and predicted amplicon sizes for 
different CTX-M groups 
Targets Primer sequence (5' to 3') Amplicon size (bp) 
Multiplex PCR for 
CTX-M groups 
Group 1 F- GCS' ATG TGC AGC ACC AGT AA 666 
R- ACA AAC CGT Y'GG TGA CGA TT 
Group 2 F- CTC AAT AS'C GCC ATT CCA GG 355 
R- CCG TGG GTT ACG ATT TTC GC 
Group 8/25 F- GCS' ATG TGC AGC ACC AGT AA 529 
R- GTC GTA CCA TAA Y'CR' CCG CT 
Group 9 F-AR'TGCAACGGATGATGTY'CG 846 
R- GAT GAT TCT CGC CGC TGA AG 
Sequencing primers for 
CTX-M type 
F-AAA AAT GAT TGA AAG GTG GT 
R-CAG CGC TTT TGC CGT CTA AG 
^Oligonucleotides with degenerate bases S, Y or R were synthesized as an equal mixture 
of G and C, C and T or A and G, respectively. 
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4.2.6.3. Reverse line hybridization (RLH) 
The reverse line hybridization assay was performed according to the method 
of Ensor et al (2006a) to know the precise CTX-M-types in the bacterial 
isolates. However, the RLH was performed only in 14 isolates taken from 
this study, which were carried to U.K. (Ensor et al. 2006b), along with 
bacterial collection from other specimens, during the Commonwealth 
Academic Fellowship availed by the candidate of this Doctoral work. 
Remaining 48 isolates could not be characterized by RLH because of lack of 
facilities for RLH in the present Indian laboratory. However, representative 
isolates from these remaining bacteria were sequenced to know the exact 
CTX-M-type. 
4.2.6.3.1. Control strains 
The control strains used in RLH were producing following B-lactamases: 
group 1: CTX-M-1, -3,-12,-15 and -32; group 2: CTX-M-2, -6, -7 and 
Toho-1; group 8: CTX-M-8, -26 and group 9: CTX-M-9, -13,-14, -17 and-
] 9 (Ensor et al 2006a, Ensor et al. 2006b). 
4.2.6.3.2. Methodology for RLH 
The oligonucleotides used for performing RLH are shown in Table 12. 
Oligonucleotides were synthesized by MWG Biotech-AG, Ebersberg, 
Germany with an amino-link at the 5' terminus for covalent binding to 
activated carboxyl groups on the membrane. 
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Table 12. Oligonucleotides designed for reverse-line hybridization assay 
CTX-
M 
group 
1 
Sequence (5' 
—>3' (modified 
at C6 of 5'end 
with amino-
iink) 
GAG ATC 
AAA AAA 
TCT GAG 
YTT GTT 
AAC 
CGG GAG 
GGG TGG 
CTATG 
GGG GAG 
GGG TGA 
CTA TGG 
GGG GGA 
AAG TCT 
GGG TAA 
TCT 
GGC GGA 
AAC TCT 
GGG CAA 
TCT 
TCT GAG 
GTT GTT 
AAG TAT 
Length 
27 
17 
18 
21 
21 
25 
(bp) 
Binding 
position(taking 
base A of start 
codon ATG of 
bla„x-u ORF as 
first base) 
295-321 
714-731 
714-732 
567-587 
567-587 
307-331 
T . (°C) 
58.1 
60.0 
60.5 
59.8 
61.8 
59.7 
Optimum 
concentration 
(pmol/tiL)" 
10 
25 
10 
10 
10 
Untested 
Actual optimal was 
temperature (°C) 
65 
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AGT CCG A 
GGC CGC 
GGC CGC 
CGT 
GGG ATA 
AAA CCG 
GCA GCT 
GTG 
CAC TGG 
CTG AGC 
TCA GCG 
CGG GCG 
GGT CTG 
CCG 
GGC GGA 
AAG GCG 
TCGG 
GTC GGG 
ATA TTC 
TGG CTG 
GTC GGG 
AGT TTC 
TGG CTG 
GTC GGG 
ATG TTC 
TGG CTG 
GGC AGC 
GGA GGT 
TATGG 
21 
15 
16 
17 
234-248 
704-724 
362-379 
673-687 
816-831 
827-844 
827-844 
827-844 
715-731 
64.2 Untested 
61.8 Untested 
60.5 Untested 
61.5 10.0 
59.4 1.0 
56.0 5.0 
58.2 5.0 
58.2 5.0 
57.6 Untested 
62 
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GTTATC 19 
TGG CCG 
GCA AAC C 
8/25 GATGGC 15 
GGT AGC 
GGC 
751-769 58.8 Untested 
GAT GGC 
GGC AGC 
GGC 
GCT GCC 
AGC ATT 
CGGGC 
GCT GCC 
GGC ATT 
CAGGC 
GAT GGC 
AGC CGC 
GGC 
CCT CAG 
ACT TGG 
TTAAC 
GGC AGC 
GGC GAC 
TACG 
TGC CCG 
CGA GAT 
CGGC 
GAC GAG 
TGC GGG 
231-245 59.4 1.0 
15 231-245 62.0 1.0 
17 661-677 60.0 1.0 
17 661-677 57.6 1.0 
15 231-245 58.8 Untested 
20 302-321 57.3 Untested 
16 715-730 59.4 1.0 
16 462^77 59.4 10.0 
16 87-102 59.4 10.0 
58 
58 
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GCAG 
GACGCT 17 360-376 57.6 25.0 
GGC AGA 
GCTGA 
GTTATG 16 229-244 56.9 Untested 
GCG GTC 
GCGG 
CAGAAC 16 811-826 56.9 Untested 
GCA GAG 
CGCC 
GCGCGG 15 377-391 58.8 Untested 
CCG CTT 
TGC 
GCTGGG 15 141-155 58.8 Untested 
CGT CCC 
GCT 
GAG AAA 19 123-139 58.8 Untested 
AGC AGC 
GGA AGG C 
GGC AGC 15 715-729 58.8 Untested 
GGC GGC 
TAC 
^Those labelled untested were not used experimentally as no suitable standard strains were 
available. 
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4.2.6.3.2.1. Preparation of the membrane for reverse line hybridization 
Biodyne C Negatively Charged Nylon Membrane with a pore size of 
0.45 |Lim (Pall Gelman Laboratory, Portsmouth, UK) was cut to the size of a 
support cushion (Immunetics, Boston MA, USA). The membrane was 
activated by washing with 10 mL of 16% A^-(3-dimethylaminopropyl)-yV-
ethyJcarbodiimide hydrochloride (EDAC) solution (Sigma-Aldrich, 
Gillingham, UK) at room temperature for 15 min, then was rinsed with 
distilled water for 2 min, marked for orientation, and placed on the support 
cushion before being inserted into the immunoblotter (Miniblotter MN45; 
Immunetics). 
4.2.6.3.2.2. Applying oligonucleotides to the membrane 
Due to differences in optimal hybridization and washing temperatures, 
separate membranes were prepared for each CTX~M group-specific panel of 
oligonucleotides. The optimal concentration for each oligonucleotide was 
determined by performing a series of titration experiments. Each 
oligonucleotide was then diluted to its optimal concentration in 0.5 M 
NaHCOj. pH 8.4 (BDH, Poole, UK) and 150 ^L of the diluted solution was 
applied to the membrane by pipetting into a lane of the immunoblotter, with 
care to avoid the formation of air bubbles. After 1 min, excess 
oligonucleotide was aspirated and the membrane deactivated by washing in 
100 mM NaOH (BDH) for 8 min. 
4.2.6.3.2.3. Applying amplicons to the membrane for hybridization 
A membrane with appropriate group-specific oligonucleotides was selected 
according to the CTX-M group detected by multiplex PCR. After washing at 
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50°C in 0.1% SDS/2 x SSPE for 10 min, the membrane was placed on a 
fresh support cushion and re-inserted into the immunoblotter at 90° to its 
original orientation. Excess solution was aspirated from each lane. Amplicon 
(10 jLiL) was added to 150 |iL of 0.1% SDS/2 x SSPE, heated at 95° C for 
5 min and immediately placed on ice to ensure the amplicon remained single 
stranded. Each lane of the immunoblotter was then filled with 150 |iL of 
amplicon/SDS/SSPE solution. Lanes 1 and 45 were filled with 0.1%) SDS/2 
x SSPE without amplicon, as was any unused lane. The immunoblotter 
holding the membrane was then transferred to an oven for hybridization at 
50 °C for 45 min, after which excess amplicon was aspirated from each lane 
using a pipette. 
4.2.6.3.2.4. Detection of specific hybrids 
To remove non-specific hybrids, the membrane was taken from the 
immunoblotter and washed twice for 10 min in 0.5% SDS/2 x SSPE at the 
predetermined opfimal wash temperature (Table 12). It was then washed in 
10 mL of 0.5% SDS/2 x SSPE containing 5 |iL 500 U streptavidin-
peroxidase conjugate (Roche Applied Science, Penzberg, Germany) for 
30 min at 42 °C. Unbound conjugate was removed by washing twice, each 
for 10 min, in 0.5%) SDS/2 x SSPE at 42 °C, followed by two more washes 
in 2 X SSPE, each for 5 min at room temperature, to remove any SDS. 
Hybrids were visualized by enhanced chemiluminescence (ECL, Amersham 
Biosciences, Amersham, UK) and exposure to a light-sensitive film 
(Hyperfilm ECL; Amersham Biosciences, Amersham, UK) used according 
to the manufacturer's instructions. 
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4.2.6.3.2.5. Interpretation of hybridization patterns 
The expected hybridization profile for each CTX~M genotype was predicted 
based upon the correspondence of each CTX-M-encoding region and each 
oligonucleotide sequence. Optimal oligonucleotide concentration and 
washing temperatures were determined using a concentration/temperature 
titration approach, until the observed profiles for the controls of each 
genotype available matched the predicted patterns. For those CTX-M 
genotypes not available to us for testing, a profile was predicted. Table 13 
lists the confirmed and the predicted hybridization profiles for all currently 
described members of each CTX-M group. Frequently reported genotypes 
are indicated in bold. 
4.2.6.4. Nucleotide sequencing 
Twelve of the 14 isolates, taken to U.K., and found to carry blacjx-M were 
randomly selected for DNA sequencing of the blacTx-M open reading frame 
(ORF) in order to confirm the RLH result. Whole ORF was amplified using 
primers ISEcpl Ui (5'-AAA AAT GAT TGA AAG GTG GT-3') and P2D 
(5'-CAG CGC TTT TGC CGT CTA AG-3'), generafing a fragment of ca. 
1300 bp which contained the complete CTX-M coding region. The PCR 
protocol used was that of Munday et al. (2004b) as adopted previously 
(Ensor et al. 2006b). Briefly, bacterial DNA was prepared by suspension of 
one or two fresh colonies in 50 \i\ of sterile disfilled water and heafing at 95 
°C for 5 min. PCR amplificafion was carried out under the following 
conditions: 95 °C for 3 min, followed by 30 cycles of 95 °C for 1 min, 55 °C 
for 1 min, and 72 °C for 1 min, with a final extension at 72 °C for 10 min. 
The sequence of the ca. 1300 bp fragment containing the whole ORF of 
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bhcTx-M was determined using a Big Dye PCR reaction (Applied Biosystems 
Inc, Foster city, CA, USA) and analyzed on a Primus HT 3700 DNA 
analyzer by the Functional Genomics & Proteomics Laboratory, University 
of Birmingham, UK. From the remaining 48 isolates, 8 were randomly 
selected for sequencing, which was performed by courtesy of Bangalore 
Genei, Bangalore, India. Remaining isolates could not be sequenced due to 
high cost incurring in commercial sequencing and our Indian lab presently 
do not have sequencing facilities. 
4.2.7. Association oflS26 with hlucixMAs (Genetic environment) 
Recently the presence of IS2(5 in the predominant UK CTX-M-15-
producing E.coli clone, designated Clone A, was reported (Woodford et al 
2004). To determine whether these Indian isolates also carried this particular 
insertion element, all CTX-M-15-carrying isolates were screened using the 
PCR protocol described by Woodford et al. (2004). The primers used for 
PCR were 5'-GCG GTA AAT CGT GGA GTG AT-3' and 5'-ATT CGG 
CAA GTT TTT GCT GT-3' and the PCR amplification conditions were: 
initial denaturation at 94°C for 5 min; 30 cycles of 94°C for 25 s, 52°C for 
40 sand 72°C for 50 s; and a final elongation at 72°C for6 min. 
A separate collection of bacteria from different specimens, collected 
for a parallel ongoing study, and detected to carry bhcrx-M, was also 
analyzed for the IS2<5 elements and compared with the isolates of this study 
in order to determine any similarity or dissimilarity in IS26 amplicon 
insertions in the two collections. 
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Table 13. Hybridization profiles for CTX-M genotypes by group 
CTX-M group 1 CTX-M group 2 CTX-M group 8/25 CTX-M group 9 
CTX-M hybridization CTX-M hybridization CTX-M hybridization CTX-M hybridization 
genotype profile^ genotype profile' genotype profile" genotype profile" 
CTX- 1-^,1-7 CTX- 2-3,2-9 CTX-M- 8 -2 ,8^ CTX- 9-4,9-15 
M-l,- M-2, - 8 M-9 
36,-37 31,-35 
CTX- 1-2,1-4 CTX-M- 2-3,2-9,2- CTX-M- 8 -1 ,8^ CTX-M- 9-4,9-9 
M-3, - 4 12 25 13 
22, -42, -
52,-54 
CTX- 1^ ,1 -7 ,1 - CTX-M- 2-3,2-11, CTX-M- 8-2,8-3 CTX- 9-4 
M-IO 13 5 2-12,2-14 26 M-
l4/18^-
17,-19,-
48 
CTX-M- 1-2,1-3,1- CTX-M- 2-3,2-11 CTX-M- 8 -2 ,8^ CTX-M- 9-15,9-23 
11 11 6 39 16 
CTX-M- 1 ^ CTX-M- 2-3,2-11 CTX-M- 8-^1,8-5 CTX-M- 9-4,9-11 
12,-23 7 40 21,-38 
CTX- 1-2,1-3 CTX-M- 2-3,2-9,2- CTX-M- 8-2,8-4,8- CTX-M- 9-4,9-19 
M-15, - 20 10 41 6 24 
28 
CTX-M- 1-3 CTX-M- 2-3,2-8,2-
29 43 9,2,13 
CTX-M- 1^ , 1-9 TOHO-1 2-3,2-8,2-
30 9 
CTX-M- 1-3, 1-7 
32 
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CTX-M- 1-2,1-3,1- CTX-M- 9 ^ , 9 - 2 1 , 
33 10 49 9-22 
CTX-M- 1-4,1-7,1- CTX-M- 9-4,9-15, 
34 12, 1-13 51 9-18 
CTX-M- 1-3,1-7,1- TOHO-2 9-4,9-20 
53 13 
"First number of oligonucleotide indicates phylogenetic group (i.e. 1, 2, 8/25, 9). Second 
number indicates individual group specific oligonucleotide. Common CTX-M genotypes 
are indicated in bold type. 
''Open-reading frame DNA sequences identical on GenBank. 
4.2.8. AmpC studies 
4.2.8.1. Phenotypic detection of AmpC production , 
Since there are no published CLSI criteria for phenotypic screening or 
confirmatory test for AmpC (3-lactamases, a modified three-dimensional test 
(MTDT) using the whole bacterial colony as well as Enzymic extract of the 
bacterial cells, as described previously (Shahid et al. 2004), was used for the 
detection of AmpC ^-lactamase. The isolates selected for the TDT were 
those which were screen positive i.e. those with cefoxitin zone diameter of < 
18 mm and cefoxitin susceptible isolates (based on cefoxitin disk 
susceptibility) but were found to carry bla^^pc alleles. 
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4.2.8.1.1. Methods of MTDT 
4.2.8.1.1.1. Method directly using the bacterial isolates 
Lawn cultures of E. coli ATCC 25922 were prepared on Mueller-Hinton 
agar and the plates were incubated for 15 min at 37 °C, for drying. After 
drying for 15 min, five to six colonies were spot inoculated at a distance of 
10-12 nim. Cefoxitin (30^g) disks were placed centrally on the respective 
plates and overnight incubation at 37 °C was carried out. All the results were 
replicated in at least three separate experiments. 
4.2.8.1.1.2. Method using the enzymic extract 
Approximately, iO-15mg of bacterial wet weight was scraped from the 
culture plate using a sterile wire loop and suspended in 0.5mL of peptone 
water in a sterile microcentrifuge tube and incubated at 37 °C for 1 h. Crude 
enzyme extract was prepared by thrice repeated freeze-thawing. Lawn 
cultures of E. coli ATCC 25922 were prepared as described previously and 
cefoxitin (30|ig) disks were placed on respective plates. Circular wells were 
made with the broad end of a Pasteur pipette, at a distance of 7-8mm from 
the edge of the cefoxitin disks and fifty microlitres of enzyme preparation 
from respective bacteria was dispensed in wells. The inoculated media were 
incubated overnight at 37 °C. Enhanced growth of the surface organism 
around the wells towards the cefoxitin disks was interpreted as evidence for 
the presence of AmpC enzymes. Inhibition of zone distortion when 
cloxacillin or co-amoxiclav discs in enzyme extracts were used confirmed 
AmpC production. 
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4.2.8.2. Phenotypic detection of simultaneous ESBL and AmpC 
production 
To detect simultaneous ESBL and AmpC-type (3-lactamases, combination 
disks containing third generation cephalosporin, alone and with clavulanate 
as well as fourth generation cephalosporin cefepime, alone and with 
clavulanate (Oxoid, Basingstoke, UK) were used as recommended by the 
British Society for Antimicrobial Chemotherapy and Health Protection 
Agency (http://www.bsac.org.uk/_db/_documents/qsop51 i 1.1 .pdf). 
Simultaneous production of ESBL in the presence of AmpC was inferred 
when the inhibition zone was enhanced by at least 4mm in the case of 
cefepime, as detailed in the manufacturers instructions (Oxoid, Basingstoke, 
UK). 
Noticing the rewarding results of phenotypic detection of ESBLs by 
disk synergy test with piperacillin/tazobactam, simultaneous production of 
ESBLs and AmpC enzymes was also determined by utilizing the disk 
synergy between piperacillin/tazobactam and cefpirome disks. 
4.2.8.3. blttampc Detection by multiplex PCR 
All the isolates included in this study were screened for bla^^c alleles by 
multiplex-PCR. For detection of Z)/(3ampC alleles, the protocol described by 
Perez-Perez & Hanson (2002) was used with minor modifications. 
4.2.8.3.1. Preparation of template DNA 
A single colony of each organism was inoculated into 5 ml of Luria-Bertani 
(LB) broth and incubated overnight. Cells from 2 ml of the overnight culture 
were harvested by centrifugation at 12,000 rpm for 5 min. The pellet was 
resuspended in 500 \i\ of sterile distilled water and the cells were lysed by 
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heating at 95 °C for 10 min. Cell debris was removed by centrifiigation, and 
the supernatant (2 \i\) was used as the source of template for amplification. 
4.2.8.3.2. Multiplex-PCR for bla^^^c detection 
The protocol described by Perez-Perez & Hanson (2002) was used with 
minor modifications. Briefly, reaction containing 20 mM Tris-HCl (pH 8.4); 
50 mM KCl; 0.2 mM each deoxynucleoside triphosphate; 1.5 mM MgCh; 
0.6 ^M primers MOXMF, MOXMR, CITMF, CITMR, DHAMF, and 
DHAMR; 0.5 i^M primers ACCMF, ACCMR, EBCMF, and EBCMR; 0.4 
\M primers FOXMF and FOXMR; and 1.25 U of Taq DNA Polymerase 
(Banglore Genei, India) was used. The details of the primers used for 
amplification are listed in Table 14. PCR was performed with a final volume 
of 50 \i\ in 0.5 ml PCR tubes. Two \i\ of template DNA was added to 48 1^ 
of the master mixture. The PCR cycle consisted of an initial denaturation 
step at 94 °C for 3 min, followed by 30 cycles of 94 °C for 30 sec, 64 °C for 
30 sec, 72 °C for 1 min, and a final elongation at 72 °C for 10 min. Two-
microliter of PCR products was analyzed by gel electrophoresis with 2% 
agarose containing ethidium bromide (5 |ig/ml). A 100 bp and 50 bp 
hyperladders were used as markers. 
4.2.8.4. Nucleotide sequencing of the representative CIT-iike PCR 
amplicons 
Six representative E. coli and K. pneumoniae isolates were selected for 
sequencing in order to find out the presence of specific AmpC-type. The 
same primers (CITMF and CITMR), as used in the muItiplex-PCR, were 
used for sequencing reactions (see Table 14). PCR amplificafion was carried 
out under following condifions: 95 °C for 3 min, followed by 30 cycles of 95 
°C for 1 min, 55 °C for 1 min, and 72 °C for 1 min, with a final extension at 
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11 °C for 10 min. The sequences were determined using a Big Dye PCR 
reaction (Applied Biosystems Inc, Foster city, CA, USA) and analyzed on a 
primus HT 3700 DNA analyzer (courtesy Bangalore Genei, India). 
Table 14. Primers used for multiplex PCR for detection of AmpC 
groups, and for sequencing reactions 
Targets Primer sequence (5' to 3') Amplicon size (bp) 
Multiplex PCR for 
AmpC groups 
MOX Group F-GCT OCT CAA GGA GCA GAG GAT 520 
R-CAC ATT GAG ATA GGT GTG GTG C 
GIT Group F-TGG CCA GAA GTG ACA GGC AAA 462 
R-TTT CTC GTG AAC GTG GCT GGC 
DHA Group F-AAC TTT CAC AGG TGT GCT GGG T 405 
R-CCG TAG GCA TAG TGG CTT TGC 
ACC Group F-AAC AGG CTC AGC AGG CGG TTA 346 
R-TTC GCC GCA ATC ATC GCT AGC 
EBC Group F-TCG GTA AAG CGG ATG TTG CGG 302 
R-CTT CCA GTG CGG CTG CCA GTT 
FOX Group F-AAC ATG GGG TAT CAG GGA GAT G 190 
R-CAA AGC GCG TAA CGG GAT TGG 
Sequencing primers for 
AmpC type 
F-TGG CCA GAA CTG ACA GGC AAA 
R-TTT CTC CTG AAC GTG GCT GGC 
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4.2.8.5. Analyzing the isolates for co-carriage of Macrx-M ^"^ '^"ampc 
The bacterial isolates of this study were also analyzed for the co-carriage of 
bhcTx-M and bla^^c as we noticed high co-carriage of these genes in 
bacterial collection from other clinical specimens (Shahid et al. 2007d). 
4.2.8.6. RAPD-PCR typing 
All isolates found to carry bhcTx-M and bla^mpc were typed using the RAPD-
PCR (Vogel et al. 1999) to determine whether any predominant clone 
existed in this isolate collection. A separate collection of bacteria from 
different specimens, collected for a parallel ongoing study, and detected to 
carry 6/ocrx-M and bla^pc, were also typed by RAPD and compared with the 
isolates of this study to determine any common circulating clone or diversity 
in clinical isolates obtained from different samples. Other superior typing 
methods like Amplified Fragment Length Polymorphism (AFLP) or Pulse 
Field Gel Electrophoresis (PFGE) could not be performed because of their 
unavailability in the existing laboratory. Bacteria were cultured on nutrient 
agar at 37°C in air overnight. Template DNA was prepared from crude DNA 
extracts by suspending a colony in 50 |il of distilled water and heating at 95 
°C for 5 minutes. Each RAPD-PCR reaction consisted of Ready-To-Go PCR 
bead (Amersham Biosciences, Amersham, UK), 25 pmol of primer ERIC-2b 
(5'- AAG TAA GTG ACT GGG GTG AGC G- 3') and 2 ^1 of DNA 
template in a final reaction volume 25 \x\. The cycling conditions were as 
follows: one cycle at 94 °C for 2 min; 35 cycles of 94 °C for 1 min, 25 °C 
for 1 min, and 72 °C for 4 min; and a final cycle of 94 °C for 1 min, 25 °C 
for 1 min, and 72 °C for 8 min. RAPD products were separated on a 1.5% 
agarose gel containing ethidium bromide (0.5 mg/L) with TBE running 
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buffer. Molecular size marker ladders (Bioline, London, UK) were included 
on all gels. Isolates of the same species were typed in the same batch and 
products run on the same gel. Banding patterns were evaluated using 
BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium). 
Position tolerance was set at 1%. Strains having RAPD banding profiles 
with at least 85% similarity (UPGMA, Dice Coefficient) were regarded as 
being highly related and were grouped into individual clusters. 
4.2.8.7. Attempt for Plasmid analysis and curing experimentations 
Plasmid analysis of the isolates simultaneously harboring bla^m^c and 
'^ '<2cTX-M-i5 was done by using the large-scale alkaline lysis method of Davis 
et al. (1986) as adopted in our previous studies (Shahid et al 2003a). 
Plasmid samples (5 \i\) were electrophoresed through 0.8% agarose (type 1; 
Sigma) containing ethidium bromide (0.5 )ig/ml) in TBE buffer at 100 V, 60 
mA for 3.5 h. Lambda-DNA digested with HindlW (Genei, Bangalore, India) 
was used as a reference molecular mass marker. Plasmid curing was 
attempted by the method adopted previously (Shahid et al. 2003a). Ethidium 
bromide (Sibisco Research Laboratory, India) was used as the curing agent. 
The minimal inhibitory concentration of ethidium bromide was determined 
for the bacterial isolates in trypticase soy broth and the highest concentration 
permitting growth was used for plasmid curing. Subcultures were initially 
done on trypticase soy agar and the colonies were tested for antibiotic 
susceptibility. 
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4.3. RESULTS 
4.3.1. Bacterial Isolates 
Out of 137 BAL specimens tested, 104-yielded bacterial growth on aerobic 
incubation, and a total of 143 bacterial isolates were obtained from these 137 
BAL specimens; many samples showed mixed growth of bacteria. The 
details of the isolated bacteria are shown in Table 15. Klebsiella 
pneumoniae was the most frequent isolated organism noticed in 29.9% 
samples followed by Pseudomonas aeruginosa which was noticed in 26.3% 
BAL samples. Escherichia coli was isolated from 15.3% samples (Table 15). 
The beta-hemolytic streptococci, Citrobacter spp. and Acinetobacter spp., 
which were isolated from 10.9%, 6.6%, and 5.8% cases, were not 
characterized to species level as this study was focused on to only E. coli 
and K. pneumoniae. 
Table 15. Bacterial species isolated from 137 BAL fluids 
Bacteria isolated 
Klebsiella pneumoniae 
Pseudomonas aeruginosa 
Escherichia coli 
P-hemolytic streptococci 
Citrobacter spp. 
Acinetobacter spp 
Staphylococcus aureus 
Staphylococcus epidermidis 
Diplococcus pneumoniae 
Total 
* 
No. of isolates 
41 
36 
21 
15 
9 
8 
6 
4 
o J 
143 
Percentage 
29.9 
26.3 
15.3 
10.9 
6.6 
5.8 
4.4 
2.9 
2.2 
-
Many specimens showed mixed bacterial growth 
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4.3.2. Antibiotic susceptibility 
The detailed results of the antibiotic susceptibility are shown in Table 16. 
The isolates of E. coli showed maximum susceptibility to ceftriaxone-
sulbactam, a combination recently launched in India, and to meropenem in 
85.7%, each, followed by cefoxitin (53.2%) and amikacin (46.8%o). Many of 
the isolates, found susceptible to ceftriaxone-sulbactam but resistant to 
piperacillin-tazobactam, showed synergy between the two (Fig. 17 A). Three 
E. coli isolates that were found resistant to ceftriaxone-sulbactam and to 
imipenem did not gave apparent zones of inhibitions to any of the antibiotics 
tested (Fig. 17B). 
Among the E. coli isolates, the resistance to third generation 
cephalosporins cefpodoxime, cefotaxime, and ceftazidime was noticed in 
95.2% (20/21), 90.5% (19/21) and 85.7% (18/21) isolates, respectively. The 
resistance to fourth generation cephalosporins, cefepime and cefpirome, was 
noticed in 71.4%) (15/21) isolates, each. Concomitant high resistance to other 
antibiotics tested, including tetracycline (95.2%)), co-trimoxazole (95.2%)), 
ciprofloxacin (90.5%)), aztreonam (85.7%o), trimethoprim (85.7%), 
gentamicin (66.7%), was noticed in the present bacterial collection (see 
Table 16 for detailed susceptibility results). 
All the K. pneumoniae isolates, included in this study, were susceptible 
to ceftriaxone-sulbactam and imipenem. Among aminoglycosides, the 
maximum resistance was noticed against gentamicin in 63.4% isolates 
followed by amikacin (56.1%)) and tobramycin (36.6%)). Cefpodoxime, 
cefotaxime, and ceftazidime showed resistance in 97.6%o (40/41), 92.7% 
(38/41) and 92.7% (38/41) isolates, respectively. Similar to E. coli isolates, 
K. pneumoniae also showed concomitant high resistance to other antibiotics 
tested (see Table 16 for details). 
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Table 16. Antibiotics resistance rates in E. coU and K. pneumoniae 
isolates obtained from BAL against first and second line antibiotics 
tested 
Antibiotics tested 
Ampicillin 
Co-trimoxazole 
Tetracycline 
Ciprofloxacin 
Gentamicin 
Amikacin 
Tobramycin 
Cefotaxime 
Ceftazidime 
Cefpodoxime 
Cefpirome 
Cefepime 
Cefoxitin 
Aztreonam 
Trimethoprim 
Piperacillin 
E. coli (n= 
95.2 (20) 
95.2 (20) 
95.2 (20) 
90.5(19) 
66.7(14) 
47.6(10) 
61.9(13) 
90.5(19) 
85.7(18) 
95.2 (20) 
71.4(15) 
71.4(15) 
38.1 (8) 
85.7(18) 
85.7(18) 
100(21) 
Piperacillin/tazobactam 90.5 (19) 
Ticarcillin 
Ticarcillin/clavulanate 
Meropenem 
Ceftriaxone/sulbactam 
100(21) 
100(21) 
14.3 (3) 
14.3 (3) 
% Resistance (n) 
•21) K. pneumoniae (n=41) 
NT 
100(41) 
95.1 (39) 
73.2(30) 
63.4(26) 
56.1(23) 
36.6(15) 
92.7(38) 
92.7(38) 
97.6 (40) 
58.5 (24) 
58.5 (24) 
51.2(21) 
73.2(30) 
85.4(35) 
100(41) 
97.6 (40) 
100(41) 
100(41) 
0(0) 
0(0) 
Figures in parentheses indicate number of isolates. The isolates were 
resistant to multiple antibiotics. 
NT = not tested 
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Fig. 17 A. Photograph of a blacTx-M-\5 carrying isolate showing 
susceptibility to ceftriaxone-sulbactam (CRS), and resistance to 
piperacillin-tazobactam (TZP), piperacillin (Pc) and ceftriaxone (Ci). 
Fig. 17 B. blacTx-M-\5 carrying and imipenem resistant isolate showing 
resistance to ceftriaxone-sulbactam. 
Fig. l" A & B 
Bacteriological Studies 
4.3.3. ESBL studies with special reference to CTX-M-type 
4.3.3.1. Phenotypic ESBL detection 
ESBLs were detected phenotypically by disk synergy tests using co-
amoxyclav and piperacillin-tazobactam disks as source of ESBL-inhibitor, 
and by combination disk test (CDT). Comparative results of ESBL detection 
by tiiese three tests are shown in Fig. 18. 
4.3.3. LL Detection by conventional disk synergy test using co-
amoxyclav discs (Jarlier et ai 1988) 
None of the isolates, out of 62, could be detected as ESBL-producers by 
applying amoxicillin-clavulanate at 30 mm, center to center (Fig. 19 A - F). 
By applying amoxicillin-clavulanate at a distance of 20 mm, we could only 
detect 9.7% (6/62) isolates as ESBL-producers, of which 4 isolates were of 
E. coli and 2 were K. pneumoniae. Most of the isolates in the present study 
either did not or showed very small zones of inhibitions to cephalosporins. 
4.3.3.1.2. Disk synergy test using piperacillin/tazobactam disks (Shahid 
et ai 2007b) 
In the modified test, where piperacillin-tazobactam was used in place of co-
amoxyclav disk, we could detect ESBLs in total of 90.3% (56/62) isolates, 
and of which, it could be detected in 85.7% (18/21) and 92.7% (38/41) 
isolates of E. coli and K. pneumoniae, respectively. Excellent synergy 
between piperacillin-tazobactam and cephalosporins, in all the isolates, was 
seen when the discs were placed 20 mm apart. When the discs were placed 
at 30 mm, still ESBL could be detected in all the isolates, most of the 
isolates giving excellent synergistic patterns as shown in Fig. 19 A-D, 
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however few of the isolates gave patterns as shown in Fig. 19 E & F. 
Comparative sensitivity of ceftriaxone, cefotaxime and ceftazidime in ESBL 
detection by using piperacillin-tazobactam discs was found to be 90.3% 
(56/62), 88.7% (55/62), and 67.7% (42/62) respectively. 
4.3.3.1.3. ESBL detection by combination disk metliod (CDT) 
Using the CDT method, ESBL production was detected in total of 82.3% 
(51/62) isolates. Of these, ESBLs could be detected in 76.2% (16/21) oiE. 
coli and 85,4% (35/41) ofK. pneumoniae isolates. 
Fig. 18. Comparative analysis of the ESBL 
detection by three phenotypic tests used in the 
present study 
D Co-amoxyclav 
H PiperacillJn/tazobactam 
D Combination disk 
E. coli K. 
pneumoniae 
Bacterial species studied 
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Fig. 19. Photograph of /^<3CTX-M-I5 carrying isolates showing synergy 
between cephalosporins and piperacillin-tazobactam discs at 30 mm, and 
non-detection of ESBL by co-amoxyclav even at 20 mm (A to D). Isolates 
not giving good synergy but still detected as ESBL-producers by 
ceftriaxone and cefotaxime and not by ceftazidime by using piperacillin-
tazobactam disk (E & F). 
^ # © w 1 
# # # 
9 
• • • 
B 
Fig, 19 A - F 
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4.3.3.2. Detection and characterization of blucix-w alleles based on 
muitiplex-PCR, reverse line hybridization, and sequencing 
4.3.3.2.1. Multiplex-PCR 
Of the 62 bacterial isolates studied, blacjx-u could be detected in 77.4% 
(48/62) isolates using the multiplex PCR. Noting the detection of blacix-u 
alleles in E. coli and K. pneumoniae, we found their presence in 81% (17/21) 
and 75.6% (31/41) isolates, respectively. Based on the PCR-amplicon size, 
all belonged to CTX-M phylogenetic Group 1. 
4.3.3.2.2. Reverse line hybridization (RLH) assay 
Identification of the precise CTX-M genotypes using RLH identified the 
presence of Zj/^ cTx-M-isonly (Fig. 20). 
4.3.3.2.3. Sequencing of representative isolates 
Further confirmation by sequencing in representative isolates confirmed the 
presence of /^ /acTx-M-is (GenBank Accession numbers DQ 485309, DQ 
485310, EF 371799, and EF 371800) (see annexure I - IV for sequence 
details). 
4.3.4. Studies on \S26 element in A/acTX-M-i5"<^ r^ry'ng isolates 
4.3.4.1. Detection of IS25 element 
IS2<5 was detected in 20 of 48 (41.7%) isolates carrying /?/(3CTX-M-I5(9 E.COH, 
11 K. pneumoniae) (Table 17). Amplicons of ~650bp, ~750bp, ~850bp, 
~950bp, -llOObp, and >1400bp were obtained, the most common being 
~850bp (see Table 17 and Figures 21 & 22). Few of the isolates showed 
multiple bands on PCR-gel analysis (Fig. 22). Random analysis of the 
bacterial isolates, obtained from other clinical samples, for a parallel 
ongoing study also showed this diverse picture of varying IS2<5 fragments 
and even multiple banding patterns. 
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Fig. 20. Reverse-line hybridization film showing group 1 control strains 
and test isolates. These isolates were all shown to carry a group 1 blacjx-M 
of CTX-M-15 type. No other CTX-M type was detected in the present 
collection. 
CTX-Ml 
u 
CTX-M-3 
CTX-M-15 
Fig. 20 
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Table 17. Distribution and patterns of IS26 insertion in CTX-M-15-
producing isolates. 
Fragment size 
~650bp 
~750bp 
~850bp 
~-950bp 
-UOObp 
>1400bp 
Total 
E. coli 
1 
1 
5 
1 
1 
0 
9 
Detected in 
K. pneumoniae 
2 
1 
4 
1 
1 
2 
11 
Total 
3 
2 
9 
2 
2 
2 
20 
4.3.4.2. Determination of insertion oflS26 up-stream of Z»/acTX-M-i5 
DNA sequencing of representative strains enabled determination of the 
precise insertion position of IS26 within ISEcpl and confirmed linkage of 
IS26 with blacTx-M (Fig- 23). Exact amplicon size was calculated for each 
strain using the annealing sites of the IS26 forward and reverse primers and 
the DNA sequencing results. Sequences can be successfully obtained for 
representative strains showing amplicons of ~650bp (MSOl; 639bp), 
~750bp (MS03; 721bp), and ~850bp (MS02; 863bp) (Genbank Accession 
numbers DQ485311, DQ485313 & DQ485312, respectively; see annexure V 
to VII for sequence details). DNA sequencing of the ~950bp, -llOObp and 
>1400bp amplicons was unsuccessful on repeated occasions, so a precise 
insertion position cannot be reported. 
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Figure 21. PCR amplicons generated using primers located in IS26 and 5' 
end of blacjx-M-\5- Lanes M: DNA Size marker (100bp-1.5kb), Lane I: UK 
clone A 400bp amplicon, Lanes 2-4: ~650bp amplicon, Lanes 5, 6: ~750bp 
amplicon, Lanes 7-15: ~850bp amplicon, Lanes 16, 17: ~950bp amplicon, 
and Lane 18: reagent negative control. 
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4.3.5. AmpC studies 
4.3.5.1. Phenotypic detection of AmpC production 
Phenotypic detection of AmpC P-lactamase was performed by CDT using 
cefepime disk alone and with clavulanate. Phenotypic detection was also 
performed by a modified three-dimensional test (Shahid et al. 2004), which 
was developed during working on this Doctoral project, on isolates found 
resistant to cefoxitin. Simultaneous production of ESBL in the presence of 
AmpC beta-lactamases was attempted phenotypically by using disk synergy 
between piperacillin/tazobactam, third generation cephalosporins 
(cefotaxime and ceftazidime) and cefpirome disks on all the isolates of E. 
coli and K. pneumoniae included in the study. A total of 19.4% (12/62) 
isolates were detected as AmpC-producers by CDT, and of which 3 were E. 
coli and 9 were K. pneumoniae. Among the 29 cefoxitin-resistant isolates 
studied by modified three-dimensional test, 12 (3 E. coli and 9 K. 
pneumoniae) were detected as AmpC-producers, and 3 isolates (All K. 
pneumoniae) were inferred as AmpC-intermediate. Simultaneous production 
of ESBLs and AmpC enzymes could be inferred in 14.5% (9/62) isolates by 
the phenotypic method described above. 
4.3.5.2. Detection of bhampc alleles 
Of the 62 isolates, bla^^c of CIT-family were detected in 27.4% (17/62) 
isolates (Fig. 24). Of these Z)/aampc-carrying isolates, 23.8% (5/21) were E. 
coli and 29.3% (12/41) were K. pneumoniae. Sequencing of the 
representative isolates revealed the presence of CMY-6-like and CMY-18-
like AmpC p-lactamases (GenBank Accession Nos. EF 103125 and EF 
103126 for CMY-6-like; Accession Nos. awaited for CMY-18-like). The 
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Description of Fig. 24 
Fig. 24. Electrophoretogram (on 2% agarose) showing results of multiplex 
PCR for the detection of bla^mpc alleles. Lanes 1 & 12 show 50 bp and 100 
bp hyperladders, respectively. Lanes 2-5 show CIT-like amplicons from 
clinical isolates studied. Lanes 6-11 show amplicons from control strains: 
E. coli J53 pMG252 encoding FOX-5 AmC ^-lactamase of FOX-family 
(Lane 6); E. coli J53 pMG251 encoding ACT-1 of EBC-family (Lane 7); E. 
coli J53 pMG233 encoding MIR-1 of EBC-family (Lane 8); E. coli J53 
pSLK54 encoding AAC-1 of ACC-family (Lane 9); E. coli J53 pMG247 
encoding DHA-1 of DHA-family (Lane 10); and E. coli J53 pMG250 
encoding CMY-2 of CIT-family (Lane 11). 
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published details of sequences EF 103125 and EF 103126 are shown in 
annexure VIII and IX. The PCR assay detected bla^^ in 15/29 (51.7%) of 
cefoxitin-resistance isolates. Two isolates found to carry 6/aampC were 
categorized as being susceptible to cefoxitin using the zone breakpoint of 
<18 mm to infer resistance. 
4.3.5.3. Co-carriage of/>/flampc and blaCTX.u-xs 
Of the 62 isolates studied, 13 (21%) were simultaneously harboring bhampc 
and blaCTX.uAs- The frequency of simultaneous occurrence in the respective 
species was noticed in 19% (4/21) and 22% (9/41) of E. coli and K. 
pneumoniae respectively. 
4.3.6. RAPD analysis 
RAPD-typing revealed the presence of diverse bacterial population and no 
predominant clone was identified in our Indian bacterial collection (Fig. 25, 
26 & Fig. 27). Figures 25 & 26 show the RAPD typing performed on E. coli 
and K. pneumoniae isolates, respectively, and Fig. 27 demonstrates the 
dendrogram of RAPD-profiles, analyzed by BioNumerics, and illustrating 
diversity of bacterial isolates carrying /^«CTX-M-15- We could not perform 
other higher typing techniques because of their unavailability in our Indian 
laboratory. 
4.3.7. Plasmid analysis and curing experiments 
Plasmid analysis of the isolates simultaneously carrying bla^pc and 
blaCTX.u-xs showed the presence of a single plasmid in all the isolates; 
molecular weight ranging between ca. -21 to ca. -23 kb (Fig. 28). Curing 
experiments using the DNA-intercalating dye ethidium bromide was 
successful only in 38.5% (5/13) isolates. Cured isolates became susceptible 
to cephamycins and cephalosporins. 
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Description of Fig. 25 
Fig. 25. Photograph of 1.8% agarose gel illustrating diversity of £•. coli 
isolates carrying W«CTX-M-I5 in RAPD typing. Lanes M show 100 bp 
hyperladder. Lanes 1-13 show isolates collected from BAL of 
bronchogenic carcinoma patients and lanes 14-17 show RAPD profile of 
some of the isolates obtained from other clinical samples. 
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Description of Fig. 26 
Fig. 26. Photograph of 1.8% agarose gel illustrating diversity of K. 
pneumoniae isolates carrying blacTx-M-\5 in RAPD typing. Lanes M show 
100 bp hyperladder. Lanes 1-18 show some of the isolates collected from 
BAL of bronchogenic carcinoma patients and lanes 19-24 show RAPD 
profile of some of the isolates obtained from other clinical samples. 
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Description of Fig. 27 
Fig. 27. Dendrogram of RAPD-profiles, analyzed by BioNumerics, and 
illustrating diversity of bacterial isolates carrying 6/acTx-M-i5-
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Description of Fig. 28 
Fig. 28. Electrophoretogram (on 0.8% agarose) showing results of plasmid 
screening. Lanes M shows molecular weight markers (Lambda DNA 
digested with Hind III). Lanes 1-8 shows plasmid bands from clinical 
isolates studied. 
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4 4. DISCUSSION 
There has been a rapid increase in the isolation of CTX-M producing 
bacteria globally, with reports from Asia, Europe, North and South America 
and Africa (Yan et al 2000; Kariuki et al. 2001; Radice et al 2002; Brinas 
et al. 2003; Wodford et al. 2004; Munday et al. 2004b; Shibata et al. 2006; 
Lartigue et al. 2005; Luzzaro et al 2006; Valenzuela de Silva et al. 2006; 
Mohamed Al-Agamy et al. 2006). In the Far East, the first clinical strain of 
E. coli producing CTX-M-enzymes was observed in Japan in 1993 (Ishii et 
al. 1995). Since then, numerous CTX-M enzymes have been described 
(www.lahey.org/studies/webt.htm). The worlds first report of CTX-M-15 
came from New Delhi, India and was found to be produced by six unrelated 
isolates (4 E. coli, 1 K. pneumoniae, and 1 E. aerogenes strain) cultured 
between April and May 2000 (Karim et al. 2001). No further detailed 
molecular surveys have been published regarding the prevalence and precise 
CTX-M genoptyes in India, except one of our very recently published study 
(Ensor et al. 2006b) performed on 130 bacterial isolates obtained from 
various specimens including a small collection obtained from BAL of the 
study population of present work. However several studies, using phenotypic 
testing methods, have reported a high prevalence of ESBL-producing 
Enterobacteriaceae in clinical isolates from both the hospital and the 
community (Mathur et al. 2002; Tankhiwale et al. 2004; Datta et al. 2004; 
Gupta & Datta 2006). Considering the high prevalence in India of ESBLs 
and the rapid spread of CTX-M in many different countries (Tzouvelekis et 
al. 2000; Bonnet 2004; Walther-Rasmussen et al. 2004;) we surmised that 
CTX-M may be a common type of ESBL in India. 
In the present study, 48 of 62 (77.4%) isolates produced CTX-M-15 
and no other CTX-M-type ESBL was found. This finding was surprising: 
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other surveys have reported a diversity of CTX-M types within a single 
institution or country (Chanawong et al. 2002; Dutour et ai 2002; Saladin et 
al. 2002; Munday et al. 2004b; Kim et al. 2005). Faecal carriage of CTX-
M-producing bacteria has been described (Munday et al. 2004b; Valverde et 
al. 2004). The bowel is a rich environment for genetic exchange between 
commensal Enterobacteriaceae. It is plausible to suggest that conditions of 
overcrowding and poor sanitation, as well as the selective pressure created 
by overuse of antibiotics in India has enabled such widespread dispersal of 
blacTx-M-\5- The Indian population therefore, must represent a significant 
reservoir and source of /^OCTX-M-IS and we are now focusing on this aspect in 
other ongoing studies. Boyd et al. (2004) recently published the entire 
sequence of/j/acrx-M-is-carrying plasmid pC15-la isolated from an outbreak 
strain of E. coli in Canada and found that this plasmid shares a common 
RlOO backbone and some other resistance genes with /j/acix-ivi-is-carrying 
plasmid pCTX15 isolated from India. On the other hand, since ISEcpl was 
found to have inserted at different positions upstream of blacjx-M-\5 in Polish 
Enterobacteriaceae compared to the first CTX-M-15-producing 
Enterobacteriaceae from India, Baraniak and colleagues concluded that these 
genes must have been selected for independently (Baraniak et al. 2002c). 
Further work is required to investigate the genetic support of CTX-M-15-
carrying isolates from different countries compared to that of isolates from 
India to refute or confirm an evolutionary linkage. It is more difficult to 
explain why CTX-M-15 is the only CTX-M beta-lactamase found in this 
collection from India. 
We found a high level of co-resistance in isolates producing CTX-M-
15 ESBL, which has been reported for many CTX-M producing isolates 
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(Woodford et al. 2004; Pitout et al. 2004; Leflon-Guibout et al. 2004; Gupta 
& Datta 2006). In our survey, a total of 64.5% isolates were resistant to 
gentamicin, 85.5% to trimethoprim and 79% to ciprofloxacin. Resistance to 
cefoxitin was noted in 38.1% E.coli and 51.2% K. pneumoniae and was 
thought to be due to the presence of plasmidic bla^p.c. This transferable 
resistance determinant is clinically significant as it confers resistance in the 
host to beta-lactam-beta-lactamase inhibitor combinations as well as to 
narrow spectrum penicillins and expanded spectrum cephalosporins but 
spares fourth-generation cephalosporins such as cefepime and cefpirome. A 
total of 14.3% (3/21) isolates of E. coli were resistant to meropenem, 
whereas all K. pneumoniae isolates were susceptible to meropenem. 
Resistance to third and fourth generation cephalosporins has become a 
major concern worldwide. Even more alarming is the emergence of 
carbapenem resistance; the carbapenems are often considered to be a "drug 
of choice" and increasingly used in empirical therapy. Against this rising 
resistance, the role of p-lactam-p-lactamase inhibitor combinations needs to 
be considered. Sulbactam has been approved recently in many countries to 
be combined with P-lactam antibiotics (Frank et al. 2003) including, 
recently, in India. CTX-M enzymes are a recently emerged group of 
extended-spectrum p-lactamases and CTX-M-15 has emerged as the most 
prevalent ESBL in many parts of the world, including U.K. and India 
(Bonnet 2004; Ensor et al. 2006b). Comparative susceptibilities of the 
isolates against individual P-lactam antibiotics and p-lactam-(3-lactamase 
inhibitor combinations are shown in Table 16. A total of 95.2% isolates were 
susceptible to ceftriaxone-sulbactam in contrast to only 4.8% susceptible to 
piperacillin-tazobactam. This also contrasts with earlier international (Frank 
et al. 2003) and national (Gupta et al. 2006) studies, which reported that 
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combinations of P-lactam with tazobactam showed greater activity than P-
lactam- sulbactam combination against E. coli isolates. This marked 
difference may reflect different mechanism(s) in the different bacterial 
collections. In the present study, we specifically looked in CTX-M-15 
producers and found ceftriaxone-sulbactam to be a highly effective 
combination (activity being equal to that of meropenem) in contrast to 
piperacillin-tazobactam and ticarcillin-clavulanate. Three isolates that were 
resistant to ceftriaxone-sulbactam were also resistant to meropenem (Table 
16); and they carried blacix-M-is and blaampc alleles. 
In disk synergy tests, none of the 62 isolates was detected when co-
amoxiclav discs were placed 30 mm from cephalosporin disks, and only six 
isolates (9.7%) were detected when this was reduced to 20 mm. It is known 
that optimal disk placement is an important issue in such tests (Thomson 
2001). However, when piperacillin-tazobactam disks were used and the 
disks were placed 20 mm apart, we readily detected most ESBL producing 
isolates; synergy with ceftriaxone, cefotaxime and ceftazidime allowed 
detection of 90.3% (56/62), 88.7% (55/62), and 67.7% (42/62) of ESBL 
producers, respectively. When the disks were placed at 30 mm, still ESBL 
could be detected in all the isolates, most of the isolates still giving excellent 
synergistic patterns. Based on these findings, we feel that piperacillin-
tazobactam (or tazobactam alone) could be a better indicator when combined 
with ceftriaxone and cefotaxime for phenotypic detection of ESBLs 
especially in CTX-M-producers. This needs to be evaluated further and also 
against other classes of beta-lactamases. 
The CDT detected ESBL production in 82.3% isolates. This enhanced 
sensitivity, as compared to that of disk synergy between cephalosporin and 
clavulanate disks, is most likely due to use of the fourth generation 
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cephalosporin cefepime for detecting ESBL production in isolates 
simultaneously producing high levels of AmpC, and also because optimal 
disk spacing is not required for this method but is important for the DDST 
method. However, the comparative lower sensitivity of CDT as opposed to 
synergy between piperacillin/tazobactam and cephalosporin disks clearly 
indicate that tazobactam could be a better indicator when combined with 
cephalosporins for phenotypic detection of ESBLs. The phenotypic methods 
detected ESBL production in 8 isolates found not to carry a CTX-M gene. 
Although no further investigations were carried out to determine which 
ESBL genes were present in these isolates, TEM- and SHV-types are most 
likely. 
Unlike the situation in the UK where an epidemic E. coli clone A 
carrying blac\x-w-\5 has been described (Woodford et al. 2004), no 
predominant clone was identified in our Indian isolates, indicating horizontal 
transfer oiblacTx-uAs between unrelated strains. 
The association of insertion sequences with antibiotic resistance genes 
has been reported previously (Ford & Avison 2004; Miriagou et al. 2005). 
\SEcpJ is always found upstream of /^^ cTX-M-isand is strongly implicated in 
the mobilization of this antibiotic resistance gene (Saladin etal. 2002; Poirel 
et al. 2003). IS26 has also been reported in association with blaax-u 
including blacix-M-\5 and more specifically, has been found to insert within 
ISEcpl, although interestingly, the insertion of IS26 differs from strain to 
strain (Eckert et al. 2006). In the UK, IS26 has been detected in epidemic 
Clone A, which accounts for approximately 25% of all referred (the 
collection was biased by isolates from a large outbreak of clone A strains) 
E coli carrying /^«CTx-M-i5 (Woodford et al. 2004). In that study, the 
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fragment obtained after PCR amplification of the region containing \S26 and 
the immediate 5'- end of blacjx-M-\i ORF was 400bp in all but 3 isolates, 
where a 800bp fragment was obtained (Woodford et al. 2004). In our study 
of highly diverse E .coli and K. pneumoniae producing CTX-M-15, IS26 
was detected in 41.7% isolates, indicating high frequency of association of 
this element with blacwM-xs- It was interesting to note that PCR products of 
variable sizes were detected, and an amplicon of 863bp was most frequently 
observed. DNA sequencing of representative IS2d amplicons demonstrated 
insertion of this element at 3 variable positions within the transposase gene 
tnpA of ISEcpI. After repeated attempts the sequencing was unsuccessful for 
amplicons of-900 bp, ~1100 bp and >1400 bp and therefore the precise 
insertion points could not be detected for these isolates. Such diversity of 
varying IS26 amplicons was also noticed in other collections of bacterial 
isolates from different clinical samples. The apparent acquisition of \S26 
elements in Indian strains is interesting. It perhaps suggests a 'turnover' of 
plasmids in the population over time, the IS26 insertion creating a selective 
advantage in those strains carrying the ]S26 insertion. Although the numbers 
are small, the geographical consistency of the observation could make it 
broadly applicable and worthy of further investigation. None of the isolates 
was positive for IS26 elements in earlier studies, including the isolates 
collected during and before year 2000 (Karim et al. 2001; Walsh et al. 
2007). We first noticed this insertion sequence in a collection of bacteria 
obtained during 2003-2005 (Ensor et al. 2006b) and subsequently in the 
present work. Therefore, it is possible that although ^/^CTX-M-IS was widely 
established in India before 2000, the IS26 element had not yet inserted within 
ISEcp] (tnpA), and that this is a later event. In the present study, at least 
three IS26 insertion sites have been identified precisely and is being 
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postulated that such an insertion into ISEcpI traps the ESBL gene thus 
preventing it from escaping the gene pool. The recent findings indicate that 
whilst the level of CTX-M-15-positive strains has not generally increased 
since the earlier sampled period, the genetic environment of 6/(3CTX-M-!5 has 
changed through the insertion of IS26 although the consequences of these 
events remain uncertain. 
To the best of our knowledge this is the second report of such high 
mobility/diversity of IS2(5 insertion in ISEcpl, first being reported in year 
2006 (Ensor et al. 2006b) which also included few of the isolates from the 
present Doctoral work. 
Numerous reports from India have indicated a high prevalence of 
ESBLs in Gram-negative bacteria, which must be presumed to have taken a 
considerable time to reach a high prevalence. As our study suggests, CTX-
M-15 is the most common (or maybe the only) CTX-M type in India. CTX-
M-15 may have evolved in India prior to the 2000 (Karim et al. 2001). 
Indeed in 1995 ESBL production was inferred through phenotypic testing in 
15 ceftazidime-resistant K. pneumoniae (Abigail et al. 1995). 
Plasmidic ampC genes are derived from the chromosomal ampC 
genes of several (not all) members of the family Enterobacteriaceae, 
including Enterobacter cloacae, Citrobacterfreundii, Morganella morganii, 
and Hafnia alvei (Bauemfeind et al. 1998). The majority of plasmid 
mediated ampC genes are found in nosocomial isolates of E. coll and K. 
pneumoniae (Perez-Perez & Hanson 2002); however, in the present study, 
significant numbers of community-derived isolates showed the presence of 
/^^ arnpc which indicate the wide dissemination of these genes into the 
community in India. 
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Acquisition of ampC-type genes by plasmids in K. pneumoniae and E. 
coli has been known since 1989, but only recently they are being reported 
with increasing frequency (Moland et al. 2002; Alvarez et al. 2004). Despite 
of increasing recognition of this resistance mechanism worldwide, there is 
paucity of data from India, and most studies only present phenotypic data 
(Manchanda & Singh 2003; Subha et al. 2003). In our search of the 
scientific literature from the Indian subcontinent, we found only two 
publications that have characterized bla^n^^c at the molecular level, and these 
report the presence of W^^Bin-like and blacMY-4 (M'Zali et al 1997, Cao et 
al 2000). 
We report here the presence of bla^^c of the CIT family in Indian 
Enterobacteriaceae in significant numbers (27.4%). Sequencing of 
representative isolates showed the presence of Z /^ocMY-e-like and ZJ/ACMY-IS-
like (since only a fragment of the gene was sequenced and not the entire 
ORF) ampC genes which is in addition those previously published, and is 
the first report indicating the presence of CMY-6 and CMY-18 AmpC (3-
lactamases in India. 
We noticed slightly higher frequency of occurrence of bhampc in K. 
pneumoniae {29.3% (12/41)} as opposed to E. coli in {23.8% (5/21)} and 
this finding is in contrast to earlier reports (Philippon et al. 2002). We 
presume that plasmid host range and success amounts for these differences. 
The reports of other genes from India/Pakistan e.g. BCMY-2 and CMY-4 
suggest a wider survey would identify greater generic diversity, including 
other successful types in the world such as DHA. 
Woampc alleles were found in 51.7% (15/29) of the cefoxitin resistant 
isolates when the standard disc diffusion breakpoint for cefoxitin of <18 mm 
was used. When comparing the PCR positivity with cefoxitin zone diameter, 
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we noticed that 68.4% (13/19) of the isolates were found to carry bla^rnpc 
when the cefoxitin zone diameter of <14 mm was used as the cut-off 
whereas only 20% (2/10) of the isolates with cefoxitin zone diameters of 14-
17 mm were found to carry bla^^c- Interestingly 6.1% (2/33) isolates in the 
cefoxitin susceptible zone (> 18 mm) were found to carry bhampc. Based on 
these preliminary findings we feel that a cefoxitin zone diameter of <14 mm 
is a better indicator for presence of /^aampc as a resistance mechanism. 
Simultaneous occurrence of non-CTX-M ESBLs and AmpC (3-
lactamases has been reported in the literature (Potz et al. 2006; Song et a I 
2007). However the data is still fragmentary on the simultaneous occurrence 
of AmpC and CTX-M enzymes, and recently reports start coming on such 
combination resistance mechanisms (Yum et al. 2005; Woodford et al. 
2007b). Analyzing our bhampc carrying isolates for co-carriage of blacT\-M, 
we noticed simultaneous occurrence in 21% isolates. Spreading of ESBL-
producing strains with ampC genes is a concern and poses a serious 
therapeutic problem, as carbapenems remain the only active (3-lactam against 
these organisms. This information is crucial for controlling the spread of 
resistance and for decision of empirical selection of antimicrobial agents. 
Plasmid analysis of the representative isolates showed the consistent 
presence of a single plasmid ranging between ca. -21 to ca. --23 kb. 
Successfully cured isolates became susceptible to cephamycins and 
cephalosporins and thus provide evidence of carriage of/)/aampC and 6/flci\-M-
15 on same plasmid. However, we could not perform hybridization 
experiments, due to limited facilities in our Indian laboratory, to strengthen 
the above fact. However, every possible effort is being done to characterize 
plasmids properly in the near future. RAPD-t>ping of the isolates 
demonstrated great diversity and no predooiinant type, indicating either 
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horizontal transfer and/or mobilization of these genes on plasmids. Other 
higher typing techniques could not be performed in this collection because 
of their unavailability in our laboratory, however efforts are been done to 
characterize them by Genotyping based protocols for E. coli and 
K. pneumoniae using Fluorescent Amplified Fragment Length 
Polymorphism (Jonas et al. 2003; Jonas et al. 2004) or by PFGE in near 
future. 
To conclude, this is amongst the premier systematic report from India 
characterizing the occurrence and prevalence of CTX-M enzymes. We 
report here a 3GC resistance rate of 96.8% of all E. coli and K. pneumoniae 
obtained from BAL of bronchogenic carcinoma patients and in these, a 
CTX-M carriage rate of 77.4%. This is the first report looking the carriage of 
bf(^cTx-M and blacampc in Enterobacteriaceae isolated from patients of 
bronchogenic carcinoma. In this collection only CTX-M-15 was detected. 
Our report supports the urgent need for regular screening and national 
surveillance characterizing the CTX-M types and to implement strict 
antibiotics policy to limit the irrational use of antibiotics, including 
cephalosporins, so as to minimize antibiotic selective pressure, bhsmpc of 
CIT-family were detected in 27.4%) of Indian Enterobacteriaceae and the 
sequencing of the representative isolates showed presence of CMY-6- like 
and CMY-18-like AmpC ^-lactamases. Concomitant occurrence of Zj/^ ampc 
and /)/(3crx-M-i5 were noticed in significant number of isolates and the genes 
were infeired to present on plasmids ranging between ~21 to -23 kb. RAPD-
typing demonstrated great diversity and indicate transfer of these resistance 
genes on plasmids; and also wide dissemination of these resistance genes 
into the community. This is also the first report indicating the presence of 
CMY-6- and CMY-18- like ampC genes in Indian Enterobacteriaceae. 
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CHAPTER 5 
5. SUMMARY AND CONCLUSIONS 
More cases of bronchogenic carcinoma are being reported in recent 
years and these patients are more prone to secondary aspergillosis. The early 
diagnosis for such secondary infection could be of great importance since 
early antifungal treatment is associated with an improved outcome. 
However, diagnosis in the early stages is very difficult, as clinical and 
radiological signs are nonspecific and the sensitivity of fungal culture is low 
(Bretagne et al. 1995). Circulating-antigen detection may contribute to the 
diagnosis but high false positivity has been reported (Stynen et al. 1995). 
Therefore, the attention has now turned to molecular detection methods, like 
PCR. The role of PCR assays of Bronchoalveolar lavage (BAL) fluids for 
diagnosing aspergillosis does not clearly emerge in the literature 
(Spreadbury et al. 1993; Tang et al. 1993; Bretagne et al. 1995); moreover it 
is being investigated mainly for the diagnosis of definite- and probable-
invasive pulmonary aspergillosis, but not extensively in possible- and 
semi/non-invasive pulmonary aspergillosis. Again, it has been mostly 
studied in immunocompromised states like, neutropenic patients (Jones et al. 
1998), organ transplantation (Kusne et al. 1992; Denning 1998) and 
hematological malignancies (Denning 1998; Pagano et al. 2001). The 
evaluation of role of BAL-PCR for the diagnosis of aspergillosis in 
patients of bronchogenic carcinoma is completely missing in the existing 
literature. Moreover, the gross data regarding Aspergillus infection in 
bronchogenic carcinoma is limited. During our search of literature via 
Pubmed Central, we could not get any published systematic report except 
one of our previously published (Malik et al. 2003) and few occasional case 
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reports published in languages other than English (Tsai et al. 1984; Tanaka 
etal. 1993). 
The patients of bronchogenic carcinoma are debilitated and 
immunocompromised, and hence the chances of secondary bacterial 
infections are also increased in such cases. It should be emphasized here 
that, there has been a dramatic increase in the multidrug-resistance in recent 
years, and which is the major cause of concern globally (Shahid et al. 
2007c). The presence of antibiotic resistance genes on bacterial plasmids has 
further helped in the transmission and spread of drug resistance among 
pathogenic bacteria (Robin et al. 1998; Beg & Ahmad 2000). A major 
feature in the emergence of multidrug-resistant Gram-negative bacilli is the 
production of extended-spectrum ^-lactamases (ESBLs), which are 
responsible for resistance to P-lactam antibiotics. Plasmid mediated 
extended-spectrum (3-lactamases, including CTX-M-types and AmpC-types, 
in various Gram-negative bacterial species have been reported from various 
developed countries (Philippon et al. 2002; Bonnet 2004, Pitout et al. 2005; 
Eckert et al. 2006; Woodford et al. 2007a; Woodford et al. 2007b; Tarrant et 
al. 2007), however, the data on this aspect is elementary from Indian 
hospitals. Therefore, we found worth looking occurrence of CTX-M and 
AmpC P-lactamases, their specific types, and genetic environment in the 
present collection of E. coli and K. pneumoniae obtained from BAL of 
bronchogenic carcinoma patients. 
Keeping in view the above facts, the present study was conducted on 
patients of bronchogenic carcinoma attending the clinics or admitted in the 
in-patient wards of T. B. & Chest Diseases of Jawaharlal Nehru Medical 
College & Hospital, Aligarh Muslim University, Aligarh during the period 
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from June 2003 to May 2006. The whole study was broadly divided in three 
parts v.i.z. clinical, mycological, and bacteriological studies. 
During the above-mentioned study period, a total of 213 
bronchoscopy were performed and of which 159 were suspected cases of 
bronchogenic carcinoma. A total of 95, confirmed patients of bronchogenic 
carcinoma based on histopathological and cytological investigations, and not 
receiving any antifungal therapy prior to the study were included. A 
collection from 42 patients of bronchogenic carcinoma of the year 2001-
2002, on which mycological and bacteriological studies were ongoing, was 
also included. And thus, the study population of this work comprised of a 
total of 137 patients. Remaining 64 suspected patients of bronchogenic 
carcinoma were excluded from the study because of some other co-existing 
underlying immunosuppressive disorders or because the patients were taking 
antifungal therapy. Thirty-four, age and sex matched volunteers, not having 
history suggestive of any lung disease in the recent past were included as 
healthy controls. Informed written consent was taken prior to bronchoscopy 
in all study and control groups and the investigations were performed after 
the approval by Institutional Ethical Committee. 
Bronchoalveolar lavage fluids were collected to perform direct 
microscopic examination, fungal- and bacterial-culture, and PCR, and blood 
samples for serological tests. Two consecutive BAL specimens were 
collected in sterile containers and each BAL specimen was divided in three 
parts for direct microscopy, culture and PCR. Direct microscopy and culture 
was performed immediately whereas BAL specimens for performing PCR 
were kept at -20° C till tested. Blood was collected in EDTA and plain vials 
for routine hematological investigations and fungal serology respectively. 
Additional BAL and blood samples were collected from 21 patients of 
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possible- and non-IPA that could be followed-up and in whom initial culture 
or serology was negative and PCR was positive. Sera were separated and 
stored at -20° C till tested further. Specimens for histopathology and 
cytology were also collected and the investigations were performed by the 
expertise in the department of Pathology of J.N. Medical College, AMU, 
Aligarh. 
5.1. DEMOGRAPHIC AND CLINICAL STUDIES 
Majority (56.9%; 78/137) of the patients in the present study were in the age 
group of 45-<60 years, followed by in the age group of 60-<75 years 
(35.8%). The median age of the study population was 58 years and male to 
female ratio was 11.5:1. One hundred twenty-four (90.5%) patients 
provided history of smoking; 40.1% (55/137) patients were on 
chemotherapy and 29.9% (41/137) and 26.3% (36/137) patients were on 
prolonged antibiotics and corticosteroids therapy, respectively. The most 
common clinical presentation of the patients was with cough, \\ hich was 
noticed in 70% patients followed by expectoration and chest pain noticed in 
52.6% and 50.4% patients, respectively. Hoarseness of voice was noticed in 
15.3%) patients whereas history of brown plugs in sputum was elicited only 
in 8%) patients. 
Histopathological and cytological examinations revealed squamous 
cell carcinoma as the most common cancer-type in 66.4% patients followed 
by adenocarcinoma, small cell carcinoma, and large cell carcinoma in 
24.8%, 4.4%, and 2.9% patients, respectively. During bronchoscopic 
examination of the patients, the most common bronchoscopic finding was 
intraluminal growth, which was observed in 79.6% cases, followed by 
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bronchial secretions and bronchial congestion in 48.2% and 35.8% cases, 
respectively. Vocal cord palsy and widened carina was noticed in 22.6% and 
19% patients, respectively, whereas compression of bronchi was noticed in 
31.4% patients. 
Based on clinical, radiological, microbiological, and histopathological 
examinations, 18 (13.1%) patients were considered to have defmite-IPA; 
whereas, 17.5% (24/137) and 24.1% (33/137) patients were classified as 
cases of probable-IPA and possible-IPA, respectively. Sixty-two (45.3%) 
patients were classified as non-IPA cases as no signs of invasion were 
noticed, clinically, microbiologically, radiologically and histopathologically. 
5.2. MYCOLOGICAL STUDIES 
BAL culture of 42 (30.7%) patients showed growth of Aspergillus species 
and 19 of these 42 patients revealed fungal elements in direct microscopic 
examination of BAL. Of these 42 culture-positive cases, 18 were categorized 
as cases of definite-IPA and 24 of probable-IPA. Of the Aspergillus spp. 
isolated, Aspergillus fumigatus was the predominant species isolated from 
26 (61.9%) cases followed by Aspergillus flavus in 38.1% (16/42) patients. 
No other species of Aspergillus was isolated in the present study and none 
among the control group showed fungal growth in culture. 
On analysis of the isolation of Aspergillus spp. in various forms of 
IP A, it was noticed that A. fumigatus was isolated from 12 and 14 cases of 
definite- and probable-IPA, respectively, whereas, A. flavus was isolated 
from 6 and 10 cases of definite- and probable-IPA, respecfively. No 
Aspergilli was isolated from cases of possible and non-IPA, and none among 
the healthy controls showed growth of Aspergilli in the culture. On 
determination of MIC for A. fumigatus isolates, the MIC range for 
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itraconazole and amphotericin B was 0.0313-4 )ig/ml and for voriconazole, 
it was 0.0313-1 \iglm\. Whereas, for A. flavus, MIC ranges for itraconazole, 
amphotericin B, and voriconazole were 0.0313-0.5 |ig/ml, 0.25-4 p.g/ml, 
0.0313-1 )Lig/ml, respectively. 
On serological testing, the anti-Aspergillus antibodies could be 
detected in 48 (35%) patients, each, by DID and DBA. However, the 
antibodies could be detected in 54 (39.4%) patients by ELISA. And, none 
among the healthy volunteers showed anti-Aspergillus antibodies in any of 
the serological test. 
On analysis of BALs by polymerase chain reaction, the Aspergillus-
DNA could be detected in 51.8% (71/137) samples. The Aspergillus-D^A 
was detected in all the patients categorized as cases of defmite-IPA and 
probable-IPA, however, it could be detected in 69.7% (23/33) and 9.7% 
(6/62) cases of possible- and non-IPA, respectively. The PCR assay 
performed on defmite-IPA and probable-IPA cases showed amplicons of 
135 bp and 118 bp indicating the presence of A. fumigatus and A. flavus, 
respectively. The Aspergillus species detected by the PCR, in these cases, 
corresponded well with culture results. In cases of possible-IPA, 
Aspergillus-DNA could be detected in 23 patients, and of these, the PCR-
amplicons denoted the presence of A. fumigatus and A. flavus in 19 and 4 
patients, respectively. In cases categorized as non-IPA, PCR was positive in 
6 cases, and of which 5 showed amplicons denoting the presence of A. 
fiimigatus, and one with amplicon of A. flavus. None among the healthy 
control group showed presence of Aspergillus DNA by BAL-PCR. 
Based on the present study, a strong association between a positive PCR 
test and all forms of aspergillosis (P< 0.05) was noticed, with the strongest 
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association correlation found with definite- and probable-IPA (P< 0.001). 
Serological tests also showed strong association with po^tive test and 
aspergillosis in definite- and probable-IPA (P< 0.001); however the 
sensitivities dropped down drastically in possible- and non-IPA. 
The sensitivity, specificity, PPV, and NPV of PCR and serological tests 
were 100% for definite- and probable-IPA when the data was compared 
against the the healthy volunteers. When the same data was compared with 
entire dataset, the sentitivity of PCR and serological tests still remained 
100% while specificity ranged between 65-83%. This clearly denotes high 
diagnostic values of these tests in such cases. However, in cases of possible-
IPA, the sensitivity, specificity, PPV, and NPV of PCR were 69.7%, 100%, 
100% and 77.3%, respectively, when compared with healthy controls and 
these values were 69.1%, 65.1%, 32.4%), and 90%>, respectively, when 
compared against the entire dataset. These values for ELISA, in possible-
IPA, were found as 24.2%), 100%, 100% and 57.6%o, respectively, when 
compared with healthy controls and were 24.2%o, 66.7%o, 14.8%o, and 78.6%, 
respectively, when compared against the entire dataset. This strongly suggest 
that PCR has greater diagnostic role in possible-IPA as compared to those of 
serological tests. The diagnostic role of PCR was also higher than 
serological tests in cases with non-IPA. However, ELISA do play a 
diagnostic role in non-IPA, to an extent, as opposed to DID and DBA. We 
could not get any case which was PCR negative but positive by any other 
test performed. 
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5.3. BACTERIOLOGICAL STUDIES 
Of 137 BAL specimens, 104 yielded bacterial growth during culture and a 
total of 143 bacterial isolates were obtained from these 137 BAL specimens. 
Many samples showed mixed growth of bacteria. Klebsiella pneumoniae 
was the most common isolated organism noticed in 29.9% samples followed 
by Pseudomonas aeruginosa which was noticed in 26.3% BAL samples. 
Escherichia coli was isolated from 15.3% samples. Only isolates of E. coli 
and K. pneumoniae were selected for further studies. 
The isolates of E. coli showed maximum susceptibility to ceftriaxone-
sulbactam, a combination recently launched in India, and to meropenem in 
85.7%, each, followed by cefoxitin (53.2%) and amikacin (46.8%). The 
resistance to cefpodoxime, cefotaxime, and ceftazidime was noticed in 
95.2% (20/21), 90.5% (19/21) and 85.7% (18/21) isolates, respectively. 
Concomitant high resistance to other antibiotics tested, including 
tetracycline (95.2%), co-trimoxazole (95.2%), ciprofloxacin (90.5%), 
aztreonam (85.7%)), trimethoprim (85.7%)), gentamicin (66.7%), was also 
noticed. All the K. pneumoniae isolates were susceptible to ceftriaxone-
sulbactam and meropenem. Among aminoglycosides, the maximum 
resistance was noticed against gentamicin in 63.4%) isolates followed by 
amikacin (56.1%) and tobramycin (36.6%)). Cefpodoxime, cefotaxime, and 
ceftazidime showed resistance in 97.6% (40/41), 92.7% (38/41) and 92.7% 
(38/41) isolates, respectively. And similar to E. coli isolates, K. pneumoniae 
also showed concomitant high resistance to other antibiotics tested. 
Disk synergy test using co-amoxyclav disks detected ESBLs in 9.7%o 
(6/62) isolates, whereas phenotypic detection of ESBLs by a newly 
described disk synergy test (Shahid et al. 2007b), where piperacillin-
tazobactam is used in place of co-amoxyclav, was possible in total of 90.3% 
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(56/62) isolates. Using combination disks, ESBLs could be detected in total 
of82.3% (51/62) isolates. 
blacTx-M could be detected in a total of 77.4% (48/62) isolates using 
the multiplex PCR, and of which it could be detected in 81% (17/21) of E. 
coli and 75.6%) (31/41) isolates of A^ . pneumoniae. Based on the multiplex 
PCR results, CTX-M phylogenetic Group 1 was identified in all the isolates 
studied, and RLH identified the presence of ^/^CTX-M-IS only. Sequencing of 
the representative isolates confirmed the presence of 6/acTx-M-i5-
Noticing the recent appearance of IS2(5 elements in ISEcpI, in U.K. 
Enterobacteriaceae (Woodford et al 2004), we also analyzed the genetic 
environment of the Indian Enterobacteriaceae. IS26 was detected in 20 of 48 
(41.7%)) isolates carrying /^GCTX-M-IS (9 E.coli, 11 K. pneumoniae). It was 
interesting to note that amplicons of varying sizes (~650bp, ~750bp, 
~850bp, ~950bp, ~1 lOObp, and >I400bp) were obtained; the most common 
being ~850bp amplicon. 
Unlike the situation in the UK where an epidemic E. coli clone A 
carrying bhcTx-u-is has been described (Woodford et al. 2004), no 
predominant clone was identified in our Indian isolates, indicating horizontal 
transfer of i/acix-M-is between unrelated strains. 
The apparent acquisition of IS2(5 elements in Indian strains is 
interesting. It perhaps suggests a 'turnover" of plasmids in the population 
over time, the 1826 insertion creating a selective advantage in those strains 
carrying the IS2<5 insertion. Although the numbers are small, the 
geographical consistency of the observation could make it broadly applicable 
and worthy of further investigation. None of the isolates was positive for 
IS2(5 elements in earlier studies, including the isolates collected during and 
before year 2000 (Karim et al. 2001; Walsh et al. 2007). We first noticed 
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this insertion sequence in a collection of bacteria obtained during 2003-2005 
(Ensor et al. 2006b), and subsequently, in the present work. Therefore, it is 
possible that although /^(3CTX-M-I5 was widely established in India before 
2000, the IS2(5 element had not yet inserted within ISEcpl {tnpA), and that 
this is a later event. In the present study, at least three IS26 insertion sites 
have been identified precisely and is being postulated that such an insertion 
into ISEcp] traps the ESBL gene thus preventing it from escaping the gene 
pool. The recent findings indicate that whilst the level of CTX-M-15-
positive strains has not generally increased since the earlier sampled period, 
the genetic environment of blacjx-M-\5 has changed through the insertion of 
IS26 although the consequences of these events remain uncertain. 
bla^^pc of CIT-family were detected in 27.4% (17/62) isolates. Of 
these /)/aanipc-carrying isolates, 23.8% (5/21) were E. coli and 29.3% (12/41) 
were K. pneumoniae. Sequencing of the representative isolates revealed the 
presence of CMY-6-like CMY-18-like AmpC (3-lactamase. Of the 62 
isolates studied in the present study, 13 (21%) were simultaneously 
harboring /)/(7ampc and blacTx-M-\5- The frequency of simultaneous occurrence 
in the respective species was noticed in 19% (4/21) and 22% (9/41) of E. 
coli and K. pneumoniae respectively. 
Plasmid analysis of the representative isolates showed the consistent 
presence of a single plasmid ranging between ca. -21 to ca. -23 kb. 
Successfully cured isolates became susceptible to cephamycins and 
cephalosporins and thus provide indirect evidence of carriage of 6/flampC and 
blacTx-M-i5 on same plasmid. RAPD-typing of the isolates demonstrated great 
diversity and no predominant type was noticed, indicating either horizontal 
transfer and/or mobilization of these genes on plasmids. 
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CONCLUSIONS 
Based on the present study following conclusions were drawn: 
• The frequency of secondary aspergillosis was found to be 46.7% 
(64/137; cases positive both by PCR and serology) in bronchogenic 
carcinoma which demonstarte the frequent association of this 
combination disesase. 
• It is thus suggested that every patient of bronchogenic carcinoma 
should be screened for the presence of secondary aspergillosis. 
• The sensitivity, specificity, PPV, and NPV of PCR and serological 
tests were 100% for definite- and probable-IPA when the data was 
compared against the the healthy volunteers, and it denotes high 
diagnostic values of these tests in such cases. 
• When the same data was compared with entire dataset, the sentitivity 
of PCR and serological tests still remained 100%) while specificity 
ranged between 65-83%. Still, it denotes high diagnostic values of 
these tests in such cases. 
• PCR has greater diagnostic role in possible-IPA as compared to that 
of serological tests. 
• The diagnostic role of PCR was also higher than serological tests in 
cases with non-IPA. However, ELISA do play a diagnostic role in 
non-IPA, to an extent, as opposed to DID and DBA. 
• However, the laboratories which do not have facilities for PCR and 
ELISA should at least perform DID or DBA by the proposed protocol. 
• It is thus suggested that combining PCR with serological test detecting 
anXi-Aspergillus antibodies could be of help confirming the diagnosis 
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of aspergillosis. This combination test strategy would also help 
establishing the diagnosis in patients without signs of infiltration in 
radiological investigations. 
• It is also suggested that that performing PCR on consecutive BALs 
would help taking the decision to institute the antifungal therapy since 
we noticed that 10 (58.8%) out of 17 patients which were initially 
serologically negative, but PCR-positive, later on seroconverted into 
positive results. 
• This preliminary investigation suggests that both BAL-PCR and 
serological tests detecting anti-Aspergillus antibodies might be 
beneficial for use in early diagnosis of aspergillosis, especially in 
patients which do not demonstrate signs of infiltration in radiology. 
• The present preliminary study demonstrate frequent association of this 
combination disesase (secondary aspergillosis in bronchogenic 
carcinoma). 
• This is among the premier reports defining the high frequency and 
evaluating various diagnostic tests for secondary aspergillosis in 
bronchogenic carcinoma patients. 
• We report here a 3GC resistance rate of 96.8% of all E. coli and K. 
pneumoniae obtained from BAL of bronchogenic carcinoma patients 
and in these, a CTX-M carriage rate of 77.4%. 
• Numerous reports from India have indicated a high prevalence of 
ESBLs in Gram-negative bacteria, which must be presumed to have 
taken a considerable time to reach a high prevalence. As our study 
suggests, CTX-M-15 is the most common (or maybe the only) CTX-
M type in India. 
Summary & Conclusions 
• This is amongst the premier systematic report from India 
characterizing the occurrence and prevalence of CTX-M enzymes. 
• Unlike the situation in the UK where an epidemic E. coli clone A 
carrying blaci\.u-\5 has been described, no predominant clone was 
identified in our Indian isolates. 
• The acquisition of IS2(5 elements in Indian strains perhaps suggests a 
'turnover' of plasmids in the population over time. 
• It is speculated that 6/«CTX-M-I5 was widely established in India before 
2000, the 1^26 element had not yet inserted within ISEcpI (tnpA), and 
that this is a later event. 
• In the present study, three IS26 insertion sites have been identified 
precisely and is being postulated that such an insertion into ISEcpl 
traps the ESBL gene thus preventing it from escaping the gene pool. 
• To the best of our knowledge this is the second report of high 
mobility/diversity of IS26 insertion in ISEcpl, first being reported in 
year 2006 (Ensor et al. 2006b), which also included few of the isolates 
from the present Doctoral work. 
• bhajnpc of CIT-family were detected in 27.4% of Indian 
Enterobacteriaceae and the sequencing of the representative isolates 
showed presence of CMY-6- like and CMY-18-like AmpC p-
lactamases. 
• Concomitant occurrence of bla^^c and /^ /OCTX-M-IS were noticed in 
significant number of isolates and the genes were inferred to present 
on plasmids ranging between -21 to -23 kb. 
• This is the first report looking for the carriage of /^ACTX-M and blaczmpc 
in Enterobacteriaceae from the patients of bronchogenic carcinoma. 
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• This is also the first report looking for the co-carriage of 6/acTx-M and 
bldcumpc in Indian Enterobacteriaceae. 
• This would be the first report indicating the presence of CMY-6- and 
CMY-18- like ampC genes in Indian Enterobacteriaceae. 
• RAPD-typing demonstrated great diversity and indicate transfer of 
these resistance genes on plasmids; and also the dissemination of 
these resistance genes into the community. This probably also 
indicates horizontal transfer of ZJ/^ CTX-M-IS between unrelated strains. 
• Our report supports the urgent need for regular screening and national 
surveillance characterizing the CTX-M types and to implement strict 
antibiotics policy to limit the irrational use of antibiotics, including 
cephalosporins, so as to minimize antibiotic selective pressure. 
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Annexure I 
ANNEXUREI 
: DO485309. Reports Klebsiella pneumo...[gi:92428671] Links 
Features 
Sequence 
LOCUS DQ485309 955 bp DNA l i n e a r BCT 
23-APR-2006 
DEFINITION Klebsiella pneumoniae isolate MS04 insertion sequence 
ISEcpl, 
partial sequence; and CTX-M-15 beta-lactamase (blaCTX-M-
15) gene, 
complete cds. 
ACCESSION DQ485309 
VERSION DQ485309.1 GI:92428671 
KEYWORDS 
SOURCE Klebsiella pneumoniae 
ORGANISM Klebsiella pneumoniae 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Klebsiella. 
REFERENCE 1 (bases 1 to 955) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE blaCTX-M-15 from Tertiary Care Hospital of North India 
JOURNAL Unpublished 
REFERENCE 2 (bases 1 to 955) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE Direct Submission 
JOURNAL Submitted (13-MAR-2006) Microbiology, Jawaharlal Nehru 
Medical 
College & Hospital, Aligarh Muslim University, Aligarh, 
U.P. 
202002, India 
FEATURES Location/Qualifiers 
source 1..955 
/organism="Klebsiella pneumoniae" 
/mol_type="genomic DNA" 
/isolate="MS04" 
/db xref="taxon:573" 
/PCR_primers="fwd_seq: aaaaatgattgaaaggtggt, 
rev_seq: 
cagcgcttttgccgtctaag" 
repeat region <1..79 
/mobile_element="insertion sequence:ISEcpl" 
gene 80..955~ 
/gene="blaCTX-M-15" 
CDS 80..955 
/gene="blaCTX-M-15" 
/note="cefotaximase enzyme" 
/codon_start=l 
/transl_table=]J^ 
/product="CTX-M-15 beta-lactamase" 
/protein id="ABE76829.1" 
/db xref="GI:92428672" 
Annexure I 
/translation="MVKKSLRQFTLMATATVTLLLGSVPLYAQTADVQQKLAELERQS 
GGRLGVALINTADNSQILYRADERFAMCSTSKVMAAAAVLKKSESEPNLLNQRVEIKK 
SDLVNYNPIAEKHVNGTMSLAELSAAALQYSDNVAMNKLIAHVGGPASVTAFARQLGD 
ETFRLDRTEPTLNTAIPGDPRDTTSPRAMAQTLRNLTLGKALGDSQRAQLVTWMKGNT 
TGAASIQAGLPASWVVGDKTGSGGYGTTNDIAVIWPKDRAPLILVTYFTQPQPKAESR 
RDVLASAAKIVTDGL" 
ORIGIN 
1 gagctaataa a aaacacacQ tggaatttsg ggactattca tgtgcitggt'c 
atttcgtatc 
61 ttccagaata aggaatccca tggttaaaaa atcactgcgc cagttcacgc 
tgatggcgac 
121 ggcaaccgtc acgctgttgt taggaagtgt gccgctgtat gcgcaaacgg 
cggacgtaca 
181 gcaaaaactt gccgaattag agcggcagtc gggaggcaga ctgggtgtgc 
catrgattaa 
241 cacagcagat aattcgcaaa tactttatcg tgctgatgag cgctttgcga 
tgtgcagcac 
301 cagtaaagtg atggccgcgg ccgcggtgct gaagaaaagt gaaagcgaac 
cgaatctgtt 
361 aaatcagcga gttgagatca aaaaatctga ccttgttaac tataatccga 
ttgcggaaaa 
421 gcacgtcaat gggacgatgt cactggctga gcttagcgcg gccgcgctac 
agtacagcga 
481 taacgtggcg atgaataagc tgattgctca cgttggcggc ccggctagcg 
tcaccgcgtt 
541 cgcccgacag ctgggagacg aaacgttccg tctcgaccgt accgagccga 
cgttaaacac 
601 cgccattccg ggcgatccgc gtgataccac ttcacctcgg gcaatggcgc 
aaactctgcg 
661 gaatctgacg ctgggtaaag cattgggcga cagccaacgg gcgcagctgg 
tgacatggat 
721 gaaaggcaat accaccggtg cagcgagcat tcaggctgga ctgcctgctu 
cctgggttgt 
781 gggggataaa accggcagcg gtggctatgg caccaccaac gatatcgcgc 
tgatctggcc 
841 aaaagatcgt gcgccgctga ttctggtcac ttacttcacc cagcctcaac 
ctaaggcaga 
901 aagccgtcgc gatgtattag cgtcggcggc taaaatcgtc accgacggtt tgtaa 
// 
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ANNEXURE II 
DO485310. Reports Escherichia coli ...[gi:92428673] Links 
• Features 
• Sequence 
LOCUS DQ485310 954 bp DNA l i n e a r BCT 
23-APR-2006 
DEFINITION Escherichia coll isolate MS05 insertion sequence ISEcpl, 
partial 
sequence; and CTX-M-15 beta-lactamase (blaCTX-M-15) gene, 
complete 
cds. 
ACCESSION DQ485310 
VERSION DQ485310.1 GI:92428673 
KEYWORDS 
SOURCE Escherichia coli 
ORGANISM Escherichia coli 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Escherichia. 
REFERENCE 1 (bases 1 to 954) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE blaCTX-M-15 from Tertiary Care Hospital of North India 
JOURNAL Unpublished 
REFERENCE 2 (bases 1 to 954) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE Direct Submission 
JOURNAL Submitted (13-MAR-2006) Microbiology, Jawaharlal Nehru 
Medical 
College & Hospital, Aligarh Muslim University, Aligarh, 
U.P. 
202002, India 
FEATURES Location/Qualifiers 
source 1..954 
/organism="Escherichia coli" 
/mol_type="genomic DNA" 
/isolate="MS05" 
/db xref="taxon:562" 
/PCR_primers="fwd_seq: aaaaatgattgaaaggtggt, 
rev_seq: 
cagcgcttttgccgtctaag" 
repeat region <1..37 
/mobile_element="insertion sequence:ISEcpl" 
gene 38..913 
/gene="blaCTX-M-15" 
CDS 38..913 
/gene="blaCTX-M-15" 
/note="cefotaximase enzyme" 
/codon_start=l 
/ t r a n s l t a b l e a u 
/product="CTX-M-15 beta-lactamase" 
/protein id="ABE76830.1" 
/db xref="GI:92428674" 
Annexure II 
/translation="MVKKSLRQFTLMATATVTLLLGSVPLYAQTADVQQKLAELERQS 
GGRLGVALINTADNSQILYRADERFAMCSTSKVMAAAAVLKKSESEPNLLNQRVEIKK 
SDLVNYNPIAEKHVNGTMSLAELSAAALQYSDNVAMNKLIAHVGGPASVTAFARQLGD 
ETFRLDRTEPTLNTAIPGDPRDTTSPRAMAQTLRNLTLGKALGDSQRAQLVTWMKGNT 
TGAASIQAGLPASWVVGDKTGSGGYGTTNDIAVIWPKDRAPLILVTYFTQPQPKAESR 
RDVLASAAKIVTDGL" 
ORIGIN 
1 catgtggttg tatttcgtat ctccagataa ggatcccatg gttaaaaaat 
cactgcgcca 
61 gttcacgctg atggcgacgg caaccgtcac gctgttgtta ggaagtgtgc 
cgctgtatgc 
121 gcaaacggcg gacgtacagc aaaaacttgc cgaattagag cggcagtcgg 
gaggcagact 
181 gggtgtggca ttgattaaca cagcagataa ttcgcaaata ctttatcgtg 
ctgatgagcg 
241 ctttgcgatg tgcagcacca gtaaagtgat ggccgcggcc gcggtgctga 
agaaaagtga 
301 aagcgaaccg aatctgttaa atcagcgagt tgagatcaaa aaatctgacc 
ttgttaacta 
361 taatccgatt gcggaaaagc acgtcaatgg gacgatgtca ctggctgagc 
ttagcgcggc 
421 cgcgctacag tacagcgata acgtggcgat gaataagctg attgctcacg 
ttggcggccc 
481 ggctagcgtc accgcgttcg cccgacagct gggagacgaa acgttccgtc 
tcgaccgtac 
541 cgagccgacg ttaaacaccg ccattccggg cgatccgcgt gataccactt 
cacctcgggc 
601 aatggcgcaa actctgcgga atctgacgct gggtaaagca ttgggcgaca 
gccaacgggc 
661 gcagctggtg acatggatga aaggcaatac caccggtgca gcgagcattc 
aggctggact 
721 gcctgcttcc tgggttgtgg gggataaaac cggcagcggt ggctatggca 
ccaccaacga 
781 tatcgcggtg atctggccaa aagatcgtgc gccgctgatt ctggtcactt 
acttcaccca 
841 gcctcaacct aaggcagaaa gccgtcgcga tgtattagcg tcggcggcta 
aaatcgtcac 
901 cgacggtttg taatagcgga aacggaatgg ggaaactcat tccgtttttg tttc 
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ANNEXURE III 
1: ££371800. Reports Escherichia coli ...[gi: 125634305] Links 
Features 
Sequence 
LOCUS EF371800 567 bp DNA linear BCT 
17-FEB-2007 
DEFINITION Escherichia coli strain MS INC03 beta-lactamase (blaCTX-M-
15) gene, 
partxal cds. 
ACCESSION EF371800 
VERSION EF371800.1 GI:125634305 
KEYWORDS 
SOURCE Escherichia coli 
ORGANISM Escherichia coli 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Escherichia. 
1 (bases 1 to 567) 
Shahid,M. 
Escherichia coli harboring blaCTX-M-15-like from Tertiary 
REFERENCE 
AUTHORS 
TITLE 
Care 
JOURNAL 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
Muslim 
FEATURES 
source 
rev_seq: 
gene 
CDS 
Hospital of North India 
Unpublished 
2 (bases 1 to 567) 
Shahid,M. 
Direct Submission 
Submitted (17-JAN-2007) Medical Microbiology, Aligarh 
University, JN Medical College, Aligarh, UP 202002, India 
Location/Qualifiers 
1..567 
/organism="Escherichia coli" 
/mol_type="genomic DNA" 
/strain="MS INC03" 
/db xref="taxon:562" 
/PCR_primers="fwd_seq: aaaaatgattgaaaggtggt, 
cagcgcttttgccgtctaag" 
<1..567 
/gene="blaCTX-M-15" 
<1..567 
/gene="blaCTX-M-15" 
/note="cefotaximase enzyme" 
/codon_start=l 
/transl tableau 
/product="beta-lactamase" 
/protein id="ABN48407.1" 
/db xref="GI:125634306" 
/translation="DLVNYNPIAEKHVNGTMSLAELSAAALQYSDNVAMNKLIAHVGG 
PASVTAFARQLGDETFRLDRTEPTLNTAIPGDPRDTTSPRAMAQTLRNLTLGKALGDS 
Annexure III 
QRAQLVTWMKGNTTGAASIQAGLPASWVVGDKTGSGGYGTTNDIAVIWPKDRAPLILV 
TYFTQPQPKAESRRDVLASAAKIVTDGL" 
ORIGIN 
1 gaccttgtta actataatcc gattgcggaa aagcacgtca atgggacgat 
gtcactggct 
61 gagcttagcg cggccgcgct acagtacagc gataacgtgg cgatgaataa 
gctgattgct 
121 cacgttggcg gcccggctag cgtcaccgcg ttcgcccgac agctgggaga 
cgaaacgttc 
181 cgtctcgacc gtaccgagcc gacgttaaac accgccattc cgggcgatcc 
gcgtgatacc 
241 acttcacctc gggcaatggc gcaaactctg cggaatctga cgctgggtaa 
agcattgggc 
301 gacagccaac gggcgcagct ggtgacatgg atgaaaggca ataccaccgg 
tgcagcgagc 
361 attcaggctg gactgcctgc ttcctgggtt gtgggggata aaaccggcag 
cggtggctat 
421 ggcaccacca acgatatcgc ggtgatctgg ccaaaagatc gtgcgccgct 
gattctggtc 
481 acttacttca cccagcctca acctaaggca gaaagccgtc gcgatgtatt 
agcgtcggcg 
541 gctaaaatcg tcaccgacgg tttgtaa 
// 
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ANNEXUREIV 
1: EF371799. Reports Escherichia coli ...[gi: 125634303] Links 
Features 
Sequence 
LOCUS EF371799 698 bp DNA linear BCT 
17-FEB-2007 
DEFINITION Escherichia coll strain MS INB03 insertion sequence 
ISEcpl, partial 
sequence; and beta-lactamase (blaCTX-M-15) gene, partial 
cds. 
ACCESSION EF371799 
VERSION EF371799.1 GI:125634303 
KEYWORDS 
SOURCE Escherichia coli 
ORGANISM Escherichia coli 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Escherichia. 
REFERENCE 1 (bases 1 to 698) 
AUTHORS Shahid,M. 
TITLE Escherichia coli harboring blaCTX-M-15-like from Tertiary 
Care 
Hospital of North India 
JOURNAL Unpublished 
REFERENCE 2 (bases 1 to 698) 
AUTHORS Shahid,M. 
TITLE Direct Submission 
JOURNAL Submitted (17-JAN-2007) Medical Microbiology, Aligarh 
Muslim 
University, JN Medical College, Aligarh, UP 202002, India 
FEATURES Location/Qualifiers 
source 1..698 
/organism="Escherichia coli" 
/mol_type="genomic DNA" 
/strain="MS INB03" 
/db xref="taxon:562" 
/PCR_primers="fwd_seq: aaaaatgattgaaaggtggt, 
rev_seq: 
cagcgcttttgccgtctaag" 
repeat region <1..108 
/mobile_element="insertion sequence:ISEcpl" 
gene 109..>698 
/gene="blaCTX-M-15" 
CDS 109..>698 
/gene="blaCTX-M-15" 
/note="cefotaximase enzyme" 
/codon_start=l 
/transl table=ll 
/product="beta-lactamase" 
/protein__id="ABN48406.1" 
/db xref="GI:125634304" 
Annexure IV 
/translation="MVKKSLRQFTLMATATVTLLLGSVPLYAQTADVQQKLAELERQS 
GGRLGVALINTADNSQILYRADERFAMCSTSKVMAAAAVLKKSESEPNLLNQRVEIKK 
SDLVNYNPIAEKHVNGTMSLAELSAAALQYSDNVAMNKLIAHVGGPASVTAFARQLGD 
ETFRLDRTEPTLNTAIPGDPRDTTSPRAMAQTLRNLT" 
ORIGIN 
1 tctatttctt cgtgaaatag tgatttttga agctaataaa aaacacacgt 
ggaatttagg 
61 gactattcat gttgttgtta tttcgtatct tccagaataa ggaatcccat 
ggttaaaaaa 
121 tcactgcgcc agttcacgct gatggcgacg gcaaccgtca cgctgttgtt 
aggaagtgtg 
181 ccgctgtatg cgcaaacggc ggacgtacag caaaaacttg ccgaattaga 
gcggcagtcg 
241 ggaggcagac tgggtgtggc attgattaac acagcagata attcgcaaat 
actttatcgt 
301 gctgatgagc gctttgcgat gtgcagcacc agtaaagtga tggccgcggc 
cgcggtgctg 
361 aagaaaagtg aaagcgaacc gaatctgtta aatcagcgag ttgagatcaa 
aaaatctgac 
421 cttgttaact ataatccgat tgcggaaaag cacgtcaatg ggacgatgtc 
actggctgag 
481 cttagcgcgg ccgcgctaca gtacagcgat aacgtggcga tgaataagct 
gattgctcac 
541 gttggcggcc cggctagcgt caccgcgttc gcccgacagc tgggagacga 
aacgttccgt 
601 ctcgaccgta ccgagccgac gttaaacacc gccattccgg gcgatccgcg 
tgataccact 
661 tcacctcggg caatggcgca aactctgcgg aatctgac 
// 
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ANNEXURE V 
D04853H. Reports Escherichiacoli ...[gi:92428675] Links 
• Features 
• Sequence 
LOCUS DQ485311 479 bp DNA l inear BCT 
23-APR-2006 
DEFINITION Escherichia coli isolate MSOl insertion sequences ISEcpl 
and IS26, 
partial sequence; and CTX-M-15 beta-lactamase (blaCTX-M-
15) gene, 
partial cds. 
ACCESSION DQ485311 
VERSION DQ485311.1 GI:92428675 
KEYWORDS 
SOURCE Escherichia coli 
ORGANISM Escherichia coli 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Escherichia. 
REFERENCE 1 (bases 1 to 479) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE IS26 element m Indian bacterial population 
JOURNAL Unpublished 
REFERENCE 2 (bases 1 to 479) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE Direct Submission 
JOURNAL Submitted (13-MAR-2006) Microbiology, Jawaharlal Nehru 
Medical 
U.P. 
College & Hospital, Aligarh Muslim University, Aligarh, 
202002, India 
FEATURES Location/Qualifiers 
source 1. .479 
/organism="Escherichia coli" 
/mol_type="genomic DNA" 
/isolate="MS01" 
/db xref="taxon:562" 
/PCR_primers="fwd_seq: gcggtaaatcgtggagtgat, 
rev^seq: 
attcggcaagtttttgctgt" 
repeat region <1..442 
/note="disrupted by IS26 insertion element" 
/mobile_element="insertion sequence:ISEcpl" 
repeat region <1..122 
/mobile_element="insertion sequence:IS26" 
gene 443..>479 
/gene="blaCTX-M-15" 
CDS 443..>479 
/gene="blaCTX-M-15" 
/note="cefotaximase enzyme" 
/codon_start=l 
/transl table=ll 
Annexure V 
/product="CTX-M-15 beta-lactamase" 
/protein id="ABE76831.1" 
/db__xref="GI: 92428676" 
/translation="MVKKSLRQFTLM" 
ORIGIN 
1 cagcgtacgg cccacagaat gatgtcacgc tgaaaatgcc ggcctttgaa 
tgggttcatg 
61 tgcagctcca tcagcaaaag gggatgataa gtttatcacc accgactatt 
tgcaacagtg 
121 cctgtaatca tgaagttgtc ggaaaactat ccgtacaagg gagtgtatga 
aaaatgtctg 
181 gtataataag aatatcatca ataaaattga gtgttgctct gtggataact 
tgcagagttt 
241 attaagtatc attgcagcaa agatgaaatc aatgatttat caaaaatgat 
tgaaaggtgg 
301 ttgtaaataa tgttacaatg tgtgagaagc agtctaaatt cttcgtgaaa 
tagtgatttt 
361 tgaagctaat aaaaaacaca cgtggaattt agggactatt catgttgttg 
ttgatttcgt 
421 atcttccaga ataaggaatc ccatggttaa aaaatcactg cgccagttca 
cgctgatgg 
// 
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ANNEXURE VI 
D0485313. Reports Escherichia coli ...[gi:92428679] Links 
• Features 
• Sequence 
LOCUS DQ485313 665 bp DNA l inear BCT 
23-APR-2006 
DEFINITION Escherichia coll isolate MS02 insertion sequences ISEcpl 
and IS26, 
partial sequence; and CTX-M-15 beta-lactamase (blaCTX-M-
15) gene, 
partial cds. 
ACCESSION DQ485313 
VERSION DQ485313.1 01:92428679 
KEYWORDS 
SOURCE Escherichia coll 
ORGANISM Escherichia cell 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Escherichia. 
REFERENCE 1 (bases 1 to 665) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE IS26 element m Indian bacterial population 
JOURNAL Unpublished 
REFERENCE 2 (bases 1 to 665) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE Direct Submission 
JOURNAL Submitted (13-MAR-2006) Microbiology, Jawaharlal Nehru 
Medical 
U.P. 
College & Hospital, Aligarh Muslim University, Aligarh, 
202002, India 
FEATURES Location/Qualifiers 
source 1. .665 
/orqanism="Escherichia coli" 
/mol_type="genomic DNA" 
/isoIate="MS02" 
/db xref="taxon:562" 
/PCR_primers="fwd_seq: gcggtaaatcgtggagtgat, 
rev_seq: 
attcggcaagtttttgctgt" 
repeat region <1..633 
/note="disrupted by IS26 insertion element" 
/mobile_element="insertion sequence:ISEcpl" 
repeat region <1..88 
/mobile_element="insertion sequence:IS26" 
gene 634..>6^5 
/gene="blaCTX-M-15" 
CDS 634..>665 
/gene="blaCTX-M-15" 
/note="cefotaximase enzyme" 
/codon_start=l 
/transl table=ll 
Annexure VI 
/product="CTX-M-15 beta-lactamase" 
/protein id="ABE76833.1" 
/db_xref="GI:924 28 680" 
/translation="MVKKSLRQFTL" 
ORIGIN 
1 aatgccggcc tttgaatggg ttcatgtgca gctccatcag caaaagggga 
tgataagttt 
61 atcaccaccg actatttgca acagtgccct gaaaactata tcaaagaagc 
caaatacgac 
121 atggcggtgg gtcatctctt gctaaagtca ttttgggcga atgaagccgt 
gtttcaaatg 
181 atgatgcttt catataacct atttttgttg ttcaagtttg attccttgga 
ctcttcagaa 
241 tacagacagc aaataaagac ctttcgtttg aagtatgtat ttcttgcagc 
aaaaataatc 
301 aaaaccgcaa gatatgtaat catgaagttg tcggaaaact atccgtacaa 
gggagtgtat 
361 gaaaaatgtc tggtataata agaatatcat caataaaatt gagtgttgct 
ctgtggataa 
421 cttgcagagt ttattaagta tcattgcagc aaagatgaaa tcaatgattt 
atcaaaaatg 
481 attgaaaggt ggttgtaaat aatgttacaa tgtgtgagaa gcagtctaaa 
ttcttcgtga 
541 aatagtgatt tttgaagcta ataaaaaaca cacgtggaat ttagggacta 
t-i-^ atcttgt 
601 tgttatttcg LdtcTitccag aataaggaat cccatggtta aaaaatcact 
gcgccagttc 
661 acgct 
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ANNEXURE VII 
D0485312. Reports Klebsiella pneumo...[gi:92428677] Links 
• Features 
• Sequence 
LOCUS DQ485312 646 bp DNA l inear BCT 
23-APR-2006 
DEFINITION Klebsiella pneumoniae isolate MS03 insertion sequences 
ISEcpl and 
IS26, partial sequence; and CTX-M-15 beta-lactamase 
(blaCTX-M-15) 
gene, partial cds. 
ACCESSION DQ485312 
VERSION DQ485312.1 GI:92428677 
KEYWORDS 
SOURCE Klebsiella pneumoniae 
ORGANISM Klebsiella pneumoniae 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Klebsiella. 
REFERENCE 1 (bases 1 to 646) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE IS26 element in Indian bacterial population 
JOURNAL Unpabxioiicw 
REFERENCE 2 (bases 1 to 64 6) 
AUTHORS Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. 
TITLE Direct Submission 
JOURNAL Submitted (13-MAR-2006) Microbiology, Jawaharlal Nehru 
Medical 
U.P. 
College & Hospital, Aligarh Muslim University, Aligarh, 
202002, India 
FEATURES Location/Qualifiers 
source 1.. 646 
/organism="Klebsiella pneumoniae" 
/mol_type="genomic DNA" 
/isolate="MS03" 
/db xref="taxon:573" 
/PCR__primers="fwd_seq: gcggtaaatcgtggagtgat, 
rev_seq: 
attcggcaagtttttgctgt" 
repeat region <1..613 
/note="disrupted by IS26 insertion element" 
/mobile__element="insertion sequence:ISEcpl" 
repeat region <1..212 
/mobile_element="insertion sequence:IS26" 
gene 614..>646 
/gene="blaCTX-M-15" 
CDS 614..>646 
/gene="blaCTX-M-15" 
/note="cefotaximase enzyme" 
/codon_start=l 
/transl table=ll 
Annexure VII 
/product="CTX-M-15 beta-lactamase" 
/protein id="ABE76832.1" 
/db_xref="GI:92428678" 
/translation="MVKKSLRQFTL" 
ORIGIN 
1 gcgtaaattt gggggagtga tcgacattca ctccgcgttc agccagcatc 
tcctgcagct 
61 ncacggtaac tgatgccgta tttgcagtac cagcgtacgg cccacagaat 
gatgtcacgc 
121 tgaaaatgcc ggcctttgaa tgggttcatg tgcagctcca tcagcaaaag 
gggatgataa 
181 gtttatcacc accgactatt tgcaacagtg cccttcagaa tacagacagc 
aaataaagac 
241 ctttcgtttg aagtatgtat ttcttgcagc aaaaataatc aaaaccgcaa 
gatatgtaat 
301 catgaagttg tcggaaaact atccgtacaa gggagtgtat gaaaaatgtc 
tggtataata 
361 agaatatcat caataaaatt gagtgttgct ctgtggataa cttgcagagt 
ttattaagta 
421 tcattgcagc aaagatgaaa tcaatgattt atcaaaaatg attgaaaggt 
ggttgtaaat 
481 aatgttacaa tgtgtgagaa gcagtctaaa ttcttcgtga aatagtgatt 
tttgaagcta 
541 ataaaaaaca cacgtggaat ttagggacta ttcatgttgt tgttatttcg 
tatcttccag 
601 aataaggaat cccatggtta aaaaatcact gcgccagttc acgctg 
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ANNEXURE VIII 
EF103125. Reports Escherichia coli ...[gi:l 18603534] Links 
• Features 
• Sequence 
LOCUS EF103125 401 bp DNA l inear BCT 
09-DEC-2006 
DEFINITION Escherichia coli strain MS Dll beta-lactamase CMY6-li>ce 
{ampC) 
gene, partial cds. 
ACCESSION EF103125 
VERSION EF103125.1 GI:118603534 
KEYWORDS 
SOURCE Escherichia coli 
ORGANISM Escherichia coli 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Escherichia. 
REFERENCE 1 (bases 1 to 401) 
AUTHORS Shahid,M. 
TITLE CMY-6- like AmpC beta-lactamase m Enterobacteria from 
North-Indian 
Tertiary Care Hospital 
JOURNAL Unpublished 
2 (bases 1 to 401) 
Shahid,M. 
Direct Submission 
Submitted (04-NOV-2006) Microbiology, JN Medical College, 
REFERENCE 
ZVUTHORS 
TITLE 
JOURNAL 
Alxgarh 
FEATURES 
source 
Muslim University, Aligarh, UP 202002, India 
Location/Qualifiers 
1..401 
/organism="Escherichia coli" 
/mol_type="genomic DNA" 
/strain="MS Dll" 
/db xref="taxon:562" 
/PCR_primers="fwd_seq: tggccagaactgacaggcaai 
tttctcctgaacgtggctggc" 
<1..>401 
/gene="ampC" 
<1..>401 
/gene="ampC" 
/note="blaCMY" 
/codon_start=2 
/transl_table=lj^ 
/product="beta-lactamase CMY6-like" 
/protein id="ABL09145.1" 
/db_xref="GI:118603535" 
/translation="RPYRWFIPDVRXGDKAALLHFYQNWQPQWTPGAKRLYANSSIGL 
FGALAVKPbGMSYEEAMTRRVLQPLKLAHTWITVPQNEQKDYAbGYREGKPVHVSPGQ 
rev_seq: 
gene 
CDS 
Annexure VIII 
LDAEAYGVKSSVIDMARWVQANMDASHVQEK" 
ORIGIN 
1 gcggccgtac cgctggttca tccccgatgt acgantaggt gataaagccg 
cattactgca 
61 tttttatcaa aactggcagc cgcaatggac tccgggcgct aagcgacttt 
acgctaactc 
121 cagcattggt ctgtttggcg cgctggcggt gaaaccctca ggaatgagtt 
acgaagaggc 
181 aatgaccaga cgcgtcctgc aaccattaaa actggcgcat acctggatta 
cggttccgca 
241 gaacgaacaa aaagattatg ccctgggcta tcgcgaaggg aagcccgtac 
acgtttctcc 
301 gggacaactt gacgccgaag cctatggcgt gaaatccagc gttattgata 
tggcccgctg 
361 ggttcaggcc aacatggatg ccagccacgt tcaggagaaa a 
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ANNEXURE IX 
EF103126. Reports Escherichia coli ...[gi:l 18603536] Links 
• Features 
• Sequence 
LOCUS EF103126 407 bp DNA l inear BCT 
09-DEC-2006 
DEFINITION Escherichia coli strain MS D12 beta-lactamase CMY6-like 
(ampC) 
gene, partial cds. 
ACCESSION EF103126 
VERSION EF103126.1 01:118603536 
KEYWORDS 
SOURCE Escherichia coli 
ORGANISM Escherichia coli 
Bacteria; Proteobacteria; Gammaproteobacteria; 
Enterobacteriales; 
Enterobacteriaceae; Escherichia. 
REFERENCE I (bases I to 407) 
AUTHORS Shahici,M. 
TITLE CMY-6- like AmpC beta-lactamase m Enterobacteria from 
North-Indian 
Tertiary Care Hospital 
JOURNAL Unpublished 
2 (bases 1 to 407) 
Shahid,M. 
Direct Submission 
Submitted (04-NOV-2006) Microbiology, JN Medical College, 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
Aligarh 
FEATURES 
source 
Muslim University, Aligarh, UP 202002, India 
Location/Qualifiers 
1..407 
/organism="Escherichia coli" 
/mol_type="genomic DNA" 
/strain="MS D12" 
/db xref=^"taxon:562" 
/PCR_primers="fwd_seq: tggccagaactgacaggcaaa, 
tttctcctgaacgtggctggc" 
<1..>407 
/gene="ampC" 
<1..>407 
/gene="ampC" 
/note="blaCMY" 
/codon_start=2 
/transl table=ll 
/product="beta-lactamase CMY6-like" 
/protein id="ABL09146.1" 
/db_xref="GI:118603537" 
/translation="KMNWPESTGKQWQGIRLLHLATYTAGGLPLQIPDDVRDKAALLh 
FYQNWQPQWTPGAKRLYANSSIGLFGALAVKPSGMSYEEAMTRRVLQPLKLAHTWITV 
rev_seq: 
gene 
CDS 
Annexure IX 
PQNEQKDYALGYREGKPVHVSPGQLDAEAYGVK" 
ORIGIN 
1 gaaaatgaat tggccagaat cgacaggcaa acagtggcag ggtatccgcc 
tgctgcactt 
61 agccacctat acggcaggcg gcctaccgct gcagatcccc gatgacgtta 
gggataaagc 
121 cgcattactg catttttatc aaaactggca gccgcaatgg actccgggcg 
ctaagcgact 
181 ttacgctaac tccagcattg gtctgtttgg cgcgctggcg gtgaaaccct 
caggaatgag 
241 ttacgaagag gcaatgacca gacgcgtcct gcaaccatta aaactggcgc 
atacctggat 
301 tacggttccg cagaacgaac aaaaagatta tgccttgggc tatcgcgaag 
ggaagcccgt 
361 acacgtttct ccgggacaac ttgacgccga agcctatggc gtgaaat 
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Resistance to ihiid and lourth-generalion cephalosporins has 
become a majoi concern worldwide Even moie alarming is ihc 
emergence of carbapenem resistance, the carbapenenis are often 
considered to be a drug of choice' and are increasingly used 
in empirical theiapy Against this rising lesistance the role of 
p-lactani/p-lactamase inhibitor combinations needs to be con-
sidered Sulbacum has been approved lecentK in many 
cotintrics to be combined with P-laciam antibiotics ' including 
lecenlly m India 
CTX-M enzymes are a recently emeiged group of extended-
spectrum p-lactamases (ESBLs) and CTX-M-15 has emerged as 
the most prevalent ESBL in many parts o( the world, including 
the UK and India " We have evaluated the //; una efficacy ot 
ceftriaxone/sulbactam, a combmalion recently launched m India, 
in Eichenchui coli haibounng bUicTx M n Moreover, we 
described the phenotypic detection of ESBL production by the 
synergy observed between cephalosporin and piperacillin/tazo-
baciam discs and compared it with conventional disc synergy 
tests with co-amoxiclav 
Thirty-two uiinary E coli isolates previously shown to carry 
blacvx M IS. <ind 22 CTX-M-producmg E coli isolates from 
bronchoalveolar lavage and pus samples obtained during 2006, 
from Jawaharlal Nehru Medical College and Hospital, A.ligarh 
Muslim University, Aligarh, India, were studied The latter iso-
lates were shown to carry blacrx M of genogroup-1 by PCR 
with primers 5'-AAA AAT CAC TGC GCC AGT-3' and 
5' AGC TTA TTC ATC GCC ACG TF-S' Cycling conditions 
were initial denaturation at 94°C for 5 mm, 35 cycles of 94°C 
for 30 s, 52 C for 45 s, and 72''C toi I mm, and a final 
elongation at 12'C for 8 mm Precise CTX-M types were not 
identified in these 22 isolates because ot the lack ol sequencing 
facilities, but CTX-M-15 is the only variant that has been 
described to date m India ^ •* To ensure that multiple representa-
tives of particular strains were eliminated, all isolates were 
selected to have unique randomly amplified polymorphic DNA 
fingerprint patterns 
The antibiotic discs used (Table 1) were from HiMedia 
Lab Ltd, India, except piperacillin, piperaciUin/tazobactam, 
Lcllriaxonc/sulbaclam (kindly provided bv Ranbaxy Lab 1 id 
India) and imipi.ncm uhich was oblamcd from 0\oid 
BasmgMokc UK € coli ATCC 25922 / coli AlCC 3l2l8 
and KkhMclUi pneiimcmuu AICC 700603 were used as conliol 
siuiins The lesulls were inloipretcd as pei the CLSl (fomieily 
NCCLS) cnteria except lor ceftriaxone/sulbactam Because 
thcic are no published breakpoints for the latter combination the 
susceptibility ciilcnon used for this combination was >8 mm 
inciease in /one diamelei of ceftriaxone/sulbactam in compaii-
son with that ol celtriavone alone Phenotypic ESBL detection 
by disc sMicigy tests uas peiformed on all 54 isolates using 
co-amo\icla\ and pipeiacillm/tazobactam discs as a source of 
inhibitors Briefly the test inoculum (equivalent m turbidity to 
that of a 0 5 McFarland standard) was streaked on Mueller-
lliiiton agai Discs of co amoMclav (20/10 p.g) or piperacillin/ 
ta/obatlapi were placed 20 and 30 mm centre to centre, Irom 
discs containing cefota\imc (30 pg) lella/idime (30 (xg) and 
cclpiromc (30 p.g) and plates uere incubated at 37 C overnight 
I iihancemenl ol /ones ol inhibition ol cephalosporins towaids 
pipcraciUin/ia/obactam oi co amoxiclav was considered as posi-
tive ESBL lesults All tests ueie perfonned in duplicate 
Compaialive susceptibilities of the isolates against individual 
P-lactam antibiotics and P-laciam/p-lactamase inhibitor combi-
nations aie shown m Table I A total ol 96 3% isolates weie 
susceptible to ccllriaxonc/sulbactam in comparison with only 
12 97c susceptible to pipciacillin/ta/obactam This contrasts with 
pievious inieinational and iiationaF studies, which reported that 
combinations ot P-lactam uith ta/ohactam showed greater 
activity than P-laclam/sulbactam combm.itions against E coli 
isolates This maiked dilterence may rellect different mechan-
ism(s) in the diflerent bacteiial collections In the present study, 
we specifically looked in CTX-M group-1 and CTX-M-15 pro-
ducers and found ceftriaxone/sulbactam to be a highly effective 
combination (activity being equal to that of imipenem) in con-
trast to pipeiacillin/tazobactam and ticaicillin/clavulanate Two 
isolates that were resistant to ceftriaxone/sulbactam were also 
resistant to imipenem (fable I), they cairied ii/ocTX M i-. and 
hUi„„j,c alleles (data not shown) 
In disc synergy tests none of the 54 ESBL producers vi,as 
detected when co amoxiclav discs were placed 30mm from 
cephalosporin discs, and only 4 isolates (7 4%) were delected 
when this was reduced to 20 mm It is known that optimal disc 
placement is an important issue in such tests'' However, when 
pipcraciUin/tazobactam discs were used and the discs were 
placed 20 mm apart, we readily detected most ESBL-producmg 
isolates, synergy with ceftriaxone cefotaxime and ceftazidime 
allowed detection of 92 6% (50/54), 90 7% (49/54) and 70 1% 
(40/54) of ESBL producers, respectivelv When the discs were 
placed at 30 mm ESBL could still be detected in all the isolates, 
most (88 9Si with cettiiaxone and 83 3% with cefotaxime) of 
the isolates still giving excellent synergistic patterns. On the 
basis of these findings, we feel that piperacillin/tazobactam (or 
tazobactam alone) could be a better indicator when combined 
with ceftriaxone and cefotaxime for the phenotypic detection of 
ESBLs, especially m CTX-M producers This needs to be evalu-
ated further and also against other classes of P-lactamases 
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T.ibic 1. Ciiiiipjiainc suscepiihihtics ol Wi/f-rx vi cirrying C coli isoljics {ii — S4) to iiidivulu.il |i-l.iciams and |i laclam/|^-lactaniase 
iiiliihiloi conlhlMallOIl^  
Anli'iiolics discs ((j.g) hill, I (" = ^^ 2) 
PciCLiu siisLCplrMc isolalcs (/!) 
hill, i\ \ | gioup-l (;) = 22) loial {II = 54) 
Ticaicillin (75) 
Ticaicillin/claviilanaic (75/10) 
PipcrdcillmdOU) 
Pipcraciilin/la/obaclam (100/10) 
Cellriaxone (30) 
Ccllnaxonc/sulbaclain (30/15) 
Imipenem (10) 
0(0) 
0(0) 
0(0) 
9 4(3) 
0(0) 
93 8(30) 
93 8 (30) 
0(01 
0(0) 
0(0) 
18 1 (4) 
0 (0) 
100(22) 
1(K)(22) 
0 (0) 
0(0) 
0 (0) 
12 9(7) 
0(0) 
96 3(52) 
96 3 152) 
To conclude, celtiiaxone/sulbaclaiii proved to be effective 
111 vitro agam.st 54 diverse C!TX-M-I5-producing E coli strains 
This novel combination merits further investigation, as does the 
u.se of piperacillin/tazobactam discs for the phenotypic detection 
of ESBLs 
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Sir, 
Resistance to third- and fourth-generation cephalosporins has 
become a major concern worldwide. Even more alarming is the 
emergence of carbapenem resistance; the ciU'bapenems are oflen 
considered to be a 'drug oi choice' and are increasingly used 
in einpirical therapy. .A.gainst this rising resistance, the role of 
P-lactiim/p-lactamase inhibitor combinations needs to be con-
sidered. Sulbactam has been approved recently in many 
countries to be combined with p-lact<im antibiotics,' including, 
recendy. in India. 
CTX-M enzymes are a recently emerged group of exiended-
.speclrum P-lactamases (ESBLs) and CTX-M-15 has emerged as 
the most prevalent ESBL in numy parts of the world, including 
the UK and India."'^  We have evaluated the in vitro efficacy of 
ceftriaxone/sulbactam, a combination recently launched in India, 
against Escherichia coli harbouring bla^^^x-M-M- Moreover, we 
describe the phenotypic detection of ESBL production by the 
synergy observed between cephalosporin and piperacillin/lazo-
baciam discs and compare it with conventional disc synergy 
tests with co-amoxiclav. 
Thirty-two urinary E. coli isolates previously shown to carry 
'''"cTX-M-1.5.' and 22 CTX-M-producing E. coli isolates from 
bronchoalveolar lavage and pus samples obtained during 2006, 
from Jawaharlal Nelmj Medical College and Hospital, Aligarh 
Muslim University. Aligarh, India, were studied. The latter iso-
lates were shown to carry i'/acrx-M of genogroup-1 by l^ CR 
with primers 5'-AAA AAT CAC TGC GCC AGT-3' and 
5'-AGC ITA TIC ATC GCC ACG lT-3'. Cycling conditions 
were initial dcnaturation at 94"C for 5 min; 35 cycles of 94'"C 
for 30 s, 52X for 45 s and ITC for 1 min: and a final 
elongation at 72"~C for 8 min. Precise CTX-M types were not 
identified in these 22 isolates because of the lack of .sequencing 
facilities, but CTX-M-15 is the only variant that has been 
described to date in India.'''' To ensure that multiple representa-
tives of particular .strains were eliminated, all isolates were 
Table 1. Comparative suscepdbilitics of ft/a^Tx-M-'^^iTying E. coli isolates (;j = 54j to individual p-lactams and |i-lactam/(i-lactaniase 
inhibitor combinations 
Antibiotics discs (jx,g) 
Percentage of susceptible i.solatcs (n) 
bla(_rx-M-ii (" = 3-) WotTX-M group-1 (1 = 22) total (n = 54) 
Ticareillin (75) 
Ticarcillin/clavulanatc (75/10) 
Piperacillin (100) 
Pipcracillin/tazobactam (100/10) 
Ceftria.ione (30) 
Ceftriaxone/sulbactam (30/15) 
Imipenem (10) 
0(0) 
0 (0) 
0 (0 ) 
9.4 (3) 
0 (0 ) 
93.8 (30) 
93.8 (30) 
0(0) 
0(0) 
0(0) 
18.1 (4) 
0(0) 
KX)(22) 
100(22) 
0 (0) 
0(0) 
0(0) 
12,9(7) 
0 (0) 
96.3 (52) 
96.3 (52) 
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selcclcd 10 have unique randomly amplified polymorphic DNA 
tingcrpnnt paKerns. 
The antibiotic discs used (.Table 1) were from HiMcdia 
Lab. Ltd, India, except piperacillin, piperacillin/tazobactam. 
ccftriaxonc/suibactain (.kindly provided by Ranbaxy Lab. Ltd, 
India) and imipencni, which were obtained from Oxoid, 
Basingstoke, UK. E. coli ATCC 25922. E. coli ATCC 35218 
and Klebsiella pneumoniae ATCC 700603 were used as control 
strains. The results were interiirclcd as per the CLSI (fomierly 
NCCLS') cnlena. except for cel'lnaxone/sulbactam. Because 
there are no published breiikpoints for the latter combination, the 
susceptibility criterion used for this combination was >8 ram 
increase in zone diameter of ceflriiuone/sulbactam in compari-
son with that of ceftriaxone alone. Phenotypic ESBL detection 
b> disc synergy tests was performed on all 54 isolates using 
co-amoxiclav and piperacillin/tazobactam discs as a source of 
inhibitors. Brielly. the test inoculum (equivalent in turbidity to 
that of a 0.5 McFarland standard) was streaked on Mueller-
Hinton agar. Discs of co-amoxiclav (20/10 (xg) or piperacillin/ 
tazobaclam were placed 20 and 30 mm, centre to tenlre, from 
di.scs containing cefotaxime (30 p,g), ceftazidime (30 |jig) and 
cefpirome (30 |j.g) and plates were incubated at 37'C overnight. 
Enhancements of zones of inhibition of cephalosporins towards 
piperacillin/tazobactam or co-amoxiclav were considered as 
positive ESBL results. All tests were performed in duplicate. 
Comparative susceptibilities of the isolates against individual 
P-laclam antibiotics and p-lactam/|3-Iaclamase inhibitor combi-
nations are shown in Tabic 1. A total of 96.39r of isolates were 
susceptible to ceftriaxone/sulbactam in comparison with only 
I2.y'/r susceptible to piperacillin/tazobactam. This contrasts with 
previous intenialional' and national^  studies, which reported that 
combinations of }i-lactani with lazobactam showed greater 
activil) than p-laciam/sulbactam combinations against E. coli 
isolates. This marked difference may refieet different mechan-
isniis) in the different bacterial collections. In the present study, 
we specifically looked at CTX-M gioup-1 and CTX-M-15 pro-
ducers and found ceftriaxone/sulbactam to be a highly effective 
combination (activity being equal to that of imipcnem) in con-
trast to piperacillin/tazobactam and ticarcillin/clavulanate. Two 
isolates that were resistant to ceftriaxone/sulbactam were also 
resistant to imipcnem (Table I); they carried /'/«CTX-.M-I5 ""d 
hlii„,„pc alleles (data not .shown). 
In disc synergy tests, none of the 54 ESBL producers was 
detected when co-amoxiclav discs were placed 30 mm from 
cephalosporin discs, and only 4 isolates (1.4'7c) were detected 
when this was reduced to 20 mm. It is known that optimal disc 
placement is an important issue in such tests.'' However, when 
piperacillin/tazobactam discs were used and the discs were 
placed 20 mm apait, we readily detected most ESBL-producing 
isolates: synergy with ceftriaxone, cefotaxime and ceftazidime 
allowed detection of 92.6% (50/54). 90.7% (49/.541 and 74.1% 
(40/54) of ESBL producers, respectively. When the discs were 
placed at 30 mm, ESBL could still be detected in all the 
isolates: mo.st (88.9% with ceftriaxone and 83.3% with 
cefotaxime) of the isolates still giving excellent synergistic pat-
terns. On the basis of these findings, we feel that piperacillin/ 
tazobactam (or tazobactam alone) could be a better indicator 
when combined with ceftriaxone and cefotaxime for the pheno-
typic detection of ESBLs, especially in CTX-M producers. Tliis 
needs to be evaluated further and also against other classes of 
p-laclamases. 
To conclude, ceftriaxone/sulbactam proved to be elTective 
in vitro against 54 diverse CTX-M-15-producing E. coli strains. 
This novel combination merits further investigation, as does the 
use of piperacillin/tazobactam discs for the phenotypic detection 
of ESBLs. 
Transparency declarations 
None lo declare. 
References 
1. Frank U, Mutter J, Schmidt-Elsenlohr E etal. Comparative in vitro 
activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobac-
tam against nosocomial pathogens isolated from Intensive care 
patients. Clin Microbiol Infect 2WZ; 9:1128-32. 
2. Bonnet R. Growing group of extended-spectrum p-lactamases: 
the CTX-IVl enzymes. Antimicrob Agents Chemother 2004; 48:1-14. 
3. Ensor Vivl, Shahid M, Evans JT etal. Occurrence, prevalence and 
genetic environment of CTX-M p-lactamases in Enterobacteriaceae from 
Indian hospitals. JAntimicmb Chemother 2006; 58: 1260-3. 
4. Walsh TR, Toleman MA, Jones RN. Comment on: Occurrence, 
prevalence and genetic environment of CTX-M p-lactamases in 
Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 
2007; 59: 799-800. 
5. Gupta V, Dutta P, Agnihotri N et al. Comparative in vitro activities 
of seven new p-lactams, alone and in combination with p-lactamase 
inhibitors, against clinical isolates resistant to third generation cepha-
losporins. Braz J Infect Dis 2006; 10: 22-5. 
6. Thomson KS. Controversies about extended-spectaim and AmpC 
p-lactamases. Emerg Infect Dis 2001; 7: 333-6. 
Journal of Antimicrobial Chemotherapy 
doi:10.1093/jac/dkml77 
Advance .Access publication 24 May 2007 
In vitro interaction of micafungin and fluconazole 
against Candida 
M. Mar Rodriguez', Mery Ruiz', F. Javier Pastor'*. 
G. Quindos-. A. Carrillo' and Joscp Guarro' 
'Unitat de Microhiologia, Facitltat de Medicina i Ciencies 
de la Salut. Universitat Rovira i Virgili, Reus, Espana;; 
-Deparlamenio de Inmunologia, Microhiologia y 
Parositologi'a. Facultiid de Medicina y Odontologt'a, 
Universidad del Pais Vasco, Bilbao, Espana and 
'Departamento de Microhiologia, Asesoria Cieiitifica y de 
Investigacion Aplicada, Barcelona, Espana 
Keywords: antifungal drugs, echinocandins, azoles 
•Corresponding author. Tel: -f 34-977-759359; Fax: -1-34-977-
759322: E-mail: franciscojavier.pastor@urv.cat 
Sir, 
Candida albicans and other emerging Candida spp. are a 
common cause of severe disseminated infections. Fluconazole 
has been traditionally used in the treatment of candidacmia. 
However, its activity against some species of Candida, such as 
Candida krtisei and Candida glabrata, is very limited or even 
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Occurrence, prevalence and genetic environment of CTX-M 
p-lactamases in Enterobacteriaceae from Indian hospitals 
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Received IS Julv 2006: relumed 12 Se/iwrnber 2006: revised 22 SejUember 2006; occepted 25 Sepiendier 2006 
Objectives: To determine occurrence, prevalence and CTX-M genotypes produced by Enterobacteri-
aceae from clinical samples from three geographically distant Indian hospitals and to detect linkage of 
\S26 with blacjx-w and map its precise insertion position. 
Methods: A total of 130, non-duplicate Escherichia coli and Klebsiella pneumoniae resistant to a 
third-generation cephalosporin (3GC) from three Indian centres were screened for extended-spectrum 
3-lactamase (ESBL) production using phenotypic detection methods. All isolates were screened for 
b'^cTx-M using multiplex PCR. Precise CTX-M genotype was identified using reverse-line hybridization. 
All CTX-M-producing isolates were screened for linkage of IS26with biacrx-wi- DMA sequencing was used 
to map the exact insertion position of this mobile element. 
Results: Ninety-five of 130 3GC-resistant (73%) (73% of total E. coli, 72% of total K. pneumoniae) isolates 
were found to carry Wacix-M-is- No other CTX-M genotype was detected. iS26 linkage with blac-rx -M-1S w a s 
detected in 31% of isolates carrying b/acrx-M-is- DNA sequencing revealed variable insertion of this 
mobile element within tnpA of \SEcp1. RAPD-PCR typing demonstrated great diversity in isolates 
carrying b/acix-M-is; no predominant clone was identified. 
Conclusions: In contrast with other studies where greater diversity exists, CTX-M-15 was the only CTX-M 
ESBL produced in this Indian collection of unrelated E. coli and K. pneumoniae. This is the first 
systematic survey report from India detecting CTX-M-type p-lactamases This is also the first report 
indicating such high mobility/diversity of insertion of IS26in close association with blacjx-M ' " a single 
bacterial collection. 
Keywords: ESBLs, IS26, CTX-M-15, India 
Introduction '" '"dia. the very first repon of the presence of CTX-M-
producing Enterobacteriaceae came from New Delhi.' Six isolates 
In recent years CTX-M extended-spectrum (3-lactamases from 2000 were investigated, all of which were found to be 
(ESBLs) have very rapidly disseminated and are now unrelated and all produced CTX-M-15. Since then severallndian 
frequently reported from countries all over Europe and much surveys have reported the presence of ESBLs in clinical isolates 
of Asia.' More than 50 WUCTX-M genotypes are described based on phenotypic tests. Recent reported rates vary widely 
(hltp://www.lahcy.oig/studies/inc_webt.asp). Epidemiological (12.6-71%),''••'' with most studies reporting a prevalence rale 
reports demonstrate that some enzymes are more frequently of around 50% and upwards. Considering a population of 
reported than others, that predominant enzyme type varies ~ l . l billion in India, this represents a very large reservoir of 
with country and that diverse CTX-M types often exist within a resistance genes. We were unable to find any report in our search 
single country." of the literature using the Entrez PubMcd database provided by 
^Correspondence address. Health Protection Agency. Heartlands Hospital, Birmingham B9 5SS, UK. Tel: -H44-I2 1-424-1240; Fax: •f44-I2l-
772-6229; E-mail: peter.hawkey@heartofengland.nhs.uk 
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CTX-M ESBLs in India 
ihe National Centre for Biotechnology Information (www ncbi 
nln. nih gov/entrez) that specifically looked for W«CTX M and then 
determined the precise genotype present Therelore, we planned 
this study to identify the occurrence, species distribution and 
CTX-M genotypes present in clinical isolates from a large tertiary 
care hospital in North India A collection of isolates from two 
geographically distant centres was also included to determine any 
diversity in isolates and CTX-M-genotype present in the three 
geographically separated regions of India 
Materials and methods 
A total of 130 non duplicate third-generation cephalosporin (3GC)-
resisianl Escherichia coli or Klebsiella pneumoniae were investigated 
in this study Of these, 111 isolates were cultured from clinical 
samples taken from patients at JNMCH, Aligarh, Utcah Pradesh 
Piovince, North India, 74 of which were coUec'ed in a 4 week period 
in 2005 and 37 of uhich were collected between 2003 and 2004 
Of the remaining 19 isolates, 9 were eollecied from a centre 560 km 
jvvay in Varanasi, Ultar Pradesh, North India, and 10 were colletied 
liom a centre m Hubli, Karnataka, South India, and 1430 km from 
Aligarh These isolates were included to determine any genetic 
diversity or difference m CTX-M types from the geographically 
disianl centres compared with Ihe main study centre Most isolates 
(98/nO 7^*^) were cultured from unne samples The remaining 
isoliitcs were cultured trom respiratory or pus samples 
Susceptibility testing to 12 antimicrobial agents (Table I) was 
performed using the BSAC standardized disc diffusion method 
(htip //w\\« bsac org uk/susceptibility_testing/bsac_standardized_ 
disc_susceptibility_method cfm) ESBL production was deter-
mined using the combination disc test method* Discs containing 
celoiaxime ceftazidime and cetepime were used alone and in 
combination with clavulanate, and tests were set up and results 
interpreted according to the manufacturer's instructions (Oxoid, 
Brsingstoke UK) 
All isolates were screened lor the presence of /)/«c"rx M using a 
new muluplex PCR designed to detect and identify phylogenetii. 
group in one PCR ' Precise CTX M genotype was identified using 
reverse line hybridization (RLH)' To determine whether Indian 
isolates carried IS26 in association with hlacrx M the pnmers and 
PCR protocol previously described by Wo(xlford ei al * were used In 
this protocol, the forward primer is designed within IS2(5 and the 
reverse pnmer withm W<1CT\ M. therefore a product confirms linkage 
Products obtained were then sequenced to determine the precise 
insertion point of IS2(5 upstream of fc/aci \ M 
RAPD-PCR** was used to determine an) genetic relaledness 
amongst isolates Banding patterns were analysed using BioNumerics 
software version 4 5 (Applied Maths, Sml-Manens-Latem, Belgium) 
Position tolerance was set at 1% Strains with at least 857c similantv 
(UPGMA, Dice CoefHcienl) were regarded as being highly related 
and were grouped into clusters 
Results and discussion 
ESBL production was confirmed in 115 (899c) of the 130 3GC 
resistant isolates investigated using the combination disc test 
method 01 these, 72 of^gS (73%) E coli and 23 of 32 (72'r) 
K pneumoniae were found to carry hlac-\\ M b> multiplex PCR 
all of which identihed as hlacr\ M IS b\ RLH This is interesting 
and IS in contrast to other sur\e\s that have reported sanation ol 
CTX-M genotypes present withm a single country " 
Denominator data were onl) available lor the isolates collected 
in Aligarh over the 4 week studs period in 2005 During this time 
52% of all E coll and K pnewnonuie isolated at the Aligarh 
centre were found to be resistant to a 3GC This is similar to 
previous reports Ironi India but much higher than the ESBL 
prevalence rates in most European countries " Results ol 
antimicrobial susceptibility testing are shown m Table I Con 
coniitant resistance to ciproHosacin trimclhoprini and gcntamicin 
Table 1. -Xniibactenal resistance rates of genetically dncrse cephalosponn-resisianl E loU and K pneiimonuu liom three geographicalh 
distant centies in India 
Number and peicentage resistant by organism and b> piescncc and absence of bhic ix s, 
t mil {n = 98) A piii uinaiiuu (ii = i2) 
CTX-M positn 
(" = 72) 
CTX \I ncgaiiNc 
(-1 = 26) 
CIX M posiinc 
(« = 21) 
CTX M 
negative [n = 9; 
Antibacterial agent % 
Centamicin 
Trimethoprim 
Cipronovacin 
Piperacilhn/tazobactam 
A/treonani 
Cefoxitin 
Ccfta/idime 
Cefotaxime 
Cefpodoxime 
Celepinis 
McropcnLiii 
Ertapcncm 
63 
65 
68 
32 
66 
31 
70 
72 
72 
61 
0 
0 
88 
90 
94 
44 
92 
41 
97 
100 
UX) 
8-1 
0 
0 
16 
21 
19 
5 
16 
3 
15 
18 
26 
12 
0 
0 
62 
81 
73 
19 
62 
12 
SS 
69 
100 
46 
0 
0 
18 
22 
20 
I I 
21 
8 
23 
23 
23 
18 
0 
0 
78 
96 
87 
48 
91 
15 
100 
100 
100 
78 
0 
0 
s 
7 
6 
"> 
4 
S 
6 
7 
9 
4 
0 
0 
"^ 6 
78 
67 
22 
45 
56 
67 
78 
11)0 
45 
0 
0 
1261 
Elisor et al. 
Table 2 Occurrence ci isolates with a Wacrx M is-linked IS26 insertion within IShcpl by organism type and centre 
IS2rt/W<([T^ M amplicon size JNMCH Hubh Varanasi 
gel eletrophorcsis DNA sequencing E coit K pneumoniae t coli K pneumoniae t. coli K pneumoniae 
DNA sequencinj; of this amplicon was unsuccessful after repeated attempts so precise size cannot be reported 
Total 
-.6-^0 bp 
- 7 0 0 bp 
~90() bp 
~9S0 bp 
Tota l with/?/«(_-[X M 
Total with Wflcix M 
IS26 
IS 
IS 
639 bp 
721 bp 
863 bp 
linked with IS26 
not linked with 
4 
3 
8 
4 
19 
47 
1 
2 
1 
0 
4 
10 
0 
0 
0 
0 
0 
4 
0 
1 
2 
0 
3 
2 
0 
0 
1 
0 
1 
1 
0 
0 
1 
1 
2 
2 
S 
6 
13 
5 
29 
66 
was frequent, and a higher proportion of both E coli and 
K pneumoniae with blacyx M were resistant to the antibiotics 
tested than those isolaics found not to carry Wocrx M All isolates 
were susceptible to both ertapenem and meropenem Isolates 
(ound not to carry bhicrx M most likely carry another ESBL gene 
C /^^ 'ihM or hlusuv) although this has not yet been investigated 
further Resistance to cefoxitin was noted in 35% of E coli and 
4I';r ol K pneiiimmme Using a previously published protocol,'^ 
this resistance in strains tested so far is attributed to the 
production of an Anip-C P-lactamase Further work is required 
to characterize genotypes present more fully 
Unlike the situation in the UK where an epidemic E coli clone 
carrying hluc rx M is has been described," RAPD-PCR typing of 
these Indian hlocrx M IS carrying E coli or K pneumoniae 
deiiionsiraied great diversity and no predominant type, indicating 
eithei horizontal transfer of WUCTX M IS and/or mobilization of 
W"cTx M II by genetic mobile elements as well as widespread 
geographical dissemination in both North and South India The 
association of insertion sequences with antibiotic resistance genes 
has been reported previously ISEcpl is always found upstream of 
W«crxMis and is strongly implicated in the mobilization of 
this antibiotic resistance gene '•* 1S26 has also been repoiletd 
in association with hUicryx M including WocrxMis and more 
specifically, has been found to insert within ISEcpl. although 
interestingly the insertion of IS26 differs from strain to strain ' 
In our study of highly diverse E coli and K piieunumuie 
producing CTX M 15, IS26 was found in association with 
''/"CTXMis m 31% of isolates, indicating high frequency of 
association of this element with WOCTX M IS DNA sequencing of 
1S26-W«CTX M PCR products enabled precise size determination 
ol the amplicons obtained It is interesting to note that PCR 
products of variable sizes were delected from all three Indian 
study centres, and an amplicon of 863 bp was most frequently 
observed (Table 2) DNA sequencing of representative 1S26-
W«cTx M amplicons also enabled precise determination of the 
insertion point of this element, which was found to be at three 
variable positions within uipA, the transposase-coding gene of 
ISEcpl To our knowledge this is the first report of such high 
mobility and diversity of IS26 insertion into tnpA of ISEcpl It is 
entirely plausible to speculate that since first being reported in 
India m 2000, hlcicrx M may have been mobilized on many 
occasions as seems to be the case for blii^u\,.'^ perhaps 
explaining its presence in such a highly diverse collection of 
isolates from the three study centres The fact that 1S26 was found 
to be linked to Wucrx M U in as many as one-third of CTX-M-15 
producing isolates suggests this mobile element may have a more 
central role in the catalysis of the mobilization of /)/I'CTX M 'han 
has thus far been recognized We have not looked lor a second 
copy of IS26 downstream of W^CTX M although two copies ol this 
insertion sequence have been found to bracket W^SHS forming a 
composite transposon, providing the mechanism for mobilization 
of this resistance gene from the chromosome of K pneumoniae 
Further work is planned to look for the presence of IS26 
downstream of WacrxMis m our isolates The evolutionaiy 
advantage (if any) that may be conferred by the presence of tv.o 
different mobile elements in close association of a resistance gene 
remains to be determined In the UK epidemic CTX-M 15 
producing E coli clone, it has been suggested that IS26 insertion 
separates bUicjx M \s 'rom its usual promoter (provided by 
ISEcpl) resulting in reduced resistance to cephalosporin aiiti 
biotics * Perhaps the function of IS26 insertion into inpA of 
ISEcpl IS to inhibit further ISfcp/ mediated WucrxMis 
mobilization, effectively trapping blcicrx M onto the plasmid 
and ensuring that it is maintained in the gene pool 
The bowel is a rich environment for genetic exchange between 
commensal Enterobacieriaceae Faecal carriage of CTX-lvI-
producing bacteria has been described'"" It is plausible to 
suggest that conditions of overcrowding and iX)or sanitation, and 
the selective pressure created by overuse of antibiotics in India 
has enabled such widespread dispersal of W«cnx M IS The Indian 
population, therefore, must represent a significant reservoir and 
source of Wacrx M IS 
This IS the first systematic molecular survey report from 
India characterizing the occurrence and prevalence of CTX-M 
enzymes Our report supports the urgent need for regular 
screening and national surveillance characterizing the CTX-M 
types and to implement strict antibiotics policy to limit the 
irrational use of antibiotics, including cephalosporins, so as to 
minimize antibiotic selective pressure 
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study was to characterize VIM-1 genotypes and to evaluate 
clonal relationships among VIM-1 produang ENT strains 
isolated in Greece dunng the course of the SENTRY Program 
Methods: All isolates received as part of the SENTRY Program 
were susceptibility tested by reference CLSI methods against 
>25 antimicrobials ENT isolates (except Proteus mirabilis and 
indole-positive Proteae) with MIC > 2 mg/L for imipenem (IMI) 
and meropenem (MER) were screened for metallo-beta-lacta-
mase (MBL) by disk approximation test followed by PCR ENT 
isolates from Greece with positive MBL screen test results were 
further evaluated MBL gene and its genetic context were 
revealed by PCR and sequencing techniques The isolates were 
also epidemiologically typed by PFGE 
Results: In the 2001-2005 penod 16 K pneumoniae (KPN) and 2 
£ aerogenes (EAE) isolates from a medical center m Greece were 
found to produce VIM-1 Multiple distinct clonal outbreaks of 
VIM-1 producing ENT were identified dunng this penod 
Susceptibihty and molecular typing results are summanzed m 
the table 
Organism 
KPN 
EAE 
PFGE (no 
of isolates) 
C ( l ) 
0 ( 9 ) 
E (2 ) 
F ( l ) 
G ( I ) 
H ( l ) 
1(1) 
A (2) 
Integron 
sne (bp) 
>2700 
2000 1500 
1300 800 
BOO 
>2700 1000 
2000 
>2700 
2000 
1500 1300 
IMI 
>B 
4 . 8 
B 
>B 
4 
>8 
4 
>8 
MEM 
>6 
1 >16 
2-4 
4 
4 
>e 
2 
>8 
MIC range (r^ 
CAZ 
>16 
>16 
>16 
>16 
>16 
>16 
>16 
>16 
P/7 
>64 
>64 
>64 
>64 
>64 
>64 
>64 
>64 
ig f l j -
ATM 
>16 
CO 12>16 
>16 
>16 
<0 12 
>16 
50 12 
>16 
CIPRO 
>4 
4 >4 
' 
2 
<0 03 
a 
>a 
>A 
a CAZ - ceftailafme P/T - tiiperaciilin/razoDactam ATM - aztreonam ana CIPRO = cipronoxacin 
Conclusions: blaVIM-1 emerged and rapidly became endemic 
among ENT in Greece The high mobility of bla VIM-1 was 
demonstrated by the finding of i) different PFGE patterns 
among VIM-1 producing KPN, ii) vanable sizes of the integron 
amplicons, and in) the emergence of VIM-1 in EAE Our results 
also demonstrated that bla VIM-1 is disseminating horizontally 
as well as vertically within the medical center These findings 
represent a critical problem for the healthcare facility as 
carbapenems remain the last antimicrobial resort for treatment 
of infections caused by multi-drug resistant Gram-negative 
bacilli In addihon, this is the first report of EAE producing VIM-
P1405 
VIM-1 producing Enterobacter cloacae strains 
from Madrid, Spain: report from the SENTRY 
Antimicrobial Surveillance Program 2005 
L Deshpande, H Sader, M Tato, F Baquero, R Jones, 
R Canton (North Liberty, US) 
Objective: To characterize Enterobactermceae (ENT) strains with 
reduced susceptibility (S) to carbapenems (CARB) isolated in 
Madnd, Spam 
Methods: As part of the SENTRY Program bacterial isolates are 
S tested by reference CLSI methods against >25 antimicrobial 
agents ENT isolates (except Proteus mirabilis and indole + Pro-
teae) exhibiting MIC results at >=2 mg/L to imipenem (IMI) and 
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meropenem (MER) were screened for metallo-beta-lactamases 
(MBL) and Bush-Jacoby-Medeiros group 2f carbapenemases by 
disk approximation (DA) and PCR PCR amplicons were 
sequenced for epidemiological purposes as well as to reveal 
genetic context of resistance genes Isolates were also typed by 
PFGE 
Results: Two E cloacae (ECL) strains (2700A and 726C) showed 
elevated CARB MIC values as well as resistance to all beta-
lactams, except aztreonam (AZT) m strain 726C (Table 1) The 
strains were isolated m March 2005 (12 days apart) from 
bloodstream and respiratory tract infections of patients hospit-
alized in two distinct hospital units The strains showed distinct 
antibiograms and PFGE patterns (Table 1) Both strains showed 
positive DA test results and PCR screens positive for blaVIM 
with a Class 1 integron of approximately 2 5 kb Sequencing of 
integron from the index strain (726C) revealed bla VIM-1 along 
with aacA4 and aadAl genes 
Sttjin* 
720C 
27Q0A 
IMI 
e 
MER 
•* 
Ertjp.n.m 
•8 
8 
ftZT 
8 
>10 
MIC (m^A.) 
Cip'otoxjon T<l 
0 12 
ir.cycin. 
4 
Totixnycn 
4 
7 
TMP/SMX 
<«0 5 
PFGE 
e 
Conclusions: This is the first report of VIM-l-producmg ECL 
from Spam VIM-1 has been recently reported in ENT (K 
pneumoniae and E coli) from Barcelona, Spain The finding of 
blaVIM-1 in two clonally unrelated strains emphasizes the 
mobility of these genes Thus, MBL may be emerging as a 
significant, geographically diverse resistance mechanism among 
ENT in Spam It is imperative to screen ENT isolates with 
modestly elevated (not resistant) MIC values of either IMI or 
MER for carbapapenamse production and to control the spread 
of this resistance mechanism in ENT isolates causing nosocomial 
infections 
P1406 
Occurrence and prevalence of CTX-M type beta-
lactamases in Gram-negative bacteria from 
tertiary care hospital. North India 
M Shahid, V M Ensor, P M Hawkey (Ahgarh, IN, Bimnngham, 
UK) 
Objectives: CTX-M beta-lactamases are increasingly reported 
worldwide Although the ESBL phenotype has been reported 
from India, no further molecular surveys have been published 
with the exception of the first report of CTX-M-15 type This 
shidy was designed to identify the presence, species distnbu-
tion, and sub-types of CTX-M genes in a large terhary hospital 
between 2003-2005 
Methods: Gram-negative bactena from vanous clinical samples 
submitted to the department of Microbiology, J N Medical 
College & Hospital Ahgarh, India, for routine culUire and 
susceptibility testing were studied 130 ncn-duplicate isolates 
resistant to a third generation cephalosponn were randomly 
selected These were subjected to a Multiplex PCR designed to 
identify all geno-groups of a blaCTX-M Further identification of 
the specific CTX-M types was done by Reverse Line Hybndiza-
tion (RLH) 
Results: A total of 130 bacterial isolates from 130 non-repeat 
clinical samples (Unne = 108, Bronchoalveolar lavage 
(BAD = 16 and Pus = 6) were included in the study Unnary 
isolates were Escherichia cob (n = 91), Klebsiella pneumoniae 
(n = 9), Acmetobacter (n = 6), Klebsiella oxytoca (n = 1) and Cit-
robacter spp (n = 1) The isolates from BAL were £co/i (n = 11) 
Abstracts 
and K pneumoniae (n = 5) and from pus were £ colt (n = 2) and 
K pneumoniae (n = 4) Eighty-two (631%) of the 130 isolates 
were found to be CTX-M Group-1 positive by PCR RLH 
identified all of them as CTX-M-15 type beta-lactamase produc-
ers 
Conclusion CTX-M Group-1 beta-lactamases are the only CTX-
M type m our area, and only CTX-M-15 was found It is 
surprismg that no other CTX-M subtypes are present in this 
survey population m contrast with other countries This is the 
first systematic survey report from India detecting CTX-M-15 
type beta-lactamases 
P1407 
Characterization of class 1 integrons carrying the 
genes for VIM- and IMP-type metallo-beta-
lactamases in Pseudomonas aeruginosa strains 
from Russia 
O Shevchenko, M Edelstein, V Kretchikov, L Stratchounski 
(Smolensk, RU) 
Objectives- To investigate the genetic context of metallo-beta-
lactamase (MBL) coding genes in Russian strains of P aerugi 
nosa 
Methods- The six strains studied were isolated respectively in 6 
hospitals of 3 cities of Russia as part of the RESORT national 
surveillance study in 2002-2004 Based on results of our recent 
study (O Shevchenko, et al , 45th ICCAC, P C2-105), five of 
them were found to produce VIM-2 beta-lactamase and were 
assigned to 3 distinct clonal groups One unrelated isolate 
produced a single (E59K) mutation variant of IMP-1 A PCR 
with primers facing outward from the intll and blaVIM or 
blaIMP genes was used to confirm the location of MBL genes in 
class 1 integrons The entire cassette arrays were then amplified 
using the pnmers matching conserved sequences at the 5' (intll) 
and 3' (qacEdeltal) ends of integrons, separated by gel electro-
phoresis and sequenced using the nested mtll-, qacEdeltal- and 
cassette-specific pnmers 
Results: All the MBL genes were associated with class I 
integrons Sequence analysis demonstrated that the blaVIM-2 
gene cassettes were all identical to that reported from In58 in 
France (GenBank ace no AF263520), however the structure of 
the blaVIM-2-carrying integrons was different Two out of 3 
isolates representing the same clone broadly disseminated in 
Russia contained the cassette array aacA7, blaVIM-2, dhfr, 
aacC-A5, whose sequence was 100% identical to that of the 
recently descnbed outbreak strain from the USA (GenBank ace 
no AY943084) The genetic content of the blaVIM-2-carrying 
integron from the third clonally related isolate was distinct 
aadB, bla VIM-2, and aacA4 gene cassettes The integron of one 
of the remaining unrelated strains contained only two gene 
cassettes blaVIM-2 and aadAl, and that of another one carried 
bla VIM-2 and aadB cassettes separated by the unknown frag-
ment of 315 bp that includes a 150-bp sequence 90% homologous 
to the orfE-like gene (GenBank ace no AYl 39595) The genetic 
environment of the novel blaIMP gene was also unique There 
was an aadB gene cassette located upstream of blaIMP, and 
downstream of it there was a 305-bp unknown sequence 
followed by cmlA and blaOXA gene cassettes 
Conclusion. The results of our study demonstrate an increasing 
complexity and diversity of class I integrons carrying MBL 
genes in P aeruginosa 
P1408 
Prevalence of AmpC over-expression in 
bloodstream isolates of Pseudomonas aeruginosa 
V H Tam, A N Schilling, M T LaRocco, L O Gentry, K Lolans, 
] P Quinn, D A Melnick, K W Garey (Houston, Chicago, 
Witmmglon, US) 
Objectives: The prevalence of AmpC over-expression m Pseu 
domonas aeruginosa (PA) as a mechanism of beta-lactam resist-
ance was reported to be 6% in France previously (De Champs, 
AAC 2000) However, its prevalence is not well established in 
the U S We examined the contnbution of AmpC over-expres-
sion towards beta-lactam resistance in clinical isolates of PA 
obtained in our hospital 
Methods: All bloodstream PA isolates obtained m 2003 were 
screened foi ceftazidime (CAZ) resistance with and without 
the presence of clavulanic acid (4 /jg/mL) AmpC stable 
derepression was ascertained phenotypically by a spectropho-
tometric assay (with and without prior induction by imipe-
nem) using nitrocefin as the substrate, and subsequently 
confirmed by real-time quantitative PCR of the ampC gene 
The presence of AmpC was confirmed by isoelectnc focusing 
(with cloxaciUin inhibition) The clonal relatedness of the 
AmpC over-expressed mutants was assessed using PFGE In 
addition, the ampC and ampR genetic sequences were 
determined by PCR For companson, 2 standard wild type 
(PAOl and ATCC 27853) and 3 multi-drug susceptible PA 
isolates were used as controls 
Results- ' b non-repeat bloodstream PA isolates were available 
Stable derepression of ampC [a single beta-lactamase inhibited 
by cloxacil'm (pi = 8 7)] was confirmed in 14 isolates (preval-
ence rate -- 18 4%), and consisted of 7 distinct clones The most 
prevalent point mutations in ampC were found to be G27D, 
V205L, and G391A, respectively 
Conclusi3n: In contrast to the previous study, AmpC over-
expression 16 a significant mechanism of beta-lactam resistance 
m PA Understanding the prevalence and mechanism of beta-
lactam resistance in PA may guide the choice of empinc therapy 
tor nosocomial infections in our hospital 
P1409 
Characl^-rization of ESBL producing Salmonellae 
isolated in Hungary in 2000 - 2004 
N NograJy, A Toth, J Paszti, M Fuzi (Bud.ipest, HW 
In case of 'j/mjne/to infections caused by multiple resistant 
strains, for infants, elderly or immuno-compromised patients 
extended-spectrum cephalosponns (ESCs) are recommended for 
treatment Consequently, since the 1990s outbreaks and cases of 
infections caused by Salmonella resistant to ESCs have been 
increasingly reported The aim of the study was to screen the 
Salmonella isolates received by the 'Johan Bela' National Centre 
for Epidemiology, Hungary, dunng 200O-2004, for isolates 
producing extended-spectrum-beta-lactamase (ESBL) and to 
charactense the strains by molecular methods An initial 
screening for cefotaxime resistant (CtxR) strains was performed 
by disk diffusion method The ESBL phenotype of the CtxR 
strains wai confirmed by double disk approximation test and 
ESBL Ete^ 'it The strains were investigated by PCR using 
conserved 'pnmer sets specific for blaTEM, blaSHV and 
blaCTX-M genes and also for class 1 integron The PCR products 
were sequerccd The .ransterability of the identified ESBL genes 
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A b s t r a c t s 
Results The GenoType® Enterococcus assay produced correct 
species and van gene identification for all 40 (100%) VRE 
isolates, including 7 E faecahs vanB, 12 E faecium vanA, 12 E 
faecium vanB, 6 E galhnarum vanCl, 1 E gallimrum vanA-vanCl, 
and 2 E cassebflavus vanC2/3 The only minor discrepancy was 
an £ cassebflavus that hybridized very weakly with the vanCl 
probe in addition to the expected vanC2/C3 probe The costs 
per specimen were comparable for each test method However, 
the GenoType® Enterococcus assay could be completed within a 
normal working day in contrast to conventional testing, which 
required a minimum of two days from the point of isolation on 
the vancomycin-screen media 
Conclusion: From this preliminary evaluation, the GenoType® 
Enterococcus amplification-detection assay provides VRE 
species and van genotype identification m a rapid and cost-
effective manner, supenor to conventional culture methods 
Although further study is required, this kit may have clinical 
utihty during a VRE outbreak 
P1748 
Application of minimal sequence quality values 
prevents misidentification of blashv type in 
single bacterial isolates carrying different SHV 
extended-spectrum beta-lactamase genes 
N Al Naiemi, B Duim, K Schipper, C M Vandenbroucke-
Grauls, A Bart (Amsterdam, NL) 
Background- Detection of extended spectrum beta-lactamase 
(ESBL) genes by PCR and sequence analysis is the gold standard 
for detection of SHV-type beta lactamases Usually, quality 
values of sequence analyses are not reported Dunng a study on 
ESBL epidemiology, three strains for which the default sequence 
assembly showed an SHV-2 or SHV-5 gene, showed low quality 
values at certain positions in individual sequence traces We 
investigated the reason for these lower values 
Methods. SHV genes were amplified by PCR from three isolates 
(Escherichia colt, Enterobacter cloacae and Pseudomonas aeruginosa) 
Individual sequence traces were analysed with the computer 
programs PHRED and Codon Code PCR products were ligated 
in vector pCR2 1 and transformed to £ colt Sequence analysis 
was [performed on eight individual clones from each 
transformation 
Results: Visual inspection of the low quality positions m the 
sequence traces showed signals for two different nucleotides at 
three positions in the SHV sequence A or T at position 92, A or 
G at position 402 and A or G at position 703 The 
polymorphisms at positions 92 and 703 lead to ammoacid 
substitutions, the four different combinations would give SHV 
types 2, 2a, 5 or 12 The double signals suggested that two or 
more blaSHV alleles were amplified PCR amplicons were 
cloned m E colt, in the sequences of individual clones only two 
combinations of the three polymorphisms were present 
A92G402A703 and T92A402G703 These two combinations 
correspond to SHV-2 and SHV-12, respectively 
Conclusions: (i) In isolates of three different species, two 
different SHV genes were present SHV-2 and SHV-12 (ii) 
Genotypic detection with default sequence assembly parameters 
may lead to misidentification of the number and type of SHV 
genes earned by a single strain (in) Careful interpretation of 
sequence data of SHV genes, including analysis of low quality 
positions, may further improve our understanding of the 
epidemiology and evolution of these ESBL genes 
P1749 
Antimicrobial susceptibilities and 
epidemiological analysis of Salmonella 
typhimurium human isolates in Slovakia by 
phage typing and pulsed-field gel electrophoresis 
V Majtan, L Majtanova, M Szaboova (Bratislava, SK) 
Objectives- Salmonella Typhimurtum is a common cause of 
salmonellosis among humans and animals in many countries 
In the last few decades the incidence of multidrug-resistant S 
Typhimurtum infections appears to pose a particular health risk 
The objechves of this study were analysis by antibiotic 
susceptibihly, phage typmg and pulsed-field gel 
electrophoresis (PFGE) of S Typhtmunum human isolates 
Methods: A total of 145 straiiK isolated dunng 1997-September 
2005 were analysed The susceptibility of isolates to ten 
antibiotics was evaluated by a disk diffusion method The 
phage types were identified according to Anderson et al (1977) 
m the National Reference Center for phage typing of 
Salmonellae PFGE was used to resolve Xbal macro restnction 
fragments from all strains 
Results- Of human isolates 88 (60 7%) were resistant to more 
than two antibiotics Sixty-three of isolates (43 4%) showed a 
classic DTI 04 resistance profile to ampiallin, chloramphenicol, 
streptomycin, sulfonamides, tetracychne (ACSSuT) Among this 
resistance type 37 2% were DT104, 7 6% were DT120 and one 
strain was DT20a Isolates encompassed 18 phage types The 
majority of isolates was found to be definitive phage type 
DTI 04, representing 62 8% of all isolates Other phage types 
were mainly DT120, DT41 and DT20a Nine pulsotypes and 18 
subpulsotypes were obtained using Xbal restnction enzyme, but 
pattern XI with its subtypes predominated (869%) A major 
pulsotype XI was represented by 51 7% of DT104 isolates and 
was also found among DT120 isolates 
Conclusion: Results indicated the spread of different clones of 
the multidrug-resistant S Typhimunum in the Slovakia, but with 
predominance of one clone represented mainly by DT104 
isolates The phage typing as well as PFGE may offer an 
improved level of discnmination for the epidemiological 
investigation of S Typhimunum human strains 
P1750 
Novel reverse hybridisation assay to identify 
CTX-M genotj^je in cephalosporin-resistant 
isolates from UK and India 
V M Ensor, M Shahid, R Hope, M Warner, N Woodford, 
D M Livermore, P M Hawkey (Btrmingham, UK, Altgarh, IN, 
London, UK) 
Objectives- a) To develop a novel reverse hybndisation assay 
for identification of CTX-M genotypes among large collections of 
cephalosponn-resistant Enterobactenaceae isolated dunng 
surveillance studies m South-East England and North India b) 
To validate the assay results by DNA sequencmg 
Methods: Isolate collection 1 110 Enterobactenaceae resistant 
to extended-spectrum cephalosponns, isolated m London and 
South-East England These isolates were known to carry 
phylogenetic group 1 blaCTX-M, but precise genotypes had 
not been determined Isolate collection 2 130 Enterobactenaceae 
resistant to extended-spectrum cephalosponns, isolated in Ali-
garh. North India Resistance determinants had not been 
investigated previously A novel muUiplex PCR was used to 
amplify blaCTX-M Reverse hybndisabon was earned out using 
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biotinylated PCR amplicon and sequence-specific oligonucleo-
tides designed to identify members of CTX-M phylogenetic 
group 1 Hybridisation results were validated by DNA sequen-
ang for 20 representative isolates from each collection 
Results: 109/110 London and SE England isolates known to 
carry group 1 blaCTX-M gave a consistent profile, 
corresponding to that for CTX-M-15 and CrX-M-28, 1/110 
gave a profile corresponding to CTX-M-3 and CTX-M-22 82/130 
Indian isolates had blaCTX-M genes, all of which belonged to 
group 1, and all these gave a hybridisation profile 
corresponding to CTX-M-15 or CTX-M-28 CrX-M-28 and 
CTX-M-22 are rare variants, suggesting that the enzymes 
present were more likely to be CTX-M-15 and CTX-M-3, and 
this was confirmed by DNA sequencing 
Conclusions: This is the first reported application of this novel 
reverse hybridisation assay to the analysis of large numbers of 
cephalosponn-resistant Enterobactenaceae Results were 
validated by DNA sequencmg The assay is cheap and 
convenient, enables reasonable throughput, provides results 
within one day and can be used in place of DNA sequencing 
We believe it will be valuable for monitoring the prevalence and 
genotypes of blaCTX-M genes in Enterobactenaceae 
P1751 
Detection of mexA and mexX efflux genes in 
P. aeruginosa: correlation between QC-RT-PCR 
and real-time PCR 
N Mesaros, Y Glupczynski, D Pierard, A Dediste, 
Y Van Laethem, P Tulkens, M Mingeot-Leclercq, 
F Van Bambeke (Brussels, Yvoir, BE) 
Objectives: Efflux systems are rarely identified as such in 
clinical microbiology laboratories Yet, over expression of 
transporters such as MexAB-OprM and MexXY-OprM are 
likely to cause antibiotic multi- and cross-resistance in 
Pseudomonas aeruginosa, leading to potential clinical treatment 
failures because of their induable character We have previously 
developed and validated with reference strains a QC-RT-PCR 
method to quantify mexA and mexX expression levels (ECCMID 
2005, P1731) In the present study, we have developed a Real-
Time-PCR assay and present here the correlation between both 
methods using control strains and clinical isolates 
Methods: Expression levels of mexA and mexX were measured 
by both techniques in (i) 4 reference strains expressing only one 
of these efflux mechanisms [mexA (2) or mexX (2)], and (ii) 8 
climcal isolates, in comparison with the wild-type strain PAOl 
(basal mexA and mexX expression levels) 
Results: Real-Time PCR showed an inter-day reproducibility of 
95 ± 5 3% (tnplicates of 10 strains) Among the clinical strains, 5 
over expressed mexA and 3 mexX The Table shows (i) the mean 
level of overexpression of mexA and mexX in comparison with 
the wild type strain PAOl (set at 1), as detected by Real-time 
PCR for all strains, (ii) the raho of these values to those observed 
by QC-RT-PCR for the corresponding transporters 
mexA (n=7) mexX(n=5) 
ReaHime-PCR ratio to OC-RT PCR Real-Time PCR ratio to QC RT PCR 
103±022 6 8 3 J 0 3 1 09M17i 
Conclusions: Both QC-RT-PCR and Real-Time-PCR are poten-
tially useful in chmcal laboratones as sensitive and rapid 
diagnostic tools to quantify the expression level of mexA and 
mexX in P aerugmosa Combined with phenotypic charactenza-
tion, this approach may help in a better understanding of the 
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resistance mechanisms and epidemiology of resistance in this 
difficult-to-treat nosocomial pathogen 
P1752 
Molecular detection of penicillin resistance in 
Streptococcus pneumomiae 
N G Rizk, N A Abo Khadr, S M Abdel Salam, N M Gamil, 
M Hassan (Alexandria, EG) 
Objectives: The aim of the study was to detect penicillin 
resistant Streptococcus pneumoniae by using seminested polym-
erase chain reaction (PCR) and to compare it with minimum 
inhibitory concentration (MIC) of penicillin G 
Methods: Fifty clinical isolates of Streptococcus pneumoniae 
where isolated from patients admitted to Alexandria Mam 
University Hospital in Egypt and were recovered from sputum 
(36 strains), throat swabs (11 strains), and pleural effusion (3 
strains) Two species-specific pnmers lA-1 and lA-2, which 
amplified 1043 bp region of the pbplA penicillin-binding gene, 
were used for pneumococcal detection Two resistance pnmers, 
lA-Rl and 1A-R2, were used to bind to altered areas of pbplA 
gene which, together with the down stream primer lA-2, 
amplify DNA sequences of 224 bp and 569 bp from isolates 
with penicillin MIC > 0 1 and 2 1 /Jg/ml respectively Results 
compared with the MIC values obtained by E-test Penicillin G 
strips 
Results: For 98% of the isolates tested, PCR results were m 
agreement with MIC data The sensitivity of PCR assay m 
detection of penicillin resistance was 96 4%, and the specificity 
was 100% The positive and negative predictive values of the 
assay were 100% and 95 6% respectively 
Conclusion: The semmested PCR is a rapid specific method in 
diagnosis of Streptococcus pneumoniae, which can be applied 
directly on clinical specimens Meanwhile it can detect resistant 
strains and differentiate between intermediate and high level 
resistance 
P1753 
Lipopolysaccharide-binding protein is a marker 
of severity in patients with bacteraemia 
S Gami, S S Pedersen, C Pedersen, O G Koldkjaer (Odense, 
S0nderborg, DK) 
Objective: Lipopolysacchande-binding protein (LBP) is an 
acute phase protein produced in the hver The objective of our 
study was to evaluate LBP as a marker of seventy and prognosis 
in patients with bacteraemia 
Methods: 42 adult patients with community-acquired bacterae-
mia were included in a prospective manner Daily blood 
sampling for LBP and InterIeukin-6 (IL-6) was performed The 
patients were classified according to the Systemic Inflamma-
tory Response Syndrome (SIRS) criteria Demographic data, 
co-morbidity, microbiological aaettology, routine biochemical 
parameters, focus of infection, seventy score and mortahty on 
day 28 were recorded LBP and IL-6 levels were analysed on 
plasma samples with a chemiluminescent immunometnc assay 
(Immuhte-lOOO*) 
Results: The median age was 71 yrs The mortahty rate on day 
28 was 16 6% 5 patients had bacteraemia without SIRS, 17 
patients had sepsis and 20 patients had severe sepsis LBP 
concentrations are presented as medians and range 32 2 ;<g/ml 
(28 2-341) in patients without SIRS, 45 4/ig/ml (20-85 6) in 
patients with sepsis and 50 9 /ig/ml (22 9-96 5) in patients with 
severe sepsis (P < 0 05) LBP levels correlated to levels of IL-6 (rs 
.loiimal of Antiniicrohial Chemnthcrapv (2004) 54, 684-687 
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Phenotypic detection of extended-spectrum and AmpC 
p-lactamases by a new spot-inoculation method and modified 
three-dimensional extract test: comparison with the conventional 
three-dimensional extract test 
M. Shahid*, Abida Malik, Mithlesh Agrawal and Sanjay Singhal 
Department ofMicrohioloi^y, Jawaharlal Nehru Medical Collei^e and Hospital, Aligarli Muslim University. 
Aligarh—2Q2002, Uitar Pradesh. India 
Received 21 March 2004; relumed 10 May 2004: revised 20 June 2004: accepted I July 2004 
Objectives: To develop an easy, rapid and reproducible spot-inoculation method for phenotypic detec-
tion of extended-spectrum p-lactamases (ESBLs) and AmpC p-lactamases and to make the existing 
three-dimensional extract test more convenient for use in routine diagnostic laboratories. 
Methods: ESBL and AmpC producing and non-producing isolates of Escherichia coli, Klebsiella pneu-
moniae and Pseudomonas aeruginosa, as identified by the conventional three-dimensional extract 
test, w/ere used to evaluate the modified procedures. Whole bacterial cells and freeze-thaw prep-
arations, as p-lactamase sources, were strategically applied to culture plates near ceftazidime and 
cefoxitin discs on a lawn Inoculum of E. coli ATCC 25922. Technical variations of the test included pla-
cing the p-lactamase-containlng inoculum Into slits, wells and trenches, or onto the surface as spots 
at varying distances from the discs, and adding clavulanate or cloxacillin to the three-dimensional 
Inoculum to confirm the presence of ESBLs and AmpC p-lactamases, respectively. 
Results: All the methods adopted for ESBL and AmpC detection by using the whole bacterial cells 
gave positive results. However, the best results were given by the spot-inoculation method. In modifi-
cations using the enzymic extracts, the enhanced growth of surface organisms was better appreciated 
in the designed modifications compared with the conventional methods. 
Conclusions: The method described here is simple and cost-effective. Furthermore, up to 16 isolates 
may be tested on a single culture plate, thus it is a less labour-intensive and more economic technique 
than other reported phenotypic methods. 
Keywords: direct-spot test, well-extract test, modified enzymic extraction, modifications, user-friendly method 
Introduction Double disc-synergy (DDST) and three-dimensional extract 
tests (TDET) have been used for the detection of ESBLs in 
Extended-spectrum P-lactamases (ESBLs) are enzymes mani- members of the family Enterobacteriaceae." The current NCCLS 
festing considerable hydrolytic activity on a wide variety of documents do not indicate the screening and confirmatory tests 
P-lactam antibiotics including oxyimino-cephalosporins and that should be used for the detection of AmpC P-lactamases. 
aztreonam, and are inhibited by clavulanic acid. AmpC However, various workers'" have designed the TDET for the 
p-lactamases are clinically important because they may confer detection of AmpC enzymes in Gram-negative bacterial isolates, 
resistance to a wide variety of P-lactam drugs, Including As the TDET is a labour-intensive procedure, there is always a 
a-methoxy-p-lactams, such as cefoxitin, narrow-, expanded-, and search for newer methods and the aim to make existing methods 
broad-spectrum cephalo.sporins, P-lactam-P-lactamase-inhibitor more user-friendly to incorporate them in routine diagnostic lab-
combinations, and aztreonam.' Group I AmpC P-lactamases are oratories. Here, we designed a user-friendly and effective proto-
poorly inhibited by clavulanic acid; however, they are inhibited col to be applied as phenotypic characterization for the detection 
by cloxacillin. of ESBLs and AmpC enzymes, and compared our results with 
*Con-esponding author. Tel: +51-571-2720382; Fax: +91-571-2721776; E-mail: shahid.sahar@yahoo.co.in 
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Spot-inoculation and modified three-dimensional tests for p-lactamase detection 
the existing phenotypic test, l e the conventional thiee dimen-
sional extract test 
Materials and methods 
Before carrying out the modified procedures the conventional 
T D E T ' ' ' was first carried out on the isolates included in this study 
Three different kinds of results, as observed by other workers,' were 
recorded The isolates showing clear distortion of zone of inhibition 
were taken as AmpC/ESBL producers and the isolates with no dis-
tortion were taken as AmpC/ESBL non-producers Isolates showing 
minimal distortion were taken as indeterminate strains The ESBL 
production was confirmed by phenotypic NCCLS screening and 
confirmatory criteria The isolates could not be tollowed for AmpC 
detection, as per the NCCLS guidelines, because there are no 
NCCLS K'eening and conhrmatory criteria for AmpC defection 
Bacterial isolates 
A total of 18 AmpC producing isolates {Escherichia coli, 5, Kleb-
siellci pneumoniae. 5, Pseiidomonas aeruginosa 8), 10 AmpC inde-
lenninaie isolates (£ coli, 4, K pneumoniae. 2, P aeruginosa, 4) 
and 10 AmpC negative isolates (E coli, 5, K pneumoniae, 5), as 
identified by conventional TDET, were included to delect the AmpC 
enzyme by the modified procedures Twenty ESBL producing iso-
lates (£ coll, 10, K pneumoniae, 10), 10 ESBL indeterminate 
isolates (E coli, 5, K pneumoniae, 5) and 10 ESBL negative iso-
lates (C coll, 5. K pneumoniae. 5), inferred by conventional TDET, 
were also included to detect ESBL production by a modified proto-
col Quality control was achieved using a known AmpC positive 
isolate ol K pneumoniae, obtained from UCMS & GTB Hospital, 
Delhi, India, originally provided by Dr Patncia A Bradlord, Wyeth 
Laboratories, Pearl River, NY, USA and a known ESBL producing 
isolate ol K pneumoniae obtained from RAK Institute of Agncul-
tuial Sciences Aligarh, India The zone diameters o) all the bac-
terial isolates included in the study were recorded and MICs of 
cetoxitin and ceftazidime were recorded for isolates with zone diam-
eters less than IS mm 
ESBL and AmpC en:\me deledioii h\ Lonventional TDET 
The isolates were hist tested by conventional TDET tor the pro-
dtitlion of hSBL and AmpC enzymes The methods adopted weie 
ol Thomson t/ «/"' lor ESBL detection and Coudron et al! with 
some modihLations as adopted in our previous \.ork,'' lor AmpC 
detection Bnelly, 50 ^.L of a 0 5 McFarland bacterial suspension 
prepared from an overnight blood agar plate was inoculated into 
12mL of tryptic soy broth and the culture was grown lor 4h at 
^5°C The cells weie concentrated by cenirifugation, and crude 
enzyme preparations were made by freeze-thawing the cell pellets 
fi\e times The surlace of the Mueller-Hinton agar plate was inocu-
lated with E coll strain (ATCC 25922) Then 30p.g celoxitin 
(HiMedia, Mumbai India) and 30|jLg ceftazidime (HiMedia) discs 
were placed on inoculated olates for detection ol AmpC enzymes 
and hSBLs respectively With a sterile scalpel blade, a slit begin-
ning 5 mm trom the edge of the disc was cut within the agar in an 
ouivvard radial direction By using a pipette, 25-30|xL of enzyme 
pieparation was dispensed into the slit, beginning near the disc and 
moving outward Slit overfill was avoided The inoculated media 
\u i e incubated overnight at " l iT A parallel test was cairied out 
Willi a S|j.g ..loxacillin disc (HiMedia) (for AmpC conhiination) and 
l()p.g co-anio\iclav disc (HiMedia) (lor ESBL conhimation) added 
lo the eii/vmii. extiaci and the extract incubated at V°C lor 30mm 
The whole procedure was then adopted as described above and the 
parallel sets of plates were incubated overnight at 35°C Inhibition 
of zone distortion, when cloxacillin and co-amoxiclav discs in 
enzyme extract were used, confirmed AmpC and ESBL producers 
respectively 
ESBL and AmpC enzyme detection by modified procedures 
Cefoxitin (30|Ji,g) and ceftazidime (30 ng) discs were used for 
AmpC enzyme and ESBL detection, respectively E call ATCC 
25922 was used to inoculate the Mueller-Hinton agar plate Several 
modifications were attempted Broadly, the methods were divided 
into two groups (i) methods for AmpC and ESBL detection alter 
deriving the enzymic extracts, (ii) methods using the bactenal iso-
lates directly, rather than using the extracts 
Methods directly using the bacterial isolates 
Uwn cultures of E coli ATCC 25922 were prepared on Mueller-
Hinton agar and the plates were incubated for 15 mm at 37°C, for 
drying The adopted modifications (Figure la) were (i) with a ster-
ile scalpel blade, a linear cut was made beginning 5 mm trom the 
edge of the discs in an outward radial direction Eight to 10 distinct 
colonies were picked with a sterile wire loop and the slit was inocu-
lated at depth, beginning near the disc and moving outwards, (u) a 
heavy inoculum was streaked over the agar surface in a linear 
fashion, beginning 5 mm from the disc and moving outwards, 
(ill) five to SIX colonies were spot inoculated at a distance of 
Figure 1. Methods designed for detection of ESBLs and AmpC enzymes 
(a) Detection of p-lactamase production directly using the baticnal isolates 
(starting from left in a clockwise direction) bacteoul inoculation m a sli! cut 
in agar, spot inoculation at a distance of 7-8 mm from the edge of the cen 
irally placed ceftazidime disc, inoculation ol the organism over the surlate 
of the agar, spot inoculation at 10-12 mm from the ceftazidime disc 
(b) Enzymit extracts tested by (clockwise) slit in agar (as used in convcn 
lioiial methods), well at a distance ol 7-8 mm from the cella/idimc disc, 
trough prepared in agar well at a distance of 10-12 mm trom the t(.lt.i7i 
dime disc (L) Wells and spot iiiotulalion within and approximately al the 
zone of inhibition vd) Wtlls and spot moculation made withiii and outside 
the ?one ol mhihition 
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7-8mm Irom ihe edge ol the disc, and (iv) five to six colonies uere 
spot inoculated at a distance ol 10-12 mm Celoxitin and cefta/i 
dime discs vveie placed centrally on Ihe respective plates and o\ei 
nighi iiKubalion at I T T was carried out All the results weie 
replicated in at le ist tniee separate experiments 
Methods lain^ the en~\inic extract 
Approximaiely 10- 11 mg of bacterial wet weight was scraped from 
the ciilluie plate using a sterile wire loop and suspended in 0 5mL 
of peptone walei m a sterile microcentrifuge lube and incubated at 
'i7°C loi 1 h Crude enzyme extract was prepared by thrice repealed 
treeze-thawing Howevei to ensure complete membrane lysis, 
freeze-thdwing may be carried out five times Lawn cultures of 
E coll ATCC 25922 were prepared as described previously and 
cefoxitin (30p.g) and celtazidime GOjig) aiscs were placed on 
respective plates With a sterile scalpel blade, a slit beginning 5 mm 
from the edge of the disc was cut in the agar in an outward radi il 
direction, as descnbed in conventional methods, to serve as a con 
trol for comparison Figure 1(b) shows the modifications (i) a linear 
trench (3 cm x I mm) was prepared in the agar, (ii) a circular well 
made with the broad end of a Pasteur pipette, at a distance of 7 -
8 mm tiom the edge of the cefoxitin/ceftazidime disc, and (in) a cii-
culai \sell made at a distance of 10-12iTim Fifty microlities ol 
enzvme prepaiation was dispensed in trench and wells However 
W JJ.L ol the enzyme pieparation could be loaded in the slit made 
lor the conventional method and slit overfill was avoided The 
inoculated media weie incubated overnight at 37°C Enhanced 
growth of the surface organism at the point where the slit/irench 
intersected the zone of inhibition or around the wells towards the 
cefoxitin and ceftazidime discs was interpreted as evidence for the 
presence of AmpC and ESBLs, respectively Inhibition of zone dis 
tortion when cloxacillm or co-amoxiclav discs in enzyme extracts 
were used confirmed AmpC and ESBL producers, respectively 
Results and discussion 
With the spiedd of AmpC and ESBL producing strains all ovei 
the world, it is necessaiy to know the pievalence of these stiains 
in hospitals Detection of lesistant isoldtes would allow doctois 
to formuidte a policy of empincai therapy in high-risk units 
where infections due to resistant organisms are much higher 
Methods of detecting ESBL producing bacteria have been evol-
ving for moie than a decade, beginning with the description 
of the disc approximation test by Brun-Buisson et al^ and 
subsequently descnbed by Jarlier et al" The three-dimensional 
test, onginaliy descnbed by Thomson et al * is a more sensitive 
proceduie for the detection of ESBLs However, this technique 
had Its own limitations Subsequendy, the test was modified with 
the use of a slit technique with bactenai suspensions and enzyme 
extiacts, but filling these slits was a fastidious procedure" 
Despite diffeient modificdtions tried by vanous researchers, to 
date, no satisfactory technique has been estabhshed Beanng all 
these points in mind, we tried some modifications m search of a 
simple and more user-fnendly procedure than existing conven-
tional phenotypic tests 
The bacterial isolates (AmpC or ESBL producers and indeter 
mindte isoldtes, as inferred by conventional TDET) used in this 
work either did not have or had very small zones of inhibition 
(langing between 8 and 10mm zone diameters) The MICs 
(nig/L) of cefoxitin and ceftazidime ranged between 256 and 
>1024 The bacteiial isolates (ESBL producers and ESBL 
indeteiminate) used in this study fulhlled the NCCLS scieeniiig 
criteiia for ESBL (i e MIC of at least one extended spectrum 
cephalosponn (ceftazidime was used for scieening and conhi 
mation) >2nig/Ll and weie positive foi the NCCLS ESBL con 
himatoiy test (i e MIC of ceftazidime by bioth microdilution 
methcxJ decieased by >^ doubling dilutions in the presence ol 
tldvulanic acid) 
AmpC/ESBL detection directly using bacteiicd isolates 
Though all the methods adopted in this study gave positive 
results, the most discnniinatory results weie given either b> 
direct inoculation of the organism in the linear cut made in agai 
or by direct spot inoculation of the test organisms (Figuie la) 
Of these, the best results were given by spot inoculation There-
fore, all the bactenai isolates included in this study weie 
screened only by spot inoculation of the test organisms near 
cefoxitin and ceftazidime discs All the ESBL and AmpC produ-
cing isolates were detected correctly by adopting this method 
Nine of 10 indeterminate isolates for AmpC, and eight of 10 
indeterminate isolates for ESBL were identihed as AmpC and 
ESBL producers, respecti\ely, dnd the lemdining were identified 
as indeterminate by this modification It must be emphasized 
heie that the indeteiminate" result of conventional TDET looked 
like a weakei positive lesuU All AmpC and ESBL-
negative isolates gave negative results with the three dimen 
sional extract test 
AmpC/ESBL detection using enzvnuc extracts 
In the modifications for enzymic extracts all the 18 AmpC and 
20 ESBL producing bactenai isolates were detected correctl) by 
the designed modifications (trenches/wells) Companng the 
modifications with the conventional slit test, the enhanced 
giowth of surface organisms was inteipreted mote easily in the 
designed modihcations (Figure lb and c) All the isolates, 
infeiTed as AmpC and ESBL mdetemiinate by the conventional 
method, could be detected as AmpC and ESBL producers by 
adopting the designed modifications All the isolates negative for 
ESBL and AmpC enzymes were detected correctly by the modi-
fied procedures 
Among the modifications designed for the test using the enzy-
mic extracts, we have shown that the lesults with preparation of 
trenches and wells were comparatively far better than the ong 
inal slit method as samples inferred to be 'indeterminate' by the 
slit technique could be detected as 'producers' by the current 
method This could be due to the capability of loading Idige 
amounts of extract and greater diffusion towards discs, in 
trenches and wells, than in slits Another reason for infemng 
large number of isolates as 'indeterminate' by conventional 
TDET could be that slight spillage of the extract at the edge of 
slits, near the discs, could interfere with the proper visualization 
of the distortion of zone of inhibition This problem is avoided 
in our modifications The preparation of wells was found to be 
more convenient and easy than trench prepdfdtion, as preparation 
of the trench required extra skill All the methods descnbed ear-
lier used slit prepaiation, because, whatever the zone of inhi-
bition for E toll ATCC 25922 could be, it must intersect the 
prepdred slit The same is true tor tiench preparation To deter-
mine the placement of wells, we designed a few more expen-
ments The zone of inhibition o*" cefoxitin and ceftazidime discs 
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for the inoculated £. coti ATCC 25922 was noted and the wells 
were punched within the zone of inhibition (7-8 mm from the 
edge of discs), at the zone of inhibition (10-12mm) and outside 
the margin of the zone of inhibition (Figure Ib-d). Positive 
results were obtained with wells punched within, and near the 
zone of inhibition (Figure lb and c). The methods for extract 
preparation described in the previous techniques are lengthy and 
labour-intensive. Therefore, we tried the modifications that are 
simple and limit the enzyme extraction time (see the Materials 
and methods section). In addition, the tests were modified to use 
direct inoculation of the test bacteria, and excellent results were 
obtained by inoculating the organism in the depth of the slit in 
agar and also by spot inoculation (Figure la). However, spot 
inoculation was more convenient. The same experimental design 
was followed, as for punched wells, to judge the optimal 
distance for spot inoculations (Figure la, c and d). The main 
advantage of testing the organism by spot inoculation or extracts 
filled in punched wells is that multiple organisms can be tested 
on a single plate. We thus propose a more user-friendly protocol 
for phenotypic detection of ESBLs and AmpC enzymes, (i) Test 
the organisms for ESBL and AmpC enzyme production by spot 
inoculating the organisms around ceftazidime and cefoxitin 
discs, respectively, (ii) Though (i-lactamase detection by spot 
inoculation was obser%'ed to be fairly sensitive in this work, 
ESBL/AmpC (B-lactamase production could be confirmed by the 
well test (enhancement of the growth of surface organism near 
the well filled with extract, and inhibition/reduction in the 
enhanced growth in the well filled with extract treated with cla-
vulunic acid/cloxaciilin). (iii) The organisms found to be nega-
tive by the spot test, but suspected of being an ESBL/AmpC 
producer on the basis of .susceptibility or MIC testing should be 
confirmed by the well extract test. 
Diagnostic laboratories demand cheaper and easy to use tests 
for detection of ESBLs and AmpC enzymes.'" Additionally, 
there is recent emphasis on medical cost cutting and downsizing 
al a time when bacterial pathogens are increasing in complex-
ity. The current protocol is simple in terms of direct spot 
inoculation, short enzyme extraction steps, and a simple pro-
cedure for the well extract test, without any requirement for 
sophisticated equipment and extra skills. It should also be noted 
thai detection of ESBL and AmpC enzymes by the spot inocu-
lation test cuts short the reporting time by 1 day as this test 
could easily be incorporated in the routine diagnostic procedures 
and the test can be carried out alongside the first-line suscepti-
bility testing. Furthermore, up to 16 bacterial i.solates can be 
screened for ESBL/AmpC production by .spot inoculation lest or 
well extract test on a single culture plate. Thus, it is more cost-
effective and less labour intensive than other existing phenotypic 
tests. We suggest that the protocols described here for detection 
of ESBLs and AmpC enzymes could be incorporated in diagnos-
tic laboratories along with otner routine diagnostic procedures. 
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D O T B L O T A S S A Y A N D ITS A P P L I C A T I O N IN D I A G N O S I S O F 
A S P E R G I L L O S I S 
M. Shahid', Abida Malik and R. Bhargava" 
Departments of Microbiology, J N Medical College & Hospital, Aligarh Muslim Uiiiversit> 
Aligarh-202002 (U P ) 
ABSTRACT 
Sera of 100 individuals (88 palicnis ol chronic lung diseases and 12 healthy 
conlrols) were analysed for presence of anli-aspergillus antibodies b> 
Immunodiffusion (ID) Enzyme linked immunosorbent assay (CLISA) and also b) 
the method of Dot blot assay (DBA) which was developed m our laborator\ The 
sensitivity of DBA (86 3%) was found to be slightly louer than LLISA but higher 
than ID in the whole study population Similar sensitivits of DBA was noted in 
comparison to PI ISA and ID m patients ol bronchogenic carcinoma and pulmonar\ 
tuberculosis however in bronchial asthma patients the sensitivity of DBA (66 6%) 
was lower but markedly higher than ID (16 6%) when compared with LLISA As the 
method of DBA is cheap and easy to perform in comparison to CLISA hence we 
suggest that peripheral laboratories which do not ha\e facilities tor LI ISA can 
perform Dot blot assay for diagnosing aspergillosis 
Key words. Aspergillosis Chronic lung diseases Dot blot assay Serodiagnosis 
INTRODUCTION 
The past few decades have witnessed a dramatic change in man's environment and 
iinmune defences, consequently, fungi have assumed a major role m respiratory and systemic 
diseases Bronchopulmonary aspergillosis are being diagnosed more frequent!) m recent >ears 
especially in the patients of chronic lung diseases (Edit 1987) 
Methods of definitive diagnosis of bronchopulmonary aspergillosis depends upon 
isolation of Aspergillus in culture, demonstration of specific immunological changes in the sera 
of patients, or histopathological examination of biopsy material (Richardson, 1998) but, the 
isolation of Aspergillus in culture is not always achievable because of faulty collection and 
processing of the specimen or because of non communication of the cavity with mam bronchus 
while histopathological examination is very tedious and cumbersome However, serodiagnostic 
tests aie helpful especially when direct demonstration of Aspergillus is not achievable in the 
culture (Shahid el al, 2001) Serodiagnosis of aspergillosis has been extensi\ely used, most 
commonly by precipitation methods however, problem with inter-laboratory reproducibility, low 
sensitivity in immunocompromised patients and low specificity have encouiaged the 
development of alternative approach like ELISA for serodiagnosis (Richardson and Warnock 
'983) Again, as the ELISA technique is time consuming and requires sophisticated and costly 
equipments theiefore, we developed a method of Dot blot assay (DBA) as an alternati\e and 
cheaper substitute of ELISA for diagnosing aspergillosis in chronic lung disease patients 
Corresponding author: Dept of Microbiology, J N Medical College, A M U Aligarh-202002 India 
E-Mail shahidsahar@rediffinail com, Shahidsahat(gyahoo co in 
"Dep t of I B & Chest Diseases, J N Medical College <1 Hospital, Aligarh Muslim University 
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M. Shaliid, Abida Malik and R. Bhargava 
MAJ ERIALS AND METHOD?* 
I lie pieseiit study was conducted in the Departments of Microbiology and T B & Chest 
diseases, JN Medical College and Hospital, A M U Ahgarh Eighty-eight patients of various 
thionic lung diseases attending the out patient or admitted m the wards of the department of T B 
&. Chest diseases of J N M C H Ahgarh during the period of one year were included in the study 
gioup Twelve healthy age and sex matched uidividuals not having history suggestive of any lung 
disease foi the past one year were included as control group Blood was collected in plain sterile 
\ idK loi serological investigations Sera were separated and stored at -20"C till tested 
Seroloffical techniques: 
I'repaiation of antigens The Aspergillus was grown for 3 weeks in glucose asparagine broth 
I he iincelial mat was separated and transferred into 95% alcohol and kept for 48 hrs It was 
s(iueczed gently between two layers of filter paper and dried in a dessicator with anhydrous 
Iciuni chloride The dried fungal pellicles were finely pulverised and passed through sieve of 
^ ) mesh /sq cm to get fine powder This powder was defatted by shaking in the solvent 
•^  lone (3 to 4 vol of material) The acti\e allergenic substances from the defatted powder were 
.'Lted with highly alkaline buffer (NaCI - 7 gm, Potassium phosphate - 0 36 gni, Sodium 
I isphate - 7 gm, Phenyl crystals - 4 gm, double distilled water - I lit) pH 8 The soluble active 
p-icdients weie filtered and dialysed against normal saline for 48 hrs Standardisation was done 
\ N\eight by volume method (1 50) 
Ininiunodiffusion ID was carried out according to Ouchterlony (1953) making slight 
modifications as described by Kauffman e/a/ (1983) 
I LISA Indirect ELISA was performed by methods described by Kauffman et al. (1983) with 
^ome modifications Briefly, maxisorp E microtitre plates (Nagle NUNC) were sensitised with 
hpeigillus antigen (50 (ig/ml) in bicarbonate buffer (pH 9 6) at a volume of 200 [il/well for 2 
his at 37"C followed by overnight incubation at 4°C The plates were washed thrice with TBS-T 
and unoccupied sites were blocked with 200 )il of fat free dry milk (5%) in TBS 200 (il of 
individual patient's serum diluted 1 '00 as well as 200 |il of positive and negative control sera 
weie added and incubated at 3 7"C lollowed by overnight incubation at 4°C Microtitre plates 
were washed thrice with TBS-T & 1 BS respectively 200 ^1 of anti immunoglobulin alkaline 
phosphatase conjugate (diluted in TBS) was added and incubated for 2 hrs at room temperature 
Plates were washed again and 200 |il of substrate (P-nitrophenyl phosphate) was added and 
icaclion was allowed to develop for 30 minutes IN NaOH was added to stop reaction and 
ibsoibence was recorded at 405 nm 
Dot Blot Assay : The method for Dot Blot was developed in our laboratory Strips were cut from 
Immobilon Polyvinylidene difluonde (PVDF) membrane, 2 |il of antigen having a 
tonceiitration of 2 nig/ml were coated as drops and strips were kept at 60''C for 30 mm Strips 
vvere washed with TBS and unoccupied sites were blocked by 1% bovine serum albumin for 2 
his Stiips were washed again, a drop of 1 100 dilution individual sera were added ovei the 
antigen drop and strips were incubated at 37'C for 30 min Secondary HRP conjugate diluted in 
1 BS was added after washing and allowed to slay for I hr at room temperature Strips were 
washed and HRP colour substrate system (50 mM Tris-HCI, pH 8 0, 0 48 mM 4-chloro 1 
naphthol, 200 mM NaCI & 17% methanol) was added The reaction was started with the addition 
/iio-S't leiice Reseiircli Bulletin. Vol. 19 (No. I) 2003 
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of Hydrogen peroxide at the cone of 0 01% v/v The colour was allowed to develop for 5 
minutes The substrate was removed and the membrane was dried 
Tabic-1 : Chronic lung disease patients and their serological results 
Clinical disease 
Bronchogenic carcinoma 
Pulmonary tubeiculosis 
Bronchial Asthma 
Bronchiectasis 
Military Tuberculosis 
Chronic Pneumonitis 
Pleural effusion 
Sarcoidosis 
Emphysema 
Total 
Total No. of 
cases 
42 
20 
10 
3 
2 
6 
2 
1 
2 
88 
Aspergillus antibody by 
ID 
9 
. 5 
1 
-
1 
1 
-
-
-
17 
ELISA 
9 
5 
6 
-
1 
1 
-
-
-
22 
DBA 
9 
5 
4 
-
0 
1 
-
-
-
19 
RESULTS 
Tabulated data (Table-!) shows the patients of various chronic lung diseases included in 
the study and their serological results Out of 88 patients, anti-aspergillus antibodies were 
detected in 17(19 3%) cases by ID, 22(25%) by ELISA and in 19(21 5%) cases by DBA 
Viewing the disease wise break up we noted that anti-aspergillus antibodies were detected 
cqiiall) by ID ELISA and DBA in 9(21 4%) and 5(25%) cases of bronchogenic carcinoma and 
pulmonar) tubeiculosis respectively In bronchial asthma patients antibodies could be detected in 
1(10%) by ID, 6(60%) by ELISA while they could be detected in 4(40%) cases by DBA (Table-
1) None of the healthy control group was found positive for anti-aspergillus antibodies by any of 
ilie above menlioned methods 
DISCUSSION 
Aspeigillosis IS primarily a pulmonary disease whereas other areas like nasal sinuses, 
cMeinal ear canal, eyes and burn eschars may also be involved (Milne, 1996) There is a high 
pievalcnce of aspergillosis in our Lountry however, despite of high prevalence the diagnosis of 
aspergillosis is usually missed as the tests for their detection can not be undertaken in routine 
diagnostic laboratoiies (Shahid et al, 2001) 
Various serological methods like Immunodiffusion (ID), Counter current 
Immunoelectrophoresis (CIE), Enzyme linked immunosorbent assay (ELISA) and Radio-immuno 
assay (RIA) have been used for the demonstration of antibodies against Aspergillus (Randhava 
and Khan, 1987) Each method has its advantages as well as disadvantages as, ID is cheap and 
(.asy to perform but it can detect only precipitating antibodies ELISA and RIA can detect both 
leaginic as well as piecipitatmg antibodies but these techniques are time consuming and requires 
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sopliistrcated equipments Considering these facts we developed and standardised the method of 
Dot blot assay and compared it with ID and ELISA as a'diagnostic tool for aspergillosis 
CONCLUSION 
In our study, keeping ELISA as a standard, we found the sensitivity of DBA(86 3%) to 
be greater than ID(72 3%), however, it was slightly lower than ELISA which may be due to 
subjective error Although, the sensitivity of DBA, ELISA and ID was same in bronchogenic 
carcinoma and pulmoirary tuberculosis cases which showed that DBA may not have aii> 
additional advantage over ID and ELISA in these patients but DBA may be used as an alternative 
method to ELISA as it is cheap and easy to perform Again, DBA was found to be better 
diagnostic method than ID m patients of bronchial asthma as the sensitnity of DBA was 66 6% 
and ID was 16 6% m comparison to ELISA Although we missed 2 cases of aspergillosis in 
bronchial asthma patients and one case in milliary tuberculosis patient by DBA, however the) 
were diagnosed by ELISA, it is a matter of question whether we missed them by chance or was 
theie any relation with particular lung disease Comparative study regarding the DBA and 
vaiious chronic lung diseases is scanty in our country therefore, we conducted a base line stud>, 
however individual lung diseases with a large sample size needs to be evaluated in future In the 
span of time we suggest that peripheral laboratories, which not have facilities to perform ELISA, 
can opt for Dot blot technique for diagnosing aspergillosis 
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Prevalence of aspergillosis in bronchogenic carcinoma 
Abida Malik, M Shahid and R Bhargava' 
Abstract: Bronchoalveolar lavage of42 patients ofbronchogenic carcinoma was studied to find out the prevalence 
of aspergillosis. Sera cfthepatients were cdso andysedforpresence ofanti-Aspergillus antibodies by Immunodiffusion 
(ID), Enzyme linked immunosorbent assay (EUSA) and dot blot assay (DBA). Aspergillus was isolated in culture 
from 6(14.2%) patients ofbronchogenic carcinoma. Aspergillus fumigatus was the predominant species isolated. 
All the strains of Aspergillus were sensitive to itraconazole, ketoconazole and amphotericin B while resistance 
(33.3%) was found withfluconazole. Anti-aspergillus antibodies were detected equally by ID, EUSA and DBA in 
9(21.4%) cases. Thepresent study reDealedpreodenceandseroprevalanceofAspergillus in bronchogenic carcinoma 
to be 14.2% and 21.4% respectively. Consistent reactivity against 18 kDa Aspergillus fumigatus antigen was 
noted in serologically positive cases. Antibodies against 18 kDa protein antigen in western blotting may be used as 
a reference marker for diagnosis ofaspergillosis in bronchogenic carcinoma. It is also suggested that the simplest 
serological technique like ID may be performed along with culture for diagnosing Aspergillosis in patients of 
bronchogenic carcinoma since ID, EUSA and DBA showed similar sensitivity. 
Keywords: aspergillosis, bronchogenic carcinoma, irrununoblotting, prevalence 
Indian J Pathol Microbiol 2003; 46(3): 507-510 
Introduction 
Fungal infections of the lung, especially broncho-
pulmonary aspergillosis, are becoming increasingly 
common in recent years due to greater use of broad-
spectrum antibiotics, corticosteroids, immuno-
suppressive drugs and intensive cytotoxic therapy.' The 
data regarding Aspergillus infection in various dironic 
lung diseases is available. ^ '^ However there is paucity 
of literature on fungal infection in bronchogenic 
carcinoma. 
In recent years more cases of bronchogenic 
carcinoma are being reported due to changed personnel 
habits and advancement in medical technology. The 
data regarding aspergillosis in bronchogenic carcinoma 
is insufficient especially in India. The prevalence of this 
infection and the tests to diagnose this infection needs 
to be evaluated. This study was therefore planned with 
the aims and objectives (a) to find out the prevalence of 
aspergillosis in bronchogenic carcinoma (b) to study 
various laboratory diagnostic tests for aspergillosis in 
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bronchogeruc carcinoma patients and also (c) to know 
the antifungal susceptibility pattern of the isolates. 
Materials and Methods 
The present study was conducted on patients of 
bronchogenic carcinoma attending the outpatient 
department or admitted in the ward of tuberculosis 
and chest diseases of J.N. Medical College Hospital 
Aligarh during a period of 1 year. 42 patients were 
included in the study group. None of the selected patient 
had received any anti-fungal therapy prior to the study. 
12 healthy, age & sex matched individuals, not having 
history suggestive of any lung disease in the recent past 
were included as control group. 
Broncho-alveolar lavage (BAL) and blood samples 
were collected. Bronchoscopy was performed according 
to Wimberley et al.^ Three consecutive BAL specimens 
were collected in sterile container with all aseptic 
precautions. Blood was collected in EDTA and plain vial 
for routine haematological investigations and fungal 
serology respectively. Sera were separated and stored 
at -20°C till tested. Cytology of BAL specimen was also 
performed. 
Direct Microscopy: BAL was homogenised and subjected 
to direct microscopy by using 10% KOH mount and 
Lacto Phenol CottOn Blue (LPCB) mount. 
Culture: BAL was streaked on two sets of Sabouraud's 
Dextrose Agar (SDA) plain and SDA with Chloram-
pherucol (0.05 mg/ml). One set was incubated at 25°C 
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and the other at 37°C. All the fungal isolates were 
confirmed and characterised according to standard 
techniques.' 
Antifungal Susceptibility: Antifungal sensitivity against 
Amphotericin B, Itraconazole, Fluconazole and 
Ketoconazole was performed by broth microdilution 
method according to Ingroff et aU 
Serological techniques 
Preparation ofAntigens:An'dger\soi Aspergillusfumigatus, 
Aspergillus Jlavus and Aspergillus niger were prepared in 
our laboratory as described in our previous report*. 
Briefly, the fungi were grown in glucose asparagine 
broth for 3 weeks. The mycelial mat was separated and 
transferred into 95% alcohol and kept for 48 hrs. It was 
squeezed gently between two layers of filter paper and 
dried in a dessicator with anhydrous calcium chloride. 
The dried fungal pellicles were finely pulverised and 
passed through sieve of 150 mesh /sq. cm. to get fine 
powder. This powder was defatted by shaking in the 
solvent acetone (3 to 4 vol. of material). The active 
allergenic substances from the defatted powder were 
extracted with highly alkaline buffer (NaCl - 7 gm. 
Potassium phosphate - 0.36 gm. Sodium phosphate - 7 
gm. Phenyl crystals - 4 gm, double distilled water - 1 
lit.) pH 8. The soluble active ingredients were filtered 
and dialysed against normal saline for 48 hrs. 
Standardisation was done by weight by volume method 
(1:50). 
Immunodiffusion (ID): ID was carried out according to 
Ouchterlony' with slight modificatior\s as described by 
Kauffmaneffl/."' 
Enzyme Linked Immunosorbent Assay (ELISA): Indirect 
ELISA was performed by methods described by 
Kauiiman etal}° 
Dot Blot Assay (DBA): DBA was performed according 
to the method developed in our laboratory.' Briefly 
strips of immobilon polyvinylidene diflouride (PVDF) 
were coated with 2 il of antigen in a concentration of 2 
mg/ml as drops and strips were kept at 60°C for 30 min. 
Strips were washed with TBS and unoccupied sites 
were blocked by 1% bovine serum albumin for 2 hrs. 
Strips were washed again a drop of 1:100 diluted 
individual sera added and strips were incubated at 
37 °C for 30 min. Secondary HRP conjugate diluted in 
TBS was added after washing and allowed to stay at 
room temperature for 1 hour. Strips were washed, HRP 
colour substrate system was added and reaction was 
started by adding Hfi^ in a concentration of 0.01% v/v. 
The colour was allowed to develop for 5 minutes. 
Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) : Before performing 
Immunoblotting (Western Blotting), SDS-PAGE of the 
Aspergillus antigen was performed according to the 
method described by Laemmli". Acrylamide gel (8%) 
was used. 
Western Blot: All the serum samples positive by above 
mentioned serological tests were subjected to western 
blotting. The method for western blotting was used as 
described by Towbin et al^^. 
Observations 
Among the 42 patients studied, majority (50%)'were in 
the age group of 45-60 yrs. Of them 40 (95.2%) were 
male and 2 ((4.7%) were females (Table-1). The mean age 
of the patient was 52.5 + 16.2 yrs. and male to female 
ratio was 20:1. Out of 42 patients, 39 were past or 
present smokers, 38 (97.4%) of them were males and 1 
(2.5%) was a female patient. The main presenting feature 
of the patients was cough followed by chest pain and 
loss of appetite while only 11.9% gave history of cough 
with expectoration of brown plugs in their sputum. 
Most of the patients had multiple symptoms (Fig. 1). On 
cytopathological examination squamous cell carcinoma 
was found to be most common type in 29(69.04%) cases 
followed by adenocarcinoma in 10(23.8%) patients. Two 
patients (4.7%) were diagnosed as small cell carcinoma 
and one case (2.3%) could not be typed. 
BAL culture of 6 (14.2%) patients showed growth of 
Aspergillus species at least in 3 consecutive specimens. 
Three of these 6 cases revealed fungal elements in direct 
microscopic examination of BAL. Aspergillus fumigatus 
was the predominant species isolated from 4 (66.6%) 
cases followed by Aspergillus flavus which was isolated 
in 2 (33.6%) cases. No other species of Aspergillus was 
isolated in the present study and none among the 
control group showed fungal growth in the culture. 
All the isolated strains were found sensitive by 
amphotericin B, itraconazole and ketoconazole while 
only 4 (66.6%) strains were found sensitive by 
Table 1 
Age and sex distribution of the patients of broncho-
genic carcinoma 
Age group 
(in years) 
15-<30 
30 - < 45 
45-<60 
60 - < 75 
>75 
Total 
No. of 
cases 
-
9 (21.4) 
21 (50.0) 
11 (26.1) 
1(2.5) 
42 (100) 
Male 
. 
8 (88.9) 
20 (95.2) 
11 (100) 
1(100) 
40 (95.2) 
Female 
-
1(11.1) 
1(4.8) 
-
-
2(4.7) 
Figures in parentheses indicate percentage 
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Table 2 
Antifungal susceptibility and MIC ranges of the fungal isolates 
Antifungal 
drugs 
No. of 
isolates 
tested 
No. of 
isolates 
sensitive 
Percentage MIC 
ranges 
Amphotericin B 6 
Itraconazole 6 
Fluconazole 6 
Ketoconazole 6 
100 
100 
66.6 
100 
0.25-1 
0.064-0.25 
0.25-1 
0.25-1 
fluconazole. The result of antifungal susceptibility and 
MIC ranges of the isolates are shown in table 2. 
Serodiagnosis of all the patients was performed by 
ID, ELISA and Dot blot assay (DBA). Immunoblotting 
(Western blotting) was performed only in serologically 
positive cases. Out of 42 patients, 9 (21.4%) showed 
precipitation bands in ID and these nine cases also 
showed anti aspergillus antibodies by ELISA and DBA. 
One person in healthy control group was found weakly 
positive for anti-aspergillus antibodies. Immuno-
blotting of all these cases showed the presence of anti-
aspergillus antibodies against 18 kDa protein antigen 
(Fig. 2). 
Discussion 
In recent years, more cases of bronchogenic carcinoma 
are diagnosed and reported as the leading cause of 
cancer death in both men and women." 
In the present study the mean age of the patients of 
bronchogenic carcinoma was 52.5 ± 16.2 yrs. Majority 
of these patients (92.8%) were smokers, 97.4% being male 
and 2.5% females (statistically sigriificant, P<0.05). These 
findings correspond well with Oihabra et a/." The mean 
age for aspergillosis in bronchogenic carcinoma was 
found to be 45.2 ± 11.4 years (P>0.05) and male to female 
ratio was 5:1. Orie et aP^ also reported almost similar 
results. Histologically, squamous cell carcinoma was 
found to be the most frequent cell type in the present 
study similar to the findings of Bucdieri et a/." 
In ou'- study, Aspergillus from BAL was isolated in 6 
cases and A.fumigatus was predominant spedes isolated 
similar to findings of Bordane et al." Among the azoles, 
although resistance was noted against fluconazole but 
all the strains were sensitive to itraconazole and 
ketoconazole. Out of six patients from whom Aspergillus 
was isolated we could follow only 3 of them and all of 
them showed clinical and microbiological improvement 
regarding Aspergillosis after administration of 
itraconazole. This emphasises the need of early detection 
and prompt treatment of the patients of Aspergillosis. 
In the present study culture positivity was fouund 
in 14.2% patients of bronchogenic carcinoma while 
21.4% showed anti-aspergillus antibody by ID, ELISA 
and DBA. The detection of anti-aspergillus antibody by 
ID, ELISA and DBA showed similar sensitivity but these 
results could not be compared due to paucity of 
literature on this aspect. 
On correlating culture and serological methods, it 
was noted that 14.2% cases had evidence of 
Aspergillosis by culture as well as by serology while 
7.1% additional cases showed only seropositivity. 
Hence, the prevalence and Seroprevalance of 
Aspergillosis in bronchogenic carcinoma was 14.2% 
and 21.4% respectively. 
Low molecular weight (18 kDa) protein antigen was 
demonstrated in allergic broncho-pulmonary 
Aspergillosis (ABPA) and 40 kDa in invasive or systemic 
Asf)ergillosis.^*'" However in our series of patients of 
Aspergillosis a consistent reactivity of 18 kDa Aspergillus 
fumigatus antigen in immimoblot analysis was foxind. 
We characterised our cases of Aspergillosis as local 
invasive type according to the classification of Crofton 
& Douglas^ since comparative literature on immunoblot 
analysis for Aspergillosis in bronchogenic carcinoma 
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Fig. 1. Clinical presentations of the patients. 
Fig. 2. Acrylairude gel electrophoretogram of Aspergillus fumigatus 
antigen and f)ositive immunoblot nitrocellulose strip from one of 
the patients. WB = Western Blot, SDS-PAGE -= Sodium dodecyl 
sulphate polyacrylamide gel electrophoresis, MW •= Molecular 
weight markers. {BSA = Bovirre Serum Albumin (67 kDa), OA •= Ov 
Albumin (42.5 kDa), Cyt •= Chymotrypsinogen (24 kDa) and Cyc •= 
Cytochrome C (12.4 kDa)l 
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could not be found The present study showed that 
antibodies against 18 kDa protein antigen in western 
blotting may be used as a reference marker for diagnosis 
of Aspergillosis m bronchogeruc carcmoma 
As ID, ELISA and DBA showed similar sensibvity m 
our study, we suggest that the simplest serological 
techruque like ID may be performed along with culture 
for diagnosmg Aspergillosis m patients of bronchogemc 
caranoma 
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Doctoral theses 02 
M.D. theses 04 
Project Ongoing: 
1. "Screening of community and hospital isolates of Enterobacteriaceae for 
prevalent ESBLs, AmpC p-lactamases, and carbapenemases: exploring 
the reservoir and genetic environment" awarded by Department of 
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Science & Technology, Ministry of Science & Technology, 
Government of India, N. Delhi, costing about INR 17,00,000 (Euro 
30,357) 
Project submitted: 
2. "Screening of community and hospital isolates of Enterobactehaceae for 
CTX-M and AmpC type 3-lactamases: accessing the load and molecular 
characterization" submitted to Department of Biotechnology, Ministry 
of Science & Technology, Government of India, N. Delhi, costing 
about INR 24,00,000 (Euro 42,857) 
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Publication List of M. Shahid 
A) Book/Book Chapter 
1 Shahid, M. (2007) Honey in bacterial disease management In 
Antibacterial Drug Discovery Natural Products and New 
Trends, Ed Ahmad, I (Wiley Interscience), Germany (In Press) 
2 Shahid, M., Khan, H M , Mustafa, S and Shujatullah, F (2008) 
Nanotechnology Implications of Nanoparticles in Medical Science 
In Emerging Trends in Biotechnology, Sayyed, R Z , and Patil, 
A 8 Eds Scientific Publisher, India (In Press) 
B) Research Articles In Journals 
Research Publications in International Journals 
Published 
1. M. Shahid, M Singhai, A Malik, I Shukia, H M Khan, F Shujatullah, 
and F Tahira (2007). In vitro efficacy of ceftnaxone-sulbactam against 
Escherichia call isolates producing CTX-M-15 extended-spectrum p-
lactamase Journal of Antimicrobial Chemotherapy. 60: 187-188 
(Published by Oxford University Press, U.K.; Imfact Factor 3.8) 
2 IVI. Shahid, Anwar Shahzad, Abida Malik and M Anis (2007) 
Antibactenal activity of aenal parts as well as in vitro raised calli of the 
medicinal plant Saraca asoca (Roxb) de Wilde Canadian Journal of 
Microbiology 53(1) 75-81 (Published by National Research Council, 
Canada; Impact Factor 1.18) 
3 M. Shahid (2007). Aminoglycoside ammocyclitol antibiotics- A wonder, 
but toxic drugs development and clinical implications Antiinfective 
Agents in Medicinal Chemistry 6(2) 107-117 (published by 
Bentham Science Publications U.S.A.) 
4 M Akram , M. Shahid and A U Khan (2007) "Etiology and antibiotic 
resistance patterns of community acquired urinary tract infections in the 
JN Medical hospital, Aligarh India" Annals of Clinical Microbiology and 
Antimicrobial Agents 6 4 (impact 1.62) Published online 
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5. V.M. Ensor, M. Shahid, J.T. Evans and P.M. Hawkey (2006). 
Occurrence, Prevalence and Genetic Environment of CTX-M Beta-
iactamase in Enterobacteriaceae from Indian Hospitals. Journal of 
Antimicrobial Chemotherapy, 58, 1260-1263 (published by Oxford 
University Press, U.K.; Imfact Factor 3.8). 
6. M. Shahid, Vicki M. Ensor & Peter M. Hawkey. (2006). Occurrence and 
Prevalence of CTX-M type Beta-lactamases in Gram-negative Bacteria 
from a Tertiary Care Hospital of North India. Clinical Microbiology & 
Infection (Impact Factor 2.3), 12 SuppI 4, P 1406. 
7. Vicki M. Ensor, M. Shahid, R. Hope, M. Warner, N. Woodford, D.M. 
Livermore & Peter M. Hawkey. (2006). Novel reverse line hybridization 
assay to identify CTX-M genotype in cephalosporin-resistant isolates 
from UK and India. Clinical Microbiology & Infection, (Impact Factor 
2.3),12 SuppI 4, P 1750. 
8. M. Shahid, A Malik, M.W. Rizvi and M. Singhai. (2006). Protein profile of 
a fluconazole-resistant Candida albicans isolated from HIV -1 infected 
patient: evaluation of protein extraction methods and development of a 
simple procedure. Global Journal of Biotechnology, 1: 1-6. 
9. M. Shahid, Abida Malik, Mithlesh Agrawal and Sanjay Singhai. (2004). 
Phenotypic detection of the extended-spectrum and AmpC b-lactamases 
by a new spot inoculation method and modified three-dimensional extract 
test: comparison with conventional three-dimensional extract test. 
Journal of Antimicrobial Chemotherapy, 54, 684-687 (published by 
Oxford University Press, U.K.; Imfact Factor 3.8). 
10.M. Shahid, Abida Malik & Sheeba. (2003). Multi-drug resistant 
Pseudomonas aeruginosa strains harbouring R-Plasmids and Amp C p -
lactamase isolated from hospitalised burn patients in a tertiary care 
hospital of North India. FEMS Microbiology Letters (Impact Factor 
1.8), 228(2), 181-186. 
11. M. Shahid, Abida Malik & R. Bhargava. (2003). Dot Blot Assay and its 
application in diagnosis of Aspergillosis. Bioscience Research Bulletin, 
19(1), 19-22. 
12. M. Shahid and Abida Malik. (2002). A Comparative study on two culture 
media for the growth of pathogenic Aspergillus species: An aid to early 
diagnosis. Bioscience Research Bulletin. 18 (2), 65-70. 
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Papers accepted for Publication 
13. M. Shahid, A. Malik, M. Akram, L. M. Agrawal, A.U. Khan and M. 
Agrawal. (2007). Prevalent Phenotypes and Antibiotics Resistance in 
Escherichia coli and Klebsiella pneumoniae in an Indian Tertiary Care 
Hospital: Plasmid-Mediated Cefoxitin resistance. International Journal 
of Infectious Diseases (Official publication of International Society 
for Infectious Diseases; Impact Factor: 2.1). Manuscript is In Press; 
acceptance letter has already been forwarded to AvH. 
Publications in Indian Journals of International 
circulation (Indexed and of International repute) 
14. M. Shahid & Abida Malik. (2005). Resistance due to aminoglycoside-
modifying enzymes in Pseudomonas aeruginosa isolates from burns 
patients. Indian Journal of Medical research, 122, 324-329. (Official 
publication of Indian Council of Medical Research; Impact Factor: 
0.6) 
15.M. Shahid & Abida Malik. (2004). Plasmid mediated amikacin resistance 
in clinical isolates of Pseudomonas aeruginosa. Indian Journal of 
Medical Microbiology, 22(3) 182-185. (Official publication of Indian 
Association of Medical Microbiologist) 
16.Abida Malik, M. Shahid & R. Bhargava. (2003). Prevalence of 
Aspergillosis in Bronchogenic Carcinoma. Indian Journal of Pathology 
and Microbiology, 46: 507-510. (Official publication of Indian 
Association of Microbiologist and Pathologists) 
17.M. Shahid & Abida Malik. (2003). Mycological and Serological study of 
Pulmonary Aspergillosis in Central India. Indian Journal of Medical 
Microbiology, 21 (1), 64. 
18.A. Malik, SE Hasani, M. Shahid, HM Khan, AJ Ahmad. (2003). 
Nosocomial Klebsiella infection in neonates in a Tertiary Care Hospital: 
Protein Profile by SDS-PAGE and Klebocin typing as Epidemiological 
markers. Indian Journal of Medical Microbiology, 21 (2), 82-86. 
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19. M. Shahid and Abida Malik. (2003). MDR Pseudomonas aeruginosa 
strains in bum wounds: Plasmid mediated resistnace. Bionotes, 5 (1), 6-
7. 
20. M. Shahid and Abida Malik. (2003). Protein Profile of Candida albicans 
evaluated by Sodium dodecyl Sulphate Polyacrylamide gel 
electrophoresis (SDS-PAGE). Bionotes, 5 (2), 36. 
21.l\/[. Shahid and Abida Malik. (2002). Increased incidence of 
Bronchopulmonary Aspergillosis due to Aspergillus flavus in milliary 
tuberculosis. Bionotes, 18(2), 65-70. 
22. M. Shahid, Abida Malik, R. Bhargava. (2001). Prevalence of 
Aspergillosis in chronic lung diseases. Indian Journal of Medical 
Microbiology, 19 (4), 201-205. 
23. M. Shahid and Abida Malik. (2001). Hospital acquired Secondary 
Aspergillus infection in patients of Bronchogenic Carcinoma. Bionotes, 3 
(3), 57. 
24. M. Shahid and Abida Malik. (2001). Dot Blot Assay: An alternative and 
rapid diagnostic approach for Aspergillosis in Chronic lung diseases. 
Bionotes, 4 (3), 57. 
Papers requested by the journals for revision 
International 
1. Shahid M., A. Malik, and R. Bhargava. Bronchogenic carcinoma and 
secondary Aspergillosis- common yet unexplored: evaluation of role of 
Bronchoalveolar lavage (BAL)- culture, BAL-PCR, and serological 
methods to establish early diagnosis. Cancer (revision submitted; 
Manuscript No. C-1721-07.R2). Cancer is an official journal of 
American cancer Society with an Impact factor of 5.6. 
2. M. Shahid, A. Malik and R. Bhargava. Secondary Aspergillus in 
Bronchoalveolar Lavages (BAL) of Pulmonary Tuberculosis Patients 
from North-India. Revision Submitted to "World Journal of Medical 
Sciences". 
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3. M. Shahid, A. Malik and R. Bhargava. Prevalence and Seroprevalence 
of Aspergillus in Bronchial asthma Journal of Applied Biology. 
4. Mehnaz W. Rizvi, A. Malik, S. Singhal and M. Shahid. Evaluation of 
SDS-PAGE for characterization of Candida albicans isolates. Indian 
Journal of Medical Microbiology. 
5. F. Shujatullah, H.M. Khan, A. Malik and M. Shahid. Evaluation of 
Diagnos Malaria Stix (antigen detection assay) in diagnosis of malaria. 
Journal of Indian Medical Association (an official journal of Indian 
Medical Association). 
6. F. Shujatullah, H.M. Khan, A. Malik and M. Shahid. Acridine orange 
staining in diagnosis of malaria. Indian Medical Gazette. 
Papers under review/Communicated to Journals 
International 
7. M. Shahid, V.M. Ensor, and P.M. Hawkey. Emergence and 
dissemination of Enterobacteriaceae with plasmid-mediated CTX-M-15 
and CMY-6-like beta-lactamases in India. Emerging Infectious 
Diseases (Journal of CDC with an Impact Factor of 5.5). (Under 
review). 
8. M. Shahid , T. Rahim, Tajuddin, A. Latif, T. Fatma, M. Rashid, M. Adil, 
and S. Mustafa. Antimicrobial, anti-inflammatory, analgesic, and 
antipyretic potentials of the extracts from roots of a medicinal plant 
Berberis aristata DC. Journal of Ethnopharmacology. (Under review). 
9. F. Tahira, H.M. Khan, I. Shukia, F. Shujatullah, M.A. Malik, M. Shahid. 
Prevalence of Cryptosporidium in children suffering from diarrhoea in 
North-Indian tertiary care hospital. (Submitted to Japanese Journal of 
Infectious Diseases). 
10. H.M. Khan, A. Raza, I. Shukia, F. Shujatullah, A. Malik, A. A. Mahdi, M. 
Shahid. Levels of Ascorbic acid concentrations in patients of acute 
Plasmodium falciparum malaria in relation to parasitemia. (Submitted to 
Medical Science Monitor, USA). 
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11.H.M. Khan, F. Tahira, I. Shukia, F. Shujatullah, M.A. Malik, M. Shahid, 
N. Fatima. Study of epidemiological factors in Cryptosporidiasis in 
children with diarrhoea. Communicated to Indian Journal of 
Community Medicine. 
C)Published contributions to academic conferences 
International Conferences 
1. M. Shahid, Anwar Shahzad, Abida Malik and M. Anis. 
Antibacterial activity of S. asoca explants as well as their in vitro 
raised leaf callus against some medically important bacteria with 
special reference to intestinal pathogens. Proceedings of Global 
Medicinal Plant Summit, held at Mauritius during 25 - 30 
September 2003). 
2. M. Shahid, M. Akram, Abida Malik, A.U. Khan, & Mithlesh 
Agrawal. Antibiotic resistance in E. coli and K. pneumoniae in an 
Indian tertiary Care Hospital. Proceedings of 104'^  General 
meeting of American Society for Microbiology, held at New 
Orleans, U.S.A. during 23-27 May 2004. 
3. M. Shahid, Anwar Shahzad, M. Tariq, Abida Malik, A. Latif, 
Tajuddin, and M. Anis. Antibacterial potential of Berberis aeristata. 
Proceedings of World Conference on Dosing of Antiinfectlves 
(WCDA), Held at Nurnberg, Germany during 6-14 Sept. 2004. 
4. M. Shahid , V.M. Ensor and P.M. Hawkey . Occurrence and 
prevalence of CTX-M type beta-lactamases in gram-negative 
bacteria from tertiary care hospital of North-India. Proceedings of 
16'^  European Congress of Clinical Microbiology and Infectious 
Diseases, held at France during 1-4 April 2006. 
5. . Vicki M. Ensor, M. Shahid, R. Hope, M. Warner, N. Woodford, 
D.M. Livermore & Peter M. Hawkey. Novel reverse line 
hybridization assay to identify CTX-M genotype in cephalosporin-
resistant isolates from UK and India. Proceedings of 16'^  
European Congress of Clinical Microbiology and Infectious 
Diseases, held at France during 1-4 April 2006. 
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National conferences 
6. M. Shahid, Abida Malik, R' Bhargava Aspergillosis in chronic 
lung diseases and its serological evaluation Proceedings of XXIV 
National Congress of Indian Association of Medical 
Microbiologists, Oct. 17-19, 2000, held at Belgaum, Karnataka. 
7. A Malik, SE Hasani, M. Shahid, HM Khan, AJ Ahmad Klebsiella 
Nosocomial infection in neonates Proceedings of National 
Conference on Hospital Infection Control held at Jaipur, Feb. 1-
4,2001. 
8. Abida Malik, Ashraf Malik, M. Shahid, Sobia Khan and Pervin 
Ahmad Seroprevalence of Respiratory Syncytial virus in infants 
and children Proceedings of XI Annual Congress of UP Chapter 
of Indian Association of Pathologists and Microbiologists held at 
Meerut, Oct. 6-7, 2001. 
9 M. Shahid, Abida Malik, R Bhargava Prevalence of Aspergillosis 
in bronchial asthma held at Meerut, Oct 2001 Proceedings of XI 
Annual Congress of UP Chapter of Indian Association of 
Pathologists and Microbiologists held at Meerut, Oct. 6-7, 2001. 
10.M. Shahid, Abida Malik, R Bhargava Secondary Aspergillus 
infection in cases of bronchogenic carcinoma Proceedings of 
XXV National Congress of Indian Association of Medical 
Microbiologists, held at AIIMS, New Delhi Nov. 22-25, 2001. 
H.Shoaib Ehsan Hasani, Abida Malik, M. Shahid and HM Khan 
Bactenological profile of Hospital Acquired Neonatal infections 
Proceedings of VI HISCON - 2001, National Conference on 
Hospital Infection Control held at Jaipur, Feb. 1-4, 2001. 
12.Abida Malik, M. Shahid, P Ganguly, M Younus, S E Hasani 
Epidemiological study of postoperative hospital acquired bacterial 
infections in surgical wards Proceedings of VI HICCON - 2001, 
National Conference on Hospital Infection Control in Indian 
Hospitals- challenges and strategies held at AIIMS, New Delhi 
Oct. 2001. 
13.M. Shahid & Abida Malik Protein profile and evaluation of various 
protein extraction methods of C albicans by SDS-PAGE 
Proceedings of XXVI National Congress of Indian Association of 
Medical Microbiologists, held at NIMHANS, Bangalore, Nov. 20-
24, 2002. 
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U.Abida Malik, M. Shahid and D.K. Pandey. Prevalence of HIV 
Infection in tuberculosis patients in and around Aligarh. 
Proceedings of XXVI National Congress of Indian Association of 
Medical Microbiologists, held at NIMHANS, Bangalore, Nov. 20-
24, 2002. 
15. M. Shahid, Abida Malik, Mithlesh Agrawal, Lavneesh M. Agrawal 
and Fatima Shujatullah. Increasing aminoglycoside resistance in 
clinical Gram-negative bacterial isolates and a reflection of 
increased aminoglycoside usage- our worst nightmare. 
Proceedings of 3'''^  annual conference of Society of 
Pharmacovigilance, India, held at Agra,11-13 Dec. 2003. 
16.M. Shahid and A. Malik. Aminoglycoside resistance in multidrug-
resistant clinical isolates of Pseudomonas aeruginosa: Detection 
of prevalent aminoglycoside resistance mechanism(s) due to 
aminoglycoside modifying enzymes. Proceedings of XXVII 
National Congress of Indian Association of Medical 
Microbiologists, held at Mumbai, Nov. 5-9, 2003. 
17.M. Shahid, Anwar Shahzad, Abida Malik and M. 
Anis.Antibacterial activity of extracts derived from leaves and in 
vitro raised leaf calli of Sansevieria cylindrica and Cletoria 
ternatia. Proceedings of XXVII National Congress of Indian 
Association of Medical Microbiologists, held at Mumbai, Nov. 5-9, 
2003. 
18. Mehnaz W. Rizvi, A. Malik, S. Singhal and M. 
Shahid. Evaluation of SDS-PAGE for characterization of Candida 
albicans isolates. Proceedings of 2nd UP Chapter of Indian 
Association of Medical Microbiologists, held at Varanasi, Feb. 
2006. 
19. M.Shahid, M.Singhai, Abida Malik, Indu Shukia, 
H.M.Khan. ESBL phenotypes and prevalent genotype of CTX-M type 
p-lactamases In clinical isolates of Escherichia coli in a North- Indian 
tertiary care hospital. Proceedings of 2nd UP Chapter of Indian 
Association of Medical Microbiologists, held at Varanasi, Feb. 
2006. 
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20. Mehnaz W. Rizvi, Abida Malik, M. Shahid and Monil 
Singhai. Isolation, characterization and study of virulence 
markers of Candida isolates in hospitalized high risk 
patients. Proceedings of 3nd UP Chapter of Indian Association 
of Medical Microbiologists, held at Aligarh, 24 Feb. 2007. 
2 1 . Maris M. Khan, Fatima Shujatullah, M. Shahid, Adil 
Raza, Ritu Malik. Evaluation of antigen detection 
test(diagnos malaria stix) in diagnosis of malaria. 
Proceedings of 3nd UP Chapter of Indian Association of Medical 
Microbiologists, held at Aligarh, 24 Feb. 2007. 
D) Published Genomic Sequences In Gene bank 
(GenBank) 
1. Shahid,M., Ensor,V.M., Xu,L. and Hawkey,P.M. blaCTX-M-15from 
Tertiary Care Hospital of North India. Klebsiella pneumoniae isolate 
MS04 insertion sequence ISEcpl, partial sequence; and CTX-M-15 beta-
lactamase (blaCTX-M-15) gene, complete cds. ACCESSION 
DQ485309 VERSION DQ485309.1 01:92428671 APR-2006 
2. Shahid.M., Ensor.V.M., Xu.L. and Hawkey.P.M. blaCTX-M-15 from 
Tertiary Care Hospital of North India. Escherichia coli isolate MS05 
insertion sequence ISEcpl, partial sequence; and CTX-M-15 beta-
lactamase {blaCTX-M-15) gene, complete cds. ACCESSION 
DQ485310 VERSION DQ485310.1 01:92428673 APR-2006 
3. Shahid.M., Ensor,V.M., Xu,L. and Hawkey,P.M. IS26 element in Indian 
bacterial population. Escherichia coli isolate MS01 insertion sequence 
ISEcpl and 1826, partial sequence; and CTX-M-15 beta-lactamase 
(blaCTX-M-15) gene, partial cds. ACCESSION DQ485311 VERSION 
DQ485311.1 01:92428675 APR-2006 
4. Shahid.M., Ensor,V.M., Xu,L. and Hawkey,P.M. 1826 element in Indian 
bacterial population. Klebsiella pneumoniae isolate MS02 insertion 
sequence ISEcpl and 1826, partial sequence; and CTX-M-15 beta-
lactamase (blaCTX-M-15) gene, partial cds. ACCESSION DQ485312 
VERSION DQ485312.1 01:92428677 APR-2006 
5. Shahid.M., Ensor.V.M., Xu,L. and Hawkey,P.M. 1826 element in Indian 
bacterial population. Escherichia coli isolate M803 insertion sequence 
ISEcpl and 1826, partial sequence; and CTX-M-15 beta-lactamase 
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(blaCTX-M-15) gene, partial cds. ACCESSION DQ485313 VERSION 
DQ485313.1 Gl:92428679 APR-2006 
6. Shahid.M. CMY-6- like AmpC beta-lactamase in Enterobacteria from 
North-Indian Tertiary Care Hospital. Escherichia coli strain MS D11 beta-
lactamase CMY6-like (ampC) gene, partial cds. ACCESSION 
EF103125 VERSION EF103125.1 61:118603534 DEC-2006 
7. Shahid.M. CMY-6- like AmpC beta-lactamase in Enterobacteria from 
North-Indian Tertiary Care Hospital. Escherichia coli strain MS D12 beta-
lactamase CMY6-like (ampC) gene, partial cds. ACCESSION 
EF103126 VERSION EF103126.1 Gl:118603536 DEC-2006 
8. Shahid, M. Escherichia coli strain MS INC03 beta-lactamase (blaCTX-M-
15) gene, partial cds. ACCESSION EF371800 VERSION 
EF371800.1 01:125634305 FEB 2007 
9. Shahid, M. Escherichia coli strain MS INB03 insertion sequence ISEcpl, 
partial sequence; and beta-lactamase (blaCTX-M-15) gene, partial cds. 
ACCESSION EF371799 VERSION EF371799.1 61:125634303 FEB 
2007 
Personal data: 
Date and Place of Birth 19/06/1972, Faizabad 
Nationality Indian 
Passport No. A8530750 
Religion Islam 
Father's Name Mr. Badiuddin Ahmad 
Marital Status Married 
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